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Abstract 
 
Respiratory Syncytial Virus (RSV) is a member of the pneumovirus genus (family 
Paramyxoviridae, subfamily Pneumovirinae). RSV is an important respiratory virus 
of both infants and the elderly, representing an underappreciated burden on health 
care systems. In addition, re-infections can occur despite the presence of pre-existing 
immunity, suggesting that immunological memory to RSV is incomplete. 
 
To date, treatment of RSV infection is limited to the provision of supportive care and 
no effective vaccine is available. Although several are currently under investigation, 
these candidates focus upon the delivery of the F and G antigens of RSV to stimulate 
the immune system, rather than the internal antigens, which may provide cross 
protection between different subtypes of RSV. 
 
Vaccine development has been greatly hindered by the lack of an appropriate animal 
model in which to study vaccine efficacy and pneumovirus pathogenesis. Pneumonia 
virus of mice (PVM) is also a member of the Pneumovirus genus and, like RSV 
infection of humans, causes a bronchiolitis and fatal pneumonia in its natural host, 
the mouse. PVM has been proposed as an appropriate model system in which to both 
study pneumovirus pathogenesis and vaccine efficacy. 
 
The PVM model system was adapted to investigate a potential vaccination strategy 
to address the lack of an available RSV vaccine. Replication deficient recombinant 
adenovirus serotype 5 (rAd5) vectors were constructed which expressed the F, M and 
N genes of PVM J3666, in addition to a control construct, which expressed the LacZ 
gene of E. coli. 
 
The constructs were administered via the intranasal route to BALB/c mice and were 
able to elicit complete protection against a lethal dose of pathogenic PVM J3666, in 
both short-term experiments and in a long-term experiment, up to 20 weeks post 
immunisation. The protection effect elicited by the constructs was observed when 
administered in a single dose, and in alternative mouse strains, C3H/He-mg and 
C57BL/6, which had differing immunity haplotypes.  
 
The rAd5 vectors generated a PVM specific IgG humoral response to PVM and Ad5 
antigen which did not correlate as the primary mediator of protection. The rAd5 
candidate expressing the N gene of PVM was shown to induce IFNγ secreting T-cells. 
The use of a peptide library of PVM N protein determined that a specific response 
could be identified towards the amino acids N41-90, N81-130, N161-210 and N281-330. Thus, 
the PVM infection model of BALB/c mice provides an immunological platform to 
facilitate the study of RSV and PVM pathogenesis, immunology and vaccine 
development. 
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Chapter 1 
 
Introduction 
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1.1 Introduction 
 
Viruses are one of the most abundant life forms on our planet and have evolved to 
parasitize all known forms of cellular life. Since the 20
th
 Century, humans have 
possessed the ability to tackle the threat of viral diseases, in the form of improved 
sanitary conditions, anti-viral drugs and vaccination of susceptible populations. In 
contrast to the wide range of antibiotics available to treat bacterial infections, the 
number of clinically available anti-viral drugs are fewer in comparison. As such, 
vaccination remains one of the most important tools for tackling viral infections.  
 
Vaccines are biological tools that aim to prevent disease arising from an infectious 
agent. Vaccination is a way of stimulating the immune system, of a host in a 
controlled manner to clear the foreign organism. This process generates an immune 
memory so that when a natural infection does occur, the immune system is already 
primed to control and clear the infection, preventing disease. To date, smallpox 
remains the most successful example of this, and is the only human disease which 
has been eradicated from the population.  
 
 
1.2 Approaches to vaccination  
 
Vaccination has been used in human populations for over 200 years, since Edward 
Jenner discovered a method to protect against smallpox in 1796. Yet despite the 
advances made in science over this period, the majority of commercially available 
viral vaccines are still developed using traditional techniques. These vaccines are 
either live vaccines, where the virus has been attenuated to prevent disease, or 
inactivated vaccines, where the replication capacity of the virus has been destroyed 
by chemical or heat treatment. Several currently available vaccines are shown in 
Table 1.1. These vaccines retain the immunogenic properties of the virus and are able 
to directly stimulate an appropriate immune response. 
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Virus Trade name  Type 
Measles M-M-R II 
Priorix 
Tresivac 
Trimovax 
Live - attenuated 
 Mumps 
Rubella 
Hepatitis A  
(HAV) 
Havrix 
Avaxrim 
Inactivated 
Subunit  
Hepatitis B 
(HBV) 
Recombivax HB 
Engerix-B 
Subunit 
Human 
papillomavirus (HPV) 
Gardasil 
Cervarix 
Subunit 
Influenza LAIV Live – attenuated 
TIV 
Pandemrix (H5N1) 
Inactivated  
Japanese encephalitis 
(JEV) 
JE-VAX 
IXIARO 
Inactivated 
 
Polio 
 
OPV (Sabin) Live – attenuated 
IPV (Salk) 
Pediarix* 
Inactivated 
Rabies Rabipur  
Rabies Vaccine BP Pasteur 
Merieux  
Live – attenuated 
Rotavirus  Rotarix 
RotaTeq pentavalent 
Live – attenuated 
Live - attenuated 
Varicella zoster virus 
(VZV) 
Priorix Tetra (
+
MMR) 
ProQuad (
+
MMR) 
Zostervax 
Live – attenuated 
Yellow fever Arilvax Live - attenuated 
Table 1.1. A summary of approved human vaccines against viral pathogens in the 
UK. Although newer preparations have been developed, the majority of these 
vaccines rely on attenuation through repeat tissue culture passage or inactivation with 
heat or chemical treatments.  
* Pentavalent preparation with Diptheria, Pertussis, tetanus and Haemopholis 
influenza B 
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Through increased knowledge of immunology and molecular virology, several 
advances in viral vaccine development have been made. These new strategies have 
encouraged the development of safer, more immunogenic vaccines and novel 
delivery systems. Such methods include inactivated subunit, peptide or DNA-based 
vaccines or live viral-vectored vaccines to express high levels of a viral antigen. 
Vaccines made by these new strategies have an advantage over traditional vaccines 
in that they can be tailored to stimulate a particular immune response; minimising 
adverse side effects whilst maximising immunogenicity.   
 
The immunogenicity of a vaccine remains the most important aspect for its success. 
As described in more detail in Section 1.6.2, a strong, protective adaptive immune 
response should be stimulated following vaccination. This should include B-cells to 
secrete neutralising antibody and the stimulation of a mixed T-cell response (van 
Drunen Littel-van den Hurk, 2007). T-cells exist in two main populations: CD8
+
 T-
cells, which have a cytotoxic effector function; and CD4
+
 T-cells, which drive and 
control the overall immune response. By stimulating these aspects of the immune 
system, immunity to a virus will develop, preventing disease in an individual who 
subsequently encounters the pathogenic virus/agent, and hence reducing disease 
incidence in a human population.  
 
The ultimate aims for a successful vaccine are: to be highly efficacious, to ensure a 
robust immune response is generated in a mixed genetic population; generate long-
lasting immunity; to be effective in the presence of maternal antibodies if it is to be 
given to infants; preferably be administered by non-invasive routes; to be heat- and 
light-resistant and easily manufactured to minimise development costs; to be safe and 
well tolerated to ensure maximum uptake of the vaccine within a population; and be 
sufficiently immunogenic to give protection following a small number, preferably 
one, or two doses.  
 
1.2.1 Inactivated virus vaccines 
Inactivated vaccines are formed from viruses which have been treated with heat or 
chemicals, to render them non-infectious. This allows specific proteins or whole-
virus preparations to be used to directly immunise the host and generate an immune 
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response. The advantages of this method are that multiple vaccines can be delivered 
simultaneously and, due to the manufacturing methods, the risk of contaminating 
agents is small. However, multiple boosters are usually required to ensure adequate 
stimulation of the immune response. Also, such vaccines are often delivered via 
intramuscular routes and often do not stimulate a strong mucosal response. Such a 
response is important, as the majority of viruses enter the host via a mucosal surface, 
so stimulating this aspect of immunity is desirable (Yuki & Kiyono, 2009). An 
additional problem is that the methods of inactivating the virus may reduce the 
immunogenicity of the preparation, resulting in a need for larger immunisation doses, 
or it can stimulate an abnormal or inadequate immune response. This was most 
dramatically demonstrated during the formalin-inactivated (FI) respiratory syncytial 
virus (RSV) vaccine trial where the vaccine stimulated a strong inflammatory 
response, upon subsequent encounter with virus that resulted in tragedy (Kim et al., 
1969). Furthermore, these vaccines are associated with a risk of inadequate 
inactivation and thus stringent procedures are required to ensure each batch is safe 
for administration. Unfortunately, the consequences of this were demonstrated during 
the Cutter incident in 1955, where a batch of polio vaccine was contaminated with 
live virus, which led to several fatalities (Offit, 2005). 
 
The first polio vaccine (SALK) is an example of a vaccine made in this manner (Salk, 
1954). The vaccine has since been updated to an inactivated polio vaccine (IPV) 
vaccine, which has enhanced potency over the original. Newer inactivated subunit 
vaccines have been developed, including the hepatitis A virus (HAV) vaccine, 
HAVRIX (Nothdurft, 2008) and the hepatitis B virus (HBV) vaccine Recombivax-
HB (Venters et al., 2004) (Table 1.1). Virus-like particles (VLPs), represent another 
inactivated vaccine strategy. This utilises the ability of some viruses to 
spontaneously form viral capsids in certain conditions. These can be manipulated to 
incorporate peptides or genomic material of another virus and used to directly 
immunise an individual by the natural route of infection. The advantage of this 
method over subunit vaccines is that IgA antibodies and a balanced T-cell response 
are stimulated (van Drunen Littel-van den Hurk, 2007). One such preparation is 
currently undergoing clinical trials to tackle influenza virus (Pushko et al., 2010) and 
other VLPs include the human papillomavirus (HPV) vaccines, Cervarix and 
Gardasil (Szarewski, 2010) (Table 1.1). Other novel delivery strategies include using 
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transgenic plants expressing VLPs from potatoes to tackle norovirus, or rice 
expressing an immunogenic dose of enterotoxins (Yuki & Kiyono, 2009). VLPs can 
also be used to deliver genetic material, which has been shown to be successful in 
mice (Wolff, 1990), particularly when immunised in a prime-boost heterologous 
fashion (Plotkin, 2009).  
 
1.2.2 Live attenuated virus vaccines 
Live attenuated vaccines are essentially replication-competent pathogens, which can 
enter and thus infect a host cell but have lost the capacity to cause disease. This is 
achieved either through multiple passage in tissue culture or through genetic 
manipulation. Such vaccines are considered to be more favourable than inactivated 
candidates as they induce a more potent and robust immune response than killed or 
subunit vaccines (Collins, 1974). This is because the virus is able to mimic a natural 
infection, entering and replicating in the target cells. This stimulates both innate and 
adaptive immune responses, generating neutralising IgA and IgG antibodies and 
virus-specific CD8
+
 T-cells in a way which more accurately reflects the normal 
response to the pathogen. The main disadvantages of these vaccines are that, 
depending on the attenuation method, they can demonstrate a reversion to virulence, 
especially if an individual is infected concurrently with the wild-type virus. Neither 
are they suitable for immunocompromised persons nor for those with underlying 
conditions as viral disease or other complications can arise. Pre-existing immunity, 
either from maternal antibodies in infants or from a previous natural infection, may 
affect the immunogenicity of the vaccine, in addition, the production of these 
vaccines is costly, as preparations must be stringently checked for contaminating 
agents or virulent virus. But these issues are overshadowed by the immunogenic 
potential of these vaccines, as they are able to stimulate strong, robust immune 
responses in fewer doses which minimises side effects, thus lowering the ‘per cost 
dose’. This enhances vaccine uptake within a population, resulting in more effective 
coverage.  
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1.2.2.1 Vectored vaccines 
Due to the risks associated with the reversion to virulence of attenuated vaccines, 
viral-vectored vaccines are an attractive prospect. A genetically stable virus can be 
genetically manipulated to be replication-deficient. This generates a platform into 
which any genetic material can be incorporated. The viral vector will be able to 
infect its target cell efficiently, ensuring effective delivery of the antigen and 
stimulating innate and adaptive immune responses to the transgene. Incorporation of 
highly active mammalian promoters, such as the cytomegalovirus (CMV) 
immediate-early gene promoter, allows high levels of transgene expression, 
maximising immunogenicity. However, immune responses towards the viral vector 
are also induced, which reduces the durability of transgene expression and can 
prevent amplification of these responses with a boost dose. Several viruses are 
currently under investigation as vectors for this method, including members of the 
adenovirus, poxvirus and paramyxovirus families (Brun, 2008). DNA viruses in 
particular, such as members of the adenovirus and poxvirus families, are attractive 
candidates as these large viruses have stable genomes, capable of withstanding 
genetic manipulation and gene insertion.  
 
1.2.3 Vaccine stimulation of mucosal immunity 
The majority of licensed vaccines are used to immunise individuals systemically, and 
are usually delivered via the intramuscular route. They therefore do not stimulate a 
mucosal response. These vaccines rely instead on the ability of the immune system to 
mobilise appropriate immune effector cells to the site of infection, providing 
immunity to a virus wherever it is subsequently encountered. However, the principle 
entry route for viruses is via a mucosal membrane and therefore a vaccine that can 
stimulate a mucosal immune response, will be more efficient at preventing viral 
infection and disease, than a systemically targeted vaccine (Holmgren & Czerkinsky, 
2005, Slatter, 2008, Vujanic et al., 2010, Yuki & Kiyono, 2009). In addition, 
stimulation of a mucosal response often results in the co-stimulation of a systemic 
response, allowing complete protection to be elicited towards a virus (Muller et al., 
1995, Staats, 1994, Staats et al., 1996, Wu & Russell, 1998). Therefore, mucosal 
vaccination is a more appropriate strategy against viruses, particularly respiratory 
pathogens (Holmgren & Czerkinsky, 2005). This method of immunisation stimulates 
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a more ‘natural’ immune response towards the virus and can promote the retention of 
memory effector T-cells at mucosal sites, allowing more rapid stimulation of the 
immune response upon subsequent encounters (Yuki & Kiyono, 2009).  
Potential mucosal immunisation includes nasal, oral, vaginal and anal delivery. 
However, the intranasal route of vaccine administration can successfully prime the 
immune response in both local and systemic compartments (Holmgren & Czerkinsky, 
2005, Slatter, 2008, Yuki & Kiyono, 2009). One potential target for consideration for 
a mucosal delivered vaccine is RSV, an important pathogen of infants and elderly 
persons. The remainder of this review focuses on adenoviruses as potential viral 
vectors to tackle RSV disease, the immunopathology of RSV, and methods to 
develop a successful vaccine candidate.  
 
 
1.3 Adenoviruses as vaccine vectors 
1.3.1 Adenoviruses molecular biology 
Adenoviruses are members of the Mastadenovirus genus of which there are more 
than 51 acknowledged serotypes, classified between six species, A-F. Species C 
viruses, which include human adenovirus 5 (Ad5), cause mild upper respiratory tract 
disease. They have been suggested as appropriate viral vector candidates for 
intranasal immunisation as they have a natural tropism to the mucosal surfaces of the 
lung, where there is extensive expression of their target receptor (Santosuosso et al., 
2005). A comparison of intranasal immunisation with either an attenuated 
replication-competent vesicular stomatitis virus, Venezuelan encephalitis virus 
replicon particles, plasmid DNA, Mycobacterium smegmatis, or a replication-
deficient Ad5 vector, determined that Ad5 was superior at eliciting an immune 
response towards an antigen (Barefoot et al., 2008). Ad5 vectors have been used in 
both oral (Sharpe et al., 2002) and intranasal immunisation routes (Van Kampen et 
al., 2005), of which the intranasal route was demonstrated to be more immunogenic 
and was able to overcome pre-existing immunity towards the vector (Barefoot et al., 
2008, Schulte et al., 2009, Thacker et al., 2009). Studies suggest that Ad vectors 
induce a more robust mucosal immune response when used to immunise animals via 
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the intranasal route than other viral vectors and thus may be potential vectors for 
respiratory vaccines (Fu et al., 2009a).  
 
Ads have non-enveloped, icosahedral shaped particles, which contain a linear 
double-stranded DNA genome which varies between 30-45kb in size depending on 
the serotype studied. Their large genome has a tightly regulated method of 
transcription (Fig. 1.1), and has a large coding capacity which can be genetically 
altered to allow foreign gene insertion (Russell, 2000, Tatsis & Ertl, 2004).  
 
 
 
Figure 1.1 The main transcription products of the adenovirus genome (Ziff, 
1980). The Ad5 genome encodes several proteins through a combination of 
alternative splicing and encoding proteins on both strands of the double stranded 
DNA genome. Upon entry to a host cell, replication is stimulated by early genes E- 
(green arrows), in a progressive manner. Early gene products encode transcriptional 
regulators and modulator proteins. These proteins stimulate late stage gene 
expression L- (red arrows). The late genes encode the structural proteins of the virus 
and are vital for capsid assembly.  
 
 
Ad viruses have two stages to their replication, early and late. Early (E) gene 
expression is essential as it creates proteins and a cellular environment necessary for 
replication of the virus genome. The E1 and E4 genes encode regulators of gene 
expression which target various host proteins and further stimulate  the expression of 
the other early gene regions, such as E2 (Fig. 1.1). The E2 region encodes proteins 
which are directly involved in Ad DNA replication, such as DNA binding protein 
(DBP) (Imler, 1995). The E3 region is non-essential for growth in tissue culture, 
however in vivo, E3 proteins have an important role in the Ad life cycle, as they are 
able to manipulate the hosts immune response, preventing recognition and clearance 
through adaptive immune responses. E3 expression can also be induced by NFκB, a 
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transcription factor involved in the induction of innate immune responses. This 
ensures that immune modulating genes are expressed in response to immune system 
stimulation. The E3 region encodes proteins such as E3-19K, which can bind to 
MHC class I molecules in the endoplasmic reticulum (ER) and prevent their 
transport to the cell surface (Burgert, 1985). This effectively down regulates MHC 
class I expression, hindering immune surveillance by CD8
+
 T-cells (Sester et al., 
2010). During late stage of replication, the late genes L1-5, are expressed (Fig. 1.1). 
These encode the 11 structural proteins which are required to construct the virus 
capsid and include the hexon, penton and fibre proteins.  
 
1.3.2 The Ad5 vector system 
Thorough understanding of Ad molecular biology has been essential for the 
successful generation of vaccine vectors. Ad5 is one of the most utilised vector 
systems due to its strong immunogenicity (Tatsis & Ertl, 2004).  
Ads have a rigid protein capsid which dictates the genome size of the virus. This 
same principle limits the amount of additional genetic material which can be 
incorporated into an Ad vector. Ads can package up to 105% of their standard 
genome length, after which the constructs become highly unstable and are more 
likely to undergo rearrangement to lose the incorporated transgene (Bett et al., 1993, 
Ghosh-Choudhury, 1987). However, vector capacity can be increased through the 
deletion of certain regions of the Ad genome.  
 
Standard Ad vectors for vaccination contain deletions in the E1 and/or E3 regions of 
the Ad5 genome, which increase the capacity for foreign DNA to 6.5kb. These were 
generated through molecular cloning and transfection of complementing cell lines, 
which ensures greater control of the Ad5 genome and eliminates the risk of potential 
contamination from helper viruses (Ghosh-Choudhury et al., 1986, Tatsis & Ertl, 
2004). The removal of the E1 genes renders the virus replication-deficient, as it 
impairs the ability of the other early genes to be expressed halting the transcription 
cascade. This significantly impairs viral replication but prevents apoptosis of the host 
cell and thus premature vector removal, and improves the safety profile of the 
constructs (McCoy et al., 2007, Tatsis & Ertl, 2004). Deletions in the non-essential 
E3 region of the Ad5 genome further increase the vector’s coding capacity for 
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foreign DNA and ensures that the E3 immune modulatory functions  are not 
expressed and thus immunity towards the transgene can be induced. Complementing 
cell lines such as HEK293 cells (Table 2.1.5), have been developed which provide 
the missing E1 gene products in trans, allowing viruses to be grown to high titres 
(Graham et al., 1977).  
Studies performed with first generation vectors ascertained that certain cellular 
factors, such as NF-IL6, were able to perform E1 like functions, thus enabling 
replication-deficient viruses to replicate in a host cell (Imperiale et al., 1984, Spergel 
et al., 1992). As such, second generation vectors were engineered primarily for gene 
therapy studies. These vectors have further deletions within the Ad genome to 
increase vector transgene capacity but also to decrease immunogenicity, and the risk 
of vector replication in complementing cell lines (Kindsmuller et al., 2009). In 
addition, third generation ‘gutless’ vectors have been developed to encode only 
minimal Ad genes within the genome. 
 
1.3.3 Advantages and disadvantages of the Ad5 vector system 
The Ad5 vaccine vector system has not, to date, yielded a successful vaccine 
platform for use in the clinic. However, their use as potential vaccine vectors has not 
subsided. A large variety of replication-deficient vaccine vectors exist with 
alternative gene deletions which reduces potential side effects associated with 
replication-competent vectors. This characteristic also ensures that they can be used 
to immunise immunocompromised individuals without the concern of overwhelming 
the immune system. The molecular cloning techniques have produced commercially 
available kits, such as the pAdEasy (Strategene) and pEntry (Invitrogen) systems. 
These kits allow the rapid generation and isolation of research grade Ad5 vectored 
vaccines to allow the rapid investigation of potential candidates.  
 
Ads also have a broad cell tropism (Nanda et al., 2005). Ad5 in particular uses the 
Coxsackie adenovirus receptor (CAR) as its primary cell receptor which is expressed 
on many cell types, including myoblasts, hepatocytes and epithelial and endothelial 
cells (Tatsis & Ertl, 2004). In the airway, CAR is not expressed but Ad5 is able to 
utilise an alternative isoform to infect these cells (Excoffon et al., 2010). This 
characteristic ensures a large number of cells can be transduced, maximising 
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transgene antigen exposure to the immune system. Therefore, the route of 
immunisation can be chosen to best stimulate the type of immune response needed to 
provide protection against a pathogen. In addition, Ad5 can infect dividing and non-
dividing cells (Tatsis & Ertl, 2004). This also ensures that transgene expression can 
be supported in a large number of cells.  
 
Standard Ad5 vectors are amenable to large scale growth for commercial production 
as they can grow to high titres in a stable manner. The generation of stable 
replication-complementing mammalian cell lines, such as HEK293 cells, allows the 
replication-deficient viruses to be propagated in tissue culture. This reduces the 
potential for contamination with other viruses or helper viruses, which could lead to 
recombination and reversion to a replication-competent virus. Furthermore, Ad5 does 
not routinely integrate into the host cell chromosomes, improving the safety of the 
vector (Xu et al., 2009).  
 
Furthermore, Ads naturally stimulate a strong immune response which is biased 
towards a Th1 response both via systemic and mucosal immunisation routes as 
discussed below in Section 1.6.2 (Santra, 2005). Upon entry to a host cell, innate 
immune responses are triggered, which in turn stimulate the adaptive response. Ads 
stimulate high avidity and high titre neutralising antibodies against encoded 
transgenes, in addition to a strong CD8
+
 T-cell response to both immunodominant 
and non-immunodominant epitopes (Barefoot et al., 2008, Santra, 2005, Tatsis & Ertl, 
2004). This can greatly enhance the potency of the vaccine as, if an increased array 
of epitopes is recognised by the immune system, it decreases the chance of virus 
escape (Santra, 2005). Although this factor is not important for vaccines against 
more stable viruses, those with a high mutagenic rate, such as HIV and influenza, are 
therefore less likely to overcome the immune system and result in disease.  
 
Pre-existing immunity towards Ad5 has been shown to have a negative impact on the 
immune response towards the transgene, reducing transgene expression from months 
to weeks (Zaiss, 2009). In addition, the immunogenicity of Ad5 can affect the 
efficacy of a vaccine if multiple doses are required, as these generate strong anti-Ad5 
immune responses (Santra, 2005).  Neutralising antibody typically targets the hexon, 
fibre and penton proteins and the cellular response is often directed to the E1a, E1b, 
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E2a and hexon proteins (Gahery-Segard et al., 1998, Thacker et al., 2009, Yang et al., 
1995). Serological studies have indicated a high prevalence of anti-Ad5 immunity in 
the human population, which may hinder vaccine efficacy in these populations (Mast 
et al., 2009). However, some studies have indicated anti-Ad5 immunity may not 
impede an immune response towards a vaccine transgene (Casimiro et al., 2003). 
One particular study using a bovine Ad vector demonstrated that seropositive 
animals were able to mount an effective immune response against the vaccine 
transgene in spite of pre-existing immunity against the vector (Babiuk & Tikoo, 
2000). Another group investigating this effect in humans also confirmed this finding 
(Gahery-Segard et al., 1998). Therefore, other groups suggested Ad5 could be used 
as part of a heterologous (rather than as a homologous) immunisation regime to 
minimise anti-Ad immunity issues (Natuk, 1994, Reyes-Sandoval, 2010, Santra, 
2005, Shiver et al., 2002). Heterologous regimes involve immunising individuals 
with several different types of vaccine preparation such as live recombinant, DNA 
and subunit, whereas homologous regimes involve immunisation with the same 
vaccine preparation. In response to this issue, alternative Ad serotypes are currently 
being investigated as suitable vaccine vectors. Serological studies have suggested 
that Ad25, Ad11, Ad35 and Ad3 could be used as potential vectors, however, these 
have been shown to be less immunogenic than Ad5, in terms of the transgene 
response elicited (Abbink, 2007, Barouch et al., 2004, Lemckert et al., 2005, Li et al., 
2009, Mast et al., 2009). Furthermore, these constructs are also less immunogenic 
than Ad5 when used in heterologous and homologous immunisation strategies 
(Santra et al., 2009). One solution is to replace the fibre knob of Ad5, the receptor 
attachment site, with that of another serotype, such as Ad35; this has been shown to 
retain immunogenicity but circumvent pre-existing immunity (Nanda et al., 2005). In 
addition, animal Ads particularly chimpanzee Ad serotypes such as, ChAd7, ChAd68 
and ChAd1/5 are under consideration as potential vectors because humans do not 
have pre-existing immunity towards them (Dudareva et al., 2009, McCoy et al., 2007, 
Peruzzi et al., 2009). 
 
1.3.4 Adenoviral vectored vaccines  
Ad5 vectors have been investigated as a potential proof-of- principle vaccines for a 
number of viruses. A non-exhaustive list includes: HPV (Berg et al., 2007, Tobery et 
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al., 2003); rabies (Vos et al., 2001); human immunodeficiency virus (HIV) (Flanagan 
et al., 1997, Liu et al., 2008, Pinto et al., 2004); Japanese encephalitis virus (JEV) 
(Appaiahgari et al., 2006, Peng, 2008); dengue virus (Jaiswal et al., 2003, Khanam et 
al., 2006, Khanam et al., 2009, Raviprakash et al., 2008); severe acute respiratory 
syndrome (SARS) coronavirus (Kobinger et al., 2007, Ma, 2006, See et al., 2008); 
hepatitis C virus (HCV) (Martin et al., 2008); influenza A virus (Hoelscher et al., 
2006, Naskalska et al., 2009); hantavirus (Safronetz et al., 2009); measles (Fooks et 
al., 1998, Fooks et al., 1995); western equine encephalitis virus (WEEV) (Wu et al., 
2007); and rotavirus (Both et al., 1993, Gorziglia & Kapikian, 1992, Liu, 2005).  
 
One of the most high profile Ad5 vaccine trials was the Merck Ad5-HIV vaccine 
STEP trial, which used an Ad5 E1-deleted vector expressing the gag, pol and nef 
genes of HIV-1 (Priddy, 2008). This vaccine underwent Phase III clinical trials, but 
was unsuccessful. Further investigation revealed that the vaccine did not prevent 
HIV infection or lower virus load during early infection. Of great concern was that 
the incidence of HIV infection was higher in the immunised group as opposed to the 
placebo recipients (Buchbinder et al., 2008), despite the stimulation of high levels of 
HIV specific CD8
+
 T-cells (McElrath et al., 2008). Initially, it was assumed that the 
basis for this was that CD8
+
 T-cell responses had also increased the CD4
+
 T-cell 
population; as CD4
+
 cells are the target for HIV, this would lead to enhanced 
infection rates. One group claimed this was unlikely as they could not demonstrate 
significant CD4
+
 T-cell expansion (Koup et al., 2009), however, they used a different 
vaccine candidate which contained an additional E3/E4 deletion which may have 
affected the results. Another theory suggested that the degree of pre-existing 
antibody in the vaccine recipients was the cause, leading to premature removal of the 
vaccine, reducing transgene expression and thus the immunity induced to HIV. The 
vaccine stimulated high levels of HIV specific CD8
+
 T-cells but this response did not 
correlate with protection (Buchbinder et al., 2008). A later study suggested that pre-
existing immunity was unlikely to be the cause of this failed vaccine as neutralising 
epitopes towards Ad5 are different for ‘natural’ or ‘vaccine’ exposure (Cheng et al., 
2010). This work did confirm that natural immunity was primarily directed to the 
fibre protein, so molecular manipulation of this protein may allow circumvention of 
the immune response. Regardless, the study suggested that a future vaccine must be 
capable of stimulating robust CD8
+
 and CD4
+
 responses to ensure a broad 
  15   
stimulation of the immune response as CD8
+
 T-cell responses alone may not be 
sufficient to protect against the establishment of an HIV infection (McElrath et al., 
2008).  
Despite this disappointing outcome, Ad5 still remains a vector of choice for 
development of potential vaccine candidates. One virus in particular, respiratory 
syncytial virus (RSV), has been of commercial interest for vaccine development. 
RSV is a pneumovirus and causes an acute respiratory infection. Producing a vaccine 
for this virus has a number of issues and difficulties surrounding its development, 
particularly the immunogenicity of RSV and of traditional vaccine candidates. Thus, 
recombinant delivery vectors represent an alternative option and Ad5 therefore 
represents a good system in which to generate a proof-of-principle vaccine for this 
virus.  
 
 
1.4 Introduction to Pneumoviruses 
1.4.1 Pneumovirus phylogeny 
RSV is a member of the pneumovirus genus (family Paramyxoviridae, subfamily 
Pneumovirinae (Fig. 1.2)). Within this genus there are three members but only two 
are of importance for this study, RSV and pneumonia virus of mice (PVM). Recently, 
a pneumovirus like virus has been isolated from dogs (Renshaw, 2010).  
The majority of information with regards to pneumoviruses has been derived from 
RSV but where comparisons have been made the features have proved to be 
applicable to other pneumoviruses. RSV and PVM share a high degree of similarity 
both at the molecular level in terms of gene order and function (Chambers et al., 
1990, Thorpe & Easton, 2005), and at the cellular level in terms of the pathogenesis 
of RSV infection of humans and PVM infection of mice (reviewed by (Rosenberg & 
Domachowske, 2008). All pneumoviruses, indeed all paramyxoviruses have a 
negative sense, single-stranded RNA genome. They also have considerable 
commonality in gene content and gene order (Fig. 1.2). Members of the pneumovirus 
genus differ from other members of the subfamily Pneumovirinae through the 
presence of two extra genes, NS1 and NS2, situated at the 3’ end of the RNA 
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genome. Also, the Pneumovirinae differ from the Paramyxovirinae through the 
presence of the M2 gene near the 5’ end of the genome.  
 
 
 
 
 
 
 
Figure. 1.2. The genome organisation of selected members of the virus family 
Paramyxoviridae ((Easton et al., 2004). 
Viruses within the family Paramyxoviridae all have negative sense, single-stranded 
RNA genomes. The family is subdivided into the Paramyxovirinae and 
Pneumovirinae subfamilies, the members of which cause diseases in animals and 
humans. Members of the Paramyxovirinae include the Avulavirus, Henipavirus and 
TPMV-like virus genera but of importance to human health are the Morbillivirus, 
Respirovirus and Rubulavirus genera; of which measles virus, parainfluenza virus 
and mumps viruses are members respectively.  
The second subfamily, Pneumovirinae, is further subdivided into two genera; 
Metapneumovirus and Pneumovirus. The Metapneumovirus genus contains two 
species, avian pneumovirus (APV) and human metapneumovirus (hMPV) while the 
pneumovirus genus contains RSV, bovine RSV and PVM. The genome of members 
of the Paramyxoviridae family have similar gene orders and functions. Members of 
the subfamily Pneumovirinae differ from the Paramyxovirinae in that they typically 
have 8-10 genes as opposed to 6-7. The additional genes include the M2 gene for all 
pneumoviruses, and the NS genes for the pneumovirus genus only. The genome 
organisation of representatives of each genus is shown and the genes are ordered in a 
3’-5’ manner and colour coded for similar functionality.  
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1.4.2 Pneumovirus gene function and lifecycle 
Many reviews are available which deal with pneumovirus lifecycle and gene function 
in detail but for the purposes of this study, the lifecycle of the pneumoviruses will be 
summarised (Cowton et al., 2006, Easton et al., 2004, Easton et al., 2007).  
The members of the pneumovirus genus have particles that are pleomorphic and can 
exist in filamentous and spherical enveloped forms at approximately 80-120μm in 
diameter (Compans, 1967 ), as illustrated diagrammatically in Fig. 1.3. The viruses 
have 8-10 genes, NS1, NS2, N, P, M, SH, G, F, M2 and L, which express their 
respective proteins of the same designation. For RSV, 11 proteins are translated from 
10 genes.  
 
 
Figure 1.3. The typical structure of the pneumovirus virion (Kindly provided by 
A. Easton). 
An illustration of the structure of the pneumovirus virion. The external fusion (F, red 
spikes), attachment (G, green protrusions) and small hydrophobic (SH) proteins are 
embedded in a lipid envelope derived from the host cell plasma membrane. The 
matrix (M, blue layer) protein interacts with the cytoplasmic tails of the F, G and SH 
proteins, and the ribonucleoprotein (RNP, white strands) complex to allow virus 
assembly. The RNP complex consists of the nucleoprotein (N), phosphoprotein (P), 
and viral polymerase (L) in complex with the RNA genome. The M2-1 and M2-2 
proteins may also form part of the complex.   
 
 
The lipid envelope of the virus is derived from the host cell membrane (Compans, 
1967 ). Three external proteins are embedded in lipid rafts within this membrane the 
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fusion (F), attachment (G) and small hydrophobic (SH) proteins (Fleming et al., 2006, 
Low et al., 2008). The G protein (green spike, Fig. 1.3), is involved in the attachment 
of the virus to target cells and is highly glycosylated, (Easton et al., 2004). It is 
present in two forms in an infected cell, one being the full-length protein which is 
membrane-bound and the other a smaller molecule, generated from an internal 
initiation codon. This smaller form of the G protein can be secreted and is believed to 
have an immunomodulatory function (Easton et al., 2004). The PVM G protein has 
11% amino acid sequence identity with that of RSV (Easton & Chambers, 1997) and 
is believed to be a main virulence factor, as attenuated PVM strain 15 has multiple 
differences in the G gene when compared to pathogenic strain J3666 (Krempl et al., 
2007, Thorpe & Easton, 2005). The second external protein is the F protein (red 
spike, Fig. 1.3). This protein is involved in the fusion of the viral envelope and the 
host cell plasma membrane in a pH independent manner, and is believed to be 
sufficient to achieve viral entry and exit (Easton et al., 2004, Fleming et al., 2006, 
Kahn et al., 1999, Karron et al., 1997, Techaarpornkul et al., 2001). The F protein is 
synthesised as an F0 70-kDa protein precursor which is processed by proteolytic 
cleavage in the trans Golgi network, generating two subunits F1 and F2, which are 
linked by a di-sulphide bridge (Chambers et al., 1992). The PVM F protein has 40% 
amino acid sequence identity with that of RSV and is believed to perform a similar 
function (Chambers et al., 1992, Easton & Chambers, 1997). The final external 
protein is the SH protein, which is also present on the external surface of the virus 
particle. The precise role of this protein is not known, however, it is thought that the 
SH protein of RSV is involved in the fusion process of the virus (Heminway et al., 
1994), and it may have a role in modulating the Th1 CD4
+
 T-cell response through 
the inhibition of cytokine expression (Tripp et al., 2000). The SH protein of PVM has 
22% amino acid sequence identity with that of RSV, and is significantly larger than 
its RSV counterpart (Easton & Chambers, 1997, Easton et al., 2007). It is unknown 
whether the difference in size corresponds to a difference in function between the 
two proteins. 
 
Other viral genes encode the internal proteins of the particle or non-structural 
proteins. The matrix (M) protein (blue layer, Fig. 1.3), plays a role in viral assembly 
and viral genome transcription  (Ghildyal, 2006). The protein forms a layer between 
the viral envelope and the ribonucleoprotein (RNP) complex (white strands, Fig. 1.3). 
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The M protein has an inhibitory role during viral transcription, and is imported to the 
nucleus during the early stages of infection (Ghildyal et al., 2003, Ghildyal, 2006). 
During the switch from transcription to replication of the viral genome, the M protein 
localises once again to the cytoplasm through interactions with the M2-1 protein 
(Ghildyal et al., 2009, Li et al., 2008). The M-M2-1 complex then associates with the 
RNP complex, allowing the M protein to interact with both the N protein and the 
cytoplasmic tails of the F and G proteins, hence allowing efficient assembly of the 
virus (Ghildyal et al., 2002, Teng & Collins, 1998). The M protein of PVM contains 
42% amino acid sequence identity with that of RSV (Easton & Chambers, 1997). 
 
The RNP complex is mainly comprised of the nucleocapsid (N), phosphoprotein (P) 
and the polymerase (L) proteins, complexed with a molecule of genomic RNA. The 
complex is involved in maintaining the genome structure to ensure efficient 
transcription can occur (Fig. 1.4). The PVM N protein has the greatest amino acid 
sequence similarity with its RSV counterpart at 60% (Barr et al., 1991). The N 
protein can aggregate and bind to viral RNA in a non-sequence specific manner, 
which is thought to induce a conformational change in the protein (Murphy et al., 
2003). Amino acids N352-369 at the C-terminus of the N protein have been identified 
as being essential for its function (Stokes et al., 2003), enabling the protein to interact 
with the P protein and preventing its self-aggregation. The P protein is an important 
co-factor for the polymerase and is one of the proteins which differs significantly 
between the PVM and RSV viruses; PVM P protein has 40.9% amino acid sequence 
identity with the RSV protein (Krempl et al., 2005). However, unlike RSV, the P 
gene of PVM contains an internal open reading frame (ORF), which encodes the P2-
2 protein; synthesis of this protein is initiated through an internal start codon (Barr et 
al., 1994). The P2-2 protein is thought to inhibit viral transcription in a dose-
dependent manner (Dibben et al., 2008). In addition, the RSV P protein also interacts 
with the M protein at a particular serine residue, S54, the interaction of which is 
important for viral assembly upon exit from the cell and virus uncoating upon cell 
entry (Asenjo et al., 2008). The polymerase subunit is the final member of the RNP 
complex. This viral enzyme is required for genome replication and transcription 
upon host cell entry. The polymerase has a multifactorial role: the enzyme is able to 
transcribe mRNA from the genome, adding a 5’ cap and a 3’ poly(A) tail, synthesise 
an antigenome template and also, synthesises new viral genomes from this anti-
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genome template (Edworthy & Easton, 2005, Poch et al., 1990). The L protein of 
PVM has 53% amino acid sequence identity with that of RSV (Easton & Chambers, 
1997). 
 
 
 
 
 
 
Figure 1.4. The method of transcription used by the pneumoviruses. 
The transcription of the pneumovirus genome is similar to that described for other 
non-segmented, negative-sense RNA viruses. The polymerase complex (red) 
associates with the 3’ leader sequence in the genome (Easton et al., 2004). The 
complex then initiates transcription of the first gene and synthesises a 5’ cap on the 
mRNA (Liuzzi et al., 2005), stimulating mRNA transcription (top panel). Upon 
reaching a ‘gene end’ sequence the polymerase complex can dissociate from the 
genomic template, synthesising a poly(A) tail and return to the 3’ leader sequence to 
re-initiate transcription (dotted line, panel two). Alternatively, the complex remains 
bound and scans through the intergenic region until the next ‘gene-start’ sequence is 
recognised (Kolakofsky, 2004); transcription of this gene then occurs. The second 
mechanism is not as efficient as the first, therefore generating a gradient of mRNA 
synthesis along the genome (bottom panel).  
 
 
The M2 gene expresses two proteins, M2-1 and M2-2, through a novel, tightly 
regulated coupled translation mechanism (Ahmadian et al., 1999, Ahmadian et al., 
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2000, Gould & Easton, 2005). Due to its position near to the 5’ end of the viral 
genome, the M2 proteins are expressed at low levels (Ahmadian et al., 1999). The 
significant difference between the M2 gene of RSV and PVM is that the M2 gene in 
RSV overlaps with the L gene, which does not occur in the PVM genome (Thorpe & 
Easton, 2005). For RSV, the M2-1 protein is involved in viral RNA synthesis and 
acts as a transcriptional elongation factor (Teng & Collins, 1998, Tran et al., 2009) 
whereas the role of M2-2 is believed to be a negative regulator of RNA replication 
(Cheng et al., 2005, Collins, 1996). Thus, the RSV M2-2 protein may control the 
balance between genome transcription and replication (Bermingham & Collins, 
1999). The PVM M2 proteins have 42% and 10% amino acid sequence identity 
respectively with their RSV counterparts (Easton & Chambers, 1997) and are 
associated, in part, with the RNP complex (García et al., 1993). Studies of the M2 
protein of PVM have elucidated that the function of the M2-1 protein is similar to 
that of RSV, but at high levels decreases viral RNA replication (Dibben et al., 2008). 
The M2-2 protein of PVM has been demonstrated to inhibit RNA replication in a 
dose dependent fashion (Dibben et al., 2008). Therefore, in both viruses the control 
of these genes is critical for efficient viral replication.  
 
Lastly, the virus encodes two non-structural proteins from its two 3’ proximal genes, 
NS1 and NS2. These proteins are expressed first and most abundantly from the 
pneumovirus genome (Fig. 1.4). These proteins modulate the innate immune 
response and hence contribute to viral virulence (Bossert & Conzelmann, 2002, 
Buchholz et al., 2009, Wright, 2006); they also determine host range (Bossert & 
Conzelmann, 2002, Schlender et al., 2000). RSV mutants which lack these genes 
demonstrated an attenuated phenotype in chimpanzees (Jin et al., 2000, Whitehead et 
al., 1999). Likewise, PVM ∆NS1/NS2 have an attenuated phenotype in mice 
(Buchholz et al., 2009). NS1 and NS2 proteins suppress the innate type 1 interferon 
(IFN) response, through modulating the synthesis and function of these cytokines 
(Swedan et al., 2009), particularly NS2 which inhibits the IFN system through 
multiple pathways (Buchholz et al., 2009, Ling et al., 2009). This in turn can inhibit 
dendritic cell (DC) maturation and activation, which can further affect the immune 
response (Munir et al., 2008). In addition, the NS proteins of bRSV are sufficient to 
rescue an unrelated virus from an IFN response in bovine cells (Schlender et al., 
2000). Furthermore, the proteins have been shown to have an anti-apoptotic function 
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through preventing TNF-α mediated apoptosis (Bitko et al., 2007). The NS proteins 
of PVM differ significantly in sequence from those of RSV with 15% and 20% 
amino acid sequence identity for NS1 and NS2 respectively (Krempl et al., 2005). 
The precise role of the NS1 protein of PVM has yet to be elucidated, while the NS2 
protein has been shown to be an antagonist of the type I IFN response like its RSV 
counterpart (Buchholz et al., 2009).  
 
 
1.5 Pathogenicity of pneumovirus 
1.5.1 RSV disease 
Respiratory disease is a significant health issue worldwide. RSV is a common 
causative agent of respiratory disease and globally, is estimated to cause 64 million 
infections and 160, 000 deaths annually (Cowton et al., 2006, van Drunen Littel-van 
den Hurk, 2007). RSV is a highly contagious winter pathogen in temperate climates, 
and is associated with seasonal epidemics during which two antigenic subtypes co-
circulate (Falsey et al., 2005, Noyola et al., 2007). 
RSV is more commonly associated as an infant respiratory pathogen, and is 
understood to be the single most important viral cause of respiratory tract infections 
(Bennett, 2007, Nicholson et al., 2006, Simoes, 1999). In infants, RSV causes 
bronchiolitis, a condition characterised by coughing, wheezing and breathing 
difficulties, which is associated with an acute infection in 50-90% of cases in infants 
(Bennett, 2007). The morbidity associated with RSV infection is high; however, the 
infection is resolved by innate and adaptive immune responses without further 
complications. In a few individuals, a severe RSV infection will develop. This is 
thought to occur due to the immaturity of the infant immune system, leading to an 
increased likelihood of an inflammatory response which is driven by the Th2 CD4
+
 
T-cell response (Fig. 1.5) (Section 1.6.2). Severe infections are more common if 
infants are under two years of age, are born prematurely, or have an underlying 
medical condition. The immune response generated upon severe RSV infection is 
similar to that stimulated during episodes of asthma. This generates significant 
inflammation in the respiratory tract leading to breathing difficulties and a need for 
hospital care.  
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Figure 1.5. 
Immunopatho
genesis of 
pneumovirus 
infection of 
infants 
(adapted from 
(van Drunen 
Littel-van den 
Hurk, 2007). 
Pneumoviruses 
infect the 
epithelial cells 
of the 
respiratory 
tract. TLRs 
recognise virus 
specific 
patterns which 
triggers an 
innate immune 
response where 
IFNα/β is 
released to 
stimulate an 
anti-viral state 
(Faisca et al., 
2006, 
Trinchieri & Sher, 2007). DCs, eosinophils, monocytes, lymphocytes and neutrophils 
are attracted by the cytokines released from the lung epithelium, such as TNF-α, IL-8, 
MCP-1, MIP-1α and RANTES. DCs can acquire RSV antigen and present it via 
MHC complexes to naive T-cells. Initially, a mixed T-cell response is stimulated. 
Th1 CD4
+
 T-cell are stimulated to release IFNγ, this in turn stimulates naive CD8+ T-
cells to mature into CTLs with cytotoxic capabilities and B-cells to secrete 
neutralising antibodies of the IgG2a isotype. Th2 CD4
+
 T-cells are also stimulated. 
These secrete IL-10 which inhibits DC activation of the Th1 pathway. Th2 T-cells 
release pro-inflammatory cytokines such as IL-4, IL-5 and IL-13. These attract mast 
cells and eosinophils and stimulate them to de-granulate and release histamine. This 
is an allergic immune response. In addition, B-cells are stimulated to secrete 
antibodies of the IgG1 and IgE isotypes. Both the Th1 and Th2 pathways release 
cytokines which inhibit the other pathway. It is the balance between these two 
pathways which determines the ultimate dominance of a particular pathway. If the 
Th1 pathway dominates, the individual will recover and develop protective immunity. 
However, if the Th2 pathway dominates, the individual will develop an enhanced 
disease pathology, which is allergic in nature.  
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In recent years, it has been elucidated that the cytokine and chemokine profile of the 
immune response determines the outcome of RSV disease, by affecting the outcome 
of CD4
+
 T-cell differentiation. As described in Fig 1.5, a Th1-biased response is 
associated with protection and clearance of a viral pathogen whereas a Th2-biased 
response is associated with an immune response which is more allergic in nature. 
Both responses are characterised by a distinct cytokine profiles. The morbidity 
associated with severe RSV infections is great and it is estimated that 3% of infants 
admitted to hospital with severe RSV infections will succumb to the disease (Bennett 
et al., 2007). 
 
A link has been established between viral respiratory infections, such as RSV, and 
the probability of the development and exacerbation of asthma in children (Hansbro 
et al., 2008). Asthma is a chronic inflammatory disease which is triggered upon 
exposure to particular allergens. This leads to severe airway hypersensitivity, airway 
narrowing and difficulties in breathing. Pro-inflammatory cytokines are released and 
the Th2 CD4
+
 T-cell population is activated, recruiting eosinophils to the airway. 
These release histamine, which further exacerbates the inflammatory response. 
Repeat episodes of asthma lead to damage to the mucosa of the lung epithelium 
which in turn triggers an excessive repair response. This results in airway 
remodelling, excessive mucus production and chronic disease (Hansbro et al., 2008), 
a response similar to that seen in a severe RSV infection (Kim et al., 2008, Taylor, 
2007).  
 
Evidence for a link between RSV infection and asthma includes: 80% of wheezing 
children have an associated viral infection (Johnston et al., 1995); RSV is frequently 
isolated from wheezing children (Johnston, 1999); a positive correlation has been 
demonstrated between persistent wheeze at 5 years of age and a history of an RSV 
infection with wheezing signs (Merci et al., 2007); RSV infection and allergic 
sensitisation to airborne allergens has been linked (Frick, 1979); and RSV 
bronchiolitis has been identified as an important risk factor for asthma development 
in children (Sigurs, 1995). In contrast, the link between an RSV and asthma is not 
always clear as it has been noted that the correlation between RSV infection and 
asthma development only occurs in a small proportion of infants (Merci et al., 2007, 
Murray, 1992, Pullan, 1982, Ramsey, 2007, Sims, 1978). This suggests that severe 
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infection or genetic factors may predispose individuals to asthma development 
(Mahalingam et al., 2006).  
 
Furthermore, RSV has been identified as an important cause of respiratory disease in 
adults and in particular, the elderly (Falsey & Walsh, 2000, Hall, 2001b, Han, 1999). 
In the USA, it is estimated that RSV is thought to account for up to 10% of all winter 
respiratory hospital admissions (Falsey, 1995), a rate similar to that of influenza 
virus (Han, 1999). Adult infections present with a wide range of signs, from upper 
respiratory tract ‘common cold’-like signs to respiratory failure, in contrast to the 
bronchiolitis presentation in young infants (Falsey et al., 2005, Falsey & Walsh, 
2000, Han, 1999). As with infants, the severity of the illness is dependent upon the 
presence of underlying medical conditions and the general well-being of the 
individual (Walsh, 2004a, Walsh, 2004b). Healthy adults do not develop severe RSV 
disease, presumably because the immune system is mature and fully functional. 
However, re-infections can occur despite the presence of pre-existing immunity, 
suggesting that immunological memory to RSV is incomplete (Van der Poel et al., 
1994).  
 
1.5.2 RSV treatment 
Currently, two antibody preparations are licensed for use in humans. The first is 
RSV-IGIV (RespiGam®), which is prepared from adult human sera, and to treat 
RSV infection the second is palivizumab (Synagis®), a monoclonal IgG antibody. 
Extensive use of RSV-IGIV has been discontinued as it is derived from blood and 
therefore poses a risk of transmitted blood borne pathogens. In addition, it required a 
large volume infusion which was not suitable for infants (Bennett et al., 2007). 
Palivizumab is a humanised monoclonal antibody which is directed against the F 
protein of RSV (Sidwell & Barnard, 2006). Motavizumab (Numax™) is a newer 
version of Palivizumab that is currently in Phase III clinical trials. It has been shown 
to reduce RSV disease with a lower dose than Palizumab (Bennett et al., 2007). Both 
antibodies aim to prevent the spread of RSV to the lower respiratory tract, preventing 
the more severe clinical manifestations of the disease. 
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Several anti-viral compounds intended to treat RSV are also being developed, these 
include: fusion/attachment inhibitors, siRNAs, N-protein inhibitors, viral polymerase 
inhibitors and inosine monophosphate dehydrogenase (IMPDH) inhibitors (Sidwell 
& Barnard, 2006). Ribavririn is currently the only anti-viral compound licensed 
which can be used to treat RSV infection. When phosphorylated, the drug inhibits 
IMPDH mRNA 5’ cap formation and the viral RNA polymerase (Sidwell & Barnard, 
2006). Ribavirin can inhibit RSV replication both in vivo and in vitro, however, it 
appears that the drug is not efficacious when used in infants suffering from severe 
RSV infection, as the clinical course of infection does not improve (Bennett et al., 
2007, Rosenberg et al., 2005). Further studies suggested that the efficacy of ribavirin 
could be improved when used in combination with immunomodulator agents, such as 
anti-MIP-1α, Met-RANTES and montelukast (a cysteinyl leukotriene receptor 
antagonist), as these appear to limit leukocyte recruitment, reducing the 
inflammatory response and thus disease severity (Bonville et al., 2003, Bonville et al., 
2004, Bonville et al., 2006b). Glucocorticoid (steroid) use has also been evaluated 
for the potential to reduce the inflammatory response towards pneumovirus 
infections. However, use of this treatment in the PVM infection model of 
pneumovirus disease has demonstrated that this leads to an enhanced pathology with 
accelerated mortality (Domachowske et al., 2001).  
siRNA may provide a therapeutic treatment in the future. Effective siRNAs have 
been developed that inhibit the expression of the N and P proteins of RSV (Bitko et 
al., 2005, DeVincenzo et al., 2010), which have demonstrated the potential to 
generate an anti-viral effect by reducing RSV replication, allowing time for a strong 
CD8
+
 T-cell response to be stimulated (Zhang & Tripp, 2008). Phase I clinical trials 
with ALN-RSV01, the siRNA directed against the RSV N gene, has shown 
promising results in that the siRNA was well tolerated in adults and demonstrated 
antiviral effects, irrespective of pre-existing neutralising antibody and 
proinflammatory cytokines levels (DeVincenzo et al., 2010).  
 
Although these treatments are available, they are expensive and require 
administration in a clinical setting hence limiting their application. The anti-RSV 
antibody treatment is used prophylactically in high-risk infants to prevent RSV 
infection and ribavirin is reserved for severe infections only. Thus, supportive care, 
such as mechanical ventilation and supplemental oxygen therapy, remain the 
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standard treatment for RSV patients (Rosenberg et al., 2005). It has been observed 
that mechanical ventilation may exacerbate the inflammatory response towards the 
disease, as was demonstrated in the PVM infection model, and thus contributes to 
lung damage (Bem et al., 2009).   
 
To date, no vaccine is clinically available either to treat RSV infection or promote 
the stimulation of a long-lived robust immune response. Several candidates have 
been investigated (Huang, 2009, Karron, 2005, Munoz, 2003, Plotnicky-Gilquin, 
1999), but after the disaster of the FI-RSV vaccine in the 1960s (Kim et al., 1969), 
new candidates are pursued cautiously. A vaccine which could stimulate a long-term 
protective immune response against RSV would be advantageous as it could reduce 
the incidence of severe RSV disease and also may lead to a reduction in the 
development of childhood asthma, thus reducing the disease burden within 
healthcare settings. However, two main issues have prevented a successful candidate 
from reaching the clinic. The first is the failed FI-RSV inactivated vaccine, in which 
disease following infection was exacerbated with disastrous results (Kim et al., 1969), 
and the second is a lack of an amenable animal model within which to directly 
evaluate vaccine efficacy against RSV infection.  
 
1.5.3 PVM infection in mice 
PVM, a natural pathogen of rodents, was first isolated in 1939 during experiments to 
culture human respiratory viruses in mouse lung (Horsfall, 1940). The virus was 
isolated through the passage of lung samples from apparently healthy inbred mice 
into outbred healthy mice. These developed bronchiolitis signs, which progressed to 
a fatal pneumonia in 24% of the animals (Horsfall, 1940). Further study revealed that 
infection was only possible via the intranasal route (Horsfall, 1940). The virus is a 
common pathogen of laboratory animals if suitable precautions are not taken and 
once established, can cause an asymptomatic or mild infection in mice, making it 
difficult to eradicate from laboratory colonies (Horsfall, 1946). More recently, 
serological screening services and test kits have become available to test for the 
presence of PVM in laboratory colonies, resulting in a reduced prevalence of the 
virus. PVM is also a pathogen of wild rodents. One study estimated that several 
different species were seropositive for PVM, including voles and wood mice (Kaplan, 
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1980). Interestingly, analysis of human sera has identified that approximately 80% of 
the population is seropositive for PVM or an antigenically related virus (Horsfall, 
1946, Pringle, 1986). This human seroconversion occurred by 2 years, a similar age 
as RSV, indicating that humans are readily exposed to the infection (Pringle, 1986). 
To date, the clinical relevance of these findings is unknown but the virus is not 
considered to be a burden to the health of the human population.  
Currently, three strains of PVM have been identified and sequenced; PVM J3666 and 
PVM strain 15 (ATCC) are fully pathogenic whereas PVM strain 15 (Warwick) is an 
attenuated form, believed to have arisen through multiple passage in BS-C-1 cells 
(Krempl & Collins, 2004, Randhawa et al., 1995, Thorpe & Easton, 2005). As such, 
the infection of mice by PVM serves as an excellent model for RSV pathogenesis in 
humans.  
 
1.5.4 Pneumovirus in vivo models 
Cell culture systems have proved invaluable for virus characterisation and early 
evaluation of RSV treatments. However, these models lack an immune system and 
are thus inappropriate for vaccine efficacy studies. Potential vaccine candidates for 
RSV have been developed (Section 1.7), but these studies evaluated vaccine efficacy 
in an inappropriate in vivo model, the mouse. This is because mice are at best only 
semi-permissive for RSV infection. They can be infected but do not display outward 
signs of disease. Thus, efficacy must be measured through viral titre reduction, which 
does not correlate with clinical signs (Easton et al., 2004). Neither can RSV vaccine 
candidates be studied in children. Thus, an appropriate in vivo model for RSV needs 
to be developed.   
 
1.5.4.1 RSV in vivo models. 
The main advantage of in vivo models is that the disease process of a pathogen as a 
whole can be investigated, including toxicity and immune responses. In addition, the 
impact of genetic differences within a population on these processes can be 
investigated which would be problematic to study in cell culture.  
Several species have been used to study RSV pathogenesis and also to evaluate 
vaccine candidates including chimpanzee and other primates, bovine, cotton rat, 
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guinea pig and mouse models (BALB/c, C3H and C57BL). Each model has its own 
advantages and disadvantages (Table 1.2). The main argument for the reduction in 
the use of animal models is that the findings within an animal do not necessarily 
reflect the situation in humans. Chimpanzees can be infected with RSV and exhibit 
upper respiratory tract illness but these are the most expensive and ethically 
problematic animal system; other primates also support RSV replication but do not 
demonstrate signs of disease (Belshe, 1977). The advantage of the chimpanzee model 
is that the immune responses of these animals is similar to humans, as opposed to 
rodents which do not always have the same immune genes (Moore & Peebles, 2006). 
Other primates can be used, but again, the immunological reagents available are 
extremely limited when compared to the rodent or chimpanzee model. Such animals 
also require a high inoculum of RSV in order to ensure that infection and viral 
replication occurs, which does not reflect the situation in humans (Simoes, 1999).  
  
The cotton rat model for RSV infection at present remains the best rodent model for 
studying RSV. The main problem with this system is the lack of availability of 
reagents and genetic strains, for which the mouse model is superior. Cotton rats are 
susceptible to both upper and lower respiratory tract infection with RSV, similar to 
that in humans (Prince, 1978). In addition, the immune genes of the cotton rat are 
more similar to those of humans than those within the mouse model. The cotton rat 
genome encodes Mx genes which humans also have and in addition, they also show 
diminished immune responses with increased age (Boukhvalova et al., 2009).  
 
The most commonly used animal model for RSV is the mouse, mainly due to its low 
cost, small size, availability of several genetic strains and wide range of available 
immunological reagents (Table 1.2). These animals are often used as the first stage of 
vaccine development. For some vaccines, successful evaluation in rodent models is 
sufficient to justify a move to human clinical trials. However, the knowledge of RSV 
immunosuppressive and sensitisation functions on the human immune system 
requires that potential candidates are thoroughly tested to ensure safety before use in 
humans. This often involves the use of rodents followed by primates before the 
studies are advanced to human Phase 1 clinical trials. However, despite the stringent 
evaluation of novel therapeutics before human trials, occasionally, the results from 
animals models do not reflect the effects within a human.  
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Type of model Advantages Disadvantages 
Chimpanzee Highly related to humans 
Immunological reagents available 
Similar RSV pathogenesis 
Vaccine enhanced disease observed 
Genetically varied 
Expensive 
Limited availability of animals and facilities 
Genetically varied 
Require high inoculums, 10
4
-10
6
 p.f.u. 
Expensive, ethically problematic 
Bovine (cow) Use of natural pathogen (bRSV) 
Similar disease pathogenesis 
Bronchiolitis develops 
Expensive, ethically problematic 
Limited immunological reagents available 
Bacterial superinfection common and can 
complicate findings 
No inbred strains available 
RSV requires 10
6
 p.f.u. inoculum 
Cotton rat Inbred strains available 
Greater susceptibility to RSV than mice 
Vaccine enhanced disease observed  
Mx genes (these encode proteins which block the 
replication of some viruses) 
Limited immunological reagents available 
Non-permissive for viral replication 
No knockout strains available 
Pneumonia disease rather than bronchiolitis 
RSV requires 10
5
 p.f.u. inoculum 
Guinea pigs Juveniles develop bronchiolitis 
Inbred strains available 
Large size allows repeated measurements 
Suitable for asthma studies 
Similar cost to mice 
Limited immunological reagents available 
No knockout strains available 
Pneumonia disease rather than bronchiolitis 
Mouse Multiple strains available: inbred, transgenic, knockout 
Large range of immunological reagents 
Low cost and easily bred 
Easy to manipulate large colonies 
Vaccine enhanced pathology 
Well defined immunology 
Limited viral replication 
Large dose of RSV required 
No disease observed, only histopathology 
RSV requires 10
6
 p.f.u. inoculums 
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PVM Mouse model As above for mouse model 
Use of natural pathogen (PVM) 
Bronchiolitis disease develops 
Low dose of PVM is required to cause a fatal disease 
Extensive replication of PVM is observed 
Requires 10-60 p.f.u. inoculum 
Regular screening of the colony required to ensure PVM-
free 
Difficulties in using the virus in PVM-free environments 
(may require CAT3 conditions) 
Limited PVM-specific reagents available 
 
Table 1.2. Comparison of in vivo models for evaluation of RSV treatments, including the PVM mouse model (adapted from (Moore & Peebles, 
2006, Stark, 2006). 
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The immune response towards RSV has been extensively researched in mice, of 
which the BALB/c strain was determined to be the most susceptible (Jafri, 2004, 
Moore & Peebles, 2006, Prince, 1979).  However, there are several disadvantages. A 
high dose of RSV is required to achieve infection, which results in only limited viral 
replication as the mouse is at best only semi-permissive to RSV (Bonville et al., 
2006a, Jafri, 2004). In addition, the disease profile of RSV infection in mice is 
inappropriate for pathogenesis studies, as no overt signs of disease develop. More 
importantly for vaccine development, the enhanced disease observed in human 
infants is not replicated in the mouse model (Connors et al., 1992b).  
 
1.5.5 PVM infection model 
Despite the range of animal models available for investigating RSV and potential 
vaccine candidates (Table 1.2), no model is wholly appropriate to study RSV 
infection (Sidwell & Barnard, 2006). This is because these models rely on the 
infection of a host with a foreign, rather than a natural virus, and as such, the disease 
pathogenesis observed is different from RSV in humans. In addition, the adverse 
immune response seen with inactivated RSV means that any vaccine candidate must 
be extensively tested to ensure that no adverse priming of the immune response 
occurs. This would usually involve initial studies in a mouse model, followed by 
evaluation of candidates in chimpanzees prior to clinical trials in humans.  
 
PVM infection of mice offers an attractive alternative model in which to study the 
pathogenesis of pneumoviruses. Importantly, both RSV and PVM cause a similar 
pathogenesis within their respective hosts and are highly similar at the genomic and 
molecular level (Section 1.4) (Cook et al., 1998, Cubie, 1997, Domachowske, 2000a, 
Rosenberg & Domachowske, 2008). Within their respective natural hosts, each virus 
stimulates bronchiolitis, which can also develop into a Th2 driven enhanced disease 
(Barends et al., 2004). PVM has been shown to localise to the bronchiolar epithelium, 
similar to that of RSV in humans (Bonville et al., 2006a, Welliver, 2007). In both 
infections, granulocytes are recruited to the site of infection by MIP-1α and severe 
inflammation occurs (Domachowske, 2000a, Welliver, 2007). The PVM model 
recreates the severe natural RSV infection as observed in humans. High numbers of 
eosinophils are recruited to the lung, characteristic of the Th2 response (Percopo et al., 
  33   
2009). PVM infection in mice therefore represents a good model in which to study 
respiratory virus in its relevant host (Rosenberg & Domachowske, 2008). 
PVM infection of mice only requires small inoculums (10-200 p.f.u.) for disease 
signs to be observed and disease severity is dose-dependent (Bennett, 2007, Cook et 
al., 1998, Moore & Peebles, 2006). The virus takes 4-8 days to reach the maximum 
viral titre, which is again dose-dependent, reductions in titre can therefore be used to 
measure vaccine and anti-viral efficacy (Horsfall, 1951 ). Therefore, through 
identifying and developing effective vaccine candidates against PVM in the PVM 
infection model, it is highly likely that a similar candidate for RSV could be 
successful in humans. (Bonville et al., 2006a, Cook et al., 1998, Rosenberg & 
Domachowske, 2008). 
 
 
1.6  Immune responses to pneumovirus infection 
 
Immunity to viruses requires the immune system to recognise and destroy virus-
infected cells, clearing the virus from the host. This involves the induction of both 
non-specific innate, and specific adaptive, immune responses. Studies of both RSV 
and PVM have concluded that they induce similar immune responses in their 
respective hosts (Collins & Graham, 2008, Faisca et al., 2006, Taylor, 2007). More 
information is available with regards to RSV due to its clinical significance. 
However, despite the wealth of information available, it is still disputed as to whether 
RSV pathogenesis is caused directly by the virus infection or is primarily mediated 
by the adaptive immune response towards it. Such information is useful for the 
development of a safe, effective vaccine to tackle RSV. For the purposes of this 
thesis, the immune responses to RSV and PVM will be briefly discussed but have 
been extensively reviewed elsewhere (Easton et al., 2004, Easton et al., 2007, Taylor, 
2007).  
 
1.6.1 Innate immune responses and pneumoviruses 
Innate immunity is the first arm of the immune response that is stimulated to respond 
to RSV infection. This arm of the immune system does not recognise specific viruses, 
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but rather general viral ‘patterns’ to which it responds (Trinchieri & Sher, 2007). For 
PVM in particular, these responses are powerful enough to control the replication of 
∆NS1/NS2 (attenuated) strains and render them apathogenic (Buchholz et al., 2009).  
 
Upon infection, RSV enters the respiratory tract, where it infects lung epithelial cells. 
This stimulates Toll-like receptors (TLRs); TLR3/9 recognises double-stranded RNA 
and TLR7/8 recognise single-stranded RNA (Kawai, 2008). In particular, the F 
protein stimulates TLR4, triggering a signalling cascade (Faisca et al., 2006, 
Haeberle, 2002). Adapter molecules activate NF-κB and IRF-3/7 transcription factors, 
which travel to the nucleus and promote the transcription of type I IFNs and 
proinflammatory cytokines such as TNF-α (tumour necrosis factor), MCP-1 
(monocyte chemotactic  protein), MIP-1α/β (macrophage inflammatory protein), 
RANTES (regulated upon activation, normal T cell expressed and secreted) and 
interleukins e.g. IL-8, IL-12 and IL-6 (Domachowske, 2000c, van Drunen Littel-van 
den Hurk, 2007, Wang, 2007). The possibility of a protective function of TLR4 in 
response to RSV remains an unresolved issue. One group argued that TLR4-deficient 
mouse strains do not limit RSV replication (Ehl, 2004). Another argued that F 
protein stimulation of TLR4 and CD14 correlates with protective inflammatory 
responses (Kurt-Jones et al., 2000). TLR2/6 have also been linked with protective 
anti-RSV responses mediated through cytokine release (Groskreutz et al., 2006, 
Murawski et al., 2009). RSV is also believed to stimulate Retinoic acid inducible 
gene-1 (RIG-1) (Scagnolari et al., 2009). RIG-1 recognises viral RNA in the 
cytoplasm and undergoes a conformational change allowing it to interact with IFN-β 
promoter stimulator (IPS-1), also known as mitochondrial antiviral signalling 
(MAVS). This also leads to the recruitment of signalling molecules to promote type I 
IFN and proinflammatory cytokine transcription (Yoneyama, 2010). 
  
One of the major cytokines released during the innate response is type I IFN 
(IFNα/β). IFNα/β signal the development of an ‘anti-viral’ state in a host cell. These 
soluble factors can promote this state in neighbouring uninfected cells or enhance the 
response in the same cell through a positive feedback mechanism (Fig. 1.6) (Haller et 
al., 2006). In brief, signalling pathways stimulate NF-κB and other transcription 
factors to upregulate particular genes, such as those encoding 2’, 5’ oligoadenylate 
synthetase, protein kinase R and RNase L, all of which interfere with viral replication 
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(Haller et al., 2006). Also upon RSV infection, cell surface molecules are 
upregulated to aid the recruitment of immune cells to the site of infection (Bueno et 
al., 2008). Major histocompatibility complex (MHC) class I molecules are also 
upregulated, increasing the antigen presentation for immune surveillance (Garofalo 
et al., 1996). IFNα/β promotes a Th1-biased response (Durbin et al., 2002, Johnson et 
al., 2005, Schlender et al., 2000), but additional cytokine release from immune 
effector cells can weaken or alter this bias.  
 
 
 
 
Figure 1.6. The generation of an antiviral state through induction of innate 
immune responses.  
RSV enters a host cell through membrane fusion. Detection of the RNA genomic 
material stimulates immune responses. These trigger a signalling cascade through 
adaptor molecules which results in the stimulation of transcription factors such as 
IRF-3 and NF-κB. These transcription factors can enter the nucleus and up or down 
regulate the expression of specific mRNAs. mRNA for type 1 IFNα/β, along with 
pro-inflammatory cytokines such as IL-1, IL-12 and TNF-α which are also up-
regulated. These cytokines are secreted by RSV-infected cells. Neighbouring cells 
can detect these cytokines and become stimulated to induce an ‘anti-viral’ state. 
However, infected cells are also capable of detecting these secreted cytokines, which 
therefore function as a positive feedback mechanism to further stimulate the 
induction of an antiviral state.  
 
 
  36   
The cytokine and chemokine profile generated upon RSV infection is one of the most 
powerful responses of the immune system and links the innate and adaptive response 
together. Numerous studies have attempted to define the cytokine release profile 
following RSV infection in efforts to identify biomarkers to measure disease severity 
and anti-viral targets. The cytokine profile determines the character of the adaptive 
response generated towards RSV infection in mice and humans (Bennett, 2007). 
Evidence suggests that the cytokine response may mediate RSV 
immunopathogenesis (Culley et al., 2006, Hornsleth, 2001). This includes: infants 
with severe RSV disease had elevated MIP-1α and MCP-1 levels, stimulating a Th2 
CD4
+
 biased response, whereas those with milder infections had reduced levels of 
these cytokines and a Th1 CD4
+
 biased response (Garofalo, 2001, McNamara, 2005). 
Additionally, during PVM infection, cytokine levels remained high after replicating 
virus was no longer detected, yet clinical signs persisted (Bonville et al., 2006a). 
Similar to RSV infection in humans, a more severe PVM infection of mice is 
associated with higher levels of MIP-1α (Domachowske, 2000a, Domachowske, 
2000b). RSV-infected mice also produce MIP-1α but this is not associated with 
effector cell recruitment and protection (Domachowske, 2000c). However, blocking 
MIP-1α in PVM-infected mice was associated with increased mortality from greater 
viral replication (Domachowske, 2000a). Furthermore, in PVM-infected mice, MIP-
1α in conjunction with IFNγ was required for efficient recruitment of adaptive 
effector cells such as neutrophils and eosinophils to the site of infection, which were 
associated with minimal disease signs (Bonville et al., 2009). 
 
Cytokines released from RSV infected cells, activated professional antigen 
presenting cells (APCs) such as DCs or activated CD4
+
 and CD8
+
 cells and recruit 
eosinophils and neutrophils to the site of infection (Bonville et al., 2009, 
Domachowske, 2000b). The recruitment of eosinophils and the protective or non-
protective role they may play is still unresolved. Eosinophils are typically associated 
with an allergic immune response, driven by Th2 CD4
+
 T-cells (Rosenberg et al., 
2009a, Rosenberg et al., 2005, Rosenberg & Domachowske, 2001, Rosenberg et al., 
2009b). They release enzymes that damage epithelial cells, whether RSV infected or 
not, which leads to airway damage and hypersensitivity to RSV (Rosenberg et al., 
2009b). In addition, Garofalo et al demonstrated that eosinophils recruitment was 
greater in severe RSV infections than those with milder disease (Garofalo, 1992) and 
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Harrison et al also demonstrated eosinophils were actively recruited to the lung 
during severe RSV infection (Harrison et al., 1999).   
 
Several studies suggest eosinophils play a protective role during pneumovirus 
infection. One study suggested that eosinophils reduced the infectivity of RSV for 
their target cells in vitro (Domachowske, 1998); another indicated that RSV and 
PVM can infect and replicate in eosinophils which was associated with reduced lung 
damage (Dyer et al., 2009, Kimpen, 1996). Furthermore, Castilow et al argued that 
although stimulated, eosinophils do not contribute to severe disease and that it is a 
Th1- rather than a Th2-driven response which correlated with disease signs (Castilow 
et al., 2008). Domachowske et al demonstrated that the use of glucocorticoids in 
PVM-infected mice reduced eosinophils but clinical signs remained (Domachowske 
et al., 2001, Domachowske, 2000a, Domachowske, 2000b). Neither were these cells 
able to clear RSV from infected mice, a result which may represent a fundamental 
difference between the infection of mice with RSV and PVM (Rosenberg et al., 
2009b). 
 
Other immune cells recruited to the sites of pneumovirus infection include natural 
killer (NK) cells, granulocytes and DCs (Domachowske, 2000b, Garofalo, 1992, 
Harrison et al., 1999). Arguably, the most important of these are the DC, which are 
professional APCs that are able to activate B-cells and CD4
+
 and CD8
+
 T-cells. They 
are recruited to the lung upon RSV infection where they acquire RSV antigen and 
migrate to lymphoid tissues to stimulate adaptive immune responses. At the site of 
infection, they themselves can release cytokines, such as IL-12, to stimulate NK cells. 
This cytokine can also modulate the differentiation of CD4
+
 cells, discussed later in 
Section 1.6.2.2.2. IL-12 biases the differentiation of CD4
+
 cells to the Th1 pathway. 
RSV has been demonstrated to have anti-IL-12 effects, which therefore bias CD4
+
 T-
cell differentiation away from Th1 and towards Th2 pathway in mice (Bartz et al., 
2003) and infants (Wang & Harrod, 2006). This cytokine is also associated with viral 
control as IL-12 deficient mice have a reduced ability to clear RSV due to impaired 
NK cell responses (Ehl, 2004).  
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1.6.2 Adaptive responses and pneumoviruses 
The adaptive immune response provides an ability to control and overcome a wide 
variety of pathogens, concurrently stimulating memory towards those pathogens. 
There are two main effector cells types of the adaptive response, B-cells, which 
release antibodies, and T-cells, of which CD8
+
 T-cells mediate cellular destruction 
functions and CD4
+
 T-cells modulate the overall immune response to a pathogen 
through cytokine release. The adaptive response has been associated with 
immunopathogenesis of RSV (Openshaw & Tregoning, 2005), which is directly 
affected by age, genetics and overall wellbeing of an individual (Openshaw & 
Tregoning, 2005).  
 
1.6.2.1 The humoral immune response 
The humoral response is not essential for the resolution of primary infections, 
however it does protect against re-infections for most pathogens (Hacking & Hull, 
2002). Usually, RSV infections can occur in the presence of pre-existing antibody 
suggesting that the induced immunity is transient (Sullender, 2000). B-cells are 
activated through recognition of viral peptide antigen presented by MHC class II 
molecules. Recognition is achieved either through DC or CD4
+
 T-cells, by a process 
described in Fig. 1.7. Activated B-cells can then secrete antibodies against RSV 
antigen, the isotype of which is determined by the CD4
+
 T-cell secreted cytokine 
profile.  
 
IgG, IgM and IgA antibodies are produced in response to RSV infection and are 
found in both the lungs and blood (Brearey, 2007, Collins & Graham, 2008, Welliver, 
1980). The antibody response is primarily directed against the F and G proteins, to 
which a neutralising antibody response is generated (Simoes, 1999). Non-
neutralising antibodies are also raised against the N and P proteins (Connors et al., 
1992a). Antibodies generated against the F protein are cross-reactive between 
different RSV strains, due to the highly conserved nature of the F1 protein subunit 
(Johnson et al., 1987, Muelenaer, 1991, Shao et al., 2009). In contrast, the G protein 
is antigenically variable as there is >20% amino acid variation within a subtype and 
50% variation between the two RSV subtypes (Cane, 2001, Easton et al., 2004, 
Hacking & Hull, 2002). The C-terminus of the G protein is external on the virion and 
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is a target of the antibody response. Glycosylation of this region can mask the 
epitopes, preventing the antibody response from neutralising the virus (Cane, 1997). 
In addition, the G protein can exist in a truncated, soluble form. This is secreted from 
virus-infected cells and is believed to act as decoy to subvert the immune response in 
humans. In mice however, secreted G protein does not appear to act in this way, 
perhaps because RSV is not replication permissive in mice or because the protein is 
not produced in sufficient quantities (Bukreyev et al., 2008, Cane, 2001). Infants 
under 8 months of age do not develop anti-RSV neutralising antibodies to either the 
F or G protein, partly due to the presence of maternal antibody and partly due to the 
immaturity of the immune system (Crowe, 2003). However, the IgG response to 
these proteins increases with age upon each subsequent infection (Welliver, 1980).  
 
 
Figure 1.7. Stimulation of B-
cells by T helper CD4
+
 cells.  
Viral antigen is processed by 
B-cells and displayed on the 
surface in complex with MHC 
Class II molecules (red). This 
also leads to up-regulation of 
co-stimulatory receptors. CD4
+
 
T-cells recognise the MHC-
peptide complexes on the B-
cell through the TCR (brown). 
The Th CD4
+
 T-cell is further 
stimulated by interaction with 
co-stimulatory molecules such 
as CD40-CD40L, and B7-
CD28 interactions. This in turn 
activates the CD4
+
 T-cell, 
resulting in cytokine release, 
such as IL-2, IL-4 and IL-5. 
These cytokines promote B-cell 
differentiation and proliferation 
into antibody-secreting cells. 
The particular cytokine profile 
released can affect the antibody 
isotype produced by the B-cell. 
For example, IgA can be 
secreted by epithelial cells and 
is associated with mucosal 
immunity, whereas IgE is 
associated with allergic responses.  
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1.6.2.2 The cellular immune response  
The cellular immune response is important for combating many viral infections, such 
as herpes simplex virus (HSV) (Khanna, 2003). This arm of the adaptive immune 
response has two main effector populations: CD8
+
 T-cells which mature into 
cytotoxic T lymphocytes (CTLs), which mediate cell lysis effector functions; and 
CD4
+
 T-cells which modulate the overall immune response. Both cell populations 
can only mediate their effector functions when stimulated by interaction with cell 
surface MHC molecules that are complexed with specific antigen peptide (Fig. 1.8).  
 
Briefly, for the stimulation of T-cells, antigen is acquired by an APC either from 
external sources (through phagocytosis of apoptotic cells or antibody complexed 
with pathogens), or from internal sources, such as by direct infection of a cell or 
synthesis of viral proteins. Antigen is then processed by one of two pathways. 
Internally derived antigen enters protein degradation pathways (Fig. 1.8) and the 
resulting peptide fragments are transported to the ER, where they can bind to the 
peptide binding groove of MHC class I molecules. This triggers MHC transport to 
the cell surface where the stable antigen-MHC complexes are displayed for 
recognition by CD8
+
 T-cells, APCs and NK cells. All cells express MHC class I 
molecules, including immune cells. Thus, MHC class I molecules are the primary 
immune surveillance complexes. Externally derived antigen is mainly complexed 
with MHC class II molecules, which are only found on immune cells, such as DCs 
and CD4
+
 T-cells. Antigen is acquired by these cells and undergoes proteolytic 
cleavage in proteosomes. MHC class II molecules are assembled in the ER and are 
released into the cytoplasm within endosomes which eventually fuse with the 
vesicles containing the proteosome cleavage products, where peptide fragments can 
potentially bind (Fig. 1.8). Stable antigen-MHC class II complexes form and are 
transported to the cell surface for immune surveillance. APCs, such as DCs, are 
particularly important cells in the immune system as they can prime both CD4
+
 and 
CD8
+
 T-cells through the expression of both types of MHC molecule. Upon 
acquisition of antigen, DCs localise in lymphoid issues and activate T-cells using 
multiple receptor-ligand interactions (Fig. 1.9).  
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Figure 1.8. MHC Class I and II pathways for antigen presentation.  
MHC Class II: Viruses in complex with neutralising antibody are recognised by 
APCs and enter the cells by endocytosis. The proteins are degraded into peptide 
fragments in endosomes, by enzyme such as cathepsins, and in lysosomes. The MHC 
class II molecules are synthesised, folded and assembled in the ER. They are then  
transported through and bud from the Golgi network in exocytic vesicles. The 
vesicles fuse with the endosome/lysosome vesicles containing the peptide fragments. 
To prevent the MHC class II molecules binding peptide in the ER, they associated 
with the invariant chain (Ii) protein which blocks the peptide binding groove. Once 
the exocytic vesicles fuse with the acidic endosomes, proteolytic enzymes digest the 
Ii leaving a protein called CLIP in the peptide binding groove. CLIP is removed 
through HLA-DM activity. This protein removes CLIP whilst simultaneously 
promoting peptide binding to the MHC class II molecule. The binding of peptide to 
the MHC molecule stabilises the complex, allowing it to be transported and 
displayed upon the cell surface for recognition by CD4
+
 T-cells. MHC Class I: 
Some viruses can enter the cell via endocytosis or fusion with the cellular membrane. 
Once within the cell, they are able to utilise the host cellular machinery to replicate 
and translate their genomes. This leads to the synthesis of viral proteins which can 
become ubquitinated by host cellular processes. This signals their degradation by the 
proteosome. The peptides are then transported into the ER via a transporter molecule 
known as TAP. Newly synthesised MHC class I molecules are non-covalently bound 
to TAP allowing transported peptides to bind efficiently to the peptide binding 
groove. Once bound, the peptide stabilised the MHC class I molecule, it dissociates 
from TAP and exits the ER and Golgi via exocytic vesicles. The complex is 
transported to the cell surface where it can be recognised by CD8
+
 T-cells.  
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Figure 1.9. APC activation of T-cells.  
APCs process and thus present antigen on 
both MHC class I and II molecules for T-
cell immunosurveillance. The T-cell 
receptor (TCR) on a T-cell binds in a weak 
and transient manner to a MHC molecule. If 
the TCR is specific for a peptide-MHC 
complex, the interaction becomes stronger 
and longer in duration (A). This triggers co-
receptors such as CD40L and CD28 to be 
localised to the TCR-MHC complex (B). 
CD40L binding to CD40 on an APC 
stimulates that cell to increase the 
expression of B7 molecules and IL-12 
secretion (C). B7 can bind to CD28 at the 
TCR complex which activates the T-cell to 
mediate its effector functions. It also 
stimulates proliferation, ensuring that 
sufficient numbers of that T-cell clone are 
available to mount a response. Other 
cytokines are released which can determine 
CD4
+
 T-cell differentiation, specifically 
IFNγ for Th1 and IL-4 for Th2.  
 
 
 
 
 
 
 
The cellular response mediates pneumovirus clearance and provides immunological 
memory against subsequent infection (Crowe, 2003). Therefore, stimulation of the 
cellular response is important to control pneumovirus infection, both in mice 
(Cannon, 1988, Graham, 1991) and humans (Fishaut, 1980, Hall, 1986). Evidence 
supporting this includes: individuals with T-cell deficiencies have severe and long-
lasting RSV disease and adults with a strong T-cell response have milder RSV 
infections (Hall, 2001a, Simoes, 1999); vaccine candidate BBG2Na generated CD4
+
 
T-cell dependent immunity (Plotnicky-Gilquin et al., 2000); T-cell deficient mice fail 
to eliminate PVM and often become carriers in the absence of disease, and animals 
with limited T-cell numbers are associated with limited pathology (Frey et al., 2008); 
and RSV-specific memory T-cells can persist in the lung over the long-term and can 
  43   
respond rapidly to subsequent re-infection (Ostler, 2001), indicating the role of these 
cells in the generation of pneumovirus immunopathology and immunity. 
 
1.6.2.2.1 The role of CTLs in pneumovirus infection 
CTLs are activated CD8
+
 T-cells. They recognise specific antigen class I MHC 
complexes which triggers them to induce apoptosis in the cell displaying the 
complex through enzyme release. CTLs form part of the protective response that 
develops as part of a Th1-biased CD4
+
 response. They secrete IFNγ which promotes 
Th1 and suppresses Th2 responses. The CTL response is vital against RSV, as the 
virus can evade neutralising antibody responses by facilitating cell-cell fusion as a 
means of spread in the host (Ostler, 2002). For RSV, CTLs with specificity for the 
NS2, N, M, SH and F proteins have been identified, with the N protein being a 
dominant target, but none specific for G and P proteins were detected in humans 
(Alwan et al., 1993, Cherrie et al., 1992, Corvaisier, 1993, Srikiatkhachorn & 
Braciale, 1997). In BALB/c mice, the M282-90 epitope was dominant, and suppressed 
the establishment of other immunodominant clones (Kulkarni et al., 1995, Mok et al., 
2008, Openshaw, 1990). F85-93 and N were other CTL epitopes recognised in both 
RSV-infected BALB/c mice (Chang et al., 2001, Pemberton et al., 1987) and bRSV-
infected cows (Gaddum, 1996). For PVM, CTL epitopes P261-269, M43-51 and F302-312 
have been identified experimentally in mice, in addition to a theoretical one in the N 
protein (Claassen et al., 2005).  
 
Although the main role of CTLs is beneficial, CTLs are also thought to mediate 
immunopathologic effects, with indications that a strong CTL response led to fatal 
lung damage in RSV-infected mice (Cannon, 1988, Simmons et al., 2001). Activated 
CTLs also release IFNγ which is associated with both protection and airway 
obstruction in RSV infected mice (van Schaik, 2000). However, evidence also exists 
which suggests that CTLs are not primary mediators of pneumovirus pathogenesis. 
These include studies which demonstrated that CTLs were recruited to the lungs only 
after severe infection has passed (Chiba, 1989, Lukens et al., 2010). RSV-specific 
CD8
+
 T-cells were shown to persist in local and systemic tissues long after disease 
signs had diminished (Ostler, 2002). Furthermore, a study in human infants 
suggested that severe RSV infection was characterised by an inadequate rather than a 
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robust, T-cell response (Welliver, 2007). Therefore, the balance between stimulation 
and suppression of the CTL response may be important for disease severity.  
 
1.6.2.2.2 The role of CD4+ cells in the response to pneumoviruses 
CD4
+
 T-cells modulate the overall immune response towards a pathogen. They 
achieve this through complex cytokine expression profiles and presentation of 
antigen to CD8
+
 T-cells and B-cells. CD4
+
 cells are initially activated by APCs that 
release cytokines which promote the establishment of either a Th1 or Th2-biased 
CD4
+
 response (Fig. 1.10). IL-12 and IFNγ from DCs, infected cells and other APCs 
stimulate Th1 activation and Th2 suppression. Th1 cells can then release similar 
cytokines, which activate CTLs, NK cells and macrophages. B-cells are stimulated to 
release IgA and IgG antibody isotypes. However, if eosinophils or mast cells are 
recruited to the site of infection, they release both Th2 promoting and Th1 
suppressing cytokines such as IL-10, IL-4, IL-5 and IL-13. Th2 CD4
+
 T-cells can 
then release similar cytokines and activate eosinophils, mast cells and promote B-cell 
antibody isotype switching to IgE. This response is associated with inflammation and 
leads to sensitisation; such a response is stimulated in allergic responses, such as for 
asthma.  
 
CD4
+
 T-cells are thought to exert both protective and exacerbative roles in 
pneumovirus infected individuals; therefore a careful balance between the two must 
be established (Alwan, 1992). This balanced is determine by the cytokine secretion 
profile of the immune cells and locally infected cells (Becker, 2006, van Drunen 
Littel-van den Hurk, 2007). Pneumoviruses typically stimulate Th1-biased responses 
which facilitate recovery and immunological memory towards the infection (van 
Drunen Littel-van den Hurk, 2007). It has been shown in the mouse model of RSV 
infection that initial infection stimulates a balanced Th1/ Th2 response, which usually 
later shifts to be Th1 dominant (Matsuse et al., 2000b). However, in some individuals 
severe RSV disease can develop that is associated with a Th2-biased response; 
sensitised animals initially develop Th1 responses, but these become Th2 dominant 
with subsequent infections (Dakhama, 2004, Matsuse et al., 2000a). This can occur 
through blocking of IFNγ secretion (Bartz et al., 2003).  
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Figure. 1.10. 
Differentiation of Th 
CD4
+
 T-cells. CD4
+
 T-
cells exist in separate 
subsets each associated 
with their own unique 
effector functions. 
Naive CD4
+
 cells are 
stimulated by APCs 
displaying antigen. 
The release of IL-2 
stimulates the naive 
cells to become 
activated and 
proliferate. The 
proliferating CD4
+
 
population relies on 
cytokine signals from 
the surrounding 
environment to 
determine the 
differentiation pathway 
stimulated. The 
cytokines can come 
from cellular sources 
or other activated APC 
cells. Cytokines such 
as IFNγ and IL-12 
stimulate the Th1 
subset and inhibit the 
differentiation of the 
Th2 subset. Conversely, 
the Th2 subset is 
stimulated by IL-4 and 
inhibits Th1 differentiation through IL-10 release. The differentiated T-cells use a 
positive feedback mechanism to further stimulate the differentiation pathway as they 
can respond to the cytokines they generate. 
 
 
Th2-biased responses are associated with high levels of eosinophils and 
proinflammatory cells in infected tissues in humans (Kim et al., 1969). This can lead 
to sensitisation to the virus, which leads in turn to stronger CD4
+
 responses upon 
subsequent infections (Domachowske, 1999, Graham, 1993). Infants who suffer 
severe infections demonstrate decreased Th1 and increased Th2 responses towards 
RSV, so that with each subsequent infection, severe disease occurs (Castro, 2008). 
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Th2-biased responses towards pneumoviruses have been associated with a higher risk 
of asthma development in children, which was linked to first age of infection rather 
than cytokine levels (Castro, 2008). 
CD4
+
 T-cell epitopes for RSV have been identified in the N, P, M and G proteins 
(Alwan et al., 1993, Liu et al., 2009). Experiments performed with the F, M and G 
proteins have identified the M213-223 and G381-385 epitopes which stimulated a Th1-
biased response (Claassen et al., 2007, Liu et al., 2009). Further studies demonstrated 
that Th2-biased response was stimulated when G and SH proteins were investigated 
(Connors et al., 1992a, Elliott et al., 2004). Yet the G protein in particular appears to 
be able to stimulate a mixed Th1 and Th2 response (de Graaff, 2004, de Waal, 2004). 
 
1.6.2.3  T-cell response impairment by pneumoviruses 
Animal models of pneumovirus infection demonstrated that T-cells are able to 
differentiate into memory cells that remain in the local mucosa and can be 
reactivated in response to subsequent infection. In humans, as re-infections occur 
regularly in spite of neutralising antibody and T-cell driven responses, partly due to 
RSV subtype antigenic variation and partly suggesting memory T-cell reactivation 
was impaired. One study supported RSV-specific memory cell impairment. Although 
they can be reactivated in response to specific antigen, they do not produce IL-12 
which is needed to promote the maintenance and differentiation of long-lived 
memory T-cells (Richter et al., 2005). T-cell impairment does occur naturally with 
age. This has been shown to correlate with decreased CD28 expression on memory 
T-cells (Effros, 2007). It has been suggested that these cells can have a suppressive 
effect on the general T-cell population, perhaps explaining why elderly persons are 
less able to respond to infection (Looney, 2002).  
An interesting feature of pneumovirus pathogenesis is the ability of these viruses to 
impair pulmonary responses of both CD4
+
 and CD8
+
 T-cell populations (Effros, 
2007, González, 2009). Other paramyxoviruses have been shown to demonstrate 
similar effects (Gray et al., 2005). Such an effect would be beneficial to the virus as 
it would delay viral clearance and ensure efficient viral replication. Studies have 
shown that RSV-infected mice generate large numbers of virus specific CD8
+
 T-cells 
(Chang & Braciale, 2002, Chang et al., 2001), similar to other paramyxoviruses 
(Fulton et al., 2008). However, these cells are suppressed by replicating virus, either 
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through NS protein function or through an alternative mechanism such as T-cell 
exhaustion (Bucks, 2009, Chang & Braciale, 2002, Chang et al., 2001, Mueller, 
2009). As a result, these cells do not persist in lymphoid tissues in the long term and 
only secrete low levels of IFNγ. In one study, RSV specific T-cells were shown to be 
functionally impaired in cytokine production (Chang & Braciale, 2002, Chang et al., 
2001). Similar results were found using PVM (Claassen et al., 2005) and bRSV 
(Keles, 1999). Likewise, a study of M2 protein-specific T-cell responses to RSV, 
suggested that long-term T-cell mediated immunity was not stimulated and rapidly 
waned (Kulkarni, 1993). Also, the RSV F protein can directly inhibit T-cell 
proliferation by an unknown mechanism (Schlender et al., 2002). In the case of PVM, 
specific CD8
+
 T-cell responses were found to be only partially activated, with only 
10-20% of these cells producing IFNγ upon stimulation (Claassen et al., 2005). In 
addition, Treg cells may play a role in T-cell suppression as one study showed that 
Treg cells can lower the number of RSV-specific CD8
+
 T-cells that survive into the 
memory phase and thus may decrease the immune memory of RSV (Ruckwardt et al., 
2009). Also, cytokines such as IFNα and IFNλ have been linked to RSV CD4+ T-cell 
suppression (Chi et al., 2006), as have healthy lung epithelial cells through their 
direct contact with RSV-specific T-cells preventing cytokine release (Wang et al., 
2009). Clinically, these various mechanisms of T-cell suppression could explain the 
high rate of re-infection by RSV. Additionally, if RSV specific CD8
+
 responses can 
be increased through immunisation for example, it could reduce Th2 CD4
+
 
differentiation which improves the hosts immune response to RSV, allowing 
clearance from the virus, suggesting that the immunosuppressive effect of RSV could 
contribute to the severe disease observed (Olson, 2008, Srikiatkhachorn & Braciale, 
1997). This suppressive effect has been overcome experimentally using IL-2, 
suggesting therapeutic potential for this cytokine (Chang & Braciale, 2002). 
 
1.6.2.4 Summary  
The immunopathogenesis of the pneumoviruses is due to several factors (Fig. 1.5). 
Cytokines play a role in determining the nature and intensity of the immune response 
particularly for CD4
+
 T-cell mediated functions. Neutralising antibody does not 
exacerbate infections but neither does it appear to correlate with protection. In 
contrast, T-cells have been shown to be essential for the clearance of the virus, but 
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are also associated with the development of severe disease (Fig. 1.5). It is unknown 
whether the T-cells mediate the severe disease directly or whether the cytokines they 
release play a more dominant role. Interestingly, different viral proteins appear to 
prime different responses in infants and mice, even when delivered via the same 
route (Alwan et al., 1993). Therefore, the appropriate antigen must be chosen to 
ensure that the correct immune response is stimulated. It is likely that protective 
immunity to pneumoviruses requires CD4
+
 and CD8
+
 T-cell responses as CD8
+
 
responses can be improved with CD4
+
 stimulation (Claassen et al., 2007). Therefore, 
controlled stimulation of CD4
+
 T-cells by a vaccine could mediate a protective anti-
pneumovirus response, through CTL and B-cell effector functions (Claassen et al., 
2007). Thus, the immune response to pneumovirus relies on the complex interplay 
between multiple cell types and the cytokine profile they secrete (Fig. 1.5 and 1.10). 
This results in a delicate balance between protective CD8
+
 and Th1 CD4
+
 T-cell 
responses and allergic eosinophils and Th2 CD4
+
 T-cell responses.  
 
 
1.7 RSV vaccine development 
  
The overall cellular response to pneumovirus infection is complex as illustrated in 
Fig. 1.5. The complexity of the immune response for RSV has direct implications for 
RSV vaccine development. This has been greatly hindered since the 1960s FI-RSV 
vaccine trial (Crowe, 2001). It is thought that the protective CD8
+
 and Th1 CD4
+
 
response was overwhelmed by a Th2 CD4
+
 response which led to severe disease 
(Tripp et al., 1999). An RSV vaccine must be able to stimulate a protective adaptive 
immune response which is Th1-dominant or Th1/Th2 balanced. As mentioned 
previously, the particular pneumovirus protein used to induce a response and the 
delivery method can greatly influence the nature of the response. A vaccine must 
contain a strong CD8
+
 T-cell epitope to ensure clearance and protection from the 
virus which would provide internal antigen processing (Fig. 1.8). However, 
appropriate CD4
+
 T-cell stimulation is also required to maximise CD8
+
 responses 
and prevent Th2 allergic responses from being established. The stimulation of 
neutralising antibody does not appear to correlate with protection and therefore 
should not be the focus of an RSV vaccine.  
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From this understanding of the immune response, it is evident that an appropriate 
vaccine candidate would achieve expression of one or more full length RSV proteins 
directly in a cell, for example from an adenovirus vector. The T-cell response would 
naturally focus on the immunodominant epitope(s) and as the entire protein is 
expressed, antibodies may be induced as well. The use of a full length protein 
containing several epitopes would also circumvent the issue of variable MHC 
haplotype within the population.  
 
A vaccine to be used in infants must be able to overcome any maternal immunity 
(Collins, 2007). This is likely to be achieved by a T-cell targeted vaccine. Coupled 
with this, infants have immature immune systems and cannot readily respond to 
pathogens as adults can. This was noted in a clinical trial of a vaccine candidate 
where infants under 6 months did not mount immune responses whereas older 
children did (Karron, 2005). Young children are also particularly vulnerable to 
developing a Th2 biased immune response, which can be stimulated by certain 
vaccines as the FI-RSV trial demonstrated. Therefore, any vaccine candidate must be 
stringently tested to ensure that such a response is not mounted in this population. 
The vaccine itself must not interfere with other paediatric vaccines (van Drunen 
Littel-van den Hurk, 2007). 
 
Live vaccines as opposed to inactivated vaccines have been demonstrated to be more 
appropriate for stimulating balanced Th1 responses against RSV. The data from a 
study examining the difference in immune response stimulation using different 
prime-boost strategies with either killed or live RSV indicated that the resulting 
cytokine profile of the response was initiated through the prime vaccine dose, as 
killed vaccine generated a Th2-biased response whereas the live virus stimulated a 
Th1-dominant response (Tang, 2004). Vaccines containing a live viral element 
generated CTL responses and had reduced viral replication, with live vaccine prime 
and boost immunisation regimes stimulating the best immune response (Tang, 2004). 
The ideal RSV vaccine candidate would therefore consist of a live, attenuated virus 
which was able to replicate to a high titre, ensuring the high immunogenicity was 
retained. However, due to the difficulties with the vaccine-enhanced disease, more 
focus has been placed on subunit vaccines or live viral vectors expressing full length 
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proteins or peptides. The various previous attempts to develop an RSV vaccine are 
considered below. 
 
1.7.1 Inactivated RSV vaccines 
The first RSV vaccine candidate, a formalin-inactivated whole virus preparation (FI-
RSV), was used in a clinical trial in the 1960s. The vaccine successfully immunised 
all individuals however the immune response was skewed towards a Th2 CD4
+
 T-cell 
response. Subsequent natural RSV infection was thus more likely to develop into 
severe RSV disease. During clinical trials, this led to the hospitalisation of 80% of 
the vaccines, compared to 5% of the control group (Girard et al., 2005, Kim et al., 
1969, Kneyber, 2004). As a result of this, two infants died. Therefore, an 
understanding of the molecular mechanisms behind this tragedy has been greatly 
aided through the use of animal models. In summary, it has been demonstrated that 
the Th2 CD4
+
 response was greatly enhanced through the disruption of antigen by the 
inactivation process (Openshaw, 2002, Prince et al., 2001). A more recent study has 
suggested that the response was caused by the maturation of antibodies which had a 
low affinity for the RSV antigens, due to poor activation of TLRs. These antibodies 
were non-protective and promoted the development of a Th2-biased response 
(Delgado et al., 2009).  
 
1.7.2 RSV subunit vaccines 
RSV subunit vaccines are attractive candidates as particular proteins can be used to 
immunise animals to ensure the stimulation of an appropriate immune response, 
without the need for the use of live virus. Subunit vaccines are often composed of the 
F and G proteins. These stimulate neutralising antibody, however they do not 
stimulate CD8
+
 T-cells responses and thus are unlikely to be appropriate vaccines to 
stimulate lasting immunity to RSV (Kneyber, 2004). As a result, subunit vaccines are 
often used in conjugation with adjuvant agents such as alum and cholera toxin, which 
have had limited success.  
 
RSV proteins can also be engineered to improve their immunogenicity. One such 
study fused a fragment of the G protein with Protollin adjuvant (Huang, 2009); 
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which promotes processing by the proteosome and hence antigen presentation. 
Intranasal delivery of the vaccine resulted in the stimulation of both IgG and IgA 
humoral responses towards the RSV G protein, but also reduced IL-13 expression 
which led to a decrease in eosinophil recruitment (Huang, 2009). Similarly, Protollin 
has been used as an adjuvant for an intranasal vaccine enriched with the F and G 
RSV proteins (eRSV). The eRSV vaccine with protollin adjuvant was successful in 
that intranasal immunisation in mice stimulated IgG and IgA antibody production 
and a Th1 CD4
+
-biased T-cell response, but the mice did have high IL-5 levels 
suggesting a Th2 response was also stimulated (Cyr et al., 2007a, Cyr et al., 2007b). 
Liposome-encapsulated dichloromethylenediphosphonic acid (DMDP) vaccine, 
which are viral proteins contained within a liposome capsule, have also been 
investigated for these proteins (Benoit et al., 2006).  
 
An alternative vaccine candidate used the RSV G and M2 proteins fused to a HSP70-
like protein. Subcutaneous immunisation of mice revealed that this vaccine 
stimulated stronger CD8
+
 T-cell and neutralising antibody responses than a non-
conjugated version (Zeng et al., 2008). In addition, the CD4
+
 T-cell response was 
Th1/ Th2 balanced, indicating that the vaccine did not prime for severe RSV disease 
in the animals (Zeng et al., 2006, Zeng et al., 2008). RSV F412-524 protein has also 
been complexed with cholera toxin as an adjuvant. When used to immunise mice 
intranasally, IgA and IgG neutralising antibody responses were stimulated along with 
a Th1-biased, but Th1/Th2 mixed CD4
+
 T-cell response. These data correlated with 
protection and demonstrated that recombinant subunit vaccines could be used to 
stimulate adequate mucosal immunity (Singh et al., 2007). Furthermore, the M282-90 
peptide of RSV has been fused with the E.coli heat-labile toxin and has been shown 
to stimulate CD8
+
 T-cells responses to the epitope which correlated with protection 
from the virus, but also with enhanced weight loss during viral challenge (Simmons 
et al., 2001). 
 
VLPs have been investigated as potential vaccines for RSV. One study used 
Newcastle disease virus, which is an avian paramyxovirus, to form VLPs which 
contained the G protein of RSV. Several intraperitoneal or intramuscular 
immunisations with this vaccine resulted in protection against RSV and the induction 
of moderate titres of neutralising antibody with no evidence of an enhanced 
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pathology (Murawski et al., 2010). Influenza A virus has also been used as the basis 
for an RSV subunit vaccine. Influenza virosomes were reconstituted with RSV F 
protein and used to immunise mice intramuscularly, resulting in the generation of 
neutralising antibody towards the F protein (Nallet et al., 2009). These candidates 
have yet to enter clinical trials. In addition, a lipopeptide-adjuvanted RSV virosome 
candidate has recently been demonstrated to induce high levels of neutralising 
antibody, coupled with a balanced Th1/ Th2 response in mice and cotton rats 
(Stegmann et al., 2010).  
 
Two further strategies which have been trialled were the  BBG2Na and PFP vaccines. 
BBG2Na is a G protein subunit vaccine which was able to induce neutralising 
antibodies but also biased the immune response to a Th2 response through IL-4 
release and stimulation of IgE. In addition, limited CD8
+
 T-cell activation was 
observed and thus the candidate was discontinued after Phase III clinical trials 
(Collins, 2007, Kneyber, 2004, Plotnicky-Gilquin, 1999, Plotnicky-Gilquin et al., 
2000). PFP-1, PFP-2 and PFP-3 are a range of peptide vaccines generated from 
purified F and G proteins that also gave poor results in trials. PFP-1 was first 
investigated in infants, where neutralising antibody was stimulated but immunisation 
was associated with upper respiratory tract signs which were unacceptable in such 
young infants (Kneyber, 2004). PFP-2 contains a greater amount of purified F 
protein than PFP-1. This was investigated for use in maternal immunisation 
programmes with the aim of stimulating the immunity of the foetus and infant 
through mother’s milk. However, although the vaccine was well tolerated and safe, 
the vaccine was only slightly immunogenic (Munoz, 2003). PFP-3 underwent 
clinical trials in cystic fibrosis patients, where it was deemed to be well tolerated and 
safe. 67% of vaccinees demonstrated a rise in neutralising antibody titre, however, 
this was not statistically significant when compared to control groups (Polack, 2004).  
 
1.7.3 Nucleic acid RSV vaccines 
These vaccines comprise DNA copies of RSV sequences cloned within a plasmid 
vector, allowing the antigen to be expressed by cells of the vaccine in its natural state 
as opposed to a modified form due to inactivation methods. One study used RSV F 
DNA plasmids to immunise mice intramuscularly. This resulted in the generation of 
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neutralisation antibody responses including IgG and IgA, and a mixed Th1/ Th2 CD4
+
 
T-cell response which correlated with protection from RSV (Wu et al., 2009). 
Another study used chitosan-encapsulated DNA of the F, M2 and G genes of RSV 
within an expression vector. The DNA-chitosan complex formed nanoparticles 
which were confirmed to be more stable than naked DNA and which resulted in 
enhanced transgene expression compared to naked DNA, demonstrating that this 
technique could be valuable for immunisation purposes (Boyoglu, 2009). These 
methods of immunisation were also immunogenic in the presence of maternal 
antibody and studies comparing RSV F DNA delivery with delivery of F protein 
determined that the DNA was more immunogenic and stimulated strong CD8
+
 T-
cells without evidence of enhanced pathology (Martinez, 1999).  
 
1.7.4 Attenuated RSV strains 
Two attenuated RSV strains have been developed through passage in tissue culture at 
reduced temperatures. rA2cp248/404∆SH has 5 missense mutations in the N and L 
genes due to cold-passage in tissue culture, a mutation at nucleotide position 248 
within the L gene, a further mutation at nucleotide position 404 in the M2 gene and 
complete deletion of the SH gene. rA2cp248/404/1030∆SH is similar but has an 
additional mutation at codon 1030 in the L gene (Karron, 2005). These vaccine 
candidates were attenuated in adults and well tolerated in children. 
rA2cp248/404/1030∆SH did not replicate to high levels within children (Karron, 
2005) suggesting it was over attenuated and only stimulated low levels of 
neutralising antibody (Bennett et al., 2007). Further study revealed that enhanced 
disease did not develop upon subsequent RSV infection (Wright et al., 2007). 
However, these vaccine candidates were found to be unstable after several rounds of 
tissue culture passage, suggesting that reversion to virulence in vivo may also occur 
(Lin et al., 2006). Vaccines developed using these methods are prone to failure from 
both under and over-attenuation as only in vivo studies allow the immunogenicity of 
the vaccine and pathogenesis from RSV challenge to be observed (Polack, 2004).  
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1.7.5 Recombinant viral vectors for RSV antigen delivery 
Viral vectors are popular delivery vehicles for vaccination as they can infect the 
mucosa, stimulating a more natural immune response towards the transgene. Sendai 
virus is an example of such a vector. Its advantages are that it is a mouse pathogen 
and  as such, pre-existing immunity within the human population is low. In addition, 
Sendai virus vectors have been shown to elicit strong immune responses towards the 
transgene product as well as being well tolerated in human clinical trials (Hurwitz, 
1997, Slobod, 2004). As a direct result of these studies, an RSV Sendai virus vaccine 
candidate was developed which expressed the F protein (Zhan et al., 2007). This 
study demonstrated that neutralising antibody, IFNγ+ T-cell responses towards the F 
protein and protection against challenge were induced in cotton rats following 
intranasal administration. Recombinant bovine parainfluenza virus 3 (bPIV3) has 
also been adapted for use in vaccination strategies. One candidate, MEDI-534, 
expressed the F and N proteins of human PIV3 and the RSV F protein. Experiments 
in the cotton rat model did not demonstrate the induction of enhanced RSV disease 
so this candidate has entered human clinical trials. MEDI-534 was shown to be 
replication restricted and did not generate adverse side effects. However, neutralising 
antibody titres were low in human adults (Tang et al., 2008).  
 
Vaccinia virus (VV) is an alternative viral vector currently under consideration. VV 
is a large, stable DNA virus, amenable to genetic manipulation with a well 
understood safety profile. However, pre-existing immunity to VV is high in certain 
age groups due to its use as a smallpox vaccine in the past. In addition, life-long 
immunity is induced upon vaccination with a single dose, therefore the vector can 
only be used once in an immunisation regime. Due to the size of the virus, it is 
thought that it could be manipulated to express several antigens of different human 
pathogens, providing a ‘one-shot’ strategy to prevent a variety of diseases. For RSV, 
a VV construct expressing the F and G proteins was evaluated in chimpanzees 
(Collins et al., 1990). The results of this study were not encouraging. A similar 
construct expressing the G protein of RSV was also found to stimulate a Th2 CD4
+
-
biased immune response in mice (Johnson et al., 2004a, Johnson et al., 2004b). 
Alternative candidates were generated; one encoded the entire M2 gene, and another 
the M282-90 CD8
+
 T-cell epitope. It was determined that both candidates could 
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stimulate a strong CD8
+
 T-cell response, which was discovered to be solely mediated 
by this epitope (Kulkarni et al., 1995, Kulkarni, 1993, Kulkarni et al., 1993). 
 
1.7.6 Adenovirus vectored RSV vaccines 
Adenovirus vectors have been proposed as useful vehicles to delivery immunogens. 
Several studies have explored its use in protection against RSV. However, all have 
focused on delivery of the F and G proteins as stimulators of antiviral antibody as 
opposed to other proteins which could stimulate cellular immune responses. In one 
study, different RSV vaccine candidates were compared in the cotton rat model 
including recombinant baculovirus expressing the F and G proteins of RSV (Bac-FG), 
vaccinia vectors expressing either the F or G proteins of RSV (Vac-F and Vac-G), 
adenoviral vector expressing the F protein of RSV (Ad-F) and FI-RSV (Connors et 
al., 1992a). It was shown that Vac-F and Ad-F stimulated neutralising antibody at 
levels higher than those stimulated by Bac-FG. In addition, Vac-F and Ad-F were 
associated with protection from the RSV challenge whereas Bac-FG and FI-RSV was 
less effective. It was concluded that recombinant vectors expressing RSV proteins 
could induce more robust protection than inactivated vaccines and Ad5 in particular 
is an appropriate candidate delivery vehicle (Connors et al., 1992a). 
 
The group of Hsu et al investigated rAd4, rAd5 and rAd7 ∆E1/E3 viruses, which 
expressed the F or the G proteins or a recombinant FG fusion protein of RSV, in 
ferrets immunised intranasally. The constructs were tolerated at the highest dose, and 
did not cause lung histopathology. At 4 weeks, neutralising antibody responses were 
detected in the Ad4F- and Ad5F-immunised animals but not the Ad7F animals.  The 
viruses were able to reduce RSV replication in the lung upon direct challenge, Ad5F 
being the most efficient. Animals were then immunised with Ad5F and Ad4F in 
combination, in a prime-boost regime. A low dose of AdF did not protect animals but 
was associated with neutralising antibody responses which increased over the 18 
week experiment. In contrast, those animals immunised with the middle or high 
doses use in the study, saw a decrease in antibody titre over the experimental period 
but were protected from RSV challenge (Hsu, 1994).  
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The group of Yu et al investigated rAd5 ∆E1/E3 viruses generated using the 
pAdEasy system which expressed RSV G protein epitopes from a CMV promoter. 
The original RSV G protein sequence was codon-optimised for mammalian studies 
and multiple copies of the region, G130-230, which includes multiple epitopes, cloned 
into the vector. This vaccine was used to immunise BALB/c mice via either the 
intranasal, intramuscular or oral routes with a single dose. It was found that, as 
expected, the codon-optimisation and incorporation of three copies of the protein 
fragment produced higher levels of G protein expression than a construct containing 
a single fragment. Intranasal and intramuscular immunisation induced strong IgG 
responses towards the G protein, with oral immunisation stimulating a much weaker 
response. Intranasal immunisation was also more efficient at stimulating a G protein-
specific IgA response. Animals pre-exposed to the rAd vector did not have a reduced 
immune response towards the G protein, suggesting that pre-existing immunity does 
not affect the immunisation ability of this type of vaccine. Further analysis of the T-
cell responses indicated that, in contrast to a similar construct expressed from VV, 
the rAd vaccine did not prime a specific CD4
+
 T-cell response. The G protein 
fragment is known to contain an epitope which primes for enhanced disease after 
RSV challenge (Tebbey, 1998). Therefore, this result suggested that Th2 CD4
+
 
responses were not primed by rAd5, presumably due to some feature of this vector 
system. Finally, intranasal immunised mice were shown to be protected from RSV 
challenge as the immunisation prevented detectable RSV replication within the lung 
of the animals; this protective effect remained for 10 weeks (Yu et al., 2008).  
The same group investigated another vaccine candidate using the same recombinant 
adenoviral vector which expressed a codon-optimised F1 fragment of the RSV F 
protein, F155-524. A single intranasal immunisation was sufficient to induce a strong 
mucosal IgA response and protection against subsequent RSV challenge in BALB/c 
mice. The group was unable to detect serum Ig or T-cell mediated responses towards 
the F1 fragment, concluding that the protective effect observed was primarily 
mediated by the IgA response. As before, immunisation via the intramuscular or oral 
routes was not associated with protection from RSV (Kim et al., 2010).   
 
Fu et al also generated an rAd5 ∆E1/E3 virus with pAdEasy system, which 
expressed the full length F protein of RSV under control of a CMV promoter, FGAd-
F. FGAd-F in a prime-boost regime in BALB/c mice, demonstrated enhanced CTL 
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activity against RSV when compared to an empty vector control construct. It also 
generated detectable IgG and IgA antibody titres which increased over the course of 
the immunisation period, suggesting that homologous prime-boost regimes are 
feasible when using adenovirus vectors. FGAd-F vaccinated-animals also showed 
diminished RSV replication in the lung when compared to the control group, 
suggesting that a protective effect was generated (Fu et al., 2009a).  
 
Shao et al designed an rAd ∆E1/E3 vaccine expressing RSV strain B1 F protein in 
either a truncated form lacking the sequence encoding the transmembrane domain 
(rAd-F0∆TM) or a full length copy (rAd-F0). When used to immunise BALB/c mice 
by the intranasal route, serum neutralising antibodies were detected at a similar level 
from both candidates. Following a booster dose via an alternative route, such as 
intranasal, subcutaneous or intraperitoneal, antibody titres increased for both 
vaccines; the immunisation route did not make a substantial difference to titres. Both 
rAd-F0 and rAd-F0∆TM stimulated IFNγ secreting CD4+ T-cells and some Th2-
associated cytokines, however the levels were lower than observed upon RSV 
challenge suggesting a balanced Th1/ Th2 response was induced. CD8
+
 CTL were 
also induced to the F85-93 peptide epitope. Both rAd-F0 and rAd-F0∆TM were able to 
reduce RSV titres upon subsequent challenge (Shao et al., 2009). 
 
Similar results were obtained by Kohlmann et al, using rAd5 ∆E1/E3 constructs 
expressing either full length RSV F protein (rAdV-F) or a secreted form of the F 
protein (rAdV-Fsol). The vaccines elicited neutralising antibodies towards the F 
protein which were detectable by 35 weeks post-boost. Upon challenge, viral loads 
were reduced when compared to a control suggesting that these vaccines were 
protective. In addition, rAdV-Fsol was shown to generate IFNγ secreting CD8+ T-
cells (Kohlmann et al., 2009). 
 
In summary, several studies have produced corroborating evidence to support the use 
of recombinant adenovirus as a delivery vehicle for vaccination against RSV. 
However, as discussed in Section 1.5, these studies have focused upon RSV 
pathogenesis in an inappropriate model, the mouse. Within this model RSV disease 
is absent or aberrant. Thus, RSV pathogenesis is monitored by viral lung titres. The 
absence of clinical signs in the RSV mouse model means that vaccine efficacy 
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cannot be completely determined, as it has been observed that clinical symptoms and 
cytokine release can persist during PVM infection, even after replicating virus is no 
longer detected (Bonville et al., 2006a). This issue can be addressed by using similar 
vaccine candidates expressing PVM proteins, for evaluation within the PVM 
infection model.  
 
 
1.8 Aims 
 
The first RSV vaccine to date entered ill-fated clinical trials in the 1960s. Now, in 
2010, a suitable, effective vaccine has yet to be approved for clinical use. The 
molecular understanding of RSV and PVM has increased with the development of 
reverse genetics and the availability of complete sequences from several RSV and 
PVM strains. In addition, the understanding of both RSV and PVM pathogenesis in 
their respective hosts has enabled the development of anti-viral therapeutics, as well 
as dissecting the reasons behind the failed FI-RSV vaccine trial.  
 
The overall aim of the project was therefore to advance the development of potential 
RSV vaccines by demonstrating that a live, replication-deficient, recombinant 
adenoviral vaccine expressing full-length specific proteins from a pneumovirus 
(PVM), can elicit protection against the same virus in its natural host, the mouse. In 
detail, the objectives were therefore to: 
 Generate live, replication-deficient recombinant adenovirus vectors which 
express specific genes from PVM  
 Evaluate the recombinant viruses for transgene expression 
 Evaluate the constructs within the PVM infection model; optimising the 
immunisation schedule, dose and immunisation route 
 Characterise the adaptive immune response towards the transgene        
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Chapter 2 
 
Materials and methods 
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2.1 Materials, solutions, buffers and media 
Tables 2.1.1-2.1.9 give details of the solutions, mammalian cell lines, virus and bacterial strains, animal strains and other biological reagents used 
in this thesis. 
 
2.1.1 Solutions, buffers and media  
Table 2.1.1. The composition of solutions used in this study. 
Name of Solution Composition 
Β-galactosidase substrate solution 5mM Potassium ferricyanide, 5mM Potassium ferrocyanide, 2mM Mg, 1mg/ml x-galactosidase in phosphate buffered saline 
(PBS) 
Brefeldin A (BFA) stock 5mg was dissolved in dimethyl sulfoxide (DMSO) to give 1.25mg/ml. BFA solution was diluted in PBS to give a working stock of 
200µg/ml 
Blocking solution (Western blot) ECL Advance™ Blocking Agent dissolved in PBS 0.005% (v/v) Tween®-20  
CMC agar 4% (w/v) carboxymethyl cellulose (CMC) in sterile distilled water (SDW) 
Coating solution (ELISA and ELISPOT) 20mM Na2CO3, 70mM NaHCO3 in SDW to pH9.6 
Dithiothreitol (DTT) 0.5 M, 1.55 g in 20 ml 0.01 M sodium acetate pH5.2 
DOC lysis buffer 20% (v/v) ethanol, 100mM Tris pH9 and 0.4% (w/v) sodium deoxycholate in SDW 
FACS buffer 1% FCS and 0.1% Sodium Azide in sterile PBS 
Fixative solution 0.05% Glutaraldehyde, 2% formaldehyde in PBS 
GTE solution 50mM glucose, 25mM Tris, 10mM diaminoethanetetra-acetic acid disodium salt (EDTA) pH8 in SDW, filter sterilised and  stored 
at  4°C 
  61   
GTY media 10% (v/v) glycerol, 0.125% (w/v) yeast extract and 0.25% (w/v) tryptone in SDW 
Ionomycin stock (Io) Ionomycin was made to 1mg/ml in DMSO. A working stock of 100µg/ml was made by dilution in PBS 
Isotonic buffer (RT-PCR) 150mM NaCl, 10mM Tris-HCl pH7.6 and 1.5mM MgCl2 in SDW and sterilised by autoclaving  
Ketamine/Xylazine anaesthetic  Ketamine solution was diluted from a 100mg/ml stock in sterile PBS to give 75μg/g of mouse bodyweight. Likewise 180mg/ml of 
xylazine solution was diluted to give 15μg/g of mouse bodyweight in the same solution 
Loading buffer (Agarose gel) 50% (v/v) glycerol, 50% (v/v) 2x Tris-borate-EDTA, 0.01% (w/v) bromophenol blue and 0.01% (w/v) xylene cyanol  
Luria-Bertani medium (LB) 1% (w/v)  bactotryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract in SDW and sterilised by autoclaving  
Lysis Solution (Bacterial) 1% Sodium dodecyl sulphate (SDS), 0.2M NaOH in SDW 
Neutralisation solution (Bacterial) 5M acetate and 3M potassium in SDW to pH4.8 
Noble agar overlay 1x Dulbecco’s modified Eagle medium (DMEM) with 1% (v/v) foetal calf serum (FCS), 0.375% (w/v) NaHCO3 and 18% of 2.8% 
(w/v) noble agar  
Noble agar feed 1x DMEM with 0.5% (v/v) FCS, 0.2% (w/v) NaHCO3 and 19.5% of 2.8% (w/v) noble agar 
Noble agar staining overlay 1x DMEM with 0.5% (v/v) FCS, 0.2% (w/v) NaHCO3, 5% neutral red and 19.5% (w/v) noble agar 
NZY+ medium 1% (w/v) NZ amine (casein hydrolysate), 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl in SDW to pH7.5 with 5M NaOH. The 
medium was sterilised by autoclaving. When cooled, 12.5mM MgCl2, 12.5mM MgSO4 and 0.4% (v/v) glucose (to a final 
concentration) were added 
Penicillin/Streptomycin 10,000 U/ml penicillin G and 10,000 µg/ml Streptomycin sulphate in 0.85% PBS. 
Phenol/Chloroform Equal volumes of TE-saturated phenol and chloroform were mixed and stored at 4°C  
Phorbol 12-myristate 13-acetate (PMA) 1mg PMA was dissolved in DMSO to 1mg/ml. A working stock of 10µg/ml was made by dilution in PBS 
PMA/Io 10µg/ml PMA and 100µg/ml Io in sterile PBS 
Resolving gel (10%) 9.9% (v/v) acrylamide, 425mM Tris pH8.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulfate (APS) and 0.08% (v/v) 
N,N,N’,N’- tetramethylethylenediamine (TEMED) in SDW  
RF1 buffer 100mM RbCl, 50mM MnCl2.4H2O, 30mM K acetate, 10mM CaCl2.2H2O, 15% (w/v) glycerol in SDW to pH5.8 with 0.2M acetic 
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acid. The solution was filter sterilised and stored at 4°C 
RF2 buffer 10mM 3-(N-morpholino)propanesulfonic acid (MOPS) pH6.8, 10mM RbCl, 75mM CaCl2.2H2O, 15% (v/v) glycerol in SDW to 
pH6.8 with NaOH. The solution was filter sterilised and stored at 4°C 
Running buffer (1x) (Protein gel) 25mM Tris, 190mM glycine and 0.1% (w/v) in SDS  
Sample Buffer (2x) 0.2% (w/v) SDS, 1% (v/v) glycerol, 50mM Tris pH6.8 in SDW and a few crystals of bromophenol blue added 
Sample Buffer (1x) 50% (v/v) 2x Sample Buffer and 100mM dithiothreitol (DTT) in SDW 
Stacking gel 3.6% (v/v) acrylamide, 160mM Tris (pH6.8), 0.1% (w/v) SDS, 0.08% (w/v) APS, 0.12% (v/v) TEMED 
TE buffer 10mM Tris-HCl (pH8) and 0.1mM EDTA in SDW 
Transfer Buffer (1x) 190mM glycine, 25mM Tris and 20% (v/v) methanol in SDW 
Trypsin solution 25% (v/v) trypsin in versene 
Versene 0.002% (w/v) EDTA (disodium salt) and 0.002% (w/v) phenol red 
 
2.1.2 Reagents and suppliers 
All chemicals of analytical or molecular biology grade were supplied by Sigma-Aldrich (Poole, Dorset, UK) or BDH Laboratory supplies 
(Dorest, UK) unless otherwise stated in Table 2.1.2. 
 
Table 2.1.2. Reagents used in this study 
Supplier Reagents 
BD Biosciences (Oxford, UK) BD Cytofix/Cytoperm™ Fixation/Permeabilization Solution Kit 
BD Pharmingen Allophycocyanin (APC) conjugated rat anti-mouse CD8a monoclonal (553085), Phycoerythrin (PE) conjugated rat anti-mouse CD4 
monocloncal (553652), Fluorescein isothiocyanate (FITC) conjugated rat anti-mouse IFNγ monoclonal (554411) 
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BioLine (London, UK) HyperLadder1  
BioRad (Hemel Hempstead, UK) APS, TEMED, Alkaline phosphatase (AP) conjugate substrate kit (170-6432) 
BioSera (Sussex, UK) FCS 
Fermentas  
(Helena Biosciences, Sunderland, 
UK) 
Restriction enzymes, T4 DNA ligase, T4 polynucleotide kinase, GeneRuler™, dATP, dCTP, dGTP, dTTP, Pfu DNA polymerase, Taq 
DNA polymerase, 25mM MgCl2, agarose (molecular grade), ribonuclease H, ribonuclease inhibitor, Taq DNA polymerase 
(recombinant), proteinase K, PageRuler™ Prestained Protein Ladder 
Fort Dodge, Animal Healthcare Ltd. 
(Southampton, UK) 
Ketamine solution 100mg/ml 
GE Healthcare  (Bucks., UK) Hybond™ ECL™ nitrocellulose membrane, Hyperfilm™ ECL™, ECL™ Advance Western blotting reagents, Illustra GFX™ PCR 
DNA and Gel Band Purification Kit, DNase I 
ICN Biomedicals, Inc (CA, USA) Methionine (Met)-free DMEM 
Invitrogen/Gibco BRL Life 
Technologies Ltd/Molecular Probes 
(Paisley, UK) 
Restriction enzymes, DMEM, Opti-MEM®, trypsin, Lipofectamine™2000, AlexaFluor®-conjugated secondary antibodies, calf 
intestinal alkaline phosphatase (CIAP), SuperScript II RNase H-reverse transcriptase, proteinase K, 4’-6-diamidino-2-phenylindole 
(DAPI), Roswell Park Memorial Institute (RPMI) 1640+ GlutaMAX™-1 medium,   
Mabtech (OH, USA) Capture antibody – anti-mouse IFNγ monoclonal (AN18), Detection antibody – biotinylated anti-mouse IFNγ monoclonal (R46A2) 
Merck (Nottingham, UK) Ionomycin 
Millipore (MA, USA) MAIP plates (MAIPS4510) for ELISPOT 
Mimotopes PVM N peptide library 
National Diagnostics  (Hull, UK) Protogel® (30% acrylamide/0.8% bis) 
New England Biolabs (Herts., UK) Restriction enzymes, bovine serum albumin (BSA) 
Promega UK (Southampton, UK) PureYield™ plasmid midiprep system reagents 
QIAgen (Sussex, UK) QIAprep® Spin Miniprep Kit, QIAprep® Maxiprep kit, QIAquick gel extraction kit,  
Roche (Hamps, UK) Buffer for 2,2’-azino-bis(3-ethylbenzo-thiazoline-6-sulphonic acid (ABTS), DNase I, Collagenase A 
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Sigma-Adlrich (Poole, Dorset, UK) GenElute
™
 HP Plasmid Miniprep Kit, ATP, DTT, Tri-reagent®, spermine, ABTS, Xylazine, Nonidet p40 (NP40), Concanavalin A 
(ConA), histoplaque solution, β-mercaptoethanol, BFA, PMA 
Stratagene (La Jolla, CA, USA) AdEasy™ Adenoviral Vector System, BJ5183 electroporation competent cells, XL10-Gold® ultracompetent cells 
Thermofisher (USA) 96 well flat bottom plates, 96 well U bottom plates 
University of Warwick Biological 
Sciences media preparation service 
Sterile PBS, 1x Tris-borate-EDTA (TBE) buffer, 5x Tris-acetate-EDTA (TAE) buffer, LB medium, LB agar plates, LB agar plates 
with 100µg/ml ampicillin (Amp), LB agar plates with 50µg/ml kanamycin (Kan), 100mg/ml Amp stock solution, 50mg/ml Kan stock 
solution, 10x running buffer (SDS-PAGE), 10x Tris-glycine transfer buffer (Western blotting), 1x DMEM, 2x DMEM, versene, 10% 
SDS, 0.5M EDTA pH8.0, 1x Glasgow minimal essential medium (GMEM) with non-essential amino acids (NEAA), 2x GMEM-
NEAA, SDW, penicillin/streptomycin, neutral red, glutamine  
Vector Laboratories Ltd Mounting medium (Vectorshield®) 
 
 
 
2.1.3 Virus strains 
Table 2.1.3. Virus strains used in this study. 
Virus strain Phenotype Reference 
Ad5dl327 (Ad 327) Wild type Ad5 containing the E3 deletion described for dl324  (Thimmappaya, 1982) 
PVM strain J3666 The pathogenic strain of PVM. Restricted cell culture growth temperature at 32˚C (Cook et al., 1998, Domachowske, 2002)  
PVM strain 15 (Warwick)  Non-pathogenic strain of PVM, does not have a restricted growth temperature. (Cook et al., 1998, Domachowske, 2002) 
Influenza A/WSN/40 Wild-type influenza H1N1, the mouse neurotropic variant derived from A/WSN/31 (H1N1) (Dimmock et al., 2008) 
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2.1.4 Bacterial strains and plasmids 
Table 2.1.4.  E. coli strains used in this study. 
Strain  Description Source/Reference 
E. coli BJ5183 endA1 sbcBC recBC galK met thi-1 bioT hsdR (Str
r
) 
 
Stratagene (La Jolla, CA, USA) (Hanahan, 
1983) 
E. coli DH5α F-recA1 endA1 gyrA96 thi-1 hsdR17 (rk
-
mk
+
) supE44 relA1 Δ(lacZYA-argF) U169 deoR phoA Λ-  
Φ80dlacZΔM15 
(Jessee, 1986) 
 
E. coli XL-10 Gold Tet
r∆(mcrA) 183∆(mcrCB-hsdSMR-mrr) 173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F’proAB lacIq Z ∆ M15 Tn10 (Tetr) AmyCamr] 
Stratagene (La Jolla, CA, USA) (Bullock, 
1987)  
 
 
2.1.5 Mammalian cells 
Table 2.1.5. Mammalian cell lines used in this study. 
Cell line Description Source/Reference 
A549 Human lung  carcinoma cells (Girard et al., 2005) 
BS-C-1 African green monkey kidney epithelial cells (Hopps et al., 1963) 
HEK293 Immortalised adenovirus transformed human embryonic kidney cells (Graham et al., 1977) 
HeLa Human cervical epithelial carcinoma cells (Scherer, 1953) 
P2-2 BS-C-1 cell line persistently infected with PVM J3666 Kindly provided by A.Easton 
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2.1.6 Mouse strains 
Table 2.1.6. Mouse strains used in this study.  
Mouse strain Description 
BALB/c The BALB/c mouse originated in 1923. This inbred strain is albino, with a MHC haplotype of H2
d
. 
C57BL/6 The mouse strain originated in 1921. This inbred strain is black and has a MHC haplotype of H2
b
. 
C3H/He-mg This inbred mouse strain is agouti in colour and has an MHC haplotype of H2
k
. 
 
2.1.7 Antibodies  
Table 2.1.7. Primary antibodies and secondary antibody conjugates used for Western blot, immunofluorescence and ELISA  in this study. 
Protein 
recognised 
Description Supplier/Reference  
WB 
Dilution used 
IF 
 
ELISA 
PVM F Rabbit anti-PVM F polyclonal  clone 2018  Kindly provided by  A Easton  1:10,000 1:1000    Neat 
PVM N Rabbit anti-PVM N polyclonal (Barr et al., 1994) 1:1250 1:63 Neat 
PVM P Mouse monoclonal antibody, 26/11/B5 Kindly provided by A Easton 
(Barr et al., 1994) 
1:400 1:40 Neat 
PVM M Mouse anti-PVM polyclonal  Kindly provided by R Ling 
(Ling, 1988)  
N/A 1:100 Neat 
PVM M Mouse anti-PVM M (anti-M_RLing)  Kindly provided by R Ling  
(Ling, 1988) 
N/A 1:100 N/A 
Mouse IgG Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG Sigma Aldrich 1:5000 N/A 1:7500 
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Mouse IgG Alexa488 goat anti-mouse IgG Molecular Probes N/A 1:500 N/A 
Goat IgG Alexa594 rabbit anti-goat IgG Molecular Probes N/A 1:500 N/A 
Ad5 late proteins AdJLB1 rabbit polyclonal serum (Farley et al., 2004) 1:10,000 1:1000 1:850 
DBP  Rabbit anti-DBP (DNA binding protein) polyclonal (Harfst & Leppard, 1999) N/A 1:100 N/A 
DBP Mouse anti-DBP monoclonal (mAb B6-8) (Reich et al., 1983) N/A 1:100 N/A 
Rabbit IgG HRP-conjugated goat anti-rabbit  Santa Cruz 1:200,000 N/A 1:10,000 
Influenza A 
proteins 
Mouse anti-influenza A polyclonal serum Kindly provided by L Harvey-
Smith 
N/A N/A Neat 
Mouse IgA HRP-conjugated goat anti-mouse  Santa Cruz N/A N/A 1:10,000 
Mouse CD8a APC  conjugated rat anti-mouse CD8a monoclonal (553085) BD Pharmingen N/A N/A N/A 
Mouse CD4 PE conjugated rat anti-mouse CD4 monoclonal (553652) BD Pharmingen N/A N/A N/A 
Mouse IFNγ FITC conjugated rat anti-mouse IFNγ monoclonal (554411) BD Pharmingen N/A N/A N/A 
Mouse IFNγ Capture antibody – anti-mouse IFNγ monoclonal (AN18) Mabtech N/A N/A N/A 
Mouse IFNγ Detection antibody – biotinylated anti-mouse IFNγ monoclonal 
(R46A2) 
Mabtech N/A N/A N/A 
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2.1.8 Plasmids and primers 
Table 2.1.8. Plasmids used in this study  
Plasmid Description Gene of 
Interest 
Source/Reference 
pP2 This plasmid contains the T7 promoter, the Amp
R
 gene and the P gene of PVM strain J3666. PVM P Kindly provided by O. Dibben, 
University of Warwick 
pN3 This plasmid contains the T7 promoter, the Amp
R
 gene and the N gene of PVM strain J3666. PVM N Kindly provided by O. Dibben. 
P15-FL2G This plasmid contains the T7 promoter, the Amp
R
 gene and the 10 genes of PVM strain 15 PVM F and 
M 
Kindly provided by O. Dibben.  
pBR322 General purpose cloning vector  Kindly provided by K. 
Leppard, University of 
Warwick (Bolivar et al., 1977)  
pShuttle_CMV The plasmid is provided by the AdEasy™ Adenoviral Vector System. It contains a  multiple 
cloning site (MCS), located between the cytomegalovirus (CMV) promoter  and the simian 
virus 40 (SV40),  right-inverted terminal repeat (R-ITR), left-inverted terminal repeat (L-ITR), 
pBR322 origin, Kan
R
 gene and regions of sequence homology with pAdEasy-1 which encodes 
the adenoviral genome and allows recombination to take place.  
None  Stratagene (La Jolla, CA, USA) 
pShuttle_CMV_LacZ 
(referred to throughout as 
pShuttle_CMV_Z) 
This plasmid contains the features described for pShuttle_CMV. The lacZ gene was inserted 
into the MCS and serves as a control for the generation of recombinant adenoviral construct.  
LacZ Stratagene (La Jolla, CA, USA) 
pShuttle_CMV_N1 and 
_N4 
This plasmid contains the features described for pShuttle_CMV. The PVM N gene cDNA was 
amplified by PCR from pN3 and inserted into the MCS.  
PVM N This study 
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pShuttle_CMV_P1 This plasmid contains the features described for pShuttle_CMV. The PVM P gene cDNA was 
amplified by PCR from pP2 and inserted into the MCS.  
PVM P This study 
pShuttle_CMV_F1 and 
_F2 
This plasmid contains the features described for pShuttle_CMV. The PVM F gene cDNA was 
amplified by PCR from p15-FL2G and inserted into the MCS.  
PVM F This study 
pShuttle_CMV_M7 This plasmid contains the features described for pShuttle_CMV. The PVM M gene cDNA was 
amplified by PCR from p15-FL2G and inserted into the MCS.  
PVM M This study 
pAdEasy-1 pAdEasy-1 contains the human Ad5 genome with the E1 and E3 genes deleted. The plasmid 
contains the pBR322 origin of replication and the Amp
R 
gene. A recombination event with 
pShuttle_CMV is required to generate a genome that is functional to create virus. The E1 gene 
deletion renders the rescued virus replication defective so missing E1 gene products are 
provided in trans. The E3 deletion prevents the virus from modulating the hosts immune 
response to allow evasion.  
None  Stratagene (La Jolla, CA, USA) 
pAdEasyP17 The plasmid contains the features described for pAdEasy-1. The pShuttle_CMV_P1 plasmid 
has recombined with the pAdEasy-1 plasmid at the right and left arms of homology, inserting 
the pShuttle_CMV_P1 pBR322 origin of replication, the Kan
R 
gene, R-ITR, L-ITR, CMV 
promoter and the PVM P gene. The pAdEasy-1 pBR322 origin of replication and Amp
R
 gene 
is displaced and lost during the recombination event.  
PVM P This study 
pAdEasyP26 The plasmid contains the features described for pAdEasy_P17.  PVM P This study 
pAdEasyN3 The plasmid contains the features described for pAdEasy_P17 with the exception of the PVM 
N gene sequence downstream of the CMV promoter.  
PVM N This study 
pAdEasyN20 The plasmid contains the features described for pAdEasy_N3.  PVM N This study 
pAdEasyF59 The plasmid contains the features described for pAdEasy_P17 with the exception of the PVM 
F gene sequence downstream of the CMV promoter.  
PVM F This study 
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pAdEasyF61 The plasmid contains the features described for pAdEasy_F59.  PVM F This study 
pAdEasyM2 The plasmid contains the features described for pAdEasy_P17 with the exception of the PVM 
M gene sequence downstream of the CMV promoter.  
PVM M This study 
pAdEasyM5 The plasmid contains the features described for pAdEasy_M2.  PVM M This study 
pAdEasylacZ 
(referred to throughout as 
pAdEasyZ) 
The plasmid contains the features described for pAdEasy_P17 with the lacZ gene from 
pShuttle_CMV_LacZ downstream of the CMV promoter. 
LacZ This study 
pUC18 The plasmid contains the Amp
R
 gene, the pMB1 replicon, MCS, a region of E.coli operon lac 
operon which contains the CAP protein binding site, lac promoter, lac repressor binding site 
and the 5’-terminal part of the LacZ which encodes a β-galactosidase fragment.  
None  Stratagene (La Jolla, CA, USA) 
 
 
Table 2.1.9. Oligonucleotide primers used in this study.  
Underlined regions indicate a restriction enzyme site and the sequence, direction and application of each primer is indicated.  
Primer name Sequence (5’-3’)  Direction Application 
PVMFFor GGGGTACCATGATTCCTGGCAG Forward Insertion of restriction enzyme site into the beginning of the gene 
sequence and PCR amplification. 
PVMFRev GGCTCGAGTCATGATAAAACTGTGAG Reverse Insertion of restriction enzyme site into the end of the gene sequence, 
RT-PCR and PCR amplification. 
PVMMFor GGGGTACCATGGAGGCCTACTTGGTA Forward As for PVMFFOR  
PVMMRev GGCTCGAGTCATCCACTTGTTGAGGA Reverse As for PVMFREV 
PVMNFor CCGCGGGTCGACATGTCTCTAGACAGATTGAAGC Forward As for PVMFFOR 
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PVMNRev GGCTCGAGTTAAATATCATCATCAGGAGTGTC Reverse As for PVMFREV 
PVMPFor GGGGTACCATGGAGAAATTCGCCCCC Forward As for PVMFFOR 
PVMPRev GGCTCGAGTTAACTAAAAATTAATGCCCATGATG Reverse As for PVMFREV 
N3 GGATTCTATCACATCAGAAAT Forward Sequencing the PVM N gene, kindly provided by O. Dibben. 
J2 GTATCTCTAGATCAGCTAAAT Reverse Sequencing the PVM N gene, kindly provided by O. Dibben. 
N5 TGAAAGCCGAGAAAGCCAGGT Forward Sequencing the PVM N gene, kindly provided by O. Dibben. 
M1 CAGCCAACATATCACTAACTGTG Forward Sequencing the PVM M gene, kindly provided by O. Dibben. 
M2 CACTGTACCCAGCATTACTCCCA Forward Sequencing the PVM M gene, kindly provided by O. Dibben. 
P2-A CTTTGTGGAACCCGAGGAG Forward Sequencing the PVM P gene, kindly provided by O. Dibben. 
P2-B CCCTGTACAAGCTAGCTCCCAATCCGACAA Reverse Sequencing the PVM P gene, kindly provided by O. Dibben. 
J3 AGATGAAGAACCCGGCTCTTG Reverse Sequencing the PVM P gene, kindly provided by O. Dibben. 
F1 AACCTCTTCTTCCTTTTGGACTTCAAGG Reverse Sequencing the PVM F gene. 
F2 TGGCTGGTATTGTCACAATGCTGGCTCA Forward Sequencing the PVM F gene. 
F7 TATTGAGTCATGCAAGAGCA Forward Sequencing the PVM F gene, kindly provided by O. Dibben. 
F9 CATTGTAGGCGGCATGGCTG Forward Sequencing the PVM F gene, kindly provided by O. Dibben. 
F11 ACTGTTTACTATCTTAGCAA Forward Sequencing the PVM F gene, kindly provided by O. Dibben. 
F17 TCCACTGCACTACTATAGAT Reverse RT-PCR and PCR amplification, kindly provided by O. Dibben. 
CMV1 TTTTGTGTTACTCATAGCGCGTAA Forward Sequencing the CMV promoter. 
CMV2 TATTGACGTCAATGACGGTAAATGGCC Forward Sequencing the CMV promoter.  
CMV3 TTTTGGCACCAAAATCAACGGG Forward Sequencing the CMV promoter.  
F1 AGTCATGCAAGAGCAGCAACTCGTTA Forward Sequencing and amplification of F gene in RT-PCR. 
F2 GCTGTTGTTAGCCTAACCAACGGCA Forward Sequencing and amplification of F gene in RT-PCR. 
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F3 TGTTAACGGACCGCGAACTCACCTC Forward Sequencing and amplification of F gene in RT-PCR. 
F4 CGTCGCCAACGGATTGTGAGATC Forward Sequencing and amplification of F gene in RT-PCR. 
F5 CAAAGGTATAATAAGGACTCTGCCAGAT Forward Sequencing and amplification of F gene in RT-PCR. 
F6 TTCATTCTGTATAAGGTATTGAAAATGATCAGA Forward Sequencing and amplification of F gene in RT-PCR. 
P2 CCAGAGCTGACACTGATGATGGATC Forward Sequencing the P gene. 
M3 AGCAGGCTATAAGCTCCGATGTGG Forward Sequencing the M gene. 
N1 AAGGAAAGGAATACAAAATACAAGTCCTAGATAT Forward Sequencing the N gene. 
N2 GAAGGGCTTTAAATGTGCTGAAAGCC Forward Sequencing the N gene. 
ActinF TGGGTCAGAAGGATTCCTATGTGGGC Forward Amplification of the β-actin gene in RT-PCR. 
ActinR AGCACAGCTTCTCCTTAATGTCACGC Reverse Amplification of the β-actin gene in RT-PCR. 
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2.2 Techniques related to cloning DNA 
2.2.1 DNA amplification by polymerase chain reaction 
Primers (Table 2.1.9) were reconstituted to 100µM in SDW. Each reaction was 
preceded by a 2 min. denaturation step followed by cycle of 94°C for 30 sec., DNA 
annealing at 55°C for 1 min. and a DNA extension step at 72°C for 2 min. 35 cycles 
were carried out prior to a final extension step of 72°C for 7 min. Reactions were 
constituted as described in Table 2.2.1 and processed on the mastercycler gradients 
machine (Eppendorf). When colony screening was performed by PCR, reactions 
were constituted as described in Table 2.2.1 using a non-proof reading enzyme. E. 
coli colonies were picked from an LB agar plate and introduced into the reaction 
mixture to function as template DNA.  
 
Proof reading 
reaction constituents 
Final 
concentration 
Non-proof reading 
reaction constituents 
Final 
concentration  
Primers 20 pmol each Primers 20 pmol each 
dNTP 250µM of each dNTP 250µM of each 
Pfu DNA polymerase 1µl (v/v) at 
2.5U/µl 
Taq DNA polymerase 0.2µl (v/v) at 
5U/µl 
Buffer* 10% (v/v)  Buffer** 10% (v/v) 
SDW Up to 50µl MgCl2 250µM 
  SDW Up to 20µl 
Table 2.2.1:   PCR reaction constituents. 
* 20mM Tris-HCl pH8.8, 10mM (NH4)2SO4, 10mM KCl, 0.1% (v/v) Triton ® X-100, 
0.1mg/ml BSA, 2mM MgSO4.  
** 100mM Tris-HCl pH8.8, 500mM KCl, 0.8% (v/v) NP40 
 
2.2.2 RNA amplification by reverse-transcriptase polymerase chain reaction 
For each reaction to be established, a mastermix was prepared containing (at a final 
concentration): primer (20 pmol), 250µM of each dNTP, RNA 1µg, 10% (v/v) buffer 
(50mM Tris-HCl pH8.3, 75mM KCl, 3mM MgCl2 and 10mM DTT), 1µl (v/v) 
SuperScript® II reverse transcriptase at 200U/µl and SDW up to 20µl. The reaction 
was incubated at 42°C for 1 hr. then heated to 72°C for 10 min. to inactivate the 
enzyme. The reaction was then incubated at 37°C for 30 min. with two units of 
ribonuclease H to remove remaining RNA before use as template for PCR.  
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2.2.3 DNA restriction digest  
Digestion of DNA with individual enzymes was performed in the appropriate buffer 
according to manufacturer’s instructions. Multiple enzyme digests were performed in 
the most optimal buffer or sequentially if the enzymes would not function acceptably 
under the same conditions. Restriction enzyme digestion reactions were performed in 
a total volume of 20-100µl and contained 1-10 units of enzyme per µg of DNA. 
Reactions were incubated at 37°C for 1-18 hr. and inactivated where appropriate at 
65°C for 20 min.  
 
2.2.4 DNA phosphorylation  and dephosphorylation   
1-20 pmol of DNA was phosphorylated prior to ligation using T4 DNA kinase 
according to manufacturer’s instructions. The reaction was made up to 19µl in SDW 
and incubated at 37°C for 20 min. The reaction was inactivated through incubation at 
75°C for 10 min. to denature the enzyme.  
DNA was dephosphorylated prior to transformation using CIAP according to 
manufacturer’s instructions. The reaction was made up to 50µl with SDW and 
incubated at 37°C for 30 min. EDTA, pH8.0 was added prior to incubation at 65°C 
for 3 min. to inactivate the CIAP.  
 
2.2.5 Agarose gel electrophoresis  
Agarose gels were prepared in 1x TBE at 0.5-1% agarose for small DNA fragments 
and 1x TAE at 1-1.5% agarose for larger DNA fragments. Ethidium bromide at 
0.5µg/ml was added once the solution was lukewarm. The gel solution was poured 
into the gel apparatus and assembled according to manufacturer’s instructions. Once 
set, the gel was placed into the tank and covered in 1% TAE or TBE. The samples 
were mixed with 2-5µl loading buffer and loaded onto the gel. The gel was run at 
100-150V for 90-120 min. with either GeneRuler® or Hyperladder1 as a marker 
until the fragments were separated. DNA was visualised under ultraviolet (UV) 
illuminator.  
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2.2.6 DNA purification from agarose gel 
DNA bands were visualised under UV light and cut from the gel using a sharp 
scalpel. The gel slice was extracted using either GFX™ PCR DNA and Gel Band 
Purification Kit or QIAprep® Spin Miniprep Kit according to manufacturer’s 
instructions. DNA was eluted into 20-50µl SDW.  
 
2.2.7 DNA purification from solutions   
Proteins, buffers, and enzymes were removed by DNA extraction with 
phenol/chloroform. DNA samples were made up to 0.1ml with SDW and an equal 
volume of phenol: chloroform 1:1 solution was added. The sample was mixed by 
vortexing, prior to centrifugation at 16,100 x g for 3 min. The aqueous layer was 
removed into a new microfuge tube and the organic phase discarded.  
 
2.2.8 DNA and RNA precipitation  
DNA was precipitated by adding 0.1 volumes of 3M sodium acetate (pH5.2) and 2.5 
volumes of ice-cold ethanol. The sample was mixed by vortexing and incubated at -
20°C for 1 hr. The DNA solution was centrifuged at 16,100 x g for 15 min. and the 
supernatant was discarded. 1ml of 70% ethanol was added and the DNA was 
centrifuged at 16,100 x g for 5 min. This step was repeated prior to a 30 sec. 
centrifugation to remove any remaining ethanol. The tube was then incubated at 
37°C for 15 min. to remove any traces of ethanol and resuspended in 10-50µl SDW.  
RNA was precipitated using RNase-free isopropanol using the method described in 
above. The RNA was treated with DNase according to manufacturer’s instructions to 
remove any remaining DNA and used directly for RT-PCR.  
 
2.2.9 DNA extraction from adenovirus virus infected mammalian cell lysate 
Adenovirus infected cell suspensions were centrifuged at 600 x g for 5 min. and the 
supernatant was discarded. The pellet was resuspended in 0.4ml TE pH9 with 10mM 
spermine and 0.4ml DOC lysis buffer and mixed. The solution was centrifuged at 
12,000 x g for 15 min. The supernatant was transferred into fresh microfuge tubes 
and 60µl 10% (w/v) SDS, 20µl 0.5M EDTA and 20µl of 20mg/ml proteinase K was 
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added. The reaction was incubated at 37ºC for 1 hr. before the DNA was extracted 
from the solution as described in Section 2.2.8.  
 
2.2.10 RNA extraction from transfected mammalian cell lysate 
Transfected cells were harvested by scraping the cells from a tissue culture plate 
using small rubber pieces into 1ml PBS. Duplicates were pooled together and the cell 
suspension was centrifuged at 600 x g for 3 min. The pellet was resuspended in 
0.5ml of isotonic buffer with 33µl of 10% (v/v) NP40. The suspension was incubated 
on ice for 10 min. prior to centrifugation at 600 x g for 3 min. The supernatant was 
transferred into RNase-free microfuge tubes to which 0.75ml Tri-Reagent® was 
added and the reaction was incubated at room temperature (RT) for 20 min. 0.1ml 
RNase-free chloroform was added to the reaction and a second incubation was 
performed at RT for 15 min. The reaction was then centrifuged at 16,000 x g for 15 
min. and the upper aqueous phase was transferred to a fresh microfuge tube.  
 
2.2.11 Plasmid extraction 
For the purposes of routine analysis, plasmid DNA was extracted from 1-5ml of 
fresh overnight E. coli culture. The culture was centrifuged at 16,000 x g for 1 min. 
The supernatant was discarded and the pellet was resuspended in 0.1ml GTE. 0.2ml 
of lysis solution was added and the reaction was incubated on ice for 5 min. 0.15ml 
of neutralisation solution was then added prior to centrifugation at 16,000 x g for 10 
min. The supernatant was transferred to a new microfuge tube and the DNA purified 
as described in Sections 2.2.7-8.  
Any plasmid constructs which were required for sequencing or transformation were 
prepared using 1-5ml of fresh overnight culture using either GenElute™ HP Plasmid 
Miniprep kit or QIAgen® Spin Miniprep kit according to the manufacturer’s 
instructions.  
For the purposes of mammalian cell transfections, sequencing and transformation 
experiments, plasmid DNA was extracted from 50-250ml fresh overnight culture 
using Promega PureYield™ Midiprep System according to manufacturer’s 
instructions. For cultures of 250-500ml in volume, a QIAgen® Maxiprep kit was 
used according to manufacturer’s instructions. 
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2.2.12 DNA ligation 
Ligation reactions were performed using T4 DNA ligase. For blunt end ligations, the 
reaction was set up with a molar ratio of 1:5 vector to insert, 10% (v/v) buffer 
(40mM Tris-HCl pH7.8, 10mM MgCl2, 10mM DTT and 0.5mM ATP) and 10 units 
of T4 DNA ligase and made up to a final volume of 50µl with SDW. The reaction 
was incubated overnight at 16°C in a water bath and 10µl was used to transform E. 
coli.  
 
2.2.13 DNA quantification 
Approximate DNA concentrations were determined by agarose gel fluorescent band 
intensity, Sections 2.2.2 and 2.2.3, in comparison to Hyperladder1, or determined 
based on absorbance at 260nm (1A260 = 50µg/ml) using the NanoDrop ND-1000 
spectrophotometer.  
 
2.2.14 DNA sequencing 
DNA sequencing reactions contained 100ng of template plasmid, 5pmol of primer, 
and SDW to a final volume of 10µl. Sequencing reactions were carried out at the 
University of Warwick Molecular Biology services. Sequences were analysed using 
the Chromas software program and the SeqMan™II program.  
 
 
2.3 Manipulation of E. coli strains 
2.3.1 Growth and storage of E. coli strains 
The E. coli strains outlined in Table 2.1.4 were cultured in LB medium at 37°C with 
vigorous shaking. Following plasmid transformation, bacteria were grown on LB 
agar plates or as liquid cultures and where appropriate, the cultures were 
supplemented with 100µg/ml Amp or 25µg/ml Kan. Bacterial stocks were 
maintained for short-term storage as streaked agar plates and stored at 4°C. For long-
term storage, a 15% (v/v) mix of sterile glycerol and exponential phase liquid culture 
was prepared and stored at -70°C.  
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2.3.2 Production of chemically competent E. coli strains 
The E. coli DH5α was cultured overnight from a colony in 5ml LB medium. 1ml was 
used to inoculate 100ml LB medium, which was grown to an OD600 0.39 at 37°C 
with shaking. The culture was incubated on ice for 5 min. before centrifugation at 
6000 x g for 10 min. at 4°C. The supernatant was discarded and the pelleted cells 
were resuspended in 40ml ice-cold RF1 buffer and incubated on ice for 1 hr. The 
cells were centrifuged at 6000 x g for 10 min. at 4°C and the supernatant was 
discarded. The pelleted cells were resuspended in 4ml ice-cold RF2 buffer and 
incubated on ice for 2-3 hr. Aliquots of cells were snap-frozen in a dry ice-ethanol 
bath before transfer to -70°C for long-term storage.  
 
2.3.3 Production of electrocompetent E. coli strains 
Electrocompetent E. coli BJ5183 cells were prepared by adding 25ml fresh overnight 
culture to 500ml LB medium. The cells were grown at 37°C to an OD600 0.35-0.4. 
The cultures were incubated in an ice-cold water bath for 30 min. prior to 
centrifugation at 6000 x g for 15 min. at 4°C. The supernatant was discarded and the 
pelleted cells were resuspended in 500ml ice-cold pure SDW and centrifuged at 6000 
x g for 20 min. at 4°C. The supernatant was discarded and the pelleted cells were 
resuspended in 250ml ice-cold 10% glycerol and centrifuged at 6000 x g for 20 min. 
at 4°C. The supernatant was discarded and the pelleted cells were resuspended in 1ml 
ice-cold GTY medium and diluted to OD600 1.0 with GTY medium. The cells were 
aliquoted and snap-frozen in a dry ice-ethanol bath then transferred to -70°C for 
long-term storage.  
 
2.3.4 Transformation of E. coli using purified DNA 
Extracted and purified DNA was used to transform chemically competent E. coli 
strain DH5α. E. coli aliquots were thawed in a microfuge tube and mixed with a 
minimum of 50ng DNA prior to incubation on ice for 30 min. The reaction was 
incubated at 42°C for 45 sec. then incubated on ice for 2 min. 0.5ml of pre-warmed 
LB medium was added to the cells, which were incubated at 37°C for 1 hr. or 30°C 
for 1.5 hr. with shaking. The reaction was spread on selective agar plates and 
incubated at 37°C overnight or 30°C for 24 hr. 30°C growth temperature was used 
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for transformations of plasmids over 15kbp in size. For ligated DNA, 10µl of a 
ligation reaction was added to 0.1ml of competent cells and transformed as described 
above. XL10-Gold® cells were transformed and BJ5183 cells were electroporated 
according to manufacturer’s instructions. Bacteria were spread onto LB Kan plates 
and incubated at 37°C overnight.  
 
 
2.4 Tissue culture techniques 
2.4.1 Maintenance of cell-lines  
Mammalian cell lines were maintained as detailed in Table 2.4.1, at 37°C in 5% CO2. 
All cells were cultured in 90mm tissue culture dishes or 175cm
2
 tissue culture flasks 
and were passaged when the cellular monolayer reached 90-100% confluency. To 
remove the cells from the surface of the culture container, cells were washed with 
versene then incubated at 37°C with trypsin solution. Cells were regularly observed 
until all had become detached. The cells were then centrifuged at 340 x g for 3 min. 
with an equal volume of fresh growth medium. The supernatant was discarded and 
the pellet was resuspended in fresh growth medium and transferred into new tissue 
culture dishes, plates, flasks, or bottles at the appropriate density 
 
Cell line Medium Split 
ratio 
A549 DMEM with 10% (v/v) FCS 1:4 
BS-C-1 GMEM with 5% (v/v) FCS 1:4 
HEK293 DMEM with 10% (v/v) FCS 1:4 
HeLa DMEM with 10% (v/v) FCS 1:8 
P2-2 GMEM with 15% (v/v) FCS, 2.5% (v/v) glutamine, 0.15% 
(v/v) Penicillin /Strepomycin 
1:3 
Table 2.4.1:  Cell line maintenance and growth medium conditions  
 
2.4.2 Storage and recovery of cell stocks 
Mammalian cells were harvested from 175cm
2
 tissue culture flasks using trypsin 
solution and centrifuged at 340 x g for 3 min. The pellet was resuspended in 90% 
(v/v) FCS and 10% (v/v) filter-sterilised DMSO. Approximately 1x10
7
 cells/aliquot 
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were transferred to vials and frozen overnight at -70ºC prior to long term storage in 
liquid nitrogen.  
To recover cell stocks, vials were thawed quickly from liquid nitrogen in a 37ºC 
water bath. The entire aliquot was introduced to a 175cm
2
 tissue culture flask with 
full growth medium and maintained as described in Section 2.4.1. The media was 
changed 24 hr. later to remove any traces of DMSO.  
 
2.4.3 Bulk culture of P2-2 cells 
One 175cm
2
 tissue culture flask of 80-90% confluent P2-2 cells was harvested as 
described in Section 2.4.1 and used to seed three large glass roller bottles each with 
200ml of medium. CO2 was introduced into the bottles for 30 sec., as the bottles 
were unvented, prior to incubation at 37ºC. Cells were harvested after four to seven 
days using mechanical agitation with glass beads. Lysates were pelleted by 
centrifugation at 340 x g for 3 min. before storage at -70ºC.  
 
2.4.4 Transfection of cells in 12-well plates 
HEK293 cells were transfected when cells were 80-90% confluent using 
Lipofectamine™ 2000 according to manufacturer’s instructions. The mixture was 
added in a drop-wise manner to the cells in serum-free DMEM. After incubation at 
37°C in 5% CO2 for 5 hr., the serum-free media was replaced with DMEM with 2% 
(v/v) FCS and returned to the incubator. For larger or smaller densities of cells, all 
volumes were altered accordingly.  
 
 
2.5 Virological Techniques  
2.5.1 Growth of Adenovirus stocks 
Mammalian cells were seeded into 90mm dishes to be 90% confluent the following 
day. Cells were infected with a multiplicity of infection (M.O.I) of 10 plaque 
forming units (p.f.u.)/ cell and incubated at 37°C in 5% CO2 for 1 hr., rocking every 
15 min. 10ml medium was then added to the cells. Full cytopathic effect (c.p.e.) was 
reached after approximately 2-3 days, the infected cells were harvested into a sterile 
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polypropylene tube and stored at -70ºC. Before use, virus preparations were freeze-
thawed three times using a 37ºC water bath and dry ice to achieve rigid temperature 
cycles, so that viral particles were freed from cellular material.  
 
2.5.2 Adenovirus plaque assays 
The virus stock prepared as in 2.5.1 was centrifuged at 340 x g and the liquid 
aliquoted into a new tube to remove cell debris. The stock was serially diluted into 
10-fold dilutions in serum free medium. Each virus dilution was used to infect 
monolayer 6-well cultures of HEK293 cells in triplicate, which were then incubated 
at 37°C for 1 hr. with rocking every 15 mins. to spread the inoculums. The virus 
solution was aspirated from the cells and 2ml of noble agar overlay was added to 
each well before incubation at 37°C in 5% CO2. Every 3-4 days an additional 1ml of 
noble agar feed was added until plaques were visible, a larger or smaller volume was 
used for different tissue culture plate sizes. Plaques were stained with noble agar 
staining overlay allowing plaques to be counted and the virus titre determined.  
 
2.5.3 β-galactosidase assays for constructs containing LacZ 
HEK293 cells were transfected or infected with either plasmid or virus containing 
the LacZ gene as described in Sections 2.4.4 and 2.5.1. Cells were washed with PBS 
after 24-36 hr. and fixed using 1ml fixative solution for 5 min. at RT. Cells were 
washed twice in PBS prior to incubation at 37ºC overnight in 1ml β-galactosidase 
substrate solution. Cells were assessed for β-galactosidase activity under a light 
microscope by observing the cells changing to a blue colour.  
 
2.5.4 Growth of PVM J3666 stocks 
Confluent monolayers of BS-C-1 cells in GMEM NEAA with 2% (v/v) FCS at 37°C 
in 5% CO2, were infected with stocks of PVM strain J3666 at an M.O.I of 10 p.f.u. 
Cells were incubated at 32°C and virus was harvested when c.p.e was observed. 
Virus was aliquoted and stored at -70°C.  
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2.5.5 PVM plaque assays 
BS-C-1 cells were seeded at 5x10
5
 cells/ml into 12-well plates. The virus stock was 
thawed on ice and 10-fold serial dilutions were prepared in serum free media. 4% 
(w/v) CMC agar was diluted to 2% using 2x GMEM-NEAA with 2% (v/v) FCS, 
0.15% (w/v) Penicillin/Streptomycin and 2% (w/v) glutamine. The dilutions were 
used to infect the cells in triplicate. After 1 hr. incubation at 32°C, 2ml of the CMC 
agar solution was added to each well of the plate. The assay was incubated at 32°C 
for 10-12 days until plaques were seen. To stain the assay, 2% (v/v) gluteraldehyde 
in PBS was added to each well and incubated at RT for 1 hr. The overlay was then 
removed and 1ml 1.5% (w/v) crystal violet in ethanol was added and the plate 
incubated at RT for 5 min. The stain was removed with SDW and dried at 37°C prior 
to observation of plaques under a light microscope.  
 
 
2.6 Protein Detection  
2.6.1 Immunofluorescence  
12-well plates containing sterile cover slips were incubated with 0.1µg/ml polylysine 
for 1 hr. at 37°C before cells were seeded at 5x10
5
/well prior to the experiment. To 
fix the cells at the conclusion of the experiment, the cover slips were washed three 
times in 1ml PBS prior to incubation for 10 min. at RT with 10% (v/v) formalin in 
PBS. The cells were then washed three times with 1ml PBS and incubated for 10 min. 
at RT with 0.5% (v/v) NP40 in PBS to permeabalise the cells and permit antibody 
access to internal antigens. The cells were then washed three times in 1ml PBS and 
either stored at 4°C in 2ml PBS or used immediately in an immunofluorescence (IF) 
experiment.  
 
The cells fixed onto cover slips were incubated for 1 hr. at RT with 0.5ml 1% (w/v) 
BSA in PBS prior to three 1ml washes in PBS. The cells were incubated for 1 hr. at 
RT with 0.25ml primary antibody (Table 2.1.7) diluted in 1% (w/v) BSA in PBS. 
The cells were washed three times with 1ml PBS prior to incubation for 1 hr. RT in 
the dark with 0.25ml secondary antibody (Table 2.1.7) diluted as before. The cells 
were then washed three times in PBS and the incubation steps were repeated with the 
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second primary antibody and the second secondary antibody. Once the final wash 
after staining was completed, the cells were incubated for 5 min. at RT in the dark 
with 1ml 0.001% (w/v) DAPI in PBS. The cover slips were removed from the wells 
and placed on tissue to remove excess DAPI stain. The cover slips were placed cell 
side down onto 4µl mounting solution and the edges sealed with clear nail varnish. 
Images were obtained using a Leica SP2 confocal system.  
 
2.6.2 Radioactive labelling of mammalian cellular proteins using [35S] 
methionine  
Mammalian cells were infected with recombinant adenovirus (rAd) as described in 
2.5.1. 20 hr. post-infection, the cells were pre-starved of methionine (Met) through 
addition of 0.5ml/well Met-free media for 20 min. Met-free media was then aspirated 
from the cells to which 0.1ml of [
35
S]Met was added diluted to a final concentration 
of 50µCi/ml. Cells were incubated at 37°C for 30-60 min. prior to removal of the 
[
35
S]Met. Cells were washed in 0.5ml PBS and lysed directly in 50µl 1x sample 
buffer.  
 
2.6.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Cell extracts in 1x sample buffer were denatured in a boiling water bath for 10 min. 
and loaded onto a gel comprising of stacking gel plus 10% resolving gel. SDS-PAGE 
was performed using a Mini-PROTEAN 3 electrophoresis system (BioRad) with 
electrophoresis at 150V for 90 mins. The protein marker PageRuler™ Prestained 
Protein Ladder was used as a size marker for the proteins.  
 
2.6.4 Western Blotting 
Proteins were transferred from SDS-PAGE gels to nitrocellulose membranes at 4°C 
at either 80mA overnight or 350mA for 75 min. The membrane was blocked at RT 
for 1 hr. with blocking solution or at 4°C overnight. The membrane was then 
incubated for 1 hr. at RT with primary antibody (Table 2.1.7) diluted in blocking 
solution and shaken vigorously. The membrane was then washed in PBS-Tween for 
1 hr. and with regular buffer changes. The membrane was then incubated for 1 hr. at 
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RT with secondary antibody appropriate to the primary antibody used (Table 2.1.7) 
diluted in blocking solution and shaken vigorously. The membrane was then washed 
in PBS-Tween for 1 hr. and as before changed regularly. Finally, the membrane was 
incubated for 5 min. at RT with 0.5ml ECL Advance™ Solution A and 0.5ml of ECL 
Advance™ Solution B (HRP chemiluminescent substrate). The membrane was 
placed on filter paper to remove excess substrate and exposed to X-ray film from 30 
sec. to 5 min.   
 
2.6.5 Exposure of radio labelled samples to X-ray film 
Radio labelled samples were separated by SDS-PAGE as described in Section 2.6.4. 
The gel was fixed for 1 hr. in 250ml 25% (v/v) methanol and 7% (v/v) acetic acid in 
SDW prior to drying on a gel dryer (BioRad) for 2 hr. The gel was then exposed to 
X-ray film for 1-12 hr. 
 
 
2.7 Immunogen preparation 
2.7.1 Virus particle stock isolation 
Crude adenovirus particle stocks were generated as described in Section 2.5.1. After 
full c.p.e. was reached, cells from five dishes were pelleted together at 340 x g for 3 
min. The supernatant was discarded and the pellet stored at -70°C. The pellets were 
thawed on ice and resuspended in 5ml ice cold 0.1M Tris-HCl pH8. The cell 
suspension was sonicated in an ice bath with a microtip probe sonicator (Jencons 
Scientific Ltd) using two sets of 10x1 sec. separated by 30 sec. The suspension was 
centrifuged at 5000 x g for 10 min. and the resulting supernatant was layered over 
step CsCl gradients, prepared using 3ml 1.25g/ml (w/v) CsCl and 2ml 1.40g (w/v) 
CsCl in a Beckman SW41 ultra centrifuge tube. 0.1M Tris-HCl pH8 was added to 
each gradient to ensure they were of equal weight. Gradients were centrifuged at 
35,000 rpm using a Beckman SW41 rotor for 1 hr. at 15ºC.  
 
The band of virus particles was extracted from the gradient by bottom puncture and 
collected in a SW55 ultra centrifuge tube on ice. 1.35g/ml (w/v) CsCl was added to 
each tube to within 2-3mm of the rim and weighed to ensure each gradient was of 
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equal weight. Gradients were centrifuged at 40,000 rpm in a Beckman SW55 rotor 
for approximately 18 hr. at 15ºC. Virus particles were extracted from the gradient by 
bottom puncture and collected in a microfuge tube on ice.  
 
Virus particles from CsCl gradient fractions were purified by dialysis in 400ml 20% 
(v/v) glycerol in PBS for 12-18 hr. at 4°C with one buffer change. The dialysis 
tubing was prepared by boiling for 20 min. in 2% (w/v) NaHCO3, 10mM EDTA and 
rinsed in SDW. Tubing was boiled again for 5 min. in 1mM EDTA and autoclaved 
for 1 hr. Tubing was stored in 70% (v/v) ethanol and 1mM EDTA at RT.  
 
2.7.2 Virus particle stock quantification 
1µl of virus particle solution was diluted in 25µl 1xTE containing 0.1% (w/v) SDS 
and quantified by measuring absorbance at 260nm using the nanodrop 
spectrophotometer. The virion concentration is given by the relationship that 1 A260 = 
10
12
 virions/ml (Tollefson, 2007). For each virus stock, a plaque assay was also 
performed as described in Section 2.5.1.2 to determine the infectious titre and DNA 
was isolated and amplified as described in Sections 2.2.5.2 and 2.2.1.1 respectively 
to confirm that the stocks retained the relevant PVM gene.  
 
 
2.8 In vivo related techniques 
2.8.1 Maintenance of mice 
Pathogen free BALB/c mice were purchased from B and K Universal Ltd and were 
used to set up a breeding colony housed at the University of Warwick Biomedical 
Services Unit. Male and female mice were used in experiments at between five and 
seven weeks of age. Mice were maintained in filter-top cages and routinely 
monitored for specified pathogens, including PVM.  
 
For all experiments, mice were housed within a category three isolated holding room 
once inoculated with PVM strain J3666. Room humidity and temperature, mouse 
weight and clinical signs were monitored daily for the duration of the experiment. 
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Mice were sacrificed if deemed appropriate due to health reasons, or at the end of the 
experiment, by cervical dislocation.  
 
2.8.2 Administration of immunogens to mice 
2.8.2.1 Administration of anaesthetic  
Mice were anaesthetised using 0.15-0.2ml/mouse Ketamine/Xylazine solution by 
direct injection into the lower right abdomen. After procedures were completed, mice 
left to recover in low light conditions.   
 
2.8.2.2 Inoculation with virus or vaccines 
For intranasal immunisation, mice were anaesthetised and inoculated with 50µl of 
PVM strain J3666, Influenza A/WSN, or rAd constructs. The inoculum was evenly 
distributed between the nostrils and administered in small droplets.  
For intraperitoneal immunisation, mice were inoculated with 200µl of rAd constructs 
directly into the abdomen as described for anaesthesia.  
For subcutaneous immunisation, mice were anaesthetised and inoculated with 50µl 
of rAd constructs directly into the scruff of the neck. The inocula were evenly 
distributed by gently rubbing the area.  
 
2.8.3 Sample collection 
For serum sample collection, live mice were anaesthetised or restrained mechanically, 
to allow blood collection by removal and massaging of the tail tip. Samples were 
harvested from sacrificed mice by cardiac puncture and removal of serum using a 
syringe. The blood was incubated on ice for 2 hr. prior to centrifugation, then serum 
was transferred to a fresh sterile microfuge tube and stored at -20°C.  
For lung and spleen collection, samples were harvested from sacrificed mice by 
removal of entire lung lobes or spleen. Samples were stored in 1ml PBS at -70°C for 
long-term storage. For use in ELISPOT assay, materials were stored until needed in 
1ml PBS on ice.  
For bronchoalveolar lavage (BAL) fluid collection, BAL samples were harvested 
from sacrificed mice. The entire chest cavity and trachea were exposed prior to 
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making a small incision at the top of the trachea. A blunt needle, previously loaded 
with 1ml PBS, was inserted into the trachea and secured using suture thread. The 
PBS was forced into, and withdrawn from the lungs and transferred to a sterile 
microfuge tube for storage at -70°C.  
 
 
2.9 Immunological techniques 
2.9.1 ELISA for detection of anti-PVM humoral immunity 
Several lysates of the P2-2 cell line were grown as described in 2.4.3 and pooled 
together to form a stock lysate solution. The cell lysate was sonicated in an ice bath 
with a microtip probe sonicator (Jencons Scientific Ltd) using two sets of 10x1 sec. 
separated by 30 sec. This was diluted to 1mg/ml in coating solution and plated at 
50µl/well into a flat-bottomed 96-well plate. The plate(s) were incubated at 4°C for 
12 hr. The coating solution was removed from the plate, which was then incubated 
with 0.2ml/well 5% Marvel/PBS for 2 hr. at RT. Primary serum was typically diluted 
1:85 for the initial dilution and then serially diluted 1:3 across the plate in 0.1ml/well. 
The plate was incubated at RT for 2 hr. prior to three 0.4ml/well PBS-Tween washes 
using a plate washer (Amersham Biosciences). Secondary HRP conjugated antibody 
was added at 0.1ml/well (Table 2.1.7) and the plate was incubated at RT for 2 hr. 
The three wash steps with 0.4ml/well PBS were repeated and 0.1ml/well of ABTS at  
1.8mM, was added. The plate was incubated in the dark until a colour change was 
discernable prior to the absorbance being measured at 405-410nm on Labsystems 
multiskan RC plate reader. 
 
2.9.2 ELISA for detection of anti-Ad humoral immunity 
Ad327 particles were grown and purified as described in 2.5.1.1 and 2.7. Virions 
were exposed to UV light at 253.7nm for 5 min. using a transilluminator (Gelman 
Science Ltd UK) to inactivate them. These were then diluted to 1µg/ml in coating 
solution and plated at 50µl/well into a flat-bottomed 96-well plate. The protocol as 
described in Section 2.9.1.1 was then followed.  
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2.9.3 Murine lymphyocyte ELISPOT assay 
ELISPOT plates (MAIPS4510) were coated aseptically with capture antibody in 
sterile coating solution to a final concentration of 15µg/ml at 50µl/well. The plates 
were incubated either overnight at 4°C or for at least 1 hr. at 37°C. Coating solution 
was then removed prior to addition of 100µl/well of RPMI with 10% FCS. The 
plates were then incubated at 37°C for at least 1 hr. to block the wells.  
 
2.9.3.1 Preparation of murine splenocytes 
Spleens were harvested as described in Section 2.8.3.2. Spleens from individual 
animals were pooled according to their group and mashed through a cell strainer. 
Cells were passed through the strainer several times to ensure all clumps were 
removed. The cell suspension volume was increased to 30ml with sterile PBS prior 
to the addition of 15ml Histoplaque solution underlay. The suspension was then 
centrifuged at 1200 x g for 30 min. at RT with no brake. Cells were removed from 
the interface between PBS and Histoplaque solution, and transferred to a fresh 
container. The cell suspension volume was increased to 40ml prior to centrifugation 
at 884 x g for 10 min. at RT. The supernatant was discarded and the cell pellet 
resuspended in 40ml PBS and centrifuged at 884 x g for 10 min. at RT; this step was 
repeated three times. The splenocytes were then resuspended in 1-5ml RPMI media 
with 10% FCS prior to counting using a haemocytometer.  
 
2.9.3.2 Preparation of lung lymphocytes 
Lungs were harvested as described in Section 2.8.3.2. and the lungs from individual 
animals were pooled according to their group. Tissue was chopped into very small 
pieces prior to addition of 15ml of DNase and Collagenase A at a final concentration 
of 1mg/ml and 2.4mg/ml respectively. This mixture was then incubated for a 
minimum of 30 min at 37°C with vigorous shaking, and then treated as previously 
described in Section 2.9.2.1.2.  
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2.9.3.3 Preparation of naive antigen presenting cells (APCs) 
If required, an appropriate number of naive splenocytes were centrifuged at 884 x g 
for 10 min. prior to resuspension with PVM strain J3666 virus to give an M.O.I of 1 
p.f.u./cell. APCs were incubated for 90 min. with rolling at 37°C prior to irradiation 
at 3000 rads for 15 min., then centrifuged at 884 x g for 10 min. APCs were then 
washed twice in sterile PBS before resuspending in an appropriate volume of RPMI 
with 10% FCS.  
 
2.9.3.4 Preparation of target cell populations and antigen 
Splenocytes or lung lymphocytes were diluted to an appropriate concentration in 
RPMI medium (RMPI containing 10% FCS, 0.1% β-mercaptoethanol, IL-2 at 5U/ml 
(final concentration), 10U/ml penicillin G and 10μg/ml streptomycin sulphate). Cells 
were added at 5x10
5
 cells/well in a 50μl volume to the ELISPOT plates.  
Peptides were used at a final concentration of 5µg/ml per well whereas virus-infected 
or naive splenocytes were used neat at 50µl/well.  
 
2.9.3.5 Development of ELISPOT plate 
Cell and antigen suspension was removed and the plates washed six times with PBS-
Tween. The secondary antibody, biotinylated rat anti-mouse IFNγ was diluted to 
1µg/ml and added to the plate at 50µl/well. The plate was incubated in the dark for 2 
hr. at RT. Plates were then washed six times with PBS-Tween prior to the addition of 
strepavidin AP conjugate at 1µg/ml at 50µl/well. The plates were incubated for 1 hr. 
at RT in the dark. Plates were then washed six times with PBS-Tween prior to the 
addition of AP conjugate substrate as per manufacturer’s instructions at 50µl/well. 
Plates were incubated at RT for 5-20 min. in the dark to allow the colour to develop. 
The reaction was stopped by addition of water to the plates, which were then left to 
dry for at least 1 hr. prior to reading using an AID ELISPOT reader.  
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2.9.4 Intracellular staining assay (ICS) of murine lymphocytes 
2.9.4.1 Spleen and lung lymphocyte preparation 
Splenocytes and lung lymphocytes were prepared as described in Sections 2.9.3.1-2. 
The cell suspensions were either used directly in an ICS assay or diluted to 
1.5x10
7
/ml and co-cultured in a 25cm
2
 tissue culture flask with 3x10
6
/ml of APCs, 
stimulated as described in Section 2.9.3.3. Cell suspensions were incubated at 37°C 
in 5% CO2 for seven days. Cells were harvested and were pooled appropriately in a 
sterile polypropylene tube. The cells were centrifuged at 884 x g for 10 min. prior to 
resuspension in PBS. The cells were again centrifuged at 884 x g for 10 min. and 
resuspended in 1-5ml of RPMI medium with 10% FCS prior to counting with a 
haemocytometer.  
 
2.9.4.2 Preparation of target cell populations and antigen 
Splenocytes and lung lymphocytes were diluted to an appropriate concentration in 
RPMI medium (RMPI containing 10% FCS, 0.1% β-mercaptoethanol, IL-2 at 5U/ml 
(final concentration), 10U/ml penicillin G and 10μg/ml streptomycin sulphate). Cells 
were added at 50µl/well to a round bottom 96-well plate. Peptides were used at a 
final concentration of 5µg/ml per well whereas virus infected or virus naive APCs 
were added to the plate at 50µl/well.  
The plate was then incubated for at least 3 hr. at 37°C in 5% CO2, prior to the 
addition of PMA/Io solution and BFA (Table 2.1.1). BFA was added to inhibit 
protein transport to allow effective detection of IFNγ. The plate was then incubated 
for 3 hr. prior to immunostaining with appropriate antibodies (Table 2.1.7).  
 
2.9.4.3 Intracellular fluorescent staining of lymphocytes 
The cell suspension was pelleted by centrifugation at 250 x g for 2 min. then the cells 
were washed in 100µl/well of FACS buffer. The plate was centrifuged again at 250 x 
g for 2 min. prior to the addition of extracellular staining antibody, usually anti-
mouse CD4
+
 and anti-mouse CD8
+
, both at a final concentration of 1µg/well in a 
50µl volume (Table 2.1.7). The cell suspension was incubated for 20 min. at RT in 
the dark prior to centrifugation at 250 x g for 2 min. The cells were then washed 
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twice with 100µl/well of cold PBS, prior to addition of 100µl of BD 
Cytofix/Cytoperm™ Fixation/Permeabilization solution. The plate was incubated for 
20 min. at 4°C, then washed twice with 1x BD Cytofix/Cytoperm™ Perm/Wash™ 
Buffer. Anti-mouse IFNγ (Table 2.1.7) was diluted to a final concentration of 
1µg/well in 1x Perm/Wash™ buffer. The antibody was added to the cells in a 50µl 
volume and incubated for 30 min. at 4˚C. The cells were then washed twice with 
Perm/Wash™ buffer, before resuspension in 100µl/well cold FACS buffer. Cells 
were transferred to FACS tubes containing 300µl FACS buffer prior to analysis on 
FACSCalibur (BD Biosciences). Data was analysed using CellQuestPro software.  
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Chapter 3 
 
Development of Adenovirus Serotype 5 
Recombinant Viruses 
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3.1 Introduction  
 
Adenovirus serotype 5 (Ad5) has been well characterised as a vector, both for gene 
therapy and vaccine development. Deletion of the E1 and E3 regions has increased 
the capacity of vectors to incorporate foreign DNA. These E1-E3 deleted vectors are 
replication-defective yet they are able to infect host cells, express genes, and thus 
stimulate the immune response to target cells in a natural manner. An aim of this 
study has been to clone the PVM F, M, N and P genes into an Ad5 vector using the 
AdEasy™ Adenoviral Vector System (Stratagene, USA). The system, developed by 
He and colleagues (He et al., 1998), utilises a double-recombination event in bacteria 
between the Ad5 genome backbone cloned in a plasmid, pAdEasy-1, and a shuttle 
plasmid, pShuttle_CMV, carrying the transgene. The resulting recombinant Ad 
genome can then be transfected into mammalian cells to generate infectious virus. 
This method eliminates the need for multiple plaque purification whilst generating a 
replication-defective virus. However, the E1-E3 deleted vector requires the E1 gene 
products for virus growth in tissue culture cells. The E1 gene products can be 
provided in trans by HEK293 cells, a transformed human embryonic kidney cell line 
that carries copies of the E1 genes in its genome.  
 
In this chapter, the construction of the pShuttle_CMV vectors containing the PVM F, 
M, N and P genes and subsequent generation of Ad5 recombinant plasmids through 
homologous recombination with pAdEasy-1 is described. The expression levels and 
presence of the PVM proteins following recombinant virus infection were 
investigated using Western blot, immunofluorescence (IF) or RT-PCR. Finally, virus 
stocks were characterised by PCR to confirm retention of the relevant transgene and 
titred by plaque assay.  
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3.1.1 Overview of the AdEasy™ Adenoviral Vector System 
The gene of interest can be cloned into the multiple cloning site (MCS) of 
pShuttle_CMV vector (Fig. 3.1A). The vector is then linearised by digestion with 
PmeI and co-transformed into BJ5183 cells with a plasmid containing the viral 
genome, pAdEasy-1. This promotes recombination between the two molecules of 
DNA (Fig. 3.1B). Transformed clones can then be screened for kanamycin resistance 
and through a restriction digest, using the PacI enzyme. A diagnostic digest 
generates a DNA fragment which identifies recombinants. DNA from the 
recombinants is then purified prior to transformation into XL10-Gold® cells. XL10-
Gold® cells are recA
-
, preventing further recombination events occurring and 
allowing the amplification of a stable plasmid. The endA mutation in the bacterial 
cell line improves the plasmid DNA quality as single stranded breaks in the DNA are 
less likely to be introduced. The DNA is then purified and re-screened using a 
diagnostic digest with the PacI restriction enzyme. If the correct DNA fragment is 
identified, the DNA preparation is digested completely with the PacI enzyme to 
liberate the rAd5 recombinant genome from the pAdEasy-1 plasmid. The liberated 
virus genome is then used to transfect HEK293 cells and with subsequent 
amplification steps within this cell line, the recombinant viruses can be isolated and 
grown to a high titre.  
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Figure 3.1. The overview of the AdEasy™ Adenoviral Vector System 
construction.  
(A) The pShuttle_CMV plasmid is a basic vector which allows a recombination 
event to occur with another plasmid, pAdEasy-1 to generate an adenoviral genome 
within a bacterial plasmid backbone (App. B. Fig. B.1). The plasmid encodes left and 
right inverted terminal repeats (LITR and RITR respectively), an encapsidation 
signal (ES), pBR322 origin of replication (Ori), and kanamycin resistance (Kan
R
) to 
allow for clone selection. A gene of interest, up to 6.6Kb in size can be inserted into 
the multiple cloning site (MCS) of the plasmid. The mammalian cytomegalovirus 
immediate-early promoter (CMV promoter) upstream of the MCS regulates the 
transgene expression. Downstream of the MCS is an SV40 polyadenylation signal 
(SV40 pA) which ensures polyadenylation of the gene of interest transcript.  
  96   
Through restriction digest of pShuttle_CMV and the gene of interest, the gene of 
interest can be inserted into pShuttle_CMV through directional ligation. The vector 
is then linearised by restriction digest using the PmeI restriction enzyme.  
 
(B)  The pAdEasy-1 vector contains the human Ad5 genome, an ampicillin resistance 
gene (Amp
R
), pBR322 origin of replication (Ori) and the left and right arms of 
adenoviral DNA. Linearised pShuttle_CMV containing the gene of interest can be 
co-transformed with pAdEasy-1 into E. coli strain BJ5183. This recA
+
 strain 
facilitates homologous recombination events between the plasmids in the left and 
right arms of Ad5 DNA. The recombination event is selected for by the loss of Amp
R
 
from pAdEasy-1 and the acquisition of Kan
R
 and the gene of interest from 
pShuttle_CMV. The resultant recombinant Ad5 genome (black plasmid line) is 
released from the plasmid backbone through restriction digest with the PacI enzyme.  
 
 
3.2 Cloning the PVM genes  
3.2.1 Construction of pShuttle_CMV plasmids containing the F, M and P 
genes of PVM 
The initial cloning step amplified the F and M genes from plasmid p15FL-2G 
(Section 2, Table 2.1.8) by PCR. p15FL-2G contains cDNA of the genome of non-
pathogenic PVM strain 15. The M proteins of PVM strain 15 and J3666 are identical 
with one non-coding nucleotide change, G700U. The F gene from PVM strain 15 has 
one non-coding change, G966U and two coding changes, A737G and C992U 
corresponding to amino acid changes Lys243Arg and Ala328Val respectively. The 
primers PVMFFOR and PVMFREV generated a cDNA fragment of the F gene, of 
1616bp (Fig. 3.2A) whereas the primers PVMMFOR and PVMMREV generated a 
cDNA fragment of the M gene of 770bp (Fig. 3.2B).  
 
The pP2 plasmid (Table 2.1.8) contains the P gene from PVM J3666. The P gene 
was amplified from the pP2 plasmid by PCR using the PVMPFOR and PVMPREV 
primers, generating a cDNA fragment of 894bp (Fig. 3.2C). All primers incorporated 
KpnI and XhoI restriction sites at the 5’ and 3’ ends of the genes respectively. These 
restriction sites were present in the MCS of pShuttle_CMV with sufficient separation 
to allow their simultaneous digestion (Fig. 3.3).  
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Figure 3.2. PCR amplification of the PVM genes.  
The PVM F, M, N and P genes were amplified from their parental plasmids using the 
specific primer pairs: PVMFFOR and PVMFREV (A); PVMMFOR and 
PVMMREV (B); PVMNFOR and PVMNREV (C); and, PVMPFOR and 
PVMPREV (D). The restriction sites incorporated into the cDNA fragments are 
underlined whereas start and stop codons are identified in red.  
 
 
 
The cDNA fragments and the pShuttle_CMV vector were purified prior to restriction 
digestion with KpnI and XhoI enzymes. The DNA was then re-purified and the F, M 
and P gene cDNA’s were separately ligated into the prepared pShuttle_CMV plasmid. 
The resultant reaction mixes were used to transform E. coli DH5α. The E. coli were 
screened for acquisition of kanamycin resistance using selective media. DNA from 
twenty randomly chosen colonies per construct was purified and confirmed to be 
correct by a diagnostic digest with KpnI and XhoI restriction enzymes (Fig. 3.3).  
 
DNA preparations from at least six positive clones for pShuttle_CMV_F and _M and 
one clone for pShuttle_CMV_P, were re-purified and sequenced using the original 
amplification primer pairs. Nucleotide sequence analysis confirmed no alterations 
were present within the pShuttle_CMV_M plasmid sequence as compared with the 
database sequence for this gene (AY729016.1, App. A. Fig. A.1). pShuttle_CMV_P 
was sequenced with two additional primers, P2-A and P2-B (Section 2, Table 2.1.9), 
which amplified regions within the PVM P gene. The pShuttle_CMV_P sequence 
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was compared with the database sequence for the P gene (AY573814, App. A. Fig. 
A.4) and no alterations were found to be present. Finally, pShuttle_CMV_F was 
sequenced with primers F1, F2, F7, F9 and F11, in addition to the original primers to 
ensure the entire gene was sequenced. The nucleotide sequence for the PVM F gene 
was compared with the database sequence for this gene (AY729016.1, App. A. Fig. 
A.2). Two non coding changes, T87C and T256C, and one coding change T849C 
corresponding to amino acid change P283L, were identified. 
 
 
 
 
 
 
 
 
Figure 3.3. Screening the pShuttle_CMV 
clones for successful ligation of the PVM 
genes.  
pShuttle_CMV plasmids containing the F, M 
and P genes of PVM were confirmed to be 
correct by a diagnostic digest with restriction 
enzymes KpnI and XhoI. The digest liberated 
the PVM genes from the pShuttle_CMV 
vector, yielding a positive digestion pattern of 
bands approximately sized 1.6Kbp (lane 1), 
0.77Kbp (lane 2), 0.89Kbp (lane 3) 
corresponding to the F, M and P genes 
respectively. Results are representative of 
several isolated clones.  
 
 
 
3.2.2 Construction of pShuttle_CMV plasmids containing the N gene of PVM 
The PVM N gene was amplified from the pN3 plasmid, which contains the N gene 
from PVM strain J3666 by PCR using the PVMNFOR and PVMNREV primers. A 
cDNA fragment of 1184bp was generated with SalI and XhoI restriction sites 
incorporated into the 5’ and 3’ ends respectively (Fig. 3.2).  
 
Several attempts were made to generate pShuttle_CMV_N encoding the N gene 
cDNA fragment in the correct orientation. All attempts were unsuccessful at cloning 
N cDNA in either orientation, therefore, it was concluded that the efficiency of the 
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SalI digest was insufficient to generate a clonable product. To overcome this, the 
uncut N cDNA fragment was blunt ligated into the EcoRV site of pShuttle_CMV and 
the resultant reaction was used to transform E. coli DH5α, which were then selected 
for kanamycin resistance using selective media. Finally, DNA preparations from 
twenty randomly chosen colonies were purified and the correct orientation of the 
PVM N gene was confirmed through a diagnostic digest using the restriction enzyme 
BstXI (Fig. 3.4). DNA from six of these correct colonies was re-purified and 
sequenced using the primers PVMNFOR, PVMNREV, N3, J2, and N5 (Table 2.1.9). 
Sequence analysis confirmed no alterations were present within the 
pShuttle_CMV_N plasmid sequence when compared with the database sequence for 
this gene (App. A. Fig. A.3 (AY573813)).  
 
 
Figure 3.4. Screening pShuttle_CMV_N clones for the 
correct orientation of the PVM N gene.  
A restriction digest with the BstXI restriction enzyme 
identified the PVM N gene orientation. The enzyme cuts 
within the vector and within the PVM N gene which allowed 
the orientation to be determined. A positive digest pattern of 
bands of the sizes 6.4kbp and 2.1kbp visualised on an agarose 
gel, indicated that the N gene had been inserted into the MCS 
in the correct orientation 5’-3’ (lane 1). A digest pattern of 
bands of the sizes 6.8kbp and 1.7kbp indicated N gene 
insertion into the MCS in the opposite orientation (lane 2). 
 
 
 
3.2.3 Isolation of pAdEasy plasmids containing the F, M, N and P genes of 
PVM and the LacZ gene of E. coli 
The pShuttle_CMV plasmids containing PVM genes and pShuttle_CMV_Z which 
contains the E. coli LacZ gene (Stratagene, USA) were digested with the restriction 
enzyme PmeI to linearise the plasmids. The purified plasmids were then co-
transformed with pAdEasy-1 into E. coli BJ5183 by electroporation to generate 
pAdEasy_F, _M, _N, _P, and _Z by homologous recombination. The reactions were 
plated onto kanamycin selective agar, allowing positive clones to be identified by 
acquisition of kanamycin resistance.  
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DNA preparations from several clones for each construct were purified and screened 
for the recombination event using a PacI restriction enzyme digest. DNA from 
clones F59, F61, M2, M5, N3, N20, P17, P26, Z2 and Z5 was then used to transform 
E. coli XL-10 GOLD®. DNA was purified from these clones and a diagnostic digest 
performed using the PacI restriction enzyme. As illustrated in Fig. 3.1B, the PacI 
restriction enzyme has two sites within the recombination product of pAdEasy with 
pShuttle_CMV. This is because the acquisition of pShuttle_CMV introduces an 
additional PacI restriction site. The recombination event can occur between the right 
and left arms of homology (Fig. 3.1B), or between the pBR322 origins of replication 
and the left arms of homology. The former recombination event generates a DNA 
fragment of 4.5Kbp in size upon digestion with PacI whereas if the origin of 
replication has been utilised as a recombination site, a DNA fragment of 3Kbp would 
be generated (Fig. 3.5). It was observed that during the screening process to identify 
recombinant plasmids, recombination between the origin of replication and the left 
arm of homology occurred less frequently, presumably because the origin of 
replication sequence is smaller in size than the right arm of homology and therefore 
is less likely to generate a recombination event. 
 
DNA preparations were purified in bulk and the nucleotide sequences of the relevant 
transgenes reconfirmed using the same primers as described for pShuttle_CMV 
nucleotide sequencing. No additional alterations had occurred.  
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Figure 3.5. Confirmation of the recombination of pShuttle_CMV and pAdEasy. 
A PacI diagnostic digest confirms the occurrence of the pShuttle_CMV and 
pAdEasy-1 recombination event through a positive DNA fragment pattern of a large 
fragment plus either a fragment of 4.5Kbp or 3Kbp in size. Positive results were 
obtained for pAdEasy_F59 and F61 (lanes 1 and 2), pAdEasy_M2 and M5 (lanes 3 
and 4), pAdEasy_N3 and N20 (lanes 5 and 6), pAdEasy_P17 and P26 (lanes 7 and 8) 
and pAdEasy_Z2 and Z5 (lanes 9 and 10). The majority of the recombinants 
generated a 4.5Kbp fragment apart from pAdEasy_N3 (lane 5) (see text).   
 
 
3.3 Growth and titration of recombinant Adenoviruses  
 
To isolate viruses, recombinant Ad5 genomes released from the pAdEasy plasmid 
backbones by PacI restriction digest were then used to transfect HEK293 cells. 
Cultures were then monitored for signs of cytopathic effect (c.p.e.). Cells and culture 
media were harvested after seven days and the cells lysed by freeze-thawing. 100µl 
of the lysate was used to infect a fresh 12-well culture of HEK293 cells. The cells 
and culture media were again harvested after seven days. The method was repeated 
until c.p.e was observed within a seven day period. The virus was then used to infect 
larger cultures with a high virus volume, which amplified the virus further. The 
recombinant viruses were then passaged in HEK293 cells until c.p.e. was observed 
with kinetics similar to a typical replication-competed Ad5 dl327 (Ad327, Section 2, 
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Table 2.1.3), usually within two to three days. At this stage, the recombinant viruses 
were characterised (Table 3.1) and viral titre was determined by plaque assay. 
Finally, large scale amplification was performed for selected viruses to generate 
purified stocks for subsequent experiments. rAdN20 and rAdP26 were not pursued 
further after passage four as it became evident that these recombinants grew much 
more slowly than rAdN, rAdP17 or wild-type Ad327. rAdF61, rAdM5 and rAdZ5 
demonstrated comparable growth to Ad327 but were not characterised further.  
 
Plasmid construct Recombinant virus Outcome 
pAdEasy_F59 rAdF Characterised 
pAdEasy_F61 rAdF61 Not required 
pAdEasy_M2 rAdM Characterised 
pAdEasy_M5 rAdM5 Not required 
pAdEasy_N3 rAdN Characterised 
pAdEasy_N20 rAdN20 Not required 
pAdEasy_P17 rAdP17 Characterised 
pAdEasy_P26 rAdP26 Characterised* 
pAdEasy_Z2 rAdZ Characterised 
pAdEasy_Z5 rAdZ5 Not required 
Table 3.1:   Designation of recombinant virus names used in this study. 
* For transgene expression only 
 
 
3.4 Characterisation of the Ad5 recombinants 
3.4.1 Validation of recombinant virus replication 
Late Ad5 protein expression was initially investigated to confirm that the presence of 
the PVM transgene in the recombinant viruses did not inhibit replication in the 
complementing cell line, HEK293. All characterised recombinant viruses 
demonstrated typical late Ad5 protein expression profiles by Western blot (Fig. 3.6). 
Late protein expression was detected with an antibody (AdJLB1, Section, Table 
2.1.7), which detects several Ad5 late proteins, such as hexon, penton, protein V and 
protein VI. These are structural proteins required for construction of the viral capsid. 
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The late protein expression profile for the rAds (Fig. 3.6, lanes 1-4) has a high degree 
of similarity to that of Ad327 (Fig. 3.6, lane 6), confirming that the recombinants 
could express late proteins and thus enter late stage infection to generate infectious 
progeny when their E1 deficiency is complemented. Therefore, the presence of the 
relevant transgene did not inhibit rAd replication in HEK293 cells.  
 
 
Figure 3.6. The presence 
of the transgene in the 
rAd viruses did not 
impede replication. 
1.5x10
6 
HEK293 cells in 
total, were mock-infected 
or infected with rAdF, -M, 
-N, -Z or Ad327 at a 
multiplicity of infection 
(M.O.I) of 10 p.f.u./cell. 
Cells were lysed 24 hours 
post infection (h.p.i) and 
lysates were separated by 
10% SDS-PAGE prior to 
Western blotting. The 
membrane was probed with 
anti-AdJLB1 antibody which recognises late Ad5 proteins. The late protein 
expression profile of all rAds (lanes 1-4) was similar to wild-type control Ad327 
(lane 6). The result is representative of two replicate experiments.  
 
 
3.4.2   Validation of transgene expression from recombinant viruses 
Transgene protein expression was investigated to ensure that the recombinant viruses 
expressed the relevant proteins under the control of the CMV promoter. Transgene 
expression was confirmed either by Western blot, IF, RT-PCR or by a β-
galactosidase assay. As the final characterisation step, PCR was used to confirm the 
particle stocks generated for in vivo studies retained the gene of interest.  
 
3.4.2.1 rAdF 
Detection of PVM F mRNA expression was first attempted by RT-PCR using 
PVMFFOR and PVMFREV primers (Table 2.1.9 and Fig. 3.7). This combination of 
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primers should have enabled the detection of full length F cDNA from the mRNA 
extract. However, this reaction was unsuccessful, which may have been due to 
inefficient amplification of a long nucleotide fragment (data not shown). Therefore, 
the F17 and F2 primers were used in combination with PVMFFOR and PVMFREV 
respectively to detect PVMF mRNA via amplification of shorter segments.  
Total mRNA was extracted from rAdF infected HeLa cells and F specific mRNA 
was converted to cDNA using the F17 or PVMFREV primers. For each primer, two 
reactions were performed, one with (RT
+
) and one without (RT
-
) the reverse 
transcriptase (RT) enzyme. The RT
- 
reaction acts as a control to identify 
contaminating rAd genomic DNA because no DNA fragments should be amplified 
from an RT
-
 reaction by the PCR step if mRNA was free from genomic DNA. The 
cDNA fragments generated were amplified by PCR using the same reverse primer 
and with either PVMFFOR (Fig. 3.7, lanes 1 and 2) or F2 primers (Fig. 3.7, lanes 3 
and 4). β-actin cDNA was amplified from the total mRNA extract using actinF and 
actinR primers, to act as a mRNA loading control (Fig. 3.7, lanes 5 and 6). 
PVMFFOR and F17 amplified a 260bp fragment while F2 and PVMFREV amplified 
a 1190bp fragment (Fig 3.7B). This confirmed expression of mRNA from the F gene 
however the presence/absence of a small 164bp segment (Fig 3.7A) was not tested 
using these primer pairs. The β-actin gene fragment, of 500bp was amplified and 
confirmed that the RT-PCR and PCR reactions were successful. The RT
-
 reactions 
did not generate detectable DNA fragments, proving that the RT-PCR and PCR 
amplification occurred from mRNA rather than contaminating genomic DNA.  
 
Attempts were made to detect PVM F protein expression using an anti-F polyclonal 
antibody (clone 2018, Table 2.1.7) in Western blots from rAdF-infected HEK293 
cells (Fig. 3.8A) and pShuttle_CMV_F transfected HEK293 cells (Fig. 3.8B). The F 
protein is expressed as a large protein precursor known as F0. Upon processing 
through the trans-Golgi network, F0 is cleaved into F1 and F2. The anti-F polyclonal 
antibody detected F1 expression in PVM infected positive control samples (Fig. 3.8, 
lanes 7 and 13), consistent with previously published data (Chambers et al., 1992). 
However, F protein expression was not detected from rAdF infected or 
pShuttle_CMV_F transfected cells (Fig. 3.8 lanes 1 and 8). The antibody did appear 
to react with a ~120kDa protein in cells infected with rAdZ and transfected with 
pShuttle_CMV_Z. As transfected cell samples could not have generated early or late 
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Ad5 proteins because they lack the Ad5 genome, the band is unlikely to be an Ad5 
late protein. The antibody could have reacted with LacZ as the material used to 
generate the antibody was produced in bacteria, thus potentially, some LacZ protein 
may have contaminated the preparation and subsequently immunised the animals.  
 
 
Figure 3.7. PVM F mRNA expression can be detected from rAdF infected cells.  
(A)  The nucleotide position of the primers used in the PCR reaction, PVMFFOR, F2, 
F17 and PVMFREV, in relation to the PVM F gene.  
(B)  1.6x10
6 
HeLa cells in total were infected with rAdF at an M.O.I of 10 p.f.u./cell. 
Cells were lysed at 24h.p.i and total mRNA was extracted from the lysate. mRNA 
was then DNase treated to remove any contaminating rAd genomic DNA, repurified, 
and used directly in an RT reaction with the PVMFREV, F17 and actinR primers. RT 
negative reactions (lanes 2, 4 and 6), were included to confirm cDNA amplification 
from mRNA rather that rAdF genome. The resultant cDNA was treated with RNase 
H and was used directly in PCR reactions. Lane 1 and 2 indicate the fragments 
obtained from cDNA amplification using PVMFFOR and F17 and lanes 3 and 4 
using F2 and PVMFREV. A fragment of β-actin (*) was amplified in lane 5 using 
actinF and actinR primers with the RT- control in lane 6 using the same primer pairs. 
The results illustrated in lanes 1, 2, 5 and 6 are representative of two repeat 
experiments.  
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Figure 3.8. PVM F expression cannot be detected from rAdF infected or 
pShuttle_CMV_F transfected HEK293 cells.  
(A) 1.5x10
6 
HEK293 cells in total were mock-infected or infected with rAdF, rAdZ 
or Ad327 at an M.O.I of 10 p.f.u./cell. Mock-infected BS-C-1 cells and P2-2 cells (a 
cell line persistently infected with PVM J3666) were seeded at 5x10
5
. Samples were 
lysed at 24h.p.i.  
(B) 5x10
5
 HEK293 cells were mock-transfected or transfected with 1µg of 
pShuttle_CMV_F or –Z plasmid DNA. Samples were lysed at 48h.p.i. Controls as 
panel A.  
Lysates and 1.3x10
5
 PVM J3666 virus (PVM positive control), were mixed with 
sample buffer and separated by 10% SDS-PAGE prior to Western blotting. The 
membrane was probed with anti-PVM F protein antibody (clone 2018, Table 2.1.7). 
Full length F2 (the C-terminal product of the proteolytic cleavage of F protein) was 
detected at 39kDa in the positive controls P2-2 and PVM (lanes 6, 7, 12 and 13 (*)) 
and was absent from Ad327 and mock-infected samples (lanes 3-5, 10 and 11). F 
protein expression was not detected in rAd infected cells or pShuttle_CMV 
transfected cells (lanes 1,2,8 and 9), however the antibody appeared to detect a 
~120kDa protein in samples containing LacZ (*).   
 
 
Since it was not possible to prove expression of full length PVM F from rAdF by 
either RT-PCR or Western blot techniques, IF was performed to detect F protein 
expression in rAdF infected HeLa cells; cells were also stained for rAd5 DNA 
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binding protein (DBP), which is a marker for infection. F protein expression was 
detected in both PVM-infected BS-C-1 cells and rAdF-infected HeLa cells (Fig. 3.9) 
using the same anti-PVM F polyclonal antibody that was unable to detect F protein 
expression by Western blotting. This suggests that the Western blot technique is not 
sensitive enough to detect F protein expression, or that the antibody recognises a 
configuration of F protein that is removed by lysate processing.  
 
 
 
 
Figure 3.9. PVM F protein is expressed from rAdF. 
7.5x10
5 
HeLa cells were grown on coverslips and infected with rAdF at an M.O.I of 
10 p.f.u./cell and 5x10
5
 BS-C-1 cells were mock infected or infected with PVM at an 
M.O.I of 10 p.f.u./cell. Virus-infected cell samples were fixed 24h.p.i and 
immunostained for Ad5 DNA binding protein (DBP, green) using mAb B6-8 (Table 
2.1.7), and PVM F protein (red) using anti-PVM F antibody (clone 2018, Table 
2.1.7), whereas DNA (blue) was visualised by DAPI staining. The merged panels 
show overlays of all three stains. Images were collected by confocal microscopy all 
at the same scale (scale bars 160µm (long) and 80µm (short). Arrows indicate cells 
that are positive for F protein staining.  
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PVM F protein expression was principally located in the cytoplasm of PVM or rAdF 
infected cells, with some rAdF-infected HeLa cells demonstrating strong F protein 
expression (Fig. 3.9 arrows). HeLa cells do not encode the missing Ad5 E1 gene 
products and thus should not complement rAdF growth and progression to late stage 
infection. However, several cells appeared to have progressed to late-stage Ad 
infection as judged by the DBP staining, which had altered from small nuclear bodies 
located within the nucleus to a ring-like structure at the boundaries of the nucleus. 
This suggested that the rAdF virus stocks might be contaminated with revertant wild-
type rAd5 virus, a suggestion supported also by the observation that only a subset of 
the DBP-positive cells were positive for PVM F straining. The virus preparation 
might have become contaminated with a wild-type strain during stock passages, but 
this is thought unlikely. Alternatively, a subpopulation of rAdF might have re-
acquired the E1A/B region present in the HEK293 cell line by recombination, 
allowing the virus to replicate in non-complementing cells. This problem has been 
documented previously in the use of HEK293 cells for recombinant virus growth 
(Lochmuller et al., 1994). F protein expression may be deleterious to Ad replication, 
which may have promoted loss of F gene expression and given a selective pressure 
for recombination with the E1A/B region of HEK293 cells.  
 
To determine the relative amount of replication-competent Ad in the stock of rAdF, a 
radio-labelling experiment was performed to label all newly synthesised proteins 
with radioactive [
35
S]Met (Fig. 3.10). The experiment was performed in two cell 
lines, A549 and HEK293 cells, respectively incapable and capable of complementing 
the E1-deficiences in rAd and thus allowing their full replication. It was hypothesised 
that comparing the extent of viral protein synthesis of each virus in the two cell types, 
the extend of any wild-type or replication-competent Ad5 would be discerned. In the 
complementing cell line, HEK293, the amount of key Ad protein expression from the 
rAds and Ad327 was indistinguishable (Fig, 3.10 lanes 7-12). This suggests that all 
the rAds are able to replicate equally within the complementing cells. In the non-
complementing cell line, A549, Ad327 expressed as expected a large amount of 
presumably late-stage infection proteins (Fig. 3.10 lane 5). In contrast, rAdM, rAdN 
and rAdZ generated essentially no detectable viral late proteins (Fig. 3.10 lanes 2-4 
and 6). Therefore, it was concluded that these virus stocks were unlikely to have a 
replication-competent subpopulation, however, the rAdF lysate did show small 
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amounts of the same proteins that were characteristic of Ad327 infection, confirming 
the presence of a replication-competent contaminant (Fig. 3.10 lanes 1 and 5). 
However, the quantity of their proteins was very low compared to that of wild-type 
virus and thus the revertant contamination is likely to be only a small proportion of 
the total virus present.  
 
 
 
Figure 3.10. rAdF expresses late-stage infection proteins in a non-
complementing cell line.  
5x10
5 
A549 or HEK293 cells were infected with rAdF, -M, -N, -Z and Ad327 at an 
M.O.I of 10 p.f.u./cell or mock-infected. 20h.p.i cells were pre-starved of methionine 
(Met) prior to incubation with [
35
S]Met at 50µCi/ml. After one hour, samples were 
lysed and proteins were separated by 10% SDS-PAGE. Proteins were visualised by 
autoradiography. Key viral proteins include hexon (*), penton (* white) and pVI/VI 
(*). Both protein gels are representative of two repeat experiments.  
 
 
3.4.2.2 rAdM 
PVM M protein expression detection was attempted using an anti-PVM M protein 
mouse antibody expressed from a hybridoma (anti-PVM M polyclonal, Table 2.1.7). 
The antibody was used in a Western blot to try to detect M protein expression from 
rAdM infected and pShuttle_CMV_M transfected HEK293 cells. However, M 
protein expression was not detected in either the virus infected, plasmid transfected 
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or positive control samples with either this antibody or an alternative antibody (anti-
PVM M_RLing, Table 2.17). This suggests that the epitope recognised by the 
antibodies is conformational, and hence undetectable by Western blotting, or that M 
protein was expressed at very low levels even by PVM infected cells (data not 
shown).  
 
To test for transgene expression at the RNA level, full length PVM M mRNA was 
detected through RT-PCR using PVMMFOR and PVMMREV primers (Table 2.1.9) 
using total mRNA from rAdM-infected cells. The M specific primers successfully 
amplified full length M, generating a band of 770bp in size (Fig. 3.11 lane1). There 
appeared to be a similar band in the rAdM RT
-
 reaction (Fig. 3.11 lane 2) suggested 
slight contamination from genomic DNA. However, the amount of this product was 
very low in comparison to the result obtained following reverse transcription 
showing that the rAdM RT
+
 product did come predominantly from mRNA.  
 
 
 
 
Figure 3.11. Full length M mRNA 
expression can be detected from 
rAdM infected cells.  
1.5x10
6 
HeLa cells were infected in 
total with rAdM at an M.O.I of 10 
p.f.u./cell. Cells were lysed at 
24h.p.i and total cytoplasmic 
mRNA was extracted, DNase 
treated and used directly in an RT 
reaction with the PVMMREV and 
actinR primers. RT negative 
reactions were included to confirm 
cDNA detection from mRNA rather 
than rAdM genome. The resultant 
cDNA was treated with RNase H 
and was used directly in a PCR 
reaction. Lanes 1 (RT
+
) and 2 (RT
-
) 
indicate the cDNA products from 
the M gene generated using 
PVMMFOR and PVMMREV primers. Lanes 3 (RT
+
) and 4 (RT
-
) indicate the cDNA 
products from the β-actin gene generated using the actinF and actinR primers. The 
results illustrated in this figure are representative of two repeat experiments.  
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Finally, PVM M protein expression was detected by IF on rAdM infected HeLa cells 
and PVM strain J3666 infected BS-C-1 cells (Fig. 3.12). M protein expression was 
principally located in the cytoplasm of PVM infected BS-C-1 cells (Fig. 3.12, 
arrows), an observation consistent with published data for RSV (Ghildyal et al., 
2009), indicating progression to a late stage infection. This was the expected location 
for this protein. Immunostaining for the M protein in rAdM-infected HeLa cells did 
not produce a clear signal. M protein expression in these cells appeared to be 
predominantly in the nucleus, possibly because the lack of co-expression of other 
PVM proteins had disrupted its cytoplasmic localisation. Although the antibody did 
appear to stain weakly in a non-specific manner, more frequent and stronger 
immunostaining was present in the nuclei of rAdM-infected HeLa cells than in the 
control. RSV M protein localises in the nucleus during early stages of the infection 
cycle, supporting the evidence presented here (Ghildyal et al., 2003, Ghildyal et al., 
2009). DBP immunostaining generated a large amount of cytoplasmic staining, 
together with the expected more intense staining present in the nuclei of most cells 
infected with rAdM. This diffuse nuclear staining is characteristic of cells in which 
Ad is not replicating. The presence of this additional cytoplasmic staining is 
characteristic of this polyclonal antibody (K.N Leppard, personal communication). 
These IF images, taken together with the absence of late protein expression from 
rAdM (Fig. 3.10), indicate that rAdM is unlikely to be contaminated with a 
replication competent revertant, while the weak positive signal for M protein, 
coupled with the evidence of M mRNA expression (Fig. 3.11), shows the transgene 
is expressed.  
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Figure 3.12. PVM M protein is expressed from rAdM. 
7.5x10
5 
HeLa cells were infected with rAdM at an M.O.I of 10 p.f.u./cell and 5x10
5
 
BS-C-1 cells were mock-infected or infected with PVM J3666 at an M.O.I of 10 
p.f.u./cell. Virus infected cells were fixed 24h.p.i and immunostained for PVM M 
protein (green) using mouse anti-PVM M_RLing, DBP (red) using rabbit polyclonal 
serum, whereas nuclei (blue) was visualised by DAPI staining. The merged panels 
show overlays of the images for each stain. Images were collected at the same scale 
by confocal microscopy. Scale bars: 80µm.  
 
  
3.4.2.3 rAdN 
PVM N mRNA expression from rAdN was detected by RT-PCR using PVMNFOR 
and PVMNREV primers (Table 2.1.9). These primers were able to detect full length 
N mRNA in rAdN infected cells (Fig. 3.13). RT negative reactions were included for 
both rAdN and the β-actin positive control reactions. No bands were amplified for 
the β-actin RT- reaction which indicated that β-actin cDNA amplification was from 
mRNA rather than contaminating genomic DNA. The rAdN RT
-
 reaction generated 
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only a low intensity band, which suggested that although some contaminating 
genomic DNA was present, the product obtained from rAdN RT
+
 reaction did come 
predominately from mRNA amplification (Fig. 3.13 lanes 1 and 2).  
PVM N protein expression was also detected from rAdN-infected HEK293 cells by 
Western blot. N protein was expressed to a high level in the positive controls, P2-2 
cells and PVM virus, and to a moderate level in the rAdN-infected samples (Fig. 3.14 
*), at a size consistent with published literature (Barr et al., 1991). As expected no N 
protein expression was detected in rAdZ, mock-infected or Ad327-infected samples.  
 
 
Figure 3.13. Full length PVM N 
mRNA expression can be detected 
from rAdN infected HeLa cells. 
HeLa infection and RT reactions were 
performed as for Fig. 3.9, using rAdN 
and the N specific primer PVMNREV. 
Lanes 1 and 2 indicate the cDNA 
products from the N gene generated 
by PCR using PVMNFOR and 
PVMNREV primers. Lanes 3 and 4 
indicate the cDNA products from the 
β-actin gene generated as previously 
described. The results are 
representative of two repeat 
experiments.  
 
 
 
Figure 3.14. PVM N expression can 
be detected from rAdN infected 
HEK293 cells.  
1.5x10
6 
HEK293 cells were mock-
infected or infected with rAdN, rAdZ 
or Ad327 at an M.O.I of 10 p.f.u./cell 
whereas P2-2 cells were seeded at 
5x10
5
. Samples were lysed 24h.p.i and 
resuspended in sample buffer along 
with 1.3x10
5
 p.f.u./ml PVM J3666 
virus as a PVM positive control. The 
lysates were separated by 10% SDS-
PAGE prior to Western blotting. The 
membrane was probed with anti-N 
rabbit polyclonal (Table 2.1.7) which 
detected full length PVM N 
expression in rAdN-infected cells (*). 
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3.4.2.4 rAdP 
During growth passages, rAdP demonstrated slower growth kinetics than the other 
rAd viruses. Consequently, the virus was examined at an early passage, passage four, 
to determine whether there was an apparent defect in the virus. Thus, a Western blot 
was performed to determine whether there was a defect in late Ad5 protein 
expression, which would result in inefficient replication and thus slower growth 
kinetics. The late protein expression profile of rAdP was similar to Ad327 (Fig. 3.15, 
lanes 1, 2 and 4). This indicated that the virus was able to progress to late stage 
replication in the complementing cell line, HEK293. The intensity of the penton band 
in particular was similar in both the rAdP and Ad327 samples, which suggested that 
the slower growth kinetics observed for the rAdP virus was not due to defective late 
gene expression and might therefore be due to an impediment in virion assembly and 
release.  
 
 
Figure 3.15. The PVM P 
transgene does not impede 
rAdP replication in a 
complementing cell line.  
1.5x10
6
 HEK293 cells were 
mock-infected or infected 
with rAdP at an M.O.I of 10 
and 1 p.f.u./cell (lanes 1 and 
2 respectively) or Ad327 at 
an M.O.I of 10 p.f.u./cell 
(lane 4). Cells were lysed at 
24h.p.i and lysates were 
separated by 10% SDS-
PAGE prior to Western 
blotting. The membrane was 
probed with anti-adenoviral 
late protein AdJLB1 antibody 
(Table 2.1.7).  
 
 
PVM P protein expression was investigated by Western blot analysis from rAdP 
infected HEK293 cells. A mouse anti-PVM P monoclonal antibody (Table 2.1.7) was 
used to detect P protein expression (Fig. 3.16A). Full length P protein expression was 
detected in the positive controls (Fig. 3.16A, lanes 1 and 2 (white *)) and was 
consistent with published data (Barr et al., 1994). However, no PVM P protein 
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expression was detected from rAdP-infected cells (Fig. 3.15 lanes 5 and 6). To 
investigate this further, a similar experiment was performed following transfection of 
pShuttle_CMV_P plasmid into HEK293 cells. Samples were harvested at 24 hour 
increments up to 72 hours post transfection (Fig. 3.16B, lanes 5-7). Again, P protein 
expression was detected in the positive control samples (Fig 3.16B lanes 1 and 2 
(white *)), but no P protein expression was detected from Ad327, mock-transfected 
or pShuttle_CMV_P transfected cells (Fig. 3.16B, lanes 3-7). This is in contrast to 
equivalent experiments using rAdN (Fig. 3.14) and pShuttle_CMV_N (data not 
shown) in which N protein was readily detected.  
 
 
 
 
Figure 3.16. PVM P protein expression cannot be detected from rAdP-infected 
or pShuttle_CMV_P transfected, HEK293 cells.  
(A) 1.5x10
6
 HEK293 cells in total were mock-infected or infected with rAdP or 
Ad327 at an M.O.I of 10 p.f.u./cell, lanes 3 and 6 or 1 p.f.u./cell, lane 5. P2-2 cells 
were seeded at 5x10
5
. Samples were lysed at 24h.p.i.  
(B) 1.5x10
5
 HEK293 cells were mock-transfected or transfected with 1µg/well of 
pShuttle_CMV_P plasmid DNA whereas P2-2 cells were seeded at 5x10
5
. Samples 
were lysed at 24, 48 and 72 hours post transfection. 
The lysates were separated by 10% SDS-PAGE along with 1.3x10
5
 p.f.u./100µl 
PVM J3666 virus stock which was resuspended in sample buffer. A Western blot 
was performed and the membrane was probed with a mouse anti-PVM P 26/11/B5 
monoclonal antibody (Table 2.1.7).   
 
 
To determine whether the inability to detect PVM P protein from rAdP infections 
using the Western blot technique was due to failure to express the protein or to 
produce mRNA, RT-PCR was performed to detect P mRNA expression. Thus, 
PVMPFOR and PVMPREV primers (Table 2.1.9) were unable to detect full length P 
mRNA expression from rAdP-infected HeLa cells (Fig. 3.17, lanes 1 and 2), while 
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the β-actin mRNA was successfully amplified as a control indicating that the RNA 
was of good quality. The experiment was repeated using both rAdP-infected 
HEK293 cells and pShuttle_CMV_P transfected cells with the PVMPFOR and 
PVMPREV primers and also an additional reverse internal primer, J3 (Table 2.1.9). 
Once again, PVM P mRNA expression was not detected with either primer pairs 
(data not shown). These results confirmed that the rAdP virus was non-functional 
and that this was likely due to an intrinsic defect in the P expression cassette since 
the pShuttle_CMV_P plasmid was also unable to express the PVM P mRNA or 
protein from the CMV promoter.  
 
To test the possibility that some undetected error had occurred to prevent P protein 
expression in the construction of the shuttle plasmid used to isolate rAdP, a second 
construct containing the P gene was generated. pShuttle_CMV_P2 was made from 
an alternative parental plasmid using re-synthesised primer pairs PVMPFOR and 
PVMPREV, to account for possible errors within the original primer pairs. The 
plasmid was transfected into HEK293 cells and analysed for P protein and mRNA 
expression as described previously. However, PVM P expression was unable to be 
detected from the new construct by either assay (data not shown).  
 
 
Figure 3.17. Full length P mRNA expression 
cannot be detected from rAdP-infected cells.  
1.5x10
6 
HeLa cells were infected with rAdP at an 
M.O.I of 10 p.f.u./cell. Cells were lysed at 24h.p.i 
and total mRNA was extracted, DNase-treated, 
repurified and used directly in an RT reaction with 
the PVMPREV and actinR primers. RT-negative 
reactions were included to confirm cDNA 
detection from mRNA rather than rAdP DNA. 
The resultant cDNA was treated with RNase H 
and was used directly in PCR reactions. Lanes 1 
(RT
+
) and 2 (RT
-
) indicate the cDNA products 
from the P gene generated using PVMPFOR and 
PVMPREV primers. Lanes 3 (RT
+
) and 4 (RT
-
) 
indicate the cDNA products from the β-actin gene 
generated using the actinF and actinR primers. 
The results illustrated in this figure are 
representative of two identical repeats. The red 
arrow indicates the expected size of the PVM P 
cDNA amplification product.  
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3.4.2.5 rAdZ 
LacZ transgene expression from the control virus rAdZ was confirmed by a β-
galactosidase assay in HEK293 cells (Fig. 3.18). LacZ specific enzymic activity 
increased in a dose-dependent manner in rAdZ infected samples, confirming that the 
virus was successfully expressing its transgene. The virus was used in in vivo 
experiments.  
 
 
Figure 3.18.  LacZ expression 
can be detected from rAdZ 
infected HEK293 cells.  
5x10
5
 HEK293 cells were 
mock-infected or infected with 
rAdZ at an M.O.I of 0.1, 1 and 
10 p.f.u./cell, and Ad327 at an 
M.O.I of 10 p.f.u./cell. Cells 
were fixed at 24 hours prior to 
staining for β-galactosidase 
activity.  
 
 
 
3.4.3 Characterisation of recombinant virus stocks for in vivo studies  
Each of the recombinant viruses was grown in bulk, isolated by caesium chloride 
gradient centrifugation and purified by dialysis (Section 2.7). Several stocks were 
generated for each rAd construct. Routinely, stocks were analysed by PCR to 
confirm that they retained the PVM gene of interest and titred by adenoviral plaque 
assay. All stocks were positive for their respective gene and after dialysis, were 
obtained at a concentration of at least 7x10
9
 p.f.u./ml (App. B. Table B.1).   
As described in Section 2.7.2, the particle number for each virus preparation can be 
determined from the DNA content of the particle lysate. Some variation in the ratio 
of particle number (v.p) to p.f.u. was observed (App. B. Table B.1) due to variability 
in the preparation of the viral stocks. Wild-type Ad5 usually has a v.p:p.f.u. ratio of 
20:1 (Schmick, 1998). All the rAd stocks had a greater v.p:p.f.u. ratio than typical 
wild-type Ad. This suggests that replication deficient rAds may not generate 
infectious particles as consistently as replication-competent Ads. In addition, there 
was some variability between the viral stocks for each construct, indicating 
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differences in their preparation. As such, only those stocks with similar v.p:p.f.u. 
infection ratios were used in in vivo studies. There are arguments in favour of 
standardising virus immunisation doses by either infectivity (p.f.u.) or particle (v.p). 
However since the PVM-specific immunogenicity of the rAd in this study depends 
on them infecting target cells to express their transgene, it was decided to standardise 
on infectious dose.  
 
 
3.5 Discussion 
 
The method used to generate recombinant Ad5 viruses has been demonstrated to be 
successful. rAdF, rAdM, rAdN and rAdZ viruses were grown to high titres and were 
stable. During the cloning procedure, no mutations were observed, presumably due 
to the use of the high fidelity enzyme Pfu turbo to generate the initial cDNA 
fragments. To further prevent mutations from arising in the pAdEasy genome clones, 
E. coli XL10-Gold™ was utilised to grow stocks of the plasmids which reduced the 
chance of unwanted recombination. Four recombinant viruses were generated using 
these methods, which were shown to have similar growth kinetics to wild-type Ad5 
and no alterations were introduced into the transgene from the cloning procedure, 
preventing transgene expression from the CMV promoter. However, the same 
method generated a virus, rAdP, from which P mRNA and protein expression was 
undetectable. This same fault was also found in the pShuttle_CMV_P plasmid. To 
investigate the reasons for this, the CMV promoter was sequenced to determine 
whether a mutation had occurred that prevented P protein expression, but none were 
found. The constructs were re-isolated and the routine characterisation re-performed. 
Again, the second batch of isolates were negative for PVM P protein and mRNA 
expression. Thus, rAdP generation was discontinued and was not taken forward for 
in vivo studies.  
Some additional insight into the failure of P protein expression from 
pShuttle_CMV_P has come from the work of C.Yu (personal communication), 
performed during her BSc Honours project in our laboratory. Two pShuttle_CMV_P 
constructs were generated, one containing Flag-tagged PVM P and one containing 
Flag-tagged PVM P with an intron sequence from SV40 inserted at the 3’ end. No 
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Flag-tagged protein expression was detected from pShuttle_CMV_P (Flag), 
discounting the possibility that the P epitope/antibody combination was ineffective 
for detection of P protein expressed from rAdP. However, expression was detected 
from pShuttle_CMV_P (Flag/intron) (App. C. Fig. C.1). This result suggests that the 
P gene was not expressed from the CMV promoter (Section 3.6.2.4) because of 
aberrant RNA processing or export from the nucleus. Ad5 viruses are transcribed in 
the nucleus of cells which is not the natural expression environment for the PVM 
genes. Therefore, cryptic splice site may have prevented full length P mRNA or 
protein expression from the CMV promoter and therefore, P was not detected. The 
presence of an authentic pair of splice donor and acceptor sites outside the P open 
reading frame may have suppressed this cryptic splicing. Alternatively P mRNA 
expressed from the original, non-splicing, constructs may be very inefficiently 
polyadenylated and exported from the nucleus. Transient expression of some 
heterologous transgenes has been shown previously to be strongly stimulated by the 
inclusion of splicing cassettes (Huang & Gorman, 1990). In conclusion, the 
AdEasy™ Adenoviral Vector System has been used to generate rAd viruses 
containing and expressing specific genes from PVM. These viruses will be 
investigated in vivo as vaccine candidates for PVM in the following chapters.  
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Chapter 4 
 
Development of an rAd PVM 
vaccination protocol and evaluation of 
rAd PVM construct efficacy in the 
PVM infection model 
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4.1 Introduction  
 
PVM infection of mice has been proposed as an appropriate in vivo model in which 
to evaluate ‘proof of principle’ vaccine candidates for pneumoviruses. In this chapter, 
the efficacy of the rAd constructs over short and long term experiments is described.  
 
4.1.1 The PVM infection model  
As described in Section 1.4, PVM and human RSV are members of the virus family 
Paramyxoviridae and cause a similar pathogenesis within their natural hosts (Easton 
et al., 2004). PVM infection of mice is recognised as an appropriate model in which 
to study the pathogenesis of RSV and PVM (Cook et al., 1998, Domachowske et al., 
2001), and therefore, the model can be employed to evaluate PVM vaccine efficacy.  
Horsfall and Hahn originally isolated PVM following the observation that serial 
passage of mouse lung material isolated from apparently healthy mice resulted in a 
fatal, transmissible pneumonia (Horsfall, 1940). This study documented the signs 
associated with a lethal PVM infection and determined that an infection was only 
possible through the intranasal route. For this reason, PVM inoculations in this study 
were delivered via this route.  
 
The parameters of the clinical score for PVM infection were previously defined by A. 
J. Easton and colleagues (Easton, AJ personal communication, (Cook et al., 1998)). 
These parameters were redefined for the purposes of this study as illustrated in Fig. 
4.1, because difficulties were encountered in discerning the difference between a 
clinical score of two or three, using the original scale. In addition, a direct 
relationship between increased clinical score and weight loss had previously been 
observed (Cook et al., 1998). Thus, bodyweight was monitored as well as clinical 
score throughout the PVM challenge period in all experiments. In addition to the 
characterisation of PVM infection, Cook and co-workers determined that the 
optimum volume for intranasal inoculation of PVM was 50µl (Cook et al., 1998), 
therefore, this inoculation volume was used throughout this study for both rAd and 
PVM viruses. 
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Figure 4.1. Clinical 
score parameters for 
mice infected with PVM 
strain J3666.  
Animals inoculated with a 
lethal dose of PVM strain 
J3666 progress through 
five clinical stages of 
disease. Healthy animals 
score one on the scale, 
whereas a score of two 
denotes consistently 
ruffled fur, particularly in 
the neck region of the 
animal, as indicated in the 
area circled. A score of 
three indicates the 
animals have ruffled fur 
across their entire body, a 
characteristic hunched 
posture (as shown in the 
associated image), deeper 
breathing, and lethargy. 
Progression to a score of 
four denotes a severe 
infection. These animals 
retain the characteristics 
associated with a score of 
three, but appear 
emaciated and develop a 
‘pinched waist’. The 
animals are more likely to 
be inactive and ‘huddle’ 
together, with an 
abnormal ‘waddling’ gait 
observed when movement 
does occur. Animals that 
progress to a fatal 
infection may show cyanosis of the tail and ears and tremors before death occurs. If 
animals showed signs of cyanosis, and/or severe tremors in association with a loss of 
more than 25% of their initial bodyweight, they were culled for humane reasons, in 
accordance with the Home Office project licence under which the experiments were 
conducted. During some experiments, animals were culled prior to reaching a score 
of five, for humane reasons, particularly if there was no advantage for continuing the 
experiment.  
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4.1.2 Establishment of an immunisation strategy to evaluate rAd PVM vaccine 
efficacy 
Several previous studies have utilised Ad5 as a vaccine vector for treatment to 
prevent RSV (Section 1.7.6) among other viruses. Several of these studies have 
employed a homologous prime-boost immunisation strategy. This indicates that 
animals have been immunised with the same (homologous) vaccine throughout the 
experiment rather than using the same immunogen but in a different format e.g. 
protein subunit or DNA, which is termed heterologous. The initial immunisation is 
referred to as the prime or priming dose whereas subsequent immunisations are 
known as a boost or booster dose. These studies demonstrated that animals 
immunised using this strategy generated a detectable immune response towards the 
constructs transgene product which, where tested, correlated with protection. The 
immunisation regime also allows the animals time to generate an immune response 
against the transgene product and, following a booster inoculation, to generate a 
greater magnitude of response towards it prior to challenge (Ellis et al., 2007). The 
rAd PVM constructs developed in this study were used in a similar way to immunise 
mice as detailed in Fig. 4.2, using the in vivo PVM infection model. This allowed the 
rAd constructs to be evaluated for efficacy directly against PVM in its natural host.  
 
 
 
Figure 4.2. The standard immunisation regime for the rAd PVM constructs.  
For the priming immunisation dose, mice were immunised with either a rAd PVM 
vaccine diluted to an appropriate concentration in a 50µl inoculum with PBS or 50µl 
of PBS as a control. After two weeks, the animals were boosted with an identical 
dose of the immunogen they had previously received. At four weeks, all mice were 
challenged with a lethal dose of PVM strain J3666, in a 50µl volume. Serum samples 
were collected from each animal at the two and four-week time points and upon 
termination of the experiment (red arrows), for further analysis. 
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Since PVM naturally infects the mucosal surfaces of the lung, it was likely that 
stimulation of an immune response via the mucosa would correlate with protection 
from the virus, as has been recorded for other respiratory viruses such as RSV, 
influenza and parainfluenza virus type 3 (Kohlmeier & Woodland, 2009, van Ginkel 
FW, 2000). Thus, the rAd PVM constructs were predominantly used to immunise 
animals via the intranasal route in order to stimulate this form of immunity.  
 
 
4.2 Optimisation of PVM challenge model 
 
To optimise the PVM challenge model the PVM J3666 virus stock (PVM), was 
titrated in BALB/c mice to determine its pathogenicity. Groups of mice were 
inoculated via the intranasal route with different quantities of PVM in a 50µl 
inoculum and the animals were observed for a period of three weeks, with the 
clinical score for each animal (Fig. 4.3A) and the total weight of each group (Fig. 
4.3B) being monitored throughout.  
 
For all inoculated groups, transient weight loss was observed on day one, which was 
attributed to the stress of the inoculation procedure affecting natural feeding patterns. 
Control animals were treated with PBS alone and were not challenged with PVM. 
These animals did not present with any clinical signs associated with PVM infection. 
For these animals, weight loss of up to 5% of initial bodyweight was observed on 
day’s four to six; from day 7, onwards the animals maintained a stable bodyweight 
with no further weight loss.  
 
Inoculation of 20 p.f.u. of PVM resulted in a mild illness. The mean clinical score 
increased from 1 to a peak of 1.8 on days 9 to 14 before returning to the baseline 
level. Weight loss coincided with observable clinical signs from days 9 to 16, 
reaching a maximum of 13% of bodyweight loss on day 12. Weight gain was 
observed from day 13 onwards, indicating recovery from PVM illness.  
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Figure 4.3. PVM strain J3666 titration in BALB/c mice.  
Groups of five female BALB/c mice at five weeks of age were inoculated via the 
intranasal route with 20, 200, 500 or 800 p.f.u. of PVM strain J3666 in 50µl, as 
indicated. A further two mice were inoculated with 50µl of PBS via the same route. 
Two parameters were measured for the duration of the experiment, the clinical score 
(A) and the total bodyweight (B) of each inoculation group. Mean clinical score was 
calculated from the scores of each individual in an inoculation group. Bodyweight 
was calculated using the total weight per inoculated group, averaged per animal and 
normalised to the weight on day 0 of PVM challenge (100%). Upon a death of an 
animal in a group, the clinical score and bodyweight loss continued to be monitored, 
but are illustrated thereafter by dashed lines on the graphs.  
 
 
Inoculation of 200, 500 or 800 p.f.u. of PVM resulted in a lethal infection. All groups 
presented with clinical signs from day 3 onwards, with the groups that received the 
500 and 800 p.f.u. doses showing a more rapid disease progression than the 200 p.f.u. 
group. In the groups receiving 500 and 800 p.f.u., fatalities occurred on day 8, which 
coincided with the greatest weight loss of 21% for the 500 p.f.u. group, and 23% for 
the 800 p.f.u. group. In these groups, the onset of weight loss was observed one day 
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earlier, on day five than for the 200 p.f.u. group. One fatality occurred on day eight 
within the 200 p.f.u. group with the remaining 80% succumbing on day 10, which 
corresponded with the greatest weight loss of 24%. Overall, similar disease profiles 
were observed for the 200, 500 and 800 p.f.u. inoculum groups with more rapid 
progression of disease seen with increased doses. Based on this data, 250 p.f.u. of 
PVM strain J3666 in 50µl volume was chosen as the standard challenge dose to 
ensure full lethality in control groups without accelerated disease progression. 
 
 
4.3 rAd PVM constructs can elicit protection against lethal PVM infection in 
the BALB/c mouse strain 
 
BALB/c mice between 5 and 7 weeks of age were immunised via the intranasal route 
using a prime-boost regime (Fig. 4.2). For each rAd construct investigated, the 
animals were separated into three groups and immunised as detailed in Table 4.1. 
Animals treated with PBS served as a control group to monitor PVM pathogenesis.  
 
 
Group Prime dose 
(p.f.u./50µl) 
Boost dose 
(p.f.u./50µl) 
Animals/group 
A 10
6
 10
6
 6 
B 10
7
 10
7
 6 
C PBS PBS 2 
Table 4.1. The standard vaccine dosage for rAd vaccination. 
 
 
Throughout the immunisation regime and prior to PVM challenge, no weight loss or 
clinical signs were observed for any animals (data not shown). Therefore, 
immunisation of BALB/c mice with the rAd based constructs by this route does not 
result in an observable pathogenesis. 
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4.3.1 rAdF-immunised mice are protected against lethal PVM infection 
rAdF was investigated to determine whether this construct could protect immunised 
animals against lethal PVM infection. rAdF contains the F gene of PVM, which 
expresses the fusion (F) protein; an external membrane protein involved in viral 
entry.  
Following standard challenge with PVM, all the animals immunised with either the 
10
6
 p.f.u. or 10
7
 p.f.u. doses of rAdF (groups A and B respectively) survived the 
PVM challenge. When compared to the control group C, animals in group A were 
protected against the lethal effects of  PVM infection, but did present with moderate 
clinical signs (Fig. 4.4A), and significant weight loss (Fig. 4.4B). The appearance of 
disease was delayed by two days when compared with control group C (on day 8), 
and reached a lower peak mean clinical score of 3.3 on day 9. Weight loss was 
observed in animals in group A from day 7 onwards and reached a maximum of 24% 
on day 11. From day 10 onwards, the clinical score decreased steadily until the 
baseline level was reached. However, unlike control group C, weight gain was 
observed in group A from day 13 onwards. The animals did not return to their pre-
challenge weight, but this has been previously observed with animals recovering 
from PVM infection (A.J Easton personal communication).  
 
Group B animals, which received the higher vaccine dose of 10
7
 p.f.u., were fully 
protected against the PVM challenge, and presented with only mild transient clinical 
signs and minimal weight loss. The mean clinical score increased to a peak score of 
two on day 8 (Fig. 4.4A), at which time weight loss was initially observed (Fig. 
4.4B). The clinical score returned to the baseline level by day 10, by which time the 
greatest weight loss, still only 3%, was observed. The animals began to gain weight 
thereafter and achieved 108% of their pre-challenge weight by the conclusion of the 
experiment. In contrast, the control group which had been treated with PBS (group 
C), presented with clinical signs and weight loss on day 6, with the former increasing 
in severity for three days (Fig. 4.4.A). All the animals died or were culled due to the 
PVM illness on day 9, which coincided with the greatest weight loss of 23% of initial 
average bodyweight (Fig. 4.4B). Thus, when compared to control group C, rAdF-
immunised groups A and B were both protected against PVM infection.  
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Figure 4.4. rAdF can elicit protection against lethal PVM challenge.  
Female BALB/c mice were individually immunised with a prime dose of rAdF on 
day 1 and a boost dose on day 14 as detailed in Table 4.1. Mice in groups A and B 
received 10
6
 p.f.u. and 10
7
 p.f.u. of rAdF, respectively, whereas group C were 
immunised with PBS. Animals were challenged on day 31 with a lethal dose of PVM. 
Mean clinical score (A) and percentage bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal and normalised to the weight on 
day 0 of PVM challenge (100%). The data are representative of two repeat 
experiments.  
 
 
4.3.2 rAdM-immunised animals are protected against lethal PVM infection  
In light of the positive results achieved for the rAdF construct, the immunogenicity 
of rAdM was then investigated. The rAdM construct contains the M gene of PVM, 
which expresses the matrix (M) protein of PVM; an internal protein involved in 
maintaining the integrity of the virus and virus assembly.  
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This experiment, Fig. 4.5, was performed in parallel with that described in Section 
4.3.1; using the same control PBS treated (group C) animals. Male mice were used in 
group A (immunised with 10
6
 p.f.u. of rAdM) and had a minimum clinical score of 
two throughout the PVM challenge period. This was not observed for rAdF-
immunised animals, which were all female. This difference has been attributed to the 
gender of the animals, as male mice are more aggressive than females and frequently 
fight with cage mates. In addition, male mice are frequently less meticulous in their 
grooming when compared to female mice. This affects the apparent clinical score, as 
fur ruffling is scored as a clinical sign of infection. Nevertheless, an effect of PVM 
infection was evident.  
 
Group A presented with an increase in clinical score reaching a peak score of 4 by 
day 9 (Fig. 4.5A), which included three fatalities. Weight loss was observed from 
day 6 onwards and occurred at a rate similar to that of the control group C, reaching 
28% weight loss on day 9 (Fig. 4.5B). Further fatalities were observed on day 10; 
one survivor maintained a high clinical score and did not regain weight. Therefore, 
this group was not significantly protected from PVM infection.  
 
In contrast to group A animals, mice in group B (inoculated with 10
7
 p.f.u. of rAdM) 
were protected against PVM infection though they did present with moderate clinical 
signs (Fig 4.5A) and substantial weight loss (Fig. 4.5B). This group demonstrated a 
delay in the onset of clinical signs when compared to the control group C. The mean 
clinical score reached a peak of 3 by day 9 (Fig. 4.5A), which coincided with a 
maximum weight loss of 19% (Fig. 4.5B) and one fatality. From day 10 onwards, the 
group recovered from the infection, appearing healthy from day 13 onwards. Thus, 
group B (immunised with 10
7
 p.f.u. of rAdM) were protected from PVM infection 
when compared to test group A and control group C animals.  
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Figure 4.5. rAdM can elicit protection against lethal PVM challenge.  
BALB/c mice were individually vaccinated and challenged as described in Fig. 4.4 
and Table 4.1 with rAdM. Mice in groups A and B were immunised with 10
6
 p.f.u. 
and 10
7
 p.f.u. of rAdM, respectively, whereas group C received PBS. Mean clinical 
score (A) and percentage bodyweight loss (B) were monitored throughout the 
challenge period. Mean clinical score was calculated from the scores of each 
individual in an inoculation group. Bodyweight was calculated using the total weight 
per inoculated group, averaged per animal and normalised to the weight on day 0 of 
PVM challenge (100%). Upon a death of an animal in a group, the clinical score and 
bodyweight loss continued to be monitored, but are illustrated thereafter by dashed 
lines on the graphs. Group A and B consisted of male and female mice respectively.  
 
 
 
4.3.3 rAdN-immunised mice are protected against lethal PVM infection 
The third construct, rAdN, contains the N gene of PVM, which expresses the 
nucleotide (N) protein, which is involved in maintaining virus genome integrity and 
promotes replication. As before, this experiment was conducted concurrently with 
  131   
those described in Sections 4.3.1 and 4.3.2 and the control animals were group C as 
previously described.  
 
Mice inoculated with 10
6
 p.f.u. of rAdN (group A) did not survive the PVM 
challenge dose. Clinical signs were observed from day 5 post PVM challenge and 
increased daily, reaching the maximum possible score on day 11 (Fig. 4.6A). Weight 
loss was observed from day 6 onwards (Fig. 4.6B), reaching a maximum of 29% by 
day 9. Therefore, this group was not protected against the PVM challenge dose. In 
contrast to group A, mice inoculated with the higher dose of rAdN (10
7 
p.f.u. group 
B) were protected against PVM challenge, with all animals surviving. However, 
moderate clinical signs were observed; these commenced one day after groups A and 
C and reached a lower peak score of 3 on day 9 (Fig. 4.6A). This coincided with 
bodyweight loss, which began on day 7 and reached a maximum of 16% on day 10. 
From day 11 onwards, the group recovered from the PVM infection as their clinical 
score returned to baseline levels and weight gain was evident. As for mice 
immunised with the same dose of rAdM, group B rAdN-immunised animals did not 
regain bodyweight to pre-challenge levels.  
 
4.3.4 Control rAdZ-immunised mice are not protected against lethal PVM 
infection 
The final recombinant virus investigated was the control vaccine, rAdZ, which 
contains the LacZ gene of E. coli, which expresses the β-galactosidase protein. As 
described above, mice that received 10
7
 p.f.u. of rAdF, rAdM, or rAdN were 
protected against a lethal PVM infection with or without transient clinical signs of 
disease. To confirm that these positive effects were due to generation of immunity 
against the PVM proteins, rather than to some effect of the rAd vector, animals were 
immunised with 10
6 
or 10
7
 p.f.u. of rAdZ which did not contain any PVM gene 
sequences but instead expressed an irrelevant protein, β-galactosidase, from the E. 
coli LacZ gene.  
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Figure 4.6. rAdN can elicit protection against lethal PVM challenge.  
Male BALB/c mice were individually vaccinated and challenged as described in Fig. 
4.4 and Table 4.1 with rAdN. Mice in groups A and B were immunised with 10
6
 p.f.u. 
and 10
7
 p.f.u. of rAdN, respectively, whereas group C received PBS. Mean clinical 
score (A) and percentage bodyweight loss (B) were monitored throughout the 
challenge period. Mean clinical score was calculated from the scores of each 
individual in an inoculation group. Bodyweight was calculated using the total weight 
per inoculated group, averaged per animal and normalised to the weight on day 0 of 
PVM challenge (100%). The data are representative of two repeat experiments. In the 
experiment shown, group B comprised of only three animals due to anaesthesia 
complications.  
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Figure 4.7. LacZ does not protect mice from lethal PVM challenge.  
BALB/c mice were individually vaccinated and challenged as described in Fig. 4.4 
and Table 4.1 with rAdZ. Mice in groups A and B were immunised with 10
6
 p.f.u. 
and 10
7
 p.f.u. of rAdZ, respectively, whereas group C received PBS. Mean clinical 
score (A) and percentage bodyweight loss (B) were monitored throughout the 
challenge period. Mean clinical score was calculated from the scores of each 
individual in an inoculation group. Bodyweight was calculated using the total weight 
per inoculated group, averaged per animal and normalised to the weight on day 0 of 
PVM challenge (100%). Group A and B consisted of male and female mice 
respectively.  
 
 
 
As seen in Sections 4.3.1-.3, the control animals in group C were as previously 
described. Mice inoculated with 10
6
 p.f.u. or 10
7
 p.f.u. of rAdZ (groups A and B 
respectively) were not protected against lethal PVM infection. Animals in group A 
developed observable clinical signs from day 6 onwards reaching the maximum 
possible score with the death of all mice on day 9 (Fig. 4.7A), similar to group C. 
Animals in group B presented with clinical signs one day later, on day 7, and reached 
the maximum score on day 11, two days after control group C. On day 9, 50% 
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mortality was observed for group B, with the remainder from that group dying on 
day 11. Animals in both groups A and B exhibited weight loss from day 5 post 
challenge and weight declined at the same rate witnessed for the control group C, 
reaching a maximum bodyweight loss of 25% for group A on day 9 and 27% for 
group B on day 11 (Fig. 4.7B).  
 
4.3.5 Discussion 
Each of the three PVM rAd constructs protected animals from subsequent PVM 
challenge when used at the 10
7
 p.f.u. dose in the standard prime-boost immunisation 
regime. Only rAdF was also able to protect animals from lethal PVM challenge at the 
lower vaccine dose of 10
6
 p.f.u. However, this vaccine stock was contaminated with 
a low level of a replication competent Ad5 virus, as described in Section 3.4.2.1. 
This may have affected the antigenicity of the vaccine preparation because the 
contaminant might support the replication of rAdF and if the recombinant virus were 
able to replicate then the animals would have received a greater dose of antigen. 
16.6% of animals immunised with 10
6
 p.f.u. of rAdM were protected in one 
experiment, whereas this dose failed to protect in a repeat experiment. Therefore, this 
was not judged to be significant protection against a lethal PVM infection. The 
protective effect of all three PVM rAd constructs at the 10
7
 p.f.u. dose was specific 
to the rAd PVM constructs, as the rAdZ construct, expressing an irrelevant protein, 
did not protect mice from a lethal PVM challenge at this dose. Thus, the 10
7
 p.f.u. 
dose was used as the standard immunisation dose in further experiments.  
 
 
4.4 rAds can elicit protection against lethal PVM infection in different mouse 
strains  
 
The BALB/c mouse strain is an inbred strain commonly used in in vivo experiments. 
The rAd PVM constructs were successfully able to elicit a protective response 
against lethal PVM infection in this mouse strain. This protection may be generated 
by either a humoral or a cellular immune response, as described in Section 1.6. The 
ability of the adaptive immune response to recognise and, thus respond, to antigen is 
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determined by the MHC genes. The gene region is highly polymorphic and has a 
large number of associated alleles. As mentioned in Section 1.6, the MHC complex 
directly influences the humoral and cellular arms of the immune response through 
the presentation of peptides and other antigens on the cell surface. The natural 
variation associated with this complex determines the ability of an MHC receptor to 
bind to antigen and thus to display the antigen for immune surveillance. As such, the 
expression of particular alleles may confer an advantage or disadvantage on an 
individual’s ability to recognise specific antigens.  
 
It is well known that the MHC haplotype of an individual affects their T-cell 
response towards an antigen. This occurs because genetic differences alter the range 
of antigens that can be recognised, and thus displayed, by the MHC complex. 
Therefore, this determines what antigens can be recognised and responded to by T-
cells. Less well understood is the direct effect of MHC haplotype on the B-cell 
response towards an antigen. The MHC class II haplotype will determine whether an 
antigen is recognised by CD4
+
 T-cells, which are involved in B-cell activation. 
Additionally, it is accepted that complement proteins (a group of proteins associated 
with innate immunity) are encoded within the MHC gene region. Thus, variation in 
this region may affect complement proteins, which can form cross-links with B-cell 
co-receptors and through this influence B-cell differentiation and antibody isotype 
switching (Carroll, 2008). Further evidence suggests that some innate immunity 
associated receptors such as TLRs, are linked to MHC haplotype (Rodo et al., 2006). 
Thus, co-receptor regulation has a direct effect on B-cell activation and proliferation 
towards a particular antigen.  
 
In terms of vaccine development, it is the effect of MHC class I haplotype on T-cell 
activation which is the most important, particularly against viral pathogens. MHC 
class I complexes present antigen for recognition by CTLs, which recognise and 
destroy infected cells.  Therefore, to be of value in an out-bred population, a vaccine 
such as the rAd PVM vaccines must generate a protective response against the 
transgene regardless of the MHC polymorphism of an individual. This is an 
important consideration during vaccine evaluation in mice as many laboratory mouse 
strains have been in-bred and therefore they will express an identical restricted set of 
MHC alleles. The BALB/c mouse strain, which has been primarily used in this study, 
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has an MHC haplotype of H2
d
 (Section 2, Table 2.1.6). Therefore, it could be 
possible that the protection from rAd PVM constructs observed in this mouse strain 
could be linked to its MHC haplotype. 
 
To investigate the ability of the rAd PVM recombinant viruses to elicit a protective 
response in mice with different MHC haplotypes, the C57BL/6 (H2
b
) and C3H/He-
mg (H2
k
) (Section 2, Table 2.1.6) mouse strains were immunised with the rAd PVM 
vaccines to determine whether protection against PVM infection could be generated. 
The C57BL/6 and C3H/He-mg mouse strains are known to be susceptible to PVM 
infection and disease pathogenesis in these strains is similar to that observed in the 
BALB/c mouse strain (A. J. Easton, personal communication (Anh et al., 2006), 
though C57BL/6 mice have been reported to be slightly less susceptible to PVM 
infection than BALC/c mice (Anh et al., 2006).  
 
Groups of animals between 5 and 7 weeks of age were immunised via the intranasal 
route as described in Table 4.2, using the standard prime-boost regime (Fig 4.2.). 
Animals treated with PBS served as a control group to monitor PVM pathogenesis 
during the challenge phase of the experiment. As previously observed in the BALB/c 
mouse strain, no weight loss or clinical signs were observed for any group during the 
immunisation period. This suggests that intranasal immunisation of mice with rAd 
based vaccines does not result in an observable pathogenesis, irrespective of strain 
background. 
 
 
Group Vaccine 
construct 
Prime dose 
(p.f.u./50µl) 
Boost dose 
(p.f.u./50µl) 
Animals/group 
A rAdF 10
7
 10
7
 5 
B rAdM 10
7
 10
7
 5 
C rAdN 10
7
 10
7
 5 
D rAdZ 10
7
 10
7
 5 
E N/A PBS PBS 4 
Table 4.2. The rAd vaccine dosage for protection studies against PVM in different 
mouse strains.  
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4.4.1 C3H/He-mg strain immunisation with rAd constructs 
C3H/He-mg mice were immunised with rAd PVM recombinant viruses as described 
in Table 4.2. In contrast to the control group E, animals treated with rAdF or rAdN 
(groups A and C respectively), were both protected against lethal PVM infection. 
Animals in group A presented with a mild clinical score elevation, which was 
observable from day 7 onwards, reaching a peak score of 2 on day 9 (Fig. 4.8A), and 
declined to baseline levels from day 13 onwards. Weight loss was observed from day 
3 onwards, reaching a maximum of 15% on day 9 (Fig. 4.8B). Mice in group A did 
not regain lost weight during the recovery period but maintained a bodyweight at 
85% of their pre-challenge level. Animals in group C presented with slight clinical 
signs from day 7 onwards, which fluctuated slightly above the baseline level (Fig. 
4.8A). Although the initial rate of weight loss, from day 6 was similar to control 
group E, mice in group C reached a maximum of only 9% bodyweight loss on day 7 
and then weight gain resumed (Fig. 4.8B).  
 
In contrast to animals treated with rAdF or rAdN (groups A and C), those treated 
with rAdM (group B) were only partially protected from PVM infection with some 
fatalities being observed. Clinical signs were delayed by two days when compared to 
the control group E, but were apparent from day 7 onwards reaching a peak score of 
3 on day 9 (Fig. 4.8A), which coincided with the death of two animals. One animal 
did not present with clinical signs of PVM infection prior to death whereas the other 
presented with ruffled fur and wasting, characteristic of PVM infection. The 
remaining animals maintained a moderate clinical score of 3 for the remainder of the 
experimental period. Weight loss was observed for this group from day 6 onwards, 
reaching a maximum of 13% on day 9 (Fig. 4.8B). Unlike group A, surviving group 
B (rAdM-immunised) animals began to gain weight and therefore showed signs of 
recovery from day 10 onwards, returning to their pre-challenge bodyweight by day 
13. Group D animals, which had received the control rAdZ construct, presented with 
signs from day 6 onwards, which then increased at a similar rate as for the PBS 
treated group E animals (Fig. 4.8A).  
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Figure 4.8. rAd constructs protect C3H/He-mg mice from lethal PVM challenge.  
C3H/He-mg mice from the one batch of animals were individually vaccinated as 
described in Table 4.2 using the standard immunisation protocol (Fig. 4.2), prior to 
challenge on day 28 with a lethal dose of PVM strain J3666. Animals were 
immunised with 10
7
 p.f.u. of rAdF (group A), rAdM (group B), rAdN (group C), 
rAdZ (group D) or treated with PBS (group E). Mean clinical score (A) and 
percentage bodyweight loss (B) were monitored throughout the challenge period. 
Mean clinical score was calculated from the scores of each individual in an 
inoculation group. Bodyweight was calculated using the total weight per inoculated 
group, averaged per animal and normalised to the weight on day 0 of PVM challenge 
(100%). Upon a death of an animal in a group, the clinical score and bodyweight loss 
continued to be monitored, but are illustrated thereafter by dashed lines on the graphs. 
Group A-D consisted of three female and two male mice whereas group E consisted 
of two female and two male mice.  
 
 
Similar to animals in control group E (treated with PBS), the peak clinical score for 
group D animals was reached on day 9; although it was lower than group E. This 
coincided with two deaths, with a further animal dying on day 10. The remaining 
mice maintained moderate clinical signs throughout the experimental period. Weight 
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loss was observed from day 6 onwards that was again equivalent to the control group 
E, reaching a maximum loss of 16% on day 10 (Fig. 4.8B). The surviving animals 
did not appear to regain weight and therefore did not fully recover from PVM 
infection. The pathogenicity of the challenge dose was confirmed by the weight-loss 
and clinical score of group E animals (Fig 4.8A, B).  
 
4.4.2 C57BL/6 strain immunisation with rAd recombinant viruses 
C57BL/6 mice were vaccinated with the rAd constructs as described in Table 4.2 and 
challenged with PVM as before. However, unlike the BALB/c and C3H/He-mg 
mouse strains, C57BL/6 animals in PBS-treated control group E, did not all succumb 
to PVM infection. Observable PVM-related signs were present in these animals from 
day 8 onwards and increased to a peak score of 4 by day 11 (Fig. 4.9A). This 
coincided with two fatalities while the remaining animals maintained a moderate 
clinical score of 3.5 for the remainder of the experiment. Weight loss in this group 
was evident from day 7 onwards, reaching a maximum of 25% on day 11 (Fig. 4.9B). 
This degree of weight loss was associated with high clinical scores and lethality or 
sacrifice for humane reasons in other mouse strains. The surviving animals did not 
fully recover from PVM infection as demonstrated by the absence of weight gain by 
the group for the remainder of the experiment. Thus, it appears that C57BL/6 mice 
are more tolerant of the pathogenic effects of PVM then are BALB/c or C3H/He-mg 
mice.   
 
Animals in groups A, B, and C (inoculated with rAdF, rAdM, and rAdN, 
respectively) were fully protected against lethal PVM infection. No increase in 
clinical score was observed for these groups throughout the experiment (Fig. 4.9A) 
and all animals survived the PVM challenge. Only slight weight loss was observed in 
groups A and B, reaching a maximum loss of 7% on day 10 and 3% on day 9 
respectively, while group C were completely unaffected (Fig. 4.9B). Mice in all three 
groups gained weight above their initial bodyweight and remained healthy for the 
duration of the experiment. This outcome is in clear contrast to the affect of the 
challenge dose on control group E animals. Surprisingly, group D animals 
(inoculated with rAdZ), were also protected against lethal PVM infection, however 
mild clinical signs and moderate weight loss was associated with PVM challenge for 
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this group. Clinical signs were observed from day 8, similar to that of control group 
E, but reached a lower average score of only 1.6 on day 9 (Fig. 4.9A) and quickly 
recovered to baseline levels. Weight loss was more severe, beginning on day 7 as for 
control group E, and reaching a maximum of 18.5% on day 9 (Fig. 4.9B). However, 
in contrast to group E, the group began to regain weight rapidly from day 12 onwards, 
but did not reach their pre-challenge bodyweight. 
 
 
 
Figure 4.9. rAd constructs protect C57BL/6 mice from lethal PVM challenge.  
C57BL/6 mice were individually vaccinated and challenged as described in Fig. 4.8 
and Table 4.2. Animals were immunised with 10
7
 p.f.u. of rAdF (group A), rAdM 
(group B), rAdN (group C), rAdZ (group D) or treated with PBS (group E). Mean 
clinical score (A) and percentage bodyweight loss (B) were monitored throughout the 
challenge period. Mean clinical score was calculated from the scores of each 
individual in an inoculation group. Bodyweight was calculated using the total weight 
per inoculated group, averaged per animal and normalised to the weight on day 0 of 
PVM challenge (100%). Upon a death of an animal in a group, the clinical score and 
bodyweight loss continued to be monitored, but are illustrated thereafter by dashed 
lines on the graphs. Groups A and C consisted of three female and two male mice, 
groups B and D consisted of two female and three male mice, whereas group E 
consisted of two female and two male mice.  
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4.4.3 Discussion 
The three PVM rAd vaccines were consistently able to protect different mouse 
strains from a lethal PVM infection. Thus, PVM transgene expression is able to 
stimulate a protective immune response regardless of MHC haplotype. 
rAdF and rAdN constructs were able to protect BALB/c, C3H/He-mg and C57BL/6 
mouse strains with the 10
7 
p.f.u. dose, with no associated fatalities. BALB/c and 
C57BL/6 rAdF-immunised animals consistently presented with milder clinical signs 
and less weight loss following PVM infection, with the exception of the C3H/He-mg 
strain, where the animals did not regain bodyweight during the experimental period. 
rAdN-immunised animals varied in the degree of clinical signs and weight loss 
observed after PVM challenge dependent on the mouse strain. rAdM-immunised 
BALB/c and C3H/He-mg mice presented with moderate clinical signs and weight 
loss upon PVM challenge with at least one fatality in each group. C57BL/6 rAdM-
immunised animals did not develop as severe PVM illness as the BALB/c and 
C3H/He-mg rAdM-immunised mice. PVM challenge in this group was associated 
with minimal weight loss and the absence of PVM related clinical signs.  
 
The C57BL/6 mouse strain is reportedly more resistant to PVM infection than either 
the BALB/c or the C3H/He-mg mouse strains (Anh et al., 2006); the data presented 
here confirms this. The C57BL/6 mouse strain differed from the BALB/c and 
C3H/He-mg strains in that there was a discrepancy between the degree of weight loss 
observed upon PVM infection, and the clinical signs of the animals. For example, in 
the BALB/c and C3H/He-mg strains, PBS treated mice confirmed the pathogenicity 
of the PVM challenge dose, and all animals died as a result. PBS-treated C57BL/6 
mice also served as a similar control; however, 50% of the animals survived lethal 
PVM infection (Fig. 4.9), although the survivors did not recover. In addition, 
BALB/c and C3H/He-mg mice immunised with rAdZ, were associated with 100% 
and 60% mortality, respectively, upon PVM challenge. In comparison, rAdZ-
immunised C57BL/6 animals developed only mild clinical signs, but still showed 
moderated weight loss. 
 
Unlike C57BL/6 mice, C3H/He-mg and BALB/c animals presented with a similar 
PVM pathogenesis progression. For the C3H/He-mg strain, clinical signs were more 
readily discerned and were observed for all immunised groups. Unlike the BALB/c 
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and C57BL/6 mouse strains, the C3H/He-mg strain did not tolerate substantial 
weight loss before death occurred. For example, PBS treated BALB/c mice tolerated 
approximately 23% bodyweight loss before deaths occurred (Fig. 4.4B). Equally, 
PBS treated C57BL/6 mice tolerated only approximately 25% bodyweight loss 
before fatalities occurred. Conversely, PBS treated C3H/He-mg mice tolerated only a 
16% weight loss before deaths occurred, a result which was also observed for the 
rAd-immunised groups. This result indicates that the C3H/He-mg strain is less 
resistant to PVM challenge, succumbing to infection for reasons other than weight 
loss, or that the mouse strain cannot tolerate substantial bodyweight loss. 
Unexpectedly, the control rAdZ-immunised C3H/H3-mg and C57BL/6 mice were 
partially protected against PVM infection. The rAdZ-immunised C57BL/6 mice 
presented with mild clinical signs and moderate weight loss whereas C3H/H3-mg 
mice developed severe clinical signs and moderate weight loss. This is in contrast to 
the result observed in BALB/c mice (Section 4.4, Fig. 4.7) where rAdZ-immunised 
animals were not protected at this vaccine dose and all succumbed to a PVM 
infection.  
 
Therefore, these data confirm that the rAd vaccines can stimulate protective 
immunity regardless of the MHC haplotype of an animal. In addition, it was re-
confirmed that the BALB/c mouse strain was more tractable than the other strains for 
further studies of these vaccines as no fatalities were observed in the rAd PVM 
vaccine immunised groups and no rAdZ-immunised animals were protected against a 
lethal PVM infection.  
 
 
4.5 rAd PVM constructs can elicit long-term protection against lethal PVM 
challenge 
 
Section 4.3 described how rAd PVM constructs were able to protect BALB/c mice 
against PVM infection when immunised with a 10
7 
p.f.u. dose. The protective effect 
was specific to the PVM antigen expressed by the PVM rAd recombinant virus since 
no protection was conferred by an irrelevant protein expressed in the same way. This 
confirmed that the vaccines were able to stimulate a short-term immune response 
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specific for PVM. However, in a non-laboratory environment, an individual may 
encounter a pathogen weeks, months or years after the initial vaccination. Therefore, 
a good vaccine should stimulate an immunologic memory towards the specific 
pathogen to ensure long-term protection. To investigate whether the rAd PVM 
constructs could stimulate such a response, BALB/c mice were immunised with the 
rAdM, rAdN or control rAdZ vaccine constructs and challenged with a lethal PVM 
dose at specific time points over a 20-week period, as described in Fig. 4.10.  
 
 
 
 
Figure 4.10. The rAd immunisation and PVM challenge regime for long-term 
protection studies.  
BALB/c mice were immunised with 10
7
 p.f.u. in 50µl of rAdM, rAdN or rAdZ, or 
treated with 50µl of PBS for the priming dose. After two weeks, the animals were 
given a booster dose of the same vaccine construct at 10
7
 p.f.u. in 50µl and control 
animals were again treated with 50µl of PBS. Groups of animals were challenged 
with 250 p.f.u. of PVM strain J3666 in 50µl at 8, 11, 14 or 20 weeks after the 
priming immunisation. In addition to monitoring the clinical signs and weight, serum 
samples were collected from each individual animal (red arrows) for further analysis.  
 
 
Animals between 5 and 7 weeks of age were immunised as described in Fig. 4.10 and 
Table 4.3. For each vaccine construct investigated, the animals were separated into 
four groups, split equally between males and females. Individual groups were 
challenged with a lethal dose of PVM and monitored for clinical score and weight 
loss. Each PVM group challenge contained six animals immunised with an rAd 
vaccine (groups A-D) and an additional two PBS treated animals (group E) which 
served as controls to monitor PVM pathogenesis.  
 
  144   
 
Group Prime dose 
(p.f.u./50µl) 
Boost dose 
(p.f.u./50µl) 
Challenge 
Time point (weeks) 
Animals/group 
(♂:♀) 
A 10
7
 10
7
 8 6 (3:3) 
B 10
7
 10
7
 11 6 (3:3) 
C 10
7
 10
7
 14 6 (3:3) 
D 10
7
 10
7
 20 6 (3:3) 
E PBS PBS 8, 11, 14, 20 8 (2/time point) 
Table 4.3. The rAd vaccination regime for long-term protection studies. 
 
 
4.5.1 rAdN-immunised BALB/c mice have long-lasting protection against 
PVM challenge. 
Following PVM challenge, rAdN-vaccinated animals in groups A and C (challenged 
at 8 or 14 weeks after priming immunisation, respectively) did not present with any 
clinical signs associated with PVM infection (Fig. 4.11A), whereas animals in groups 
B and D (challenged at 11 and 20 weeks after inoculation respectively), presented 
with transient mild signs.  
 
Mice in group D, with the longest delay between vaccination and challenge (20 
weeks), developed the highest clinical score of all the rAdN-immunised groups, 
reaching an average peak score of 2.5 on day 12 (Fig. 4.11A). However, this was 
substantially below the clinical score of control animals (group E). Mild weight loss 
was associated with each group following PVM challenge, beginning on day 6 for 
group B, day 7 for groups C and D, and day 8 for group A (Fig. 4.11B).  
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Figure 4.11. rAdN stimulates a long-term protective immune response against a 
lethal PVM challenge.  
BALB/c animals were vaccinated as described in Fig. 4.10 and Table 4.3 with rAdN. 
Animals were challenged at 8, 11, 14 or 20 weeks post initial vaccine dose (groups 
A-D respectively) with 250 p.f.u. of PVM strain J3666 in 50μl. Mean clinical score 
(A) and percentage bodyweight loss (B) were monitored throughout the challenge 
period. Mean clinical score was calculated from the scores of each individual in an 
inoculation group. Bodyweight was calculated using the total weight per inoculated 
group, averaged per animal and normalised to the weight on day 0 of PVM challenge 
(100%). Data for animals treated with PBS for each time point were averaged to 
generate the data set shown for group E; there was no difference in the course of 
PVM pathogenesis for these animals challenged at different time points. All 
immunised male mice presented with ruffled fur before PVM challenge as described 
in Section 4.3.2, which resulted in a slight elevation in baseline clinical score for all 
groups.  
 
 
 
No correlation was observed between length of time post-immunisation and the 
degree of weight loss associated with each group following PVM challenge, with 
group B animals losing the most weight, 12%, on day 9  (Fig. 4.11B). From day 9 
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onwards, the animals in groups A-C began to regain weight at a steady rate for the 
duration of the monitoring period. In contrast, animals in group D lost additional 
weight on day 13, prior to slight weight gain. However, in all these immunised 
groups, any observed weight loss was substantially less than was seen in control 
group E animals. These showed weight loss from day 6 onwards, reaching an 
averaged maximum of 28% by day 11 (Fig. 4.11B). There was no difference between 
as the course of PVM infection in control animals as the time course progressed. This 
confirmed the potency of the challenge dose used. Thus, the protection against lethal 
PVM infection induced by rAdN was long lasting.  
 
 
4.5.2 rAdM-immunised BALB/c mice have long-lasting protection against 
PVM challenge 
All rAdM-immunised groups of mice developed only mild clinical signs following 
lethal PVM challenge and mild or moderate weight loss (Fig. 4.12A). Unlike 
equivalent rAdN-immunised animals (Fig. 4.11), there appeared to be a possible 
correlation between the challenge time point post-immunisation and the severity of 
clinical signs observed. rAdM-immunised animals in group A (challenged 8 weeks 
after inoculation) did not develop clinical signs, other than a very small increase in 
clinical score on day 10 (Fig. 4.12A). In  contrast, animals in group B, which were 
challenged 11 weeks after inoculation, presented with peak clinical scores of 2 on 
day 10, which declined thereafter, whereas animals challenged at 14 and 20 weeks 
after inoculation (groups C and D respectively) presented with peak clinical scores of 
2.5 and 2.33, respectively, on day 9 (Fig. 4.12A). No fatalities were observed for any 
of the rAdM-vaccinated groups, in marked contrast to control group E onwards, 
which all succumbed to lethal PVM infection within the experimental period.  The 
extended time course observed for the control group animals in this experiment was 
due to the increased age of the animals upon challenge. This would have provided 
them with a greater time to gain more bodyweight prior to PVM challenge than after 
a standard four-week challenge and in turn, this would provide the animals more 
reserves to combat the PVM infection for longer before death occurred.   
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Figure 4.12. rAdM stimulates a long-term protective immune response against 
lethal PVM challenge.  
BALB/c animals were vaccinated and challenged as previously described in Fig. 4.11 
and Table 4.3. Animals were challenged at 8, 11, 14 and 20 weeks post priming 
vaccine dose (groups A-D respectively). Mean clinical score (A) and percentage 
bodyweight loss (B) were monitored throughout the challenge period. Mean clinical 
score was calculated from the scores of each individual in an inoculation group. 
Bodyweight was calculated using the total weight per inoculated group, averaged per 
animal and normalised to the weight on day 0 of PVM challenge (100%). Data for 
animals treated with PBS for each time point were averaged to generate the data set 
shown for group E; there was no difference in the course of PVM pathogenesis for 
these animals challenged at different time points. All immunised male mice 
presented with ruffled fur before PVM challenge as described in Section 4.3.2, which 
resulted in a slight elevation in baseline clinical score for all groups. In the 
experiment shown, group A comprised of only four animals due to death from 
anaesthesia complications and unknown causes.  
 
 
As was observed for rAdN-immunised animals, mild to moderate weight loss was 
associated with PVM infection of all rAdM-immunised groups, but this was 
substantially less than for control group E animals and there appeared to be little 
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correlation between the degree of weight loss observed and the challenge time point 
post-immunisation. Weight loss began from day 6 for all groups, reaching a 
maximum of 11% on day 9 for group A, 13% for groups B and D on day 10, and 
18% for group C on day 11 (Fig. 4.12B). After maximum weight loss was reached, 
all groups then began to regain weight, although only group A achieved their pre-
challenge bodyweight during the experimental period.  
 
4.5.3 rAdZ-immunised mice are not protected against immediate or delayed 
PVM challenge.  
As a control for the long-term protection experiment using rAdN and rAdM 
recombinant viruses (Fig. 4.11, 4.12), an equivalent experiment was conducted with 
the rAdZ construct. As expected, in contrast to rAdN and rAdM-immunised animals, 
animals receiving rAdZ showed little protection against PVM infection, displaying a 
high fatality rate and severe clinical signs and weight loss at all challenge times (Fig. 
4.13). PVM pathogenesis was similar for all rAdZ-immunised groups as control 
PBS-treated animals (group E). Clinical signs appeared from day 6 onwards, (Fig. 
4.13A), peaking at a high score, of at least 4, during the monitoring period. Similarly, 
severe weight loss of between a maximum of 20-30% was observed for all rAdZ-
immunised groups (Fig. 4.13B). The fatalities within all the rAdZ-immunised groups 
varied (Fig. 4.13C) and did not correlate with the length of time post immunisation 
and PVM challenge. As before, the pathogenicity of the PVM challenge dose was 
confirmed by the PBS-treated (group E) animals. 
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Figure 4.13. rAdZ did not stimulate a long-term protective immune response 
against lethal PVM challenge.  
BALB/c animals were vaccinated and challenged as previously described in Fig. 4.11 
and Table 4.3. Animals were challenged at 8, 11, 14 and 20 weeks post initial 
vaccine dose (groups A-D respectively). Mean clinical score (A), percentage 
bodyweight loss (B) and percentage survival (C) were monitored throughout the 
challenge period and calculated as described in Fig. 4.12. Upon a death of an animal 
in a group, the clinical score and bodyweight loss continued to be monitored, but are 
illustrated thereafter by dashed lines on the graphs. Data for animals treated with 
PBS for each time point were averaged to generate the data set shown for group E; 
there was no difference in the course of PVM pathogenesis for these animals 
challenged at different time points. All immunised male mice presented with ruffled 
fur before PVM challenge as described in Section 4.3.2, which resulted in a slight 
elevation in baseline clinical score for all groups. 
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4.5.4 Discussion  
These data show that rAdM and rAdN vaccines were sufficiently immunogenic to 
elicit long-term protection against pathogenic PVM strain J3666. They were 
therefore able to induce immunologic memory to PVM. Animals, which received the 
rAd PVM constructs, had markedly reduced clinical signs and less weight loss 
compared with those which received the control vaccine, rAdZ. rAdM and rAdN 
immunised mice developed milder clinical signs when the time between the boost 
dose and PVM challenge was increased when compared to animals challenged only 
two weeks after boosting (group B mice; Fig. 4.5, 4.6). Maximum weight loss in 
these groups remained at a similar percentage of around 15% of initial bodyweight. 
This suggests that the animals were able to mount a more effective immune response 
when the time between the booster immunisation and challenge was increased. A 
small proportion of rAdZ-immunised animals did survive lethal PVM infection, 
however there appeared to be no correlation between time elapsed between 
vaccination and challenge, and the survival rate. Such sporadic survivals may have 
occurred because the animals challenged in this experiment were significantly older 
than those challenged in the experiment described in Fig. 4.7. The animals would 
have increased in weight prior to PVM challenge and this increased bodyweight may 
have provided some individuals with an advantage. Possibly, increased weight delays 
PVM lethality enabling a natural immune response to be mounted against PVM that 
ultimately facilitates recovery. Thus, the rAd PVM constructs are able to stimulate 
long-term protection against PVM in the BALB/c mouse strain.  
 
 
4.6 A single immunisation with an rAd PVM construct protected BALB/c 
mice against lethal PVM challenge 
 
The rAd PVM vaccines can provide long-lived protection against lethal PVM 
infection, as shown in Sections 4.4 and 4.5. To investigate the immunogenicity of 
these vaccines further, animals were immunised as described in Table 4.4, with a 
single dose of 10
7
 p.f.u. of rAdM, rAdN or rAdZ, or treated with PBS as a control. 
Animals were challenged with a lethal dose of PVM strain J3666 six weeks after 
immunisation and monitored for clinical signs and weight loss.  
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Group Prime dose 
(10
7 
p.f.u./50µl) 
Animals/group 
(♂:♀) 
A rAdM 6 (3:3) 
B rAdN 6 (3:3) 
C rAdZ 6 (3:3) 
D PBS 4 (2:2) 
Table 4.4. The immunisation protocol for investigation of the efficacy of a single 
immunising dose of rAd PVM constructs 
 
 
The data demonstrating the clinical signs and weight loss of mice are show in Fig. 
4.14. In contrast to the control animals, rAdM-immunised animals (group A) were 
partially protected against the lethal effects of PVM challenge, but developed severe 
clinical signs and weight loss. One animal died two days after the PVM challenge, 
due to unknown causes. The remaining animals presented with PVM related signs 
from day 7 onwards, reaching a peak score of 3 on day 7 (Fig. 4.14A). Bodyweight 
declined from day 6 onwards at a similar rate to the animals in the control group D, 
reaching a maximum of 25% weight loss on day 11 (Fig. 4.14B). A further two 
animals died on days 10 and 11 (all male). The remaining animals (all female) 
recovered from PVM infection as evident through weight gain but still maintained a 
high clinical score.  
 
rAdN-immunised animals (group B) were more robustly protected against PVM 
infection, with no associated fatalities. Mild clinical signs appeared from day 8 
onwards, reaching a peak score of only 1.8 and decreasing thereafter (Fig. 4.14A). 
Three days post challenge, the animals appeared ruffled and this was attributed to the 
immunisation procedure. The group developed slight weight loss in response to PVM 
challenge, beginning on day 7 and then declining to a loss of 11% on day 9 (Fig. 
4.14B), after which the group’s weight increased indicating recovery from PVM 
infection.  
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Figure 4.14. A single immunisation of rAdN can protect BALB/c mice against 
lethal PVM challenge.  
BALB/c mice were vaccinated with a single dose of 10
7 
p.f.u. of either rAdM (group 
A), rAdN (group B), rAdZ (group C) or PBS (group D), as described in Table 4.4. 
Six weeks after vaccination, the animals were challenged with a lethal dose of PVM 
strain J3666. Mean clinical score (A) and bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal and normalised to the weight on 
day 0 of PVM challenge (100%). Upon a death of an animal in a group, the clinical 
score and bodyweight loss continued to be monitored, but are illustrated thereafter by 
dashed lines on the graphs. 
 
 
In contrast to the animals that received rAdM or rAdN, rAdZ-immunised animals 
(group C) were indistinguishable from control group D in terms of clinical signs and 
weight loss and thus were not protected from PVM challenge. Both groups C and D 
showed signs of PVM-related illness from day 6 onwards, reaching a peak score of 
4.33 and 5, respectively, on day 12 (Fig. 4.14A). Both groups presented with severe 
weight loss in response to lethal PVM challenge. Weight loss was evident from day 6 
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onwards (Fig. 4.14B), and reached a maximum loss from day 11 onwards. The 
mortality from both groups was 83%, with one animal in both groups surviving until 
termination of the experiment. These animals did not shown signs of recovery and 
maintained a high clinical score with no evidence of further weight gain. The 
mortality observed with this group of animals mirrored that of control group D, as 
two animals died unexpectedly on day 1, with a further two on day 12. An additional 
animal died on day 13, but the remaining mouse survived until the experiment was 
terminated. However, this animal did not recover from PVM infection, since it 
maintained a high clinical score and severe weight loss.  
 
These data show that a single immunisation of 10
7
 p.f.u. of rAdN was sufficient to 
confer protection and ensure the survival of all the animals in the group whereas only 
50% of rAdM animals immunised at the same dose were protected. Interestingly, the 
animals which survived in this case were all female, suggesting a gender difference 
in the susceptibility of animals to PVM infection. This has been reported previously 
(Flandre et al., 2003, Krempl et al., 2007). This experiment indicated that the 
protective immune response stimulated by a single vaccine dose of the PVM rAd 
constructs can be sufficient to protect animals against a lethal PVM J3666 infection, 
although protection is likely to be less robust than is achieved by two-dose 
vaccination schedules.  
 
 
4.7 Prime-boost immunisation with rAd vaccine mixtures is protective against 
lethal PVM infection 
 
Immunisation of animals with the lower dose of 10
6
 p.f.u. of rAdM, rAdN and rAdZ 
vaccines did not confer protection, whereas the 10
7
 p.f.u. dose of the same 
recombinant virus achieved robust protection from lethal PVM infection. To 
investigate whether a particular vaccine construct was able to provide an 
immunogenic advantage, different combinations of vaccine constructs were used to 
immunise BALB/c mice.  
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BALB/c mice between 5 and 7 weeks of age were immunised via the intranasal route 
with the standard prime-boost regime (Fig. 4.2), with a mixture of two vaccine 
constructs at 10
6
 p.f.u. each, or a 2x10
6
 p.f.u. dose of a single construct on day one. 
The animals were boosted on day 14 with the same immunisation dose and vaccine 
combination (Table 4.5). Animals treated with PBS served as a control group to 
monitor PVM strain J3666 (PVM) pathogenesis.  
 
Throughout the immunisation regime and prior to PVM challenge, no weight loss or 
clinical signs were observed for any animals vaccinated with different recombinant 
virus combinations (data not shown). The animals were challenged with a lethal dose 
of PVM at day 28 and monitored for clinical signs and weight loss throughout the 
challenge period.  
 
 
Group  Vaccine 1  Dose 
(p.f.u./50µl) 
Vaccine 2 Dose  
(p.f.u./50µl) 
Animals/group 
(♂:♀) 
A rAdN 2x10
6
 N/A N/A (3:2) 
B rAdM 2x10
6
 N/A N/A (3:2) 
C rAdZ 2x10
6
 N/A N/A (3:2) 
D PBS N/A N/A N/A (0:2) 
E rAdN 1x10
6
 rAdM 1x10
6
 (3:2) 
F rAdN 1x10
6
 rAdZ 1x10
6
 (3:2) 
G rAdM 1x10
6
 rAdZ 1x10
6
 (3:2) 
Table 4.5. The standard immunisation dose for vaccination with different 
recombinant virus combinations. 
 
 
As described in Section 4.3, animals in a previous experiment that received a prime-
boost immunisation regime of 10
6
 p.f.u. of rAdM, rAdN or rAdZ were not protected 
against lethal PVM infection. Animals rapidly developed high clinical scores (Fig. 
4.15A) and rapidly lost bodyweight in response to PVM infection (Fig. 4.15B). 
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Figure. 4.15. Immunisation of BALB/c mice with a 10
6
 p.f.u. dose of rAd PVM 
constructs does not confer protection against lethal PVM infection.  
BALB/c mice were immunised with a prime-boost regime with 10
6
 p.f.u. of a single 
rAd vaccine, rAdM, rAdN, or rAdZ, via the intranasal route. Animals were boosted 
on day 14 with the same dose and vaccine construct prior to challenge on day 31 
with a lethal PVM infection. Mean clinical score (A) and bodyweight loss (B) were 
monitored throughout the challenge period. Mean clinical score was calculated from 
the scores of each individual in an inoculation group. Bodyweight was calculated 
using the total weight per inoculated group, averaged per animal and normalised to 
the weight on day 0 of PVM challenge (100%). Upon a death of an animal in a group, 
the clinical score and bodyweight loss continued to be monitored, but are illustrated 
thereafter by dashed lines on the graphs. This data was presented previously in 
Sections 4.3.2-4 and has been included here for ease of comparison. 
 
 
Similar to animals receiving a single 10
6
 p.f.u. dose of recombinant virus, animals 
that received a 2x10
6
 p.f.u. dose of rAdM (group B) or rAdZ (group C) were not 
protected against lethal PVM infection (Fig. 4.16). Group B animals had moderate 
clinical signs associated with PVM challenge. These appeared from day 7 onwards 
and reaching a peak score of 3 on day 10 (Fig. 4.16A). Significant weight loss was 
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observed for animals in this group, beginning on day 6 and decreasing steadily at a 
rate similar to control group D, reaching 20% on day 12, which coincided with the 
death of an animal (Fig. 4.16B). Further animals were lost on days 18 and 19. The 
remaining animals did not recover from PVM infection but had a greater average 
bodyweight than those, which had succumbed. rAdZ-immunised animals (Group C), 
developed severe signs, beginning on day 5 and reaching a peak score of 3.8 on day 
12 (Fig. 4.16A). This group developed weight loss from day 5 onwards, similar to 
group B and control group D. Weight loss increased, reaching a maximum of 25% on 
day 12 which coincided with two fatalities. The remaining animals did not recover 
from PVM infection as evident from the lack of weight gain in the group and their 
persistently high clinical scores.  
 
In contrast, animals receiving 2x10
6
 p.f.u. of rAdN (group A) were protected against 
PVM infection and developed only mild clinical signs These signs were observed 
from days 6 to 15 and reached a peak score of 2.33 on day 11 (Fig. 4.16A). As for 
groups B and D (2x10
6
 p.f.u. rAdM and PBS treated, respectively), weight loss 
began on day 6 but in contrast to these non-protected groups, reached a peak of only 
8% on day 12 (Fig. 4.16B). One fatality was observed on day 11, but the remaining 
animals recovered from PVM infection, as evident from their weight gain and a 
decrease in clinical score to baseline levels.  
 
Animals were also immunised with different vaccine combinations in parallel with 
the single construct experiments described above, using the same PBS treated 
animals, group D (Fig. 4.17). Group G (immunised with both rAdM and rAdZ) was 
indistinguishable from the equivalent single vaccine groups (B and C) or the PBS 
control group D in terms of weight loss, and from group B in terms of clinical score. 
Group G developed moderate clinical signs from day 7 onwards, reaching a peak 
mean score of 2.9 on day 11 (Fig. 4.17A), which coincided with one fatality. In 
contrast to this moderate clinical score, severe weight loss was observed for this 
group, beginning on day 5 and increasing to a maximum of 23% on day 12 (Fig. 
4.17B). The remaining animals survived lethal PVM challenge but did not fully 
recover, maintaining a low bodyweight, with no indication of further weight gain and 
were therefore considered not to have been protected from PVM infection.  
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Figure 4.16. Immunisation of BALB/c mice with a 2x10
6
 p.f.u. dose of rAdN but 
not the rAdM or rAdZ constructs, is protective against lethal PVM infection.  
BALB/c mice were immunised and challenged as described in Fig. 4.15 and Table 
4.5 with 2x10
6
 p.f.u. of either rAdN (group A), rAdM (group B), rAdZ (group C) or 
PBS (group D). Mean clinical score (A) and bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal and normalised to the weight on 
day 0 of PVM challenge (100%). Upon a death of an animal in a group, the clinical 
score and bodyweight loss continued to be monitored, but are illustrated thereafter by 
dashed lines on the graphs. 
 
 
In contrast, group E (immunised with rAdN and rAdM) and group F (immunised 
with rAdN and rAdZ) were protected against lethal PVM infection, both regimes 
being associated with only mild clinical signs and less bodyweight loss. Both groups 
developed mild clinical signs from day 8 onwards (Fig. 4.17A), with groups E and F 
reaching a peak mean score of 2.3 on day 15 and 2.6 on day 10 respectively. Weight 
loss was indistinguishable between these two groups, beginning on day 6 and 
initially decreasing at a similar rate to groups B, C, D and G. However, from day 12 
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their weight stabilised at 15% bodyweight loss, (Fig. 4.17B), a less severe loss than 
groups B, C, D or G. One animal in each of groups E and F died from PVM infection 
on day 15, with the remaining animals maintaining a moderate bodyweight loss with 
only a 3% weight gain over the remaining experimental period. Due to the mild signs, 
lower bodyweight loss and survival, groups E and F were considered to have been 
partially protected from lethal PVM infection.  
 
 
 
Figure. 4.17. Immunisation of BALB/c mice with some rAd PVM recombinant 
virus combinations can protect the animals against lethal PVM infection.  
BALB/c mice were immunised and challenged as described in Fig. 4.16 and Table 
4.5 with 2x10
6
 p.f.u. of rAd constructs in different combinations. Group D received 
PBS, group E received rAdN and rAdM, group F received rAdN and rAdZ and group 
G received rAdM and rAdZ. Mean clinical score (A) and bodyweight loss (B) were 
monitored throughout the challenge period. Mean clinical score was calculated from 
the scores of each individual in an inoculation group. Bodyweight was calculated 
using the total weight per inoculated group, averaged per animal and normalised to 
the weight on day 0 of PVM challenge (100%). Upon a death of an animal in a group, 
the clinical score and bodyweight loss continued to be monitored, but are illustrated 
thereafter by dashed lines on the graphs. 
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Although some animals survived in all rAd immunised groups in this experiment, the 
degree of PVM signs and weight loss associated with specific groups was different. 
Animals which were immunised with a 1x10
6
 p.f.u. dose of rAd constructs using a 
prime-boost immunisation regime (Section 4.3.1 and Fig. 4.15) were not protected 
against PVM infection and developed severe clinical signs and weight loss. In 
contrast, groups A, B and C which received a 2x10
6
 p.f.u. dose of a single vaccine 
construct were more likely to survive PVM infection. This could be attributed to an 
increased dose of immunogen, from 1x10
6 
to 2x10
6
, which may have sufficiently 
stimulated the immune response, even non-specifically (such as rAdZ), to reach the 
threshold of an innate immune response and promote an adaptive immune response 
to give protection against PVM. Regardless, groups B and C (immunised with 2x10
6
 
p.f.u. of rAdM or rAdZ respectively) and group G (immunised with 1x10
6
 p.f.u. of 
both rAdM and rAdZ), developed a similar disease profile upon PVM infection as 
control group D. The animals maintained moderate to severe clinical signs and 
severe weight loss. No recovery was evident in these groups and groups B, C and G 
were not considered to have been protected against a lethal PVM infection. Group D 
received PBS and, as expected, was not protected against lethal PVM infection. 
These animals developed PVM related signs and weight loss at a similar rate and 
degree as other PBS treated animals in experiments, confirming the potency of the 
challenge dose used. 
 
Group A animals were protected against a lethal PVM infection, developing only 
mild clinical signs and weight loss. In addition, groups E and F, which received a 
combination of either rAdM or rAdZ with rAdN, were also protected against PVM 
infection. This suggests that the rAdN recombinant virus is more effective at 
stimulating a protective immune response when present with or without the 
combination of the other rAd PVM constructs, than the other recombinant viruses.   
 
 
4.8 Discussion 
 
This chapter has described a number of experiments to examine the qualities of rAd 
PVM constructs. These data show that the rAd PVM recombinant viruses can 
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successfully elicit protection against lethal PVM challenge in both short and long-
term experiments. 
 
Animals immunised with the 10
7
 p.f.u. dose of rAdF, rAdM or rAdN were protected 
against lethal PVM infection. This was true for the BALB/c, C57BL/6 and C3H/He-
mg mouse strains, indicating that the vaccines conferred protection against PVM 
regardless of MHC haplotype.  
 
The rAdF construct described in Section 4.3 was the only one to confer protection in 
BALB/c mice at a lower dose of 10
6
 p.f.u. The virus was previously found to be 
contaminated with a replication competent virus (Section 3.6.2.1), therefore, because 
a small proportion of the virus stock was potentially able to replicate within the host, 
the rAdF vaccine was not evaluated in long-term experiments. Animals that received 
this virus developed milder clinical signs and suffered less weight loss than those 
which had received the alternative rAd PVM constructs. This may be due to the 
antigenicity of the PVM F protein or that the animals may have received a greater 
dose of PVM protein if replication occurred, supported by the contaminating 
replication-competent virus.  
The rAdM construct was immunogenic and was able to elicit protection in animals 
when they were immunised with the 10
7
 p.f.u. dose. However, protection was not 
always absolute, with a few fatalities occurring in BALB/c and C3H/He-mg mouse 
strains (Sections 4.3 and 4.4). When the time period between immunisation and PVM 
challenge was extended, as seen in the long-term experiments, no fatalities were 
observed for rAdM-immunised animals. This suggests that the standard 
immunisation-challenge schedule detailed in Fig. 4.2, did not allow sufficient time 
for the full protective effect of rAdM to be achieved. These data were similar to 
those for rAdN-immunised animals, with the exception that no fatalities were 
associated with rAdN construct at the 10
7
 p.f.u. dose in any of the mouse strains used 
in this study. Both rAdM and rAdN-immunised animals were protected against PVM 
infection throughout the long-term experiments described in Section 4.5. The 
immunogenicity of those constructs also differed during the single immunisation 
experiment described in Section 4.6. BALB/c mice immunised with a single 10
7
 p.f.u. 
dose of rAdN were protected from a lethal PVM infection six weeks after 
immunisation with only mild clinical signs and little weight loss. In contrast, rAdM-
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immunised animals had moderate clinical signs and moderate weight loss with a 50% 
mortality rate (Fig. 4.14).  
 
These data show that the rAd PVM constructs generated specific immunity against 
PVM infection, as the rAdZ control did not confer protection in BALB/c mice at 
either the 10
6
 or 10
7
 p.f.u. doses. rAdZ-immunised animals were not protected in the 
short, long-term, or single dose experiments in BALB/c or C3H/He-mg mouse 
strains and were associated with severe disease in the C57BL/6 mouse strain. Mouse 
strain differences in survival have been reported previously (Anh et al., 2006), but 
survivors in the long-term and single dose experiments were attributed to their 
greater bodyweight during the immunisation regime. These animals would therefore 
have greater energy reserves to allow them to survive longer without feeding during 
the later stages of PVM illness. This may have allowed time for a natural immune 
response to be developed towards PVM, allowing the recovery of some individuals 
as in the long-term experiments, or allowing virus replication to be kept in check, 
preventing death as in the single immunisation experiment.  
 
The rAdM, rAdN and rAdZ constructs were also investigated for their 
immunogenicity when provided in a combination. The rAd PVM viruses were used 
to immunise animals in different combinations using the standard prime-boost 
regime. The recombinant viruses were used to immunise animals at the lower dose of 
10
6
 p.f.u. to ensure any additive protective effect could be clearly discerned, as 
previous experiments in Section 4.3 demonstrated this dose was not protective when 
single rAd PVM viruses were used. The experiment, detailed in Section 4.7, 
demonstrated that the rAdN virus was more immunogenic than rAdM. Immunisation 
with a double dose of rAdN was sufficient to protect animals from PVM infection. 
Interestingly, immunisation of a single dose of rAdN in combination with either 
rAdM or rAdZ vaccines also conferred protection against a lethal PVM infection, 
albeit with greater associated clinical signs and weight loss. In contrast, rAdM and 
rAdZ-immunised animals in combination or as a double dose, were indistinguishable 
from control animals. This data indicated that through increasing the dose of 1x10
6
 
p.f.u. to 2x10
6
 p.f.u., the immune response is stimulated to protect against lethal 
PVM infection.  
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Throughout the in vivo studies, the dose of rAd PVM constructs used to immunise 
the animals was standardised using p.f.u. values considered in Section 3.6.3. The 
p.f.u. value was chosen to standardise the dose of rAd in the in vivo model because it 
directly relates to the amount of infectious virus in the preparation rather than the 
number of particles, which may or may not be infectious. As the immunisation of 
animals is likely to be directly affected by the number of infectious virus particles, 
the p.f.u. value was chosen to standardise the immunisation dose used. As described 
in Section 3.6.3, Ad5 had a particle: p.f.u. ratio of 20. The rAd viruses used in this 
study have higher ratios than this dependent upon the preparation used (App. B. 
Table B.1). For example, this can vary from 40 to 1132 for different rAdN virus 
preparations. For this reason, if a preparation with a high particle: p.f.u. ratio was 
used to immunise animals it might be able to stimulate a strong anti-vector response 
resulting in increased recombinant virus clearance. This in turn may affect the ability 
of an animal to mount a response towards the PVM transgene. For this reason, 
preparations with high particle: p.f.u. ratios were not used to immunise animals, such 
as rAdN stocks 5, 8 and 11 (App. B. Table B.1). This residual variation in the 
particle: p.f.u. ratio of the stocks used does not explain the differences observed in 
the immunogenicity of the viruses since rAdN-immunised animals were protected 
against PVM even when virus preparations with relatively high particle: p.f.u. ratios, 
such as stock 2, were used. In addition, rAdF had lower particle: p.f.u. ratios than 
rAdM and rAdN stocks, perhaps reflecting its contamination with a replication-
competent revertant. rAdM and rAdN stocks used had a similar particle: p.f.u. ratio. 
As rAdN-immunised animals with these stocks were protected, it seems unlikely that 
rAdM-immunisation would result in virus clearance and therefore reduced 
immunogenicity. Therefore, differences in the particle: p.f.u. ratios of the various 
recombinant virus stocks do not explain the differences in the immunogenicity of the 
rAd vaccines in the in vivo model.  
 
In conclusion, the rAd PVM constructs used in the experiments described here are 
capable of inducing protection from a challenge with a lethal PVM infection. The 10
7
 
p.f.u. dose was able to elicit this protective effect and was chosen as the standard 
immunisation dose for the majority of the PVM challenge experiments. The virus 
rAdN was proven to be particularly immunogenic and was able to protect animals 
against lethal PVM challenge with a single dose (Fig. 4.14) as well as with a prime-
  163   
boost regime with immunity being provided for both the short and long-term (Figs. 
4.6 and 4.11). In addition, use of the rAdN construct consistently generated 
protection when used in a combination experiment, in contrast to the results observed 
with rAdM. This suggests that rAdN-immunisation of animals is more effective than 
rAdM or rAdF during single and short-term experiments. During long-term 
experiments, rAdN and rAdM-immunised animals were equally protected, 
suggesting that rAdM-immunisation may require a greater time period over which to 
generate sufficient immunological response and subsequent memory towards PVM. 
The evidence that the recombinant adenoviruses can establish long-term protection 
suggests that the protective mechanism is unlikely to be mediated by innate 
immunity. Thus, protection is most likely to be mediated by a long-lived humoral or 
cellular response. Overall, the rAd PVM constructs have been successfully used to 
demonstrate efficacy in the PVM in vivo modell.  
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Chapter 5  
 
Further investigation of rAd 
recombinant virus immunisation in the 
PVM infection model  
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5.1 Introduction 
 
The rAd PVM constructs have been shown to provide protection in mice against 
challenge with PVM when used to immunise mice with a 10
7
 p.f.u. dose, as detailed 
in the previous chapter. The experiments focused upon an homologous prime-boost 
immunisation regime via the intranasal route. Immunisation via this route stimulated 
a strong immune response, most likely in the mucosa of the lung. However, although 
new vaccine delivery systems are in development, the majority of currently licensed 
vaccines are delivered intramuscularly, which predominantly stimulates a systemic 
rather than a mucosal immune response.  
 
This chapter endeavours to further investigate rAd PVM vaccination in the PVM 
infection model. Mice were immunised via different routes to determine whether 
these can stimulate a protective immune response, similar to that observed via the 
intranasal route. In addition, a greater dose, of 10
8
 p.f.u., was used to immunise 
animals in a variety of short and long-term experiments to determine whether PVM 
infection-associated signs would decrease in severity, whilst retaining the protective 
effect of the vaccine.  
 
 
5.2 Immunisation via alternative routes is not protective against lethal PVM 
infection 
 
As described in Sections 1.2 and 1.6, a vaccine must stimulate the correct immune 
response in order to be protective against a pathogen. Traditionally, most vaccines 
are used to immunise individuals intramuscularly with the view to stimulating a 
strong systemic IgG response towards the pathogen. However, the majority of 
viruses enter the host via a mucosal surface so the generation of mucosal immunity is 
often more important than a general systemic response (Crowe, 2003). Newer 
vaccine strategies now recognise that it is important to stimulate the mucosal 
immune response, to allow the secretion of specific IgA, which may prevent 
infection. As detailed in the previous chapter, using rAd via the intranasal 
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immunisation route generated a protective immune response against PVM. However, 
if a systemic immune response could be shown also to be protective, immunisation 
of individuals would be easier and allow immunity to be passed between mother and 
infant.  
 
PVM rAd recombinant viruses were used to immunise BALB/c mice via 
intraperitoneal and subcutaneous routes to determine whether induction of systemic 
rather than local mucosal immunity could elicit protection against a lethal PVM 
infection. The subcutaneous route and intraperitoneal routes were investigated due to 
the relative ease of vaccine delivery by these routes on a small animal. 
 
5.2.1 Subcutaneous immunisation route 
BALB/c mice between 5 and 7 weeks of age were immunised via the subcutaneous 
route using the standard prime-boost regime (Section 4, Fig. 4.2). For each construct 
investigated, animals from the same breeding batch were separated into four groups 
and immunised as detailed in Table 5.1. Animals treated with PBS served as a 
control group to monitor PVM pathogenesis. Throughout the immunisation regime 
and prior to PVM challenge, no weight loss or clinical signs were observed for any 
of the animals. Therefore, immunisation of BALB/c mice with rAd viruses via the 
subcutaneous route does not result in an observable pathogenesis.  
 
 
Group Prime dose 
(p.f.u./50µl) 
Boost dose 
(p.f.u./50µl) 
Animals/group 
(♂:♀) 
A 10
6
 10
6
 5 (2:3) 
B 10
7
 10
7
 5 (2:3) 
C 10
8
 10
8
 5 (2:3) 
D PBS PBS 6 (3:3) 
Table 5.1. The standard protocol for BALB/c immunisation via the subcutaneous 
route.  
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5.2.1.1 rAdM-immunisation of BALB/c mice 
Animals in groups A, B and C (which received rAdM at 10
6
 p.f.u., 10
7
 p.f.u. or 10
8
 
p.f.u. respectively) were not protected against lethal PVM challenge. All animals 
developed clinical signs from day 6 onwards (Fig. 5.1A), with group A reaching the 
peak score on day 12, group B on day 10 and group C on day 13. The rate of 
development of clinical signs for rAdM-immunised groups was similar to that of 
control group D (PBS treated) animals. Substantial weight loss was also evident in 
each rAdM-immunised group and progressed at a rate similar to that of control group 
D. Group A (10
6
 p.f.u. dose) reached a maximum of 30% weight loss on day 11, with 
one death on day 9, another on day 10 and the remaining three on day 11 (Fig. 5.1B). 
Group B (10
7
 p.f.u. dose) had one fatality on day 8 and reached a maximum weight 
loss of 26% on day 9 which corresponded with the deaths of all the animals. Finally, 
group C (10
8
 p.f.u. dose) had four fatalities on day 13, with the remaining animal 
dying on day 14. Weight loss was greatest on day 13, with 39% of initial bodyweight 
(Fig. 5.1B). Group D (PBS treated) presented with clinical signs from day 7, which 
increased in severity to the maximum score of 5 by day 12 (Fig. 5.1A). Weight loss 
was also observed from day 7 onwards, reaching a maximum of 29% on day 10 (Fig. 
5.1B). Group D did not survive PVM challenge, with deaths occurring on day 9 and 
again on day 10; with the remaining three animals dying on day 12. This confirmed 
the pathogenicity of the virus stock. Thus, there was no evidence of any protective 
effect of delivering rAdM via the subcutaneous route.  
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Figure 5.1 Subcutaneous immunisation with rAdM does not protect mice from a 
lethal PVM infection.  
BALB/c mice were immunised using the standard prime-boost regime (Section 4, 
Fig. 4.2), via the subcutaneous route. Animals were primed on day 1 with the rAdM 
PVM vaccine at either a 10
6
 p.f.u. (group A), 10
7
 p.f.u. (group B) or 10
8
 p.f.u. (group 
C) dose, or PBS (group D). Animals were boosted on day 14 with the same vaccine 
dose and construct as received for the priming dose. The animals were challenged 
with a lethal dose of PVM strain J3666 (250 p.f.u. in 50µl) on day 28 of the 
experiment. Mean clinical score (A) and bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal and normalised to the weight on 
day 0 of PVM challenge (100%).  
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5.2.1.2 rAdN-immunised BALB/c mice 
Animals were immunised concurrently with the experiment described in Section 
5.2.1. The control animals were group D as previously described (Fig. 5.1), but have 
been included with these data for ease of comparison.   
 
 
Figure 5.2 Subcutaneous immunisation with rAdN does not protect mice from 
lethal PVM challenge.  
BALB/c mice were immunised and challenged as described in Fig. 5.1. Animals 
were immunised with rAdN PVM vaccine at either a 10
6
 p.f.u. (group A), 10
7
 p.f.u. 
(group B) or 10
8
 p.f.u. (group C) dose, or PBS (group D). Mean clinical score (A) 
and bodyweight loss (B) were monitored throughout the challenge period. Mean 
clinical score was calculated from the scores of each individual in an inoculation 
group. Bodyweight was calculated using the total weight per inoculated group, 
averaged per animal and normalised to the weight on day 0 of PVM challenge 
(100%).  
 
 
Similarly to rAdM-immunised animals, groups A, B and C (immunised with 10
6
,
 
10
7
, 
or 10
8
 p.f.u. rAdN respectively) were not protected against PVM challenge. Group A 
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presented with clinical signs from day 6 onwards, and reached the maximum score 
by day 11 (Fig. 5.2A). Weight loss was evident in this group from day 5 onwards, 
reaching a maximum of 32% on day 10 (Fig. 5.2B); with three animals dying on day 
10 and the remaining two on day 11. Group B (immunised with 10
7
 p.f.u.) developed 
clinical signs from day 4 onwards, reaching the peak score on day 11 (Fig. 5.2A). 
Similarly to group A, weight loss was observed from day 5 onwards and reached a 
maximum of 30% on day 10 (Fig. 5.2B). One fatality occurred on day 10 with the 
remaining animals succumbing to PVM infection on day 11. Clinical signs in group 
C (immunised with 10
8
 p.f.u.) were observed from day 7 onwards and reached a peak 
score of 4 on day 20 (Fig. 5.2B). Weight loss declined as quickly as was observed for 
groups A, B and control group D, and reached a maximum of 28% on day 12 (Fig. 
5.2B). The animals in group C survived until day 17 when two animals succumbed to 
PVM infection, with an additional animal dying on day 20. Two of the animals did 
survive PVM infection from this group but did not recover, as demonstrated by the 
lack of weight gain and consistently high clinical score. The slight increase in 
bodyweight at day 20 may reflect that these animals had lost less weight than those 
which had died. These animals are unlikely to be recovering from PVM infection due 
to their increase in mean clinical score. Therefore, the rAdN vaccine did not elicit 
protection against PVM when delivered by the subcutaneous route.  
 
5.2.1.3 rAdZ-immunised BALB/c mice 
As before, this experiment was conducted concurrently with those described above. 
The control animals were group D as previously described and have been included 
for ease of comparison. As expected, and similar to rAdM and rAdN-immunised 
animals, animals which were immunised with rAdZ via the subcutaneous route were 
not protected from PVM infection (Fig. 5.3).  
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Figure 5.3. Subcutaneous rAdZ immunised mice are not protected from lethal 
PVM challenge.  
BALB/c mice were immunised and challenged as described in Fig 5.1. Animals were 
immunised with rAdZ PVM vaccine at either a 10
6
 p.f.u. (group A), 10
7
 p.f.u. (group 
B) or 10
8
 p.f.u. (group C) dose, or PBS (group D). Mean clinical score (A) and 
bodyweight loss (B) were monitored throughout the challenge period. Mean clinical 
score was calculated from the scores of each individual in an inoculation group. 
Bodyweight was calculated using the total weight per inoculated group, averaged per 
animal and normalised to the weight on day 0 of PVM challenge (100%).  
 
 
Groups A, B and C (immunised with 10
6
, 10
7
 and 10
8
 p.f.u., respectively) were not 
protected against lethal PVM infection, as clinical score and weight loss was similar 
to that of control group D (PBS treated). Therefore, as for rAdM and rAdN-
immunised animals, rAdZ-immunised animals were not protected from PVM 
challenge via this immunisation route.  
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5.2.2 Intraperitoneal immunisation route 
BALB/c mice between 5 and 7 weeks of age were immunised with a high dose of 10
8
 
p.f.u. of  rAd constructs via the intraperitoneal route using the standard prime-boost 
regime (Fig. 4.2), except that the periods between prime and boost, and between 
boost and challenge were increased to three weeks. The increased time-period 
between immunisations, along with the delivery of a high dose of recombinant virus, 
should have maximised the chance that a systemic immune response against the 
PVM antigen would be stimulated. The animals, drawn from the same batch, were 
separated into five groups and immunised as detailed in Table 5.2. Animals treated 
with PBS served as a control group to monitor PVM pathogenesis.  
 
 
Group Vaccine Animals/group 
 
A rAdF 5 ♀ 
B rAdM 5 ♂ 
C rAdN 5 ♀ 
D rAdZ 5 ♂ 
E PBS 3 ♀ 
Table 5.2. The standard protocol for BALB/c immunisation via the intraperitoneal 
route.  
 
Throughout the immunisation regime and prior to PVM challenge, no weight loss 
was observed for any animals in the experiment when vaccinated via the 
intraperitoneal route. The animals were challenged with a lethal dose of PVM at day 
42 and monitored throughout the challenge period (Fig. 5.4). However, it was 
observed that, post-boost immunisation of all the constructs, a number of animals 
presented with non-PVM illness related abdominal signs. In particular, two animals 
which had received the rAdM construct were culled on the day of PVM challenge. 
These animals presented with very ruffled fur and had abdominal swelling. Post-
mortem analysis of these mice showed that both animals had severe bloating of the 
stomach and upper intestine. The liver in these animals was shrunken, of a pale 
colour, and uneven in texture. It was concluded that these animals had suffered from 
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severe liver pathology, presumably due to the rAd vaccine vector. For the remainder 
of the experiment, the animals were monitored closely and culled immediately if 
these signs appeared.  
 
 
 
 
Figure. 5.4. Immunisation with rAd vaccines via the intraperitoneal route does 
not confer protection against a lethal PVM challenge.  
BALB/c mice were immunised with 10
8
 p.f.u. of each of the rAd vectors or treated 
with PBS. Animals were immunised with a prime dose of rAdF (A), rAdM (B), 
rAdN (C), rAdZ (D), or PBS (E), on day 1 and boosted on day 21 with the same dose 
of vaccine construct. Animals were challenged on day 42 with a lethal dose of PVM 
strain J3666. Mean clinical score (A) and bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal and normalised to the weight on 
day 0 of PVM challenge (100%). Upon a death of an animal in a group, the clinical 
score and bodyweight loss continued to be monitored, but are illustrated thereafter by 
dashed lines on the graphs. 
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The remaining animals were challenged with a lethal dose of PVM at day 42 and 
monitored throughout the challenge period (Fig. 5.4). Similar to control group E, 
groups A-D (which received rAdF, rAdM, rAdN or rAdZ respectively) all developed 
weight loss associated with PVM illness from day 5 onwards, with groups B-D 
(rAdM, rAdN or rAdZ respectively) reaching a maximum of 20% and group A 
(rAdF-immunised) reaching a maximum of 25% on day 9. The rate and degree of 
weight loss was similar to that of the control group E (PBS treated). Clinical signs 
for groups C and D (rAdN and rAdZ-immunised animals respectively) were similar 
to that of group E, appearing from day 6 onwards and increasing rapidly until day 9. 
Signs were evident from as early as day 2 for groups A and B (rAdF and rAdM-
immunised respectively), presumably due to the complications associated with the 
rAd vector. Control group E began to show clinical signs from day 6 onwards, which 
increased in severity through to day 9, when the maximum clinical score was reached 
(Fig. 5.4); which coincided with the death of all the animals. Weight loss was clearly 
evident from day 5 onwards although there was a slight decrease in bodyweight from 
day 1 to day 3 attributed to the immunisation procedure disrupting feeding. Weight 
loss reached a maximum of 27% on day 9. Thus, the rAd-immunised animals were 
not protected against lethal PVM infection when immunised via the intraperitoneal 
route.  
 
5.2.3 Discussion 
Immunisation of BALB/c mice via the subcutaneous or intraperitoneal route with any 
of the rAd PVM recombinants was not sufficient to elicit protection from lethal PVM 
challenge. Subcutaneous immunisation was not associated with adverse signs, nor 
was swelling visible at the site of the inoculation, indicating that the regime was well 
tolerated. However, rAdM and rAdN were not able to elicit protection, by this route, 
in contrast to the intranasal route (Section 4.3), even when a range of doses were 
delivered by this route suggesting the immune response was not adequately 
stimulated.  
 
Intraperitoneal immunisation was subsequently performed with a higher dose of the 
rAd PVM constructs with increased time between immunisations to ensure the 
maximum chance of an immune response to be established. However, again 
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protection was not achieved against PVM for any of the vaccines. In addition, severe 
adverse reactions were observed in all rAd intraperitoneal immunised mice. These 
signs were not ‘typical’ of PVM infection and, for some animals, were present prior 
to PVM challenge. Moreover, PBS control mice did not present with the signs, which 
suggests that the severe liver pathology and gut related signs were a direct result of 
rAd vaccination. This result has been observed previously and is due to the natural 
liver tropism of Ad5 viruses (Flanagan et al., 1997, Yang et al., 1994). As neither of 
these alternative immunisation routes was associated with protection from PVM, 
stimulation of a local mucosal immune response may be important for protection 
from PVM infection. Thus, systemic immunisation is not sufficient to stimulate a 
protective immune response in the lung in time to prevent death from PVM infection, 
or that this regime may not have achieved systemic immunity and therefore, no 
protective effect would have been observed 
 
 
5.3 Immunisation with a high dose of 108 p.f.u. of rAd constructs is protective 
against lethal PVM infection 
 
In chapter 4, immunisation of animals using an intranasal prime-boost regime with 
vaccine doses of 10
6
 and 10
7
 p.f.u. respectively was investigated. As discussed in 
Section 4.3, animals which received the 10
6
 p.f.u. dose of the constructs were not 
protected against lethal PVM infection. In contrast, those animals which received the 
immunisation dose of 10
7
 p.f.u. were protected but still presented with some clinical 
signs and weight loss associated with PVM infection (Fig. 4.4-7). As such, it was 
hypothesised that if animals were immunised with a greater dose (10
8
 p.f.u.), 
protection against lethal PVM infection would remain and PVM related signs might 
be reduced due to the increased dose of immunogen delivered. To investigate this 
hypothesis, animals were immunised with 10
8
 p.f.u. of the rAd constructs via the 
intranasal route.  
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5.3.1 Immunisation of animals with a greater dose of rAd vectors is protective 
against lethal PVM infection 
BALB/c mice between 5 and 7 weeks of age were immunised intranasally using the 
standard prime-boost regime (Fig. 4.2). For each recombinant Ad construct 
investigated, the animals were separated into groups and immunised as detailed in 
Table 5.3.  
 
 
Group Vaccine 
construct 
Prime dose 
(p.f.u./50µl) 
Boost dose 
(p.f.u./50µl) 
Animals/group 
 
A rAdF 10
8
 10
6
 5 ♀ 
B rAdM 10
8
 10
8
 5 ♀ 
C rAdN 10
8
 10
8
 5 ♀ 
D rAdZ 10
8
 10
8
 4 ♂ 
E N/A PBS PBS 2 ♀ 
Table 5.3. The rAd immunisation protocol using the 10
8
 p.f.u. dose.  
 
 
Throughout the immunisation regime and prior to PVM challenge, no weight loss or 
clinical signs were observed for any animals vaccinated with rAdM, rAdN, rAdZ or 
treated with PBS. However, those immunised with the greater dose of the rAdF 
construct (group A) did present with ruffled fur and substantial weight loss post 
prime dose. These animals did not recover but due to these signs it was considered 
appropriate to reduce the boost dose for this group to 10
6
 p.f.u. Upon boost with the 
lower dose, no vaccine related signs were observed. All animals were challenged 
with a lethal dose of PVM on day 31 and were monitored throughout the challenge 
period (Fig. 5.5). Animals treated with PBS served as a control group to monitor 
PVM pathogenesis. 
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Figure. 5.5. Immunisation with rAd constructs confers protection against lethal 
PVM infection.  
BALB/c animals were immunised as described in Table 5.3 using the standard 
prime-boost regime (Fig. 4.2). Animals were primed with a 10
8
 p.f.u. dose of either 
rAdF (group A), rAdM (group B), rAdN (group C), rAdZ (group D) or PBS (group 
E). Animals were boosted on day 14 with the same vaccine dose and construct as 
received for the priming dose, apart from group A (rAdF) which received a lower 
dose of 10
6
 p.f.u. The animals were challenged with a lethal dose of PVM strain 
J3666 (250 p.f.u. in 50µl) on day 31 of the experiment. Mean clinical score (A) and 
bodyweight loss (B) were monitored throughout the challenge period. Mean clinical 
score was calculated from the scores of each individual in an inoculation group. 
Bodyweight was calculated using the total weight per inoculated group, averaged per 
animal and normalised to the weight on day 0 of PVM challenge (100%). 
 
 
Groups A, B and C (immunised with rAdF, rAdM, and rAdN respectively) did not 
present with weight loss or clinical signs following PVM challenge, all gaining 
weight to above their pre-challenge level. Group C presented with slight transient 
weight loss between days 7 and 10, which was not reflected in their clinical score. 
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These animals quickly recovered and gained weight above the pre-challenge level. 
Therefore, PVM rAd-immunised animals were protected from PVM challenge.  
Unexpectedly, group D (rAdZ-immunised animals), were also protected against 
lethal PVM challenge. This group presented with mild clinical signs which increased 
to a peak score of 2 (Fig. 5.5A) and slight weight loss between days 7 and 10. All 
animals survived and recovered from PVM infection as demonstrated by a return to 
baseline levels of clinical score and weight gain (Fig. 5.5B). In contrast, control 
group E (treated with PBS) presented with clinical signs and weight loss from day 6, 
which increased in severity resulting in the deaths of all the animals on day 9. This 
result, for control group E, was similar to previous experiments with PBS treated 
animals. These data demonstrated that the apparent protection from PVM caused by 
rAdZ-immunisation was real, and not an artefact of lack of potency in the challenge 
dose used. Therefore, it appeared that animals immunised with rAd constructs at a 
high dose of 10
8
 p.f.u., were protected against lethal PVM infection.  
 
5.3.2 Immunisation of animals with a high prime dose and a low boost dose of 
rAd recombinant viruses is protective against lethal PVM infection 
As hypothesised, animals immunised with the high, 10
8
 p.f.u., dose of the PVM rAd 
constructs were protected from lethal PVM infection and presented with reduced 
signs and weight loss. Unexpectedly, protection towards a lethal PVM infection was 
also demonstrated in rAdZ-immunised animals, only when the high dose was used. 
This effect cannot be attributed to a change in PVM pathogenicity as previous 
experiments (Section 4.2), detailed that the 250 p.f.u. challenge dose of PVM is fully 
lethal in PBS control mice. In addition, all experiments described previously have 
included a PBS treated group to monitor PVM pathogenesis, and in all experiments, 
animals in this group have succumbed to PVM infection.  
 
To investigate the unexpected protection observed with 10
8
 p.f.u. rAdZ-immunised 
animals, the immunisation protocol was altered. BALB/c mice were immunised with 
a high dose of 10
8
 p.f.u. of either rAdN (group A) or rAdZ (group B) or treated with 
PBS, as a control for PVM pathogenesis. Animals were boosted on day 14 with a low 
dose of 10
6 
p.f.u. of the same construct and, prior to challenge on day 28 with a lethal 
dose of PVM and monitored for clinical signs and weight loss (Fig. 5.6).  
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Figure. 5.6. A 10
8
-10
6
 p.f.u. prime-boost immunisation regime with an rAd 
construct confers protection against a lethal PVM infection.  
BALB/c mice aged between 5 and 7 weeks of age were immunised with the standard 
prime-boost regime. However, a 10
8
 p.f.u. prime dose and a 10
6
 p.f.u. boost dose 
were used to immunise mice with either rAdN (group A) or rAdZ (group B) or 
treated with PBS (group C). Animals were challenged with a lethal dose of PVM 
strain J3666 on day 28. Mean clinical score (A) and bodyweight loss (B) were 
monitored throughout the challenge period. Mean clinical score was calculated from 
the scores of each individual in an inoculation group. Bodyweight was calculated 
using the total weight per inoculated group, averaged per animal and normalised to 
the weight on day 0 of PVM challenge (100%). Upon a death of an animal in a group, 
the clinical score and bodyweight loss continued to be monitored, but are illustrated 
thereafter by dashed lines on the graphs. 
 
 
Group A (rAdN-immunised animals) did not present with clinical signs (Fig. 5.6A) 
or weight loss (Fig. 5.6B) following PVM challenge and thus were protected from 
lethal PVM infection. Group B (rAdZ-immunised animals) did present with mild 
clinical signs and moderate weight loss following PVM challenge. Clinical signs 
appeared from day 7 onwards (Fig. 5.6A), reaching a peak score of 2.5 on day 9 
before decreasing to baseline levels by day 14. Weight loss was observed from day 7 
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onwards, reaching a maximum of 14% on day 10 (Fig. 5.6B), after which the animals 
gained weight and recovered from PVM infection. This was in contrast to the solid 
protection achieved with a 10
8 
p.f.u. prime-boost regime with rAdZ (Fig. 5.5).  One 
fatality was observed on day three and was attributed to anaesthesia complications. 
As expected, control group C (PBS treated) did not survive lethal PVM infection, 
presenting with severe clinical signs (Fig. 5.6A) and significant weight loss (Fig. 
5.6B). 
 
5.3.3 Discussion 
As expected, rAd PVM constructs protected animals against lethal PVM infection 
with minimal signs. Unexpectedly, rAdZ-immunised animals were also protected, 
but only when immunised with the high dose, 10
8
 p.f.u. To further investigate the 
threshold of protection elicited by the rAdZ construct, the prime-boost regime was 
altered so that animals were primed with a high, 10
8
 p.f.u. dose and boosted with a 
low 10
6
 p.f.u. dose of the construct. Protection was still achieved with the rAdZ 
construct using this protocol. However, a lower boost dose resulted in mild clinical 
signs and moderate weight loss (Fig. 5.6), in contrast to the absence of weight loss 
upon immunisation with a high boost dose (Fig. 5.5) in this rAdZ-immunised group. 
These data suggest that the protection against PVM achieved at the high dose is dose 
dependent and therefore is likely to be conferred by the rAd vector as opposed to the 
transgene.  
 
 
5.4 Investigation into the immunogenicity of the 108 p.f.u. rAd construct dose 
 
The protection conferred by the rAd constructs against PVM was observed in a short-
term challenge experiment as previously described (Fig. 5.5). To determine the 
threshold of this protective effect further, animals were immunised using a prime-
boost regime with a high vaccine dose and challenged with a lethal PVM dose after 
increasing time intervals in a long-term experiment. In addition, animals were 
immunised with a single high vaccine dose prior to PVM challenge.  
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5.4.1 rAdZ elicited protection against PVM is long-lasting 
BALB/c mice between 5 and 7 weeks of age were immunised using a prime-boost 
regime (Section 4, Fig. 4.10). The animals were immunised with the high dose of 10
8
 
p.f.u. of either rAdN (group A) or rAdZ (group B) and were challenged at 8 and 11 
weeks post prime immunisation with a lethal dose of PVM strain J3666. After 8 
weeks, group A (rAdN-immunised animals) were fully protected against lethal PVM 
infection. No clinical signs or weight loss were observed in this group following 
PVM infection. Animals in group B (rAdZ-immunised) were also protected from 
lethal PVM challenge. The animals did present with mild clinical signs from days 9 
to 13, but the peak clinical score did not increase above 2 (Fig. 5.7A). Slight weight 
loss was demonstrated from day 6 onwards, reaching a maximum of 8% on day 10 
(Fig. 5.7B), after which the animals gained weight and recovered from PVM 
infection. In contrast PBS treated animals (group C) showed signs and weight loss 
characteristic of lethal PVM infection and were thus not protected against lethal 
PVM infection.  
 
Even after 11 weeks from priming immunisation, both groups A and B (rAdN and 
rAdZ-immunised animals respectively) only developed mild clinical signs between 
days 7 and 12 following PVM challenge (Fig 5.8A). No weight loss was observed 
over the challenge period, and both groups maintained a constant bodyweight around 
the pre-challenge level (Fig. 5.8B). As before, group C (PBS treated) animals were 
not protected against PVM. Thus, when compared to control group C, both rAdN 
(group A) and rAdZ (group B) immunised animals were protected against lethal 
PVM infection for up to 11 weeks post initial immunisation.    
  182   
 
 
Figure. 5.7. rAd recombinant viruses can confer protection against lethal PVM 
infection 8 weeks after priming immunisation. 
Female BALB/c mice between 5 and 7 weeks of age were vaccinated and challenged 
as described in Section 4, Fig. 4.10. Animals were immunised with a prime dose of 
10
8
 p.f.u. of either rAdN (group A) or rAdZ (group B) or treated with PBS on day 1. 
The animals were boosted with the same vaccine construct and dose on day 14. 
Animals were challenged at 8 weeks after initial immunisation with a lethal dose of 
PM strain J3666 (250 p.f.u. in 50µl). Mean clinical score (A) and bodyweight loss (B) 
were monitored throughout the challenge period. Mean clinical score was calculated 
from the scores of each individual in an inoculation group. Bodyweight was 
calculated using the total weight per inoculated group, averaged per animal and 
normalised to the weight on day 0 of PVM challenge (100%). Upon a death of an 
animal in a group, the clinical score and bodyweight loss continued to be monitored, 
but are illustrated thereafter by dashed lines on the graphs. 
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Figure. 5.8. rAd vaccines can confer protection against lethal PVM infection up 
to 11 weeks post prime dose.  
Female BALB/c mice were vaccinated and challenged as described in Fig. 5.7. 
Animals were challenged at 11 weeks after initial immunisation with a lethal dose of 
PVM strain J3666. Mean clinical score (A) and bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal and normalised to the weight on 
day 0 of PVM challenge (100%).  
 
 
 
5.4.2 A single high dose of rAd vaccine confers protection against PVM 
To determine the immunogenicity the 10
8
 p.f.u. dose, groups of BALB/c mice 
between 5 and 7 weeks of age were immunised with a single, high dose of 10
8
 p.f.u. 
of either rAdM (group A), rAdN (group B) or rAdZ (group C). PBS treated mice 
(group D) were included as a control for PVM pathogenesis. The animals were 
challenged with a lethal dose of PVM six weeks post immunisation and monitored 
for weight loss and signs as before (Fig. 5.9).  
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Figure. 5.9. Immunisation with a single dose of an rAd construct can confer 
protection against lethal PVM infection. 
Groups of 6 (three male and three female) BALB/c mice aged between 5 and 7 
weeks were immunised with a single dose of rAdM (group A), rAdN (group B), or 
rAdZ (group C) at 10
8
 p.f.u. As a control, a group of two male and two female 
BALB/c mice was treated with PBS (group D). Six weeks post immunisation, the 
animals were challenged with a lethal dose of PVM strain J3666 (250 p.f.u. in 50µl). 
Mean clinical score (A) and bodyweight loss (B) were monitored throughout the 
challenge period. Mean clinical score was calculated from the scores of each 
individual in an inoculation group. Bodyweight was calculated using the total weight 
per inoculated group, averaged per animal and normalised to the weight on day 0 of 
PVM challenge (100%). One animal in group B was culled on day 4 due to 
immunisation complications and was not included in the final analysis. 
 
 
Groups A and B (rAdM and rAdN-immunised, respectively) did not present with 
clinical signs or weight loss (Fig. 5.9), whereas group C presented with mild clinical 
signs (Fig. 5.9A), and slight weight loss (Fig. 5.9B) between days 7 and 12; however 
the animals recovered and gained weight. In contrast, group D (PBS treated) animals 
developed severe clinical signs and bodyweight loss (Fig. 5.9), coinciding with three 
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deaths on day 9 and the remainder on day 10. Therefore, animals were protected 
against lethal PVM infection after a single 10
8
 p.f.u. immunisation dose of the rAd 
constructs.  
 
5.4.2.1 Discussion 
The protective effect of the rAd vectors was investigated in experiments where PVM 
challenge was delayed. First, rAd-immunised animals were challenged with PVM at 
8 and 11 weeks post priming dose. The data in Section 4.5 demonstrated that the 
rAdM and rAdN constructs could elicit protection in animals immunised with 10
7
 
p.f.u. in a prime-boost regime for up to 20 weeks (Section 4, Figs. 4.11, 4.12). In 
contrast, rAdZ-immunised animals were not protected, even up to 8 weeks, using this 
regime (Section 4, Fig. 4.13). The data presented in this section demonstrates that 
rAd-immunised mice with a 10
8
 p.f.u. prime-boost regime are protected against 
lethal PVM infection for up to 11 weeks. This result is not unexpected for rAdN-
immunised animals, as protection was achieved in this manner with the 10
7
 p.f.u. 
dose. However, rAdZ-immunised animals are protected for up to 11 weeks following 
immunisation with the high dose 10
8
 p.f.u. only (Fig. 4.13, 5.7, 5.8). In addition, 
animals immunised with a single 10
8 
p.f.u. dose of the rAd constructs were protected 
against lethal PVM infection. rAdZ-immunised animals did present with mild 
clinical signs and weight loss, which distinguished them from animals similarly 
immunised with rAdN, but they were ultimately protected against PVM infection.  
These data confirm that the protective effect elicited by the rAd constructs is 
mediated by the adaptive immune response. The protective effect observed is not due 
to a stimulation of an innate, anti-viral immune response, as such a response would 
not be maintained for 11 weeks. Neither would the innate response be maintained for 
6 weeks after a single immunisation dose. These data also indicate that the 
immunogenic effect of the high dose is strong, as a single dose can confer protection 
against a lethal PVM infection for 6 weeks and a double dose for up to 11 weeks.  
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5.5 Investigation into the immunogenicity of the rAdZ recombinant virus  
 
Immunisation of mice with a 10
8
 p.f.u. dose of rAdZ construct generated a protective 
response demonstrated up to six weeks post immunisation with a single dose and up 
to 11 weeks post immunisation with a prime-boost regime. The experiments 
described in Sections 5.3 and 5.4 do not elucidate whether the immunogen mediating 
the protective effect was the rAd vector or the LacZ transgene. To investigate this 
further, BALB/c animals were immunised with additional rAd constructs. The rAd 
recombinant viruses were also investigated for their ability to confer protection 
against an unrelated respiratory virus, to determine whether the effect was virus-
specific.  
 
5.5.1 Immunisation with rAdEV and rAdGFP constructs confers protection 
against PVM with a high dose only 
BALB/c mice between 5 and 7 weeks of age were immunised via the intranasal route 
with the high (10
8
 p.f.u.) and middle (10
7
 p.f.u.) doses of two additional rAd 
constructs. The first construct was generated using the AdEasy™ protocol (Section 3) 
and did not contain a transgene in the multiple cloning site of the vector and was 
known as rAdEV (Empty Vector). The other construct, rAdGFP, was kindly 
provided by Mr S. Martin. This construct was generated by an alternative method but 
the vaccine vector was of the Ad5 serotype and contained deletions within the E1 
and E3 regions of the Ad genome broadly equivalent to those found in AdEasy-
derived vectors. Thus, the construct was replication deficient as per the recombinant 
viruses generated in this study. rAdGFP contained green fluorescent protein gene 
(GFP), expressed under the control of the CMV immediate-early promoter. GFP 
expressed from rAdGFP therefore acts as an additional irrelevant protein to elucidate 
whether the LacZ protein or the rAd vector is the cause of the non-specific protection 
observed when using rAdZ as immunogen. 
 
Animals were separated into five groups and were immunised as detailed in Table 
5.4 using the standard prime-boost regime (Fig. 4.2). Throughout the immunisation 
regime and prior to PVM challenge, no weight loss or clinical signs were observed 
for any animals vaccinated with either the rAdEV or rAdGFP constructs. 
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Group Vaccine 
construct 
Prime dose 
(p.f.u./50µl) 
Boost dose 
(p.f.u./50µl) 
Animals/group 
(♂:♀) 
A rAdEV 10
7
 10
7
 5  (3:2) 
B rAdEV 10
8
 10
8
 5  (3:2) 
C* rAdGFP 10
7
 10
7
 5 (♂) 
D* rAdGFP 10
8
 10
8
 5 (♀) 
E N/A PBS PBS 2 (♀) 
Table 5.4. The standard immunisation dose for vaccination with additional rAd 
constructs. 
*Experiment performed by Mr S. Martin 
 
 
Following PVM challenge, group A and B animals (immunised with rAdEV at the 
10
7
 and 10
8
 p.f.u. doses, respectively) did not present with clinical signs or weight 
loss associated with PVM challenge (Fig. 5.10). Animals immunised with rAdGFP at 
the 10
8
 p.f.u. dose (group D) presented with mild clinical signs, reaching a peak 
score of 2.5 on day 9 (Fig. 5.10A) and remaining constant at an average score of 2 
for the duration of the experiment. Mild weight loss was observed from day 7 
onwards, reaching a maximum of 5% on day 9 (Fig. 5.10B). Thereafter, the animals 
gained weight and recovered from PVM infection. In contrast, animals immunised 
with rAdGFP at 10
7
 p.f.u. (group C) presented with severe clinical signs and weight 
loss that began on day 6 and reached the maximum of 27% on day 10 (Fig. 5.10B), 
which coincided with the deaths of all the animals. This pathogenesis was equivalent 
to that seen in the control group E animals (PBS treated). Thus, rAdGFP protected 
animals from lethal PVM challenge only at the high (10
8
 p.f.u.) dose, similar to rAdZ.  
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Figure. 5.10. rAdEV and rAdGFP can stimulate a protective immune response 
against lethal PVM challenge.  
BALB/c mice were immunised on day 1 with rAdEV at 10
7
 p.f.u. (group A) or 10
8
 
p.f.u. (group B) or PBS (group E). The animals were boosted on day 14 with the 
same vaccine construct and dose prior to challenge on day 28 with a lethal dose of 
PVM strain J3666. Animals from a different batch were vaccinated with rAdGFP at 
the 10
7
 p.f.u. (group C) or 10
8
 p.f.u. (group D) dose in a different experiment 
conducted by S. Martin; the animals were boosted and challenged as described for 
the rAdEV construct. Mean clinical score (A) and bodyweight loss (B) were 
monitored throughout the challenge period. Mean clinical score was calculated from 
the scores of each individual in an inoculation group. Bodyweight was calculated 
using the total weight per inoculated group, averaged per animal and normalised to 
the weight on day 0 of PVM challenge (100%). Groups A and B immunised male 
animals showed signs of ruffled fur due to aggressive behaviour, therefore the 
average baseline clinical score for these groups was 1.5.  
 
 
The equivalent protection from lethal PVM infection elicited by the high (10
8
 p.f.u.) 
dose of rAdEV, rAdGFP and rAdZ, indicates that protection at this dose is attributed 
to the rAd vector, not a specific transgene. This is because it is highly improbable 
that two unrelated, irrelevant proteins, GFP and β-galactosidase, could confer a 
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protective response against PVM. As expected, animals immunised with the 10
7
 p.f.u. 
dose of rAdGFP were not protected against lethal PVM infection; a result similar to 
that of rAdZ-immunised animals. Surprisingly, rAdEV immunised animals were also 
protected from PVM infection at this dose. This result may have occurred because 
the rAdEV preparation was later found to contain a low level of a replication-
competent virus. This may have allowed the virus to replicate and thus, increase the 
dose of antigen received by the animals. Other rAds lacking a PVM transgene failed 
to protect immunised animals at this dose, which is in contrast to the rAd PVM 
constructs, which are protective at the 10
7
 p.f.u. dose.  
 
5.5.2 Immunisation of C3H/He-mg mice with rAd constructs does not elicit 
protection against influenza virus 
The standard influenza A pathogenesis model in mice uses animals of strain 
C3H/He-mg (Morgan et al., 1993). Mice between 5 and 7 weeks of age were 
immunised with a 10
8
 p.f.u. dose of either rAdEV or rAdZ vaccines via the intranasal 
route. The standard prime-boost regime was used (Fig. 4.2). As before, no weight 
loss or clinical signs were observed associated with the vaccination. On day 28, the 
animals were challenged with a previously determined lethal dose of influenza 
A/WSN virus (Section 2, Table 2.1.3). This lethal dose was equivalent to that used 
for PVM when analysed in a dose dependent manner (P.D. Scott, personal 
communication). Clinical signs of influenza illness are similar to that of PVM 
(Dimmock et al., 2008). Therefore, the same clinical score system was used to 
evaluate the animals, together with bodyweight loss, for the duration of the 
experimental period.  
 
Groups A and B animals (rAdEV and rAdZ, respectively) developed a similar 
pathogenesis to control group C (PBS treated). They developed clinical signs from 
day 4 onwards reaching the peak score of 4.5 on day 7 (Fig 5.11A). Weight loss was 
evident from day 2/3 onwards, reaching a maximum of 28% for group A on day 7 
and 27% for group B on day 6 (Fig. 5.11B). This coincided with the deaths of 83% 
of the animals in the groups. The pathogenesis seen in groups A and B was 
equivalent to that in PBS treated control mice (group C). As there was no protective 
difference between the rAd-immunised mice, groups A and B, and the control 
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animals (group C), the experiment was terminated on day 7 and it was concluded that 
the rAd vectors did not stimulate a protective response to an unrelated respiratory 
viruses. Thus, the protection against PVM elicited by recombinant Ad not expressing 
any PVM transgene is not a generalised protection, but is virus-specific to PVM.  
 
 
 
 
Figure. 5.11. rAd vaccine constructs do not protect C3H/He-mg mice from 
lethal influenza challenge. 
C3H/He-mg mice from one batch of animals were vaccinated with a prime dose on 
day 1 of either 10
8
 p.f.u. of rAdEV (group A) or rAdZ (group B) or PBS (group C). 
Groups A and B consisted of six animals, three males and three females whereas 
group C consisted of three males. The animals were boosted on day 14 with the same 
immunogen and dose prior to challenge with a lethal dose of 2.25x10
4
 p.f.u. in a 50µl 
volume of influenza A/WSN. Mean clinical score (A) and bodyweight loss (B) were 
monitored throughout the challenge period. Mean clinical score was calculated from 
the scores of each individual in an inoculation group. Bodyweight was calculated 
using the total weight per inoculated group, averaged per animal and normalised to 
the weight on day 0 of influenza virus challenge (100%). 
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5.6 Discussion  
 
In the previous chapter, rAd PVM vaccines were shown to elicit a protective immune 
response against a lethal PVM infection, that was long-lasting. In this chapter, the 
protective effect was investigated further through the evaluation of different 
immunisation routes and through an alternative dose. 
While intranasal immunisation with rAd PVM constructs at the 10
7
 p.f.u. dose was 
able to generate protection against a lethal PVM infection, immunisation via the 
subcutaneous route with either a 10
6
, 10
7
 or 10
8
 p.f.u. dose was not associated with 
protection against PVM. Intraperitoneal immunisation also did not confer protection, 
and in addition, was associated with severe vaccine-related side effects. These side 
effects included severe liver pathology and gut related signs and have been observed 
before, even with replication-deficient Ad5 vectors (Vogels et al., 2003). Even if the 
vector is replication-deficient it will, when introduced into the peritoneal cavity, 
enter liver cells and stimulate a strong immune response which, results in clearance 
of the virus and consequent liver pathology. This might  be circumvented by the use 
of alternative Ad serotypes as vaccine vectors. Interestingly, neither the 
subcutaneous nor the intraperitoneal immunisation route stimulated a protective 
immune response. This maybe because the immunisation dose was not sufficient to 
stimulate a response towards the PVM virus of sufficient magnitude to be protective. 
Alternatively, these results suggest that a systemic induced immune response may 
not be able to protect animals against a lethal PVM infection, perhaps indicating that 
a mucosal driven immune response is more effective at providing protection against 
this virus.  
 
The focus of this chapter was an investigation of a high dose, 10
8 
p.f.u. of the rAd 
vaccines and the effects such a dose elicited. As expected, the rAd PVM constructs 
were able to protect 10
8
 p.f.u. immunised animals from a lethal PVM infection, given 
that they were able to achieve this with the lower 10
7
 p.f.u. dose. As hypothesised, 
the increased dose did lead to a reduction in the clinical signs and weight loss 
observed upon PVM challenge, when compared to an equivalent experiment using a 
10
7
 p.f.u. dose. However, unexpectedly, the animals immunised with the 10
8
 p.f.u. 
dose of rAdZ were also protected against PVM infection. This was not due to an 
altered pathogenicity of the PVM stock used for challenge as PBS control animals 
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progressed to a lethal infection as observed in previous experiments. Therefore, it 
was considered that the high dose may deliver a greater amount of antigen which was 
able to stimulate a transient short-term non-specific anti-viral state within the animal.  
To determine whether the protective effect was induced by the adenovirus vector or 
the LacZ transgene, alternative vaccine constructs were used to immunise animals. 
One did not contain a transgene, rAdEV, and one contained an alternative irrelevant 
transgene, of GFP, rAdGFP. The data kindly provided by Mr S. Martin of rAdGFP-
immunised animals, coupled with the data from rAdEV-immunised animals with the 
high vaccine dose (Fig. 5.10), demonstrated that both of the vaccines could elicit the 
protective effect against PVM challenge. Therefore, it was concluded that the rAd5 
vector was the immunogen responsible for the specific protection against PVM virus.  
A similar finding has been reported previously by a different group (See et al., 2008). 
They discovered that an empty rAd5 replication-deficient construct, used to 
immunise ferrets by the intranasal route with a 10
9
 p.f.u. dose, was able to confer a 
specific protective effect against SARS virus. They attributed this result to an altered 
lung mucosal morphology upon rAd vaccination. It was also suggested that the 
down-regulation of the CAR receptor, or PVM receptor, or an additional co-receptor, 
may confer an immunogenic advantage. However, such down-regulation would be 
unlikely to be maintained for a long period of time such as observed in the 11-week 
challenge experiment (Fig. 5.8). An alternative explanation is that a serum 
component common to the rAd and PVM virus stocks may stimulate a cross-
protective immune response. However, this is deemed unlikely as both the rAd and 
PVM viruses were isolated by different methods and significantly diluted to obtain 
the immunisation and challenge doses, and in the case of the immunising rAd 
preparations, was highly purified prior to use. 
 
The long-term experiments (Figs. 5.7, 5.8) where animals were immunised with a 
prime-boost regime of 10
8
 p.f.u. of rAdN and rAdZ showed protection from PVM 
infection, persisting at least 11 weeks post-immunisation with rAdZ. In addition, a 
single 10
8
 p.f.u. dose of the vaccines was able to confer protection for six weeks 
post-immunisation (Fig. 5.9). These data most likely suggest that an adaptive 
immune response may confer the protective effect elicited by the rAd vector.  It is 
known that upon immunisation, cross reactive T-cells can be stimulated (Hutnick, 
2010). It is possible that a cross-reactive T-cell population between rAd and PVM 
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was activated by rAd, and upon a booster immunisation dose, stimulated further. 
Thus, following challenge with PVM, this population would confer specific 
protection against the virus.  
Additionally, evidence supporting an adaptive response for conferring the protective 
effect is illustrated in Appendix C. Fig. C.2. These data demonstrated that a 10
8
 p.f.u. 
dose of rAdZ in a prime-boost regime was immunogenic enough to provide 
protection against a super lethal dose of PVM (500 p.f.u of PVM strain J3666). This 
was performed to ensure that any protective effect observed was robust as opposed to 
innate immunity simply attenuating the lethality of the PVM challenge dose, 
effectively allowing the animal an opportunity to generate a natural adaptive 
response towards PVM whilst viral replication was slowed. This further suggests that 
an innate immune response is unlikely to be mediating the protective effect. 
 
However, the innate response may still be stimulated by the presence of the rAd 
vector. As vector persistence was not investigated in this study, it is unknown how 
long the rAd vector remains functional within the mouse lung. It is possible that the 
vector may persist within the mouse lung, providing recurrent stimulation of the 
innate immune system, perhaps through leaky gene expression (Imperiale et al., 1984, 
Spergel et al., 1992). This would lead to the possibility of an anti-viral state being 
induced, even up to 11 weeks post immunisation. Such a response may be 
demonstrated in Fig. 4.13C, where some rAdZ-immunised mice survived PVM 
challenge up to 20 weeks post immunisation. It is known with persistent human 
viruses, such as herpes simplex virus (HSV-1), that viral replication is inhibited upon 
infection by adaptive responses (Khanna et al., 2004). However, when the virus 
emerges from latency, it is the IFN response from both innate and adaptive sources 
which inhibit viral replication and prevent a lytic infection cycle. Therefore, leaky 
long-term expression of Ad proteins from the vector could stimulate innate responses 
in a cyclical manner, leading to the establishment of an anti-viral state which may 
have translated into apparent protection from PVM challenge by the rAd vectors as 
observed in Figs. 5.7-5.9. Furthermore, to investigate whether this protection was 
virus specific, animals were immunised with rAdZ and challenged with another 
respiratory virus, influenza. These animals were not protected against lethal 
influenza challenge (Fig. 5.11), thus, it can be concluded that the immune response 
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generated is specific against the PVM virus, or that adaptive responses are more 
important for control of influenza infection in mice. 
 
In conclusion, although the results presented in this chapter suggest that an adaptive 
response is more likely to confer the protective effect observed upon high 
immunisation doses of the rAd vector, it does not discount the possibility of innate 
immune responses providing a protective role. As such, the cause of the specific 
protective effect towards PVM mediated by the rAd vector is as yet unidentified.   
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Chapter 6 
 
Investigation into the immune 
responses generated by rAd construct 
immunisation  
6  
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6.1 Introduction 
 
The three rAd PVM constructs, rAdF, rAdM and rAdN described previously, were 
able to protect intranasally immunised mice from PVM infection. However, the 
experiments did not elucidate the mechanism behind the protective effect. As 
discussed in Section 1.6.2, the adaptive immune system involves the coordinated 
effects of both the humoral and cellular immune responses towards a pathogen. Anti-
viral immunity requires a strong humoral or a strong cellular response to be effective 
at resolving the infection (Belyakov & Ahlers, 2009). The work described in this 
chapter attempts to identify whether the humoral and/or cellular response was 
involved in the protective effect observed upon PVM rAd-immunised BALB/c mice. 
  
6.1.1 ELISA optimisation 
One of the most effective methods to characterise the humoral response towards an 
antigen is through the use of an Enzyme-Linked Immunosorbent Assay (ELISA). An 
ELISA, appropriately configured, can determine the quantity of an unknown amount 
of either antigen or antibody in a sample. The assay used in this study was an indirect 
ELISA, which involved the addition of antigen into a microtitre plate to which the 
antibody in the serum samples can bind.  
 
Two ELISA assays were developed, one to investigate the anti-PVM response and 
another to investigate the anti-Ad5 (vector) response. The anti-Ad5 ELISA had been 
previously optimised with UV inactivated Ad327 particles as antigen at a 
concentration of 1µg/ml (Flanagan et al., 1997). The anti-PVM ELISA utilised lysate 
from the persistently PVM infected P2-2 cell line as the PVM antigen. Because the 
P2-2 cell line is derived from BS-C-1 cells, this preparation is not of pure PVM 
antigen, but a mixture of PVM viral antigen and BS-C-1 cellular antigen. Therefore, 
BS-C-1 lysate, prepared in the same manner, was included in all ELISA experiments 
as a background antigen control. The assay values obtained for the BS-C-1 control 
lysate could then be used as the baseline level for the assay. Using serum from PVM 
immunised animals, the optimum concentration of P2-2 lysate was found to be 
1mg/ml (App. C. Fig. C.3). To assess the sensitivity of the anti-PVM ELISA, serum 
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from animals that had recovered from a non-lethal dose of PVM was used to 
compare UV-inactivated PVM particles and P2-2 lysate as antigen in the assay (Fig. 
6.1). The serum titre was found to be consistent between the P2-2 lysate and the UV 
inactivated particles. As PVM virus was difficult to bulk up in sufficient quantities 
for the number of ELISAs required, in this study lysate from the P2-2 cell line was 
deemed an appropriate substitute. 
 
 
 
Figure 6.1. Anti-PVM ELISA to determine the sensitivity with different PVM 
antigens.  
The PVM ELISA was performed as described in Section 2.9.11 using serum from 
animals immunised with a non lethal dose of 20 p.f.u. of PVM J3666. The serum  
was titrated against P2-2 lysate and UV inactivated PVM virus to compare the 
sensitivity of the two preparations.  
 
 
Subsequently, to confirm that P2-2 lysate contained sufficient antigen to allow the 
detection of PVM-specific antibodies, polyclonal antibodies directed against the 
PVM F and N proteins (Section 2, Table 2.1.7) were evaluated using the anti-PVM 
ELISA (Fig. 6.2). These antibodies were readily detected in the assay, thus it was 
concluded that the P2-2 cell lysate was suitable for analysing serum samples from all 
rAd PVM immunised animals for the presence of such antibodies. In addition, the 
ELISA was shown to be specific for PVM antibodies only, as no signal was detected 
using control serum from influenza-immunised animals (App. C. Fig. C.4).   
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Figure 6.2. PVM protein monoclonal antibodies can be detected within the PVM 
ELISA.  
The PVM ELISA was performed as described in Section 2.9.1.1, using the anti-PVM 
F polyclonal (clone 2018 Table 2.1.7) (A) and the anti-PVM N polyclonal (Table 
2.1.7) (B) as the serum samples. The antibodies were used from a neat preparation 
and were successfully titrated within the assay, confirming specific responses to 
particular PVM proteins could be detected. The data are representative of two 
experimental repeats.   
 
 
6.1.2 Detection of a PVM-specific response  
To generate a bench mark for PVM antibody titres, four animals were inoculated 
with 20 p.f.u. of PVM strain J3666. Sera was collected at 14 days post infection and 
analysed using a PVM ELISA assay. The end point dilution was then calculated, 
where the response observed to P2-2 antigen declined to equal that observed in the 
BS-C-1 antigen control. The result from one such animal is detailed in Fig. 6.3, 
which describes how the end point dilution for a serum sample is calculated.  
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Figure 6.3. Determining the end point dilution for a serum sample. 
A serum sample from an animal immunised with a non lethal dose of 20 p.f.u. of 
PVM strain J3666 was titrated by ELISA against P2-2 and BS-C-1 cell lysate antigen. 
The last data point against P2-2 antigen which remains above the BS-C-1 
background control (black box), was taken as the end point dilution of the serum 
sample. The relative absorbance values for every dilution end point were averaged 
for PBS-treated animals. These values are experimental background in the ELISA 
assay, as they represent a non-specific response generated from serum components, 
towards the antigens used. Once calculated, the experimental background was 
removed from the values obtained from PVM infected or rAd-immunised animals for 
each dilution point. As such, they were normalised for experimental background.  
  
 
The data for the animals was combined and demonstrated that all four animals 
produced the same anti-PVM antibody titre in response to mild PVM infection. This 
result represents an optimum response to PVM, producing a log10 end point titre of 
3.5 (Fig. 6.4). 
 
 
Figure. 6.4. The anti-PVM IgG 
titre from positive control 
animals.  
Serum samples from four animals 
immunised with 20 p.f.u. of PVM 
strain J3666 were collected on 
day 14 post immunisation. All 
samples were analysed in the 
PVM ELISA and the antibody 
endpoint dilution values 
calculated as described in Fig. 6.3. 
The normalised values were then 
illustrated on a graph as log10 values, generating a positive value for PVM-recovered 
animals. The line represents the mean titre of the samples.  
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6.2 The humoral response of prime-boost rAd-immunised animals  
 
Initially, the anti-PVM and anti-Ad5 IgG humoral responses were characterised for 
the rAd constructs. All animals immunised via the intranasal route with an rAd virus 
using the standard prime-boost strategy (Section 4, Fig. 4.2) were included in the 
analysis. Serum samples were obtained on day 14 (boost time point) and day 28 
(PVM challenge time point), and analysed by ELISA for anti-PVM and anti-Ad IgG 
responses, using an anti-mouse IgG secondary antibody (Section 2, Table 2.1.7) to 
specifically detect IgG. Data for animals immunised with each of the rAd vaccine 
constructs were collated for the 10
6
, 10
7
 and 10
8
 p.f.u. doses 
 
6.2.1 Detection of PVM-specific antibody responses. 
The anti-PVM ELISA did not detect high levels of PVM-specific IgG in the rAd 
PVM immunised animals (Fig. 6.5), when compared to the positive control PVM-
immunised animals (Fig. 6.4).  
One rAdF-immunised animal generated a detectable response towards PVM antigen 
when immunised with the first 10
6
 p.f.u. dose (Fig. 6.5A, red symbols). 
Immunisation with the 10
7
 p.f.u. dose did not increase the number of detectable 
responding animals (Fig. 6.5A, green symbols). A booster immunisation of animals 
at either of these doses did not increase either the number of detectable responders or 
the magnitude of the response. A greater number of animals immunised with the 
highest dose of rAdF, 10
8
 p.f.u. (Fig. 6.5A, blue symbols), showed a rise in PVM-
specific antibodies, particularly at the day 28 time point. However, the antibody titre 
was lower than that observed for the PVM-infected control animals. 
 
rAdM-immunised mice also did not generate high levels of anti-PVM IgG antibodies 
at any of the time points or vaccine doses used (Fig. 6.5B). In contrast, rAdN-
immunised animals demonstrated a positive relationship between the delivery of a 
boost dose and the magnitude of the anti-PVM response. Immunisation of animals 
with the highest dose of 10
8
 p.f.u. (Fig. 6.6A, blue symbols), correlated with the 
greatest number of detectable responders, some of which generated a similar anti-
PVM IgG titre to PVM infected animals (Fig. 6.4). Fewer animals showed a 
detectable positive response for either of the lower 10
6
 or 10
7
 p.f.u. doses (Fig. 6.6A, 
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red and green symbols), which was only observed at day 28. As expected, the rAdZ-
immunised animals did not generate a detectable response towards PVM antigen at 
any immunisation dose or time point analysed (Fig. 6.6B). This confirmed that the 
irrelevant LacZ transgene did not stimulate a detectable cross-reactive IgG immune 
response with PVM antigen in this assay. 
 
These data suggest that the standard prime-boost immunisation strategy via the 
intranasal route is unable to stimulate robust, detectable anti-PVM serum IgG 
responses. It is known that mice require approximately 14 days in which to establish 
a primary antibody response (Black, 1974, Miller, 1973). Thus, the prime-boost 
strategy used in this study ensures sufficient time for a primary antibody response to 
develop and be expanded upon booster immunisation. The absence of a statistically 
significant relationship between a booster dose and an increase in the titre of 
detectable serum anti-PVM IgG antibodies suggests that serum IgG may not be the 
primary mediator of protection against PVM virus.   
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Figure 6.5. The anti-PVM IgG titre for 
rAdF and rAdM immunised animals.  
BALB/c animals were immunised via the 
intranasal route using the standard prime-
boost regime (Section 4, Fig. 4.2), with rAdF 
(A) or rAdM (B) vaccines at either the 10
6
 
p.f.u. (red symbols), 10
7
 p.f.u. (green 
symbols) or 10
8
 p.f.u. (blue symbols) dose. 
Serum samples were collected from 
individual animals at the day 14 (boost) and 
day 28 (PVM challenge) time points. All 
samples were analysed in a PVM ELISA and 
the antibody titres calculated as described in 
Fig. 6.3. The normalised values were then 
illustrated on the graph as log10 endpoint 
dilution values. The data are representative 
of all experiments performed using this 
immunisation regime. The lines represent the 
mean titre of the samples.   
 
 
 
 
 
 
 
 
Figure 6.6. The anti-PVM IgG titre for 
rAdN and rAdZ immunised animals.  
BALB/c animals were immunised as 
described in Fig 6.5, with rAdN (A) or rAdZ 
(B) vaccines at either the 10
6
 p.f.u. (red 
symbols), 10
7
 p.f.u. (green symbols) or 10
8
 
p.f.u. (blue symbols) dose. Serum samples 
were collected from individual animals at 
days 14 and 28 time points. All samples were 
analysed in a PVM ELISA and the antibody 
titres calculated as described in Fig. 6.3. The 
normalised values were then illustrated on the 
graph as log10 endpoint dilution values. The 
data are representative of all experiments 
performed with this immunisation regime. 
The lines represent the mean titre of the 
samples.   
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6.2.2 Detection of rAd-specific antibody responses 
Since only a minority of animals receiving rAd PVM vaccine constructs mounted 
detectable anti-PVM antibody responses, it was unknown as to whether this reflected 
a general poor response to antigen delivery by rAd5 vectors via the intranasal route 
or a sensitivity issue with the anti-PVM ELISA assay. As such, it was of interest to 
determine whether the rAd-immunised animals mounted a response towards the Ad5 
vector. To investigate this further, the same serum samples analysed in the PVM 
ELISA described above, were used in an Ad5 ELISA assay. 
 
In contrast to the anti-PVM response, a greater number of animals generated a 
detectable response towards Ad5 antigen in the anti-Ad5 ELISA assay. There 
appeared to be a positive correlation between an increase in detectable antibody titre 
and a boost immunisation for all rAd constructs (Figs. 6.7 and 6.8). For rAdF-
immunised animals, a boost dose for the 10
6
 and 10
7
 p.f.u. immunised groups 
correlated with a significant increase in anti-Ad5 titres at day 28 (p=0.001 and 
p=0.0001, App. D. Table D.1), whereas this was not apparent for the 10
8
 p.f.u. 
immunised group. A boost dose also produced a significant increase in anti-Ad titres 
at all doses for rAdM-immunised animals (p=0.01, p=<0.0001 and p=<0.0001 App. 
D. Table D.2), the 10
7
 and 10
8
 p.f.u. doses for rAdN-immunised animals (p=<0.0001 
and p=0.001, App. D. Table D.3) and the 10
8
 p.f.u. rAdZ-immunised animals 
(p=<0.0001, App. D. Table D.4). These data indicated that the animals, including 
those that did not mount detectable anti-PVM IgG responses, had been successfully 
immunised with the viral constructs as they were able to produce detectable 
responses towards Ad5 antigen in the Ad5 ELISA assay.  
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Figure 6.7. The anti-Ad5 IgG titre for 
rAdF and rAdM-immunised animals.  
BALB/c animals were immunised and 
treated as described in Fig. 6.5 with rAdF (A) 
or rAdM (B) vaccines at either the 10
6
 p.f.u. 
(red symbols), 10
7
 p.f.u. (green symbols) or 
10
8
 p.f.u. (blue symbols) dose. All samples 
were analysed in an Ad5 ELISA and the 
antibody titres calculated as described in Fig. 
6.3. The normalised values were then 
illustrated on the graph as log10 endpoint 
dilution values. The data are representative 
of all experiments performed with this 
immunisation regime. The lines represent the 
mean titre of the samples.   
 
 
 
 
 
 
 
 
Figure 6.8. The anti-Ad5 IgG titre for 
rAdN and rAdZ-immunised animals.  
BALB/c animals were immunised and 
treated as described in Fig. 6.5 with rAdN (A) 
or rAdZ (B) vaccines at either the 10
6
 p.f.u. 
(red symbols), 10
7
 p.f.u. (green symbols) or 
10
8
 p.f.u. (blue symbols) dose. All samples 
were analysed in an Ad5 ELISA and the 
antibody titres calculated as described in Fig. 
6.3. The normalised values were then 
illustrated on the graph as log10 endpoint 
dilution values. The data are representative 
of all experiments performed with this 
immunisation. The lines represent the mean 
titre of the samples.   
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6.2.3 Summary  
The anti-PVM IgG response generated by PVM rAd-immunised animals was lower 
than that observed in PVM infected mice. There appeared to be little correlation 
between the time course of the experiment and PVM-specific antibody titres. 
Additionally, an increase in vaccine dose did not appear to have an immunogenic 
effect on the rAdF and rAdM-immunised animals at the greatest dose (10
8
 p.f.u., Fig. 
6.5A and B, blue symbols), however, this effect was observed for rAdN-immunised 
animals (Fig. 6.6A). The antibody end point dilution values were compared with 
each other using the Mann-Whitney U test. This non-parametric test determined that 
all rAds produced levels of PVM-specific antibodies which were not significantly 
different from the control construct, rAdZ.  
 
As such, the anti-Ad5 titre produced by the rAd constructs was investigated to 
determine whether these immunogens could elicit any response when delivered via 
the intranasal route. In contrast to the number of responders detected in the anti-PVM 
ELISA assay, the majority of animals tested generated a detectable response in the 
Ad5 ELISA assay. A boost dose significantly increased the anti-Ad5 titre for all of 
the rAd constructs at the majority of the immunisation doses. This indicated that the 
animals were able to be successfully immunised via the intranasal route with Ad5 
vectors. Thus, the inability to detect strong anti-PVM responses in the PVM ELISA 
assay may be due to either a sensitivity issue or an inability of these particular PVM 
antigens to stimulate a strong humoral response by this route of delivery.  
 
 
6.3 The longevity of the IgG immune response towards the Ad vaccines 
6.3.1 The anti-PVM and anti-Ad response of long-term immunised animals 
The short-term immunisation experiments described above were unable to generate 
robust, detectable anti-PVM titres. Although the mouse humoral response can be 
detected after 14 days post immunisation, the use of a replication-deficient vector 
which can infect cells and potentially express high levels of transgene could allow 
continuous immune stimulation for longer than 14 days. Thus, to determine how the 
antibody response profile altered over time, serum samples were obtained over a 
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long-term experiment as described in Section 4.5. Animals were immunised with a 
10
7
 p.f.u. dose of rAd constructs using the standard prime-boost regime (Fig. 4.2). 
Serum samples were obtained at weeks 4, 6, 8, 11, 14 and 20 post-primary 
immunisation for rAdM, rAdN and rAdZ-immunised animals and were analysed in 
both the PVM and Ad5 IgG ELISA systems. As detailed in Section 4.3, rAdF was 
not investigated due to construct purity issues.  
 
rAdM and rAdN-immunised animals were fully protected from lethal PVM infection  
for up to 20 weeks post-immunisation, as described in Section 4.5. For rAdM-
immunised animals, antibody titres were detectable from week 4 onwards, which 
corresponds to the day 28 time point in previous experiments. The response 
decreased to baseline levels by week 14, and remained undetectable up to week 20 
(Fig. 6.9A). The response appeared to peak at week 8, where the greatest number of 
positive responding animals was observed.  
 
The anti-PVM IgG response for rAdN-immunised animals peaked later, at 11 weeks 
(Fig. 6.9B), and was detectable in the ELISA from weeks 6 to 14. Similar to rAdM-
immunised animals, the anti-PVM response was undetectable by week 20. As 
expected, serum from control rAdZ-immunised animals was uniformly negative in 
the assay (Fig. 6.9C). In contrast to the anti-PVM IgG titre, the antibody response 
towards the rAd5 vector was greater in magnitude and all rAd-immunised animals 
generated a detectable response over the 20 week period (Fig. 6.10). This indicated 
that the animals had been successfully immunised with the vectors via the intranasal 
route and that IgG responses to the vector were robust and prolonged.  
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Figure 6.9. The anti-PVM IgG titre 
for long-term immunisation of rAd-
immunised animals. 
BALB/c animals were immunised as 
described in Section 4, Fig 4.10 with 
either rAdM (A), rAdN (B), or rAdZ (C) 
constructs at the 10
7
 p.f.u. dose. Serum 
samples were collected at weeks 4, 6, 8, 
11, 14 and 20 post primary 
immunisation. All samples were 
analysed in a PVM ELISA and the 
antibody titres were calculated as 
described in Fig. 6.3. The normalised 
values were then illustrated on the 
graph as log10 endpoint dilution values.  
The lines represent the mean titre of the 
samples.   
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Figure 6.10. The anti-Ad5 IgG titre for 
long-term immunisation of rAd-
immunised animals. 
BALB/c animals were immunised and 
serum samples collected as described in 
Fig. 6.9 with either rAdM (A), rAdN (B) 
or rAdZ (C) vaccines. All samples were 
analysed in an Ad ELISA and the antibody 
titres were calculated as described in Fig. 
6.3. The normalised values were then 
illustrated on the graph as log10 endpoint 
dilution values. The lines represent the 
mean titre of the samples.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.2 Summary 
The anti-PVM response observed during the long-term experiment was similar to 
that observed for the short-term experiment (Fig. 6.5 and 6.6). As before, the anti-
PVM response detected by the ELISA assay was low compared to PVM positive 
controls (Fig. 6.4). Both rAdM and rAdN-immunised animals generated a different 
anti-PVM IgG response pattern. Detectable responders in the rAdM-immunised 
group were observed from 4 weeks post-primary immunisation, peaking at week 8. 
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The response then declined to baseline levels by week 14, indicating that rAdM-
immunised animals continued to respond to PVM antigen for up to 11 weeks (Fig. 
6.9). In contrast, rAdN-immunised animals were observed to respond to antigen from 
week 6 onwards, peaking at week 11 before returning to baseline levels by week 20. 
This indicated that the anti-PVM response towards N antigen took longer to become 
established but was detectable over a similar time period to that observed for the 
rAdM-immunised groups (Fig. 6.9). However, no statistical difference was evident 
within or between the rAd-immunised groups at each time point analysed. These data 
indicate that the anti-PVM IgG response continues to build for some weeks after the 
immunisation regime is completed. This is because the PVM antigen can be 
continuously expressed by the rAd vector and is therefore dependent on the level of 
vector persistence.  
 
In contrast to the transient anti-PVM response, the anti-Ad IgG response was 
detectable in all rAd-immunised animals. The response was observed from week 4 
onwards and was maintained over the time course of the experiment. Unlike the anti-
PVM response, this response was long-lived and did not decline. This suggests that 
the rAd vector was able to persist within the mouse model for a substantial period 
before clearance. This is because if the antigen was cleared within the 20 week 
period, the antibody response would be expected to begin to show evidence of a 
decline, which it does not (Fig. 6.10). It is notable that the anti-PVM IgG response 
detected using the PVM specific ELISA did not correlate with protection against a 
lethal PVM infection as rAd PVM constructs were able to protect animals at 20 
weeks (Section 4, Fig. 4.11 and 4.12), in the absence of a detectable anti-PVM IgG 
response (Fig. 6.9).  
 
 
6.4 The IgG response of animals immunised with rAd constructs via 
alternative routes  
 
The previous data suggested that a humoral response to PVM did not correlate with 
protection against a lethal dose of PVM J3666 in short or long-term experiments. 
Furthermore, the intranasal immunisation route did not achieve the generation of a 
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robust anti-PVM response similar to that observed in PVM infected animals (Fig. 
6.4). In Section 5.2, animals were immunised with rAd constructs via alternative 
routes to determine whether the establishment of systemic immunity could protect 
animals against intranasal challenge. Concurrently, serum samples were obtained 
from immunised animals at the boost and pre-challenge time points and were 
analysed using an anti-PVM and anti-Ad ELISA to determine whether rAd 
immunisation via these routes could stimulate a detectable anti-PVM IgG response.  
 
Animals were immunised with rAdM, rAdN or control rAdZ via the subcutaneous 
route using the standard prime-boost regime (Fig. 4.2). Serum samples were 
collected at 14 and 28 days. Subcutaneous immunisation with 10
6
 p.f.u. or 10
7
 p.f.u. 
of rAd PVM constructs did not generated a detectable anti-PVM IgG response (data 
not shown). Subcutaneous immunisation with the highest dose, 10
8
 p.f.u., was 
associated with the generation of one detectable responder in both the rAdM and 
rAdN-immunised groups (Fig. 6.11A, red and green symbols). As expected, control 
rAdZ-immunised animals did not generate a detectable anti-PVM response (Fig. 
6.11A, blue symbols). However, all animals generated a detectable anti-Ad response 
(Fig. 6.11B), indicating that they had been successfully immunised with the rAd 
vector.  
 
Figure 6.11. The anti-PVM and anti-
Ad5 IgG titres for the subcutaneous 
immunisation route.  
BALB/c animals were immunised with 10
8
 
p.f.u. of rAdM, rAdN or rAdZ using the 
standard prime-boost immunisation 
strategy (Fig. 4.2) via the subcutaneous 
route. Serum samples were collected at 
days 14 and 28 and were analysed in a 
PVM (A) and Ad5 (B) ELISA assay. The 
antibody titres were calculated as 
described in Fig. 6.3. The normalised 
values were then illustrated on the graph as 
log10 endpoint dilution values. The lines 
represent the mean titre of the samples.   
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Animals were also immunised with the highest dose, 10
8
 p.f.u. via intraperitoneal 
route with either rAdF, rAdM, rAdN or control rAdZ. Only rAdM and rAdN-
immunised animals generated a detectable response to PVM antigen (Fig. 6.12A), at 
a level similar to the subcutaneous experiment (Fig. 6.11). Similarly, all animals 
generated an anti-Ad response against the vector post boost immunisation indicating 
immunisation via this route was successful (Fig. 6.12B).  
 
 
Figure 6.12. The anti-PVM and anti-
Ad5 IgG titres for the intraperitoneal 
immunisation route.  
BALB/c animals were immunised on 
days 0 and 21 with a 10
8
 p.f.u. dose of 
rAdF, rAdM, rAdN or rAdZ via the 
intraperitoneal route. Serum samples 
were collected at days 21 and 42 and 
were analysed in a PVM (A) and Ad5 (B) 
ELISA assay. The antibody titres were 
calculated as described in Fig. 6.3. The 
normalised values were then illustrated 
on the graph as log10 endpoint dilution 
values. The lines represent the mean titre 
of the samples.   
 
 
 
 
 
 
 
 
 
 
For the anti-PVM response, no statistical difference was evident within or between 
the rAd-immunised groups at each time point analysed. These data suggest that 
systemic immunisation routes for vaccination with rAd PVM constructs are no better 
at generating anti-PVM IgG antibody titres than the intranasal route (Fig. 6.5 and 
6.6). The detection of anti-Ad5 responses similar to those observed upon intranasal 
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immunisation indicates that systemic immunisation routes can establish a response 
towards an antigen. However, as described in Section 5.2, immunisation of animals 
via these routes in contrast to delivery intranasally, did not result in protection 
against PVM challenge.  
 
 
6.5 The anti-PVM IgA response of rAd-immunised animals 
 
The data presented previously indicate that the anti-PVM serum IgG responses 
generated upon PVM rAd vaccination are relatively weak, transient and did not 
correlate with protection against lethal PVM challenge. Since protection following 
rAd construct immunisation correlated with delivery via a mucosal route, which did 
correlate with protection, it was possible that the main antibody response generated 
was of the IgA isotype. IgA is a class of antibody which can be secreted and is 
associated with mucosal immunity (Abbas, 2000). As such, the anti-PVM ELISA 
was adapted to investigate the IgA response generated upon rAd PVM vaccination.  
 
Animals were immunised with a 10
7
 p.f.u. dose of either rAdM, rAdN or control 
rAdZ via the intranasal route, using the standard prime-boost regime (Fig. 6.13). 
Groups of three animals were sacrificed on days 19, 22 or 25 post primary dose, to 
obtain bronchoalveolar lavage (BAL) samples (Fig. 6.13). Samples were analysed in 
anti-PVM and anti-Ad5 ELISA assays, modified to use an anti-mouse IgA secondary 
antibody to detect IgA specifically (Table 2.1.7).  
 
 
Figure 6.13. The 
immunisation regime 
for the investigation 
of the IgA response in 
rAd-immunised mice. 
For the priming 
immunisation dose, mice were immunised with either rAdM, rAdN or rAdZ 
constructs at a 10
7
 p.f.u. dose in a 50µl inoculum with PBS. After two weeks, the 
animals were boosted with an identical dose of the immunogen they had previously 
received. At days 19, 22 and 25 post prime, groups of three mice for each vaccine 
construct were sacrificed and bronchoalveolar lavage fluid was sampled for each 
individual animal (red arrows), for further analysis.  
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Animals which received either the rAdM, rAdN or rAdZ constructs (Fig. 6.14, red, 
green and blue symbols respectively) did not generate a detectable anti-PVM IgA 
immune response in BAL samples at day 19. By days 22 and 25 a few animals 
generated a detectable anti-PVM response in the assay (Fig. 6.14), which was of a 
very low titre. This suggests that either the IgA response in rAd-immunised animals 
was not detectable in this assay or that little or no IgA response was generated at the 
time points analysed. As such, the sensitivity of either the anti-PVM IgA ELISA or 
the secondary anti-IgA antibody, may not be adequate to detect the IgA response in 
the samples obtained, particularly as obtaining BAL samples was technically 
challenging and the initial dilution from the animal is greater than that applied to 
serum.  
 
 
Figure 6.14. The anti-PVM IgA titre for 
rAd-immunised animals. 
BALB/c animals between 5 and 7 weeks 
of age were immunised via the intranasal 
route using the standard prime-boost 
regime (Fig. 4.2). The mice were 
immunised with a 10
7
 p.f.u. dose of either 
rAdM (red symbols), rAdN (green 
symbols) or rAdZ (blue symbols). Groups 
of three animals from each vaccine 
construct were sacrificed on days 19, 22 
and 25 post boost. Bronchoalveolar lavage 
samples were obtained from each individual animal and analysed in the anti-PVM 
ELISA and the antibody titres calculated as described in Fig. 6.3. The normalised 
values were then illustrated on the graph as log10 endpoint dilution values. The lines 
represent the mean titre of the samples.   
 
 
6.6 The cellular immune response towards the rAd vaccines 
 
The data described previously demonstrates that the anti-PVM IgG response does not 
correlate with protection from lethal PVM infection. This is perhaps not surprising 
since as detailed in Section 1.6.2, the cellular immune response has been observed to 
be more important in combating RSV infection (Crowe, 2003). The internal antigens, 
such as the M and N proteins of PVM, are not the primary targets of the neutralising 
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antibody response. However, both the external and internal antigens are equally 
likely to elicit T-cell responses as they are all synthesised intracellularly and can all 
be presented by class I MHC molecules. Also, they can be equally presented by class 
II MHC molecules through virus particle or through infected cell internalisation by 
APCs such as DCs. Thus, the rAd PVM constructs described in this study are likely 
to contain immunogenic T-cell epitopes which may mediate the protective effect 
discussed in Sections 4 and 5. As the rAdN construct appeared to be more potent in 
the protection experiments, this vaccine construct was used to identify and 
characterise the cellular response elicited by the rAd vaccine constructs.  
 
Two ex vivo assays were used to evaluate the cellular responses induced by the rAd5 
PVM constructs, an IFNγ ELISPOT assay (Section 2.9.3), and an intracellular 
staining assay (ICS, Section 2.9.4). The ELISPOT assay analysed the number of 
antigen specific IFNγ secreting T-cells, whereas the ICS assay determined the 
frequencies of the IFNγ+ T-cell subpopulation through the use of fluorescent-
conjugated antibodies.  
 
6.6.1 rAdN-immunised animals generate a PVM-specific T-cell response 
To identify the cellular response towards the PVM rAdN construct, animals were 
immunised via the intranasal route using the standard prime-boost immunisation 
regime (Fig. 4.2) with a 10
7
 p.f.u. dose of either the rAdN or rAdZ vaccine constructs. 
Control animals were either treated with PBS in accordance to the immunisation 
schedule, or infected on day 0 with 20 p.f.u. of PVM J3666. Animals were culled on 
day 20 and the spleens and lung lymphocytes were isolated and analysed for PVM-
specific T-cell responses using the ICS assay. The lymphocytes were re-stimulated in 
vitro by infection with either PVM J3666 at an M.O.I of 1 p.f.u./cell, the same 
volume of BS-C-1 tissue culture medium as a negative control, or Phorbol 12-
myristate 13-acetate (PMA)/ Ionomycin (Io), as a positive control.  
 
All immunised animals provided splenocyte populations that had similar frequencies 
of CD4
+
 T-cells (Fig. 6.15A), indicating that the T-cell subpopulations were 
comparable between the immunised groups. Both PVM J3666 infected and rAdN-
immunised animals produced a specific CD4
+
 IFNγ T-cell response against PVM 
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antigen, applying the criterion of a twofold greater frequency of IFNγ+ cells than in 
the negative control stimulated population. This response was specific to these 
immunised groups as neither the control rAdZ-immunised or PBS treated animals 
produced such a response. Representaitive dot plots for this experiment are 
illustrated in  Appendix C. Fig. C.6. 
 
 
Figure 6.15. PVM-specific IFNγ+-secreting CD4+ splenocytes can be detected in 
rAdN-immunised animals.  
BALB/c mice between 5 and 7 weeks of age were immunised with 10
7
 p.f.u. of 
either rAdN or rAdZ, or were treated with PBS in accordance to the standard prime-
boost regime (Fig. 4.2). In addition, four animals were infected with 20 p.f.u. of 
PVM J3666 via the intranasal route on day 0. Splenocytes were harvested on day 20, 
pooled for each immunisation group and re-stimulated in vitro with either PVM 
J3666 at an M.O.I of 1 p.f.u./cell (blue bars), the same volume of BS-C-1 control 
tissue culture medium (red bars), or PMA/Io as a positive control (data not shown). 
Splenocytes were stained for surface CD4 antigen with PE-conjugated anti-mouse 
CD4
+
 (Table 2.1.7) and for intracellular IFNγ with FITC-conjugated mouse IFNγ+ 
(Table 2.1.7) and analysed by flow cytometry using Cellquest software. The 
percentage of total CD4
+
 lymphocytes (A) and total CD4
+
 IFNγ+ lymphocytes (B) 
and were expressed as a percentage of the total lymphocyte population.  
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The same cells were analysed for a PVM-specific CD8
+
 IFNγ+ response. All CD8+ 
population frequencies were similar for each immunisation group indicating that the 
immunisation groups were comparable (data not shown). However, no specific CD8
+
 
IFNγ+ response was detected for either the PVM J3666 infected or rAdN-immunised 
animals (Fig. 6.16).  
 
 
 
Figure 6.16. PVM-specific IFNγ+-secreting CD8+ splenocytes cannot be detected 
in rAdN-immunised animals.  
Splenocytes from the same animals, as described in Fig. 6.15, were re-stimulated in 
vitro with either PVM J3666 at an M.O.I of 1 p.f.u/cell (blue bars) the same volume 
of BS-C-1 control tissue culture medium (red bars), or PMA/Io as a positive control 
(data not shown). Splenocytes were stained for surface CD8 antigen with APC-
conjugated anti-mouse CD8
+
 (Table 2.17) and for intracellular IFNγ with FITC-
conjugated mouse IFNγ+ and analysed as described in Fig. 6.15. The graph shows the 
CD8
+
 IFNγ+ T-cell population as a percentage of the total lymphocyte population.  
  
 
The lung lymphocytes from the same animals were used in the ICS assay to detect 
the frequencies of CD4
+ IFNγ+ (Fig. 6.17A) and CD8+ IFNγ+ (Fig. 6.17B) T-cells in 
the total lymphocyte populations. As before, the proportions of CD4
+
 and CD8
+
 cells 
in the lung lymphocyte populations were similar between samples and thus were 
comparable for each antigen stimulated group (data not shown). Cells from PVM 
J3666 infected animals generated the strongest CD4
+ IFNγ+ response towards PVM 
J3666 re-stimulation (Fig. 6.17A), as observed previously (Fig. 6.15B). However, in 
contrast to splenocytes, lung lymphocytes from rAdN-immunised animals did not 
display a significant response towards PVM antigen (Fig. 6.17A). The frequency of 
CD8
+ IFNγ+ lung lymphocytes for PVM re-stimulated PVM J3666 infected animals 
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was also significant (Fig. 6.17B). However, similar to the CD4
+ 
population, CD8
+
 
lung lymphocytes from rAdN-immunised animals did not display a specific response 
to PVM J3666 antigen (Fig. 6.17B). 
 
 
 
Figure 6.17. PVM-specific IFNγ+-secreting CD4+ and CD8+ lung lymphocytes 
cannot be detected in rAdN-immunised animals. 
Lung lymphocytes from the same animals as described in Fig. 6.15 were re-
stimulated in vitro with either PVM J3666 at an M.O.I of 1 p.f.u/cell (blue bars) the 
same volume of BS-C-1 control tissue culture medium (red bars), or PMA/Io as a 
positive control (data not shown). Lung lymphocytes were stained and assayed for 
CD4
+ IFNγ+ T-cells (A) as described in Fig. 6.15 and CD8+ IFNγ+ T-cells (B) as 
described in Fig. 6.16 and were expressed as a percentage of the total lymphocyte 
population. 
 
 
 
These data collectively suggest that PVM J3666 infected animals respond to PVM 
antigen, producing both IFNγ-secreting CD4+ and CD8+ lung lymphocytes and IFNγ-
secreting CD4
+
 splenocytes. In contrast, no significant IFNγ+-secreting CD8+ 
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population was detected in the rAdN-immunised animals in either the splenocytes or 
lung lymphocyte populations, although, a PVM antigen-specific CD4
+
 IFNγ+ 
response was observed in these animals. Thus, the ICS assay was able to detect 
PVM-specific T-cell responses in positive control (PVM infected) and rAdN-
immunised animals. The frequencies of IFNγ+ CD4+ or CD8+ T-cells were greater in 
the PVM J3666 infected group, presumably because the range of antigens to which a 
cellular response could be generated was greater. The response observed from rAdN-
immunised animals was lower than that observed for the PVM-infected positive 
control presumably because only one PVM protein was present to stimulate the 
response.  
 
In an attempt to increase the PVM-specific response observed in rAdN-immunised 
animals, an alternative immunisation regime was used (Fig. 6.18). The animals were 
immunised via the intranasal route with either rAdN or rAdZ at a 10
7 
p.f.u. dose, or 
were PBS treated as a control, on days 0, 14 and 28. The additional boost dose was 
used to ensure that the T-cell populations were strongly stimulated with PVM 
antigen.  
 
 
Figure. 6.18. The 
immunisation regime 
for the investigation 
of cellular response in 
rAd-immunised mice.  
For the priming 
immunisation dose, BALB/c mice between 5 and 7 weeks of age were immunised 
with either rAdN or rAdZ vaccines at a 10
7
 p.f.u. dose in a 50µl inoculum or with 
PBS. After two and four weeks, the animals were boosted with an identical dose of 
the immunogen they had previously received. At five weeks post priming dose, the 
animals were sacrificed and the lung and spleens were removed. Splenocytes and 
lung lymphocytes were isolated (Section 2.8.3.2) for further analysis.  
 
 
As before, the frequencies of CD4
+
 and CD8
+
 T-cells within the recovered 
lymphocyte populations were similar across all immunisation groups (data not 
shown). rAdN-immunised animals generated a PVM-specific CD4
+
  IFNγ+ response 
which was significant when compared to the BS-C-1 medium control and when 
compared to the response elicited by these antigens in the control immunised groups 
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(Fig. 6.19A). This result was expected as two-dose rAdN-immunised animals also 
generated such a response (Fig. 6.15B). However, unlike the two-dose rAdN-
immunised animals, those receiving three doses produced a PVM-specific CD8
+ 
IFNγ+ response which was significant when compared to the BS-C-1 media control 
antigen and the control immunised animals (Fig. 6.19B). 
 
The extended immunisation regime did increase the frequency of CD4
+
/CD8
+
 IFNγ+ 
T-cell populations for rAdN-immunised animals. The two-dose regime for rAdN 
gave 0.15% CD4
+
 IFNγ+ splenocytes and 0% CD8+ IFNγ+ splenocytes, whereas the 
three-dose regime for rAdN gave 1.1% CD4
+
 IFNγ+ splenocytes and 1.9% CD8+ 
IFNγ+ splenocytes. These data strongly suggest that rAdN-immunised animals can 
produce specific anti-PVM CD4
+
 and CD8
+
 T-cell responses that are detectable in 
the ICS assay. This supports the theory that the protective effect observed upon rAd 
PVM vaccination with the 10
7
 or 10
8
 p.f.u doses could be primarily mediated by a 
cellular response.  
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Figure 6.19. rAdN-immunised animals generate a PVM N-specific T-cell 
response. 
BALB/c mice between 5 and 7 weeks of age were immunised as described in Fig. 
6.18, with a 10
7 
p.f.u. dose of either rAdN or rAdZ, or PBS, on days 0, 14 and 28. 
The splenocytes were harvested on day 35 and were pooled for each immunisation 
group. The cells were re-stimulated in vitro with either PVM J3666 at an M.O.I of 1 
p.f.u./cell (blue bars), the same volume of BS-C-1 control tissue culture medium (red 
bars), or PMA/Io as a positive control (data not shown). Splenocytes were stained for 
CD4
+
 and CD8
+
 antigen and IFNγ as detailed in Figs. 6.15 and 6.16 respectively and 
then analysed by flow cytometry gated using Cellquest software for the lymphocyte 
population. Splenocytes were stained and assayed for CD4
+ IFNγ+ T-cells (A) and 
CD8
+ IFNγ+ T-cells (B)  and were expressed as a percentage of the total lymphocyte 
population.  
 
 
6.6.2 rAdN-immunised animals generate a PVM N-specific T-cell response 
The precise nature of the antigen(s) stimulating the cellular response towards PVM 
during PVM infection is unknown, however, it has been shown that the RSV N 
protein contains T-cell epitopes (Bangham et al., 1986). The PVM and RSV N 
proteins share over 60% amino acid sequence identity (Barr et al., 1991), which 
  221   
suggests that the PVM N protein may also be capable of inducing a T-cell response. 
In addition, a theoretic T-cell epitope has been identified in the PVM N gene 
(Claassen et al., 2005). In support of this, rAdN, which only expresses the N protein 
of PVM, was shown above to stimulate a PVM-specific T-cell response. 
 
The cellular response towards PVM N protein was investigated with the aim of 
identifying immunodominant epitopes for the PVM N protein. Currently, no T-cell 
epitopes for either a CD4
+
 or CD8
+
 T-cell population have been characterised for the 
PVM N protein in vivo. Therefore, possible antigenic targets needed to be identified. 
To investigate this, a peptide library of the entire N protein was produced, 
comprising 77 15-mer peptides that overlapped by 10 amino acids (identified in App. 
E. Table E.1).  
 
Animals were immunised via the intranasal route using the extended immunisation 
regime (Fig. 6.18), with 10
7
 p.f.u. of either rAdN or rAdZ, or PBS (control). The 
splenocytes were harvested and pooled for each immunisation group. The peptides 
were combined into pools of eight and were used to re-stimulate the splenocytes in 
vitro, and the resulting responses were analysed by the ICS assay. As for previous 
experiments, the total frequency of the CD4
+
 and CD8
+
 T-cells in the lymphocyte 
population was consistent between immunisation groups.  
 
When the peptide-specific CD4
+
 response of rAdN-immunised animals was 
compared with control rAdZ-immunised and PBS treated animals, one peptide pool 
stimulated a specific CD4
+
 IFNγ+ T-cell response (Fig. 6.20A), applying the criterion 
of a twofold greater frequency of IFNγ+ cells towards the PVM N peptides than in 
the negative control (rAdZ-immunised) populations. This included peptide pools 9-
16 and 17-24 which corresponded to amino acids N41-90 and N81-130 respectively 
(Table 6.1 and App. E. Table E.1).  
 
When the CD8
+
 population was analysed, a larger range of peptide pools was shown 
to stimulate an IFNγ+ response from rAdN splenocytes (Fig. 6.20B). rAdN-
immunised animals produced CD8
+
 T-cells that were activated specifically by 
peptide pools 9-16, 17-24, 25-32, 33-40, 49-56, and 57-64 (Fig. 6.20B and Table 6.1). 
As before, the result was judged positive if the T-cell population was twofold or 
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more greater for the rAdN-immunised animals then that observed for the control 
groups. These data indicated that the PVM N protein may contain several epitopes to 
which a T-cell response can be directed. 
 
 
 
Figure 6.20. PVM N peptide-specific IFNγ+-secreting CD4+ and CD8+ 
splenocytes can be detected in rAdN-immunised animals.  
BALB/c mice were immunised with 10
7
 p.f.u. of rAdN (blue bars) or rAdZ (red bars), 
or PBS treated (data not shown), as described in Fig. 6.18. Splenocytes were 
harvested and pooled for each immunised group. PVM N peptides were combined 
into pools of eight and were used to re-stimulate splenocytes in vitro, along with BS-
C-1 tissue culture medium as a control. Splenocytes were stained for surface CD4 
with PE-conjugated anti-mouse CD4
+
, or APC-conjugated anti-mouse CD8
+
, and 
with FITC-conjugated anti-mouse IFNγ+ for intracellular IFNγ staining (Table 2.1.7) 
and analysed using Cellquest software. Total CD4
+ IFNγ+ (A) and CD8+ IFNγ+ (B) 
cell frequencies were expressed as a percentage of the total lymphocyte population.  
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To corroborate the data observed in the ICS assay, the extended immunisation 
experiments were repeated but the re-stimulated T-cells were analysed via an 
alternative assay, an ELISPOT assay. The ELISPOT assay was optimised using 
animals immunised with the non-pathogenic PVM-strain 15 (Table 2.1.3), or PBS 
treated animals (App. C. Fig. C.5) and was shown to detect specific anti-PVM T-cell 
responses from PVM-infected animals. The ELISPOT assay can be more sensitive 
than ICS assays as translational regulation can occur, providing a more accurate 
insight into the directly secreted cytokine profile of a T-cell population. In addition, 
rare cell populations which produce high cytokine levels are captured by the 
membrane and thus allow rare populations to be visualised.  
 
Animals were immunised with 10
7
 p.f.u. of rAdN or rAdZ (control) via the intranasal 
route using the extended prime-boost immunisation regime (Fig. 6.18). Splenocytes 
and lung lymphocytes were harvested and pooled for each  immunisation group. The 
lymphocytes were re-stimulated in vitro with the PVM N peptides, pooled into 
groups of eight as used previously.  
As observed previously, a PVM-specific response was determined if T-cells from 
rAdN-immunised animals generated a response which was twofold or more greater 
towards the PVM N peptide pools than that observed for the rAdZ-immunised 
animals. On this basis, splenocytes from rAdN-immunised animals demonstrated a 
PVM-specific IFNγ+ response to peptide pools 9-16, 17-24, 33-40, 41-48, 49-56, and 
57-64 (Fig. 6.20A) although as discussed below, the media control value is high. 
Likewise, lung lymphocytes from the rAdN-immunised animals demonstrated a 
PVM specific IFNγ+ response to peptide pools 9-16 and 33-40 (Fig. 6.20B). 
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Figure 6.21. The PVM N peptide-specific T-cells can be detected in rAdN-
immunised animals by IFNγ ELISPOT assay. 
BALB/c mice between 5 and 7 weeks of age were immunised intranasally with 10
7
 
p.f.u. of rAdN (blue bars) or rAdZ (red bars) using the extended prime-boost 
immunisation regime (Fig. 6.18). The splenocytes and lung lymphocytes were 
harvested and pooled for the respective immunisation groups. Lymphocyte 
populations were re-stimulated in vitro with either the PVM N peptides, combined in 
pools of eight or BS-C-1 tissue culture medium control. The number of IFNγ+ spot 
forming cells in 5x10
5
 splenocytes (A) or lung lymphocytes (B) was observed. Error 
bars represent standard error of the averaged value of two replicate wells.  
 
 
 
These data confirmed that the ELISPOT assays for the lung lymphocytes and 
splenocytes were successful at identifying PVM-specific T-cell responses. However, 
the spots formed within the assay were small, indicating that IFNγ was not released 
in great quantities (data not shown). As pneumoviruses are known to functionally 
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impair T-cells (Section 1.6.2.3), IL-2 was included in the medium for all of these 
experiments. IL-2 is a cytokine which stimulates T-cell proliferation and increases 
cytokine synthesis for all T-cell populations (Abbas, 2000). IL-2 was also included to 
increase the spot size to ensure adequate detection in the assay.  
 
For both assays, a medium control was incorporated in the assay (Fig. 6.21). For the 
lung lymphocyte assay, the background stimulation by medium was low for both 
rAdN and rAdZ-immunised animals (Fig. 6.21B). However, for splenocytes re-
stimulation, rAdN-immunised animals generated a robust response towards the tissue 
culture medium control (Fig. 6.21A). Upon inspection of that particular well, the 
high background could either be attributed to contamination from the T-cell 
stimulator PMA/Io which was used elsewhere in the assay, or due to membrane 
damage from the pipette tip, resulting in darker areas to be generated on the 
ELISPOT membrane. As the result for rAdZ-immunised animals was low for 
medium stimulation, it confirms the medium used was not contaminated with 
PMA/Io or an equivalent compound. However, T-cells from rAdN-immunised 
animals still responded specifically to PVM antigen when compared to lymphocytes 
from rAdZ control immunised animals.  
 
6.6.3 Summary 
These data collectively demonstrate that similar peptide pools were identified as 
containing potential T-cell epitopes in both the ICS and ELISPOT assay. These 
peptide pools are summarised in Table 6.1. The peptide pools highlighted in bold are 
pools to which rAdN-immunised T-cells specifically responded in several 
experiments. These pools were from several regions of the N protein, amino acids 
N41-90, N81-130, N161-210 and N281-330. Two of these pools overlap and therefore they 
could detect the same T-cell epitope or distinct epitopes. Therefore, these data show 
that a specific T-cell response can be detected towards PVM N protein in rAdN-
immunised animals and that the T-cell response is directed against multiple epitopes.  
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 IFNγ+ CD4+ 
Splenocytes 
(Fig. 6.20A) 
IFNγ+ CD8+ 
Splenocytes 
(Fig. 6.20B) 
IFNγ+ 
Splenocytes 
(Fig. 6.21A) 
IFNγ+ 
Lung 
Lymphocytes 
(Fig. 6.21B) 
N protein 
amino acid 
position 
Peptide pool  
9-16 
17-24 
 
 
 
 
57-64 
1-8 
9-16 
17-24 
25-32 
33-40 
 
49-56 
57-64 
 
9-16 
17-24 
 
33-40 
41-48 
49-56 
57-64 
 
9-16 
 
 
33-40 
1-50 
41-90 
81-130 
121-170 
161-210 
201-250 
241-290 
281-330 
Table 6.1. N protein peptide pools to which cells recovered from rAdN-immunised 
animals responded specifically.  
Pools highlighted in bold represent those for which a positive response was identified 
across several experiments. The amino acid positions represented by each pool are 
indicated in the right-hand column.  
 
 
6.7 Discussion 
 
Animals which received a low dose, 20 p.f.u., of PVM J3666 were observed to 
generate a robust serum IgG response towards PVM antigen in the anti-PVM ELISA 
(Fig. 6.4). In contrast short-term experiments with rAd PVM-immunised mice 
showed only weak responses in a minority of mice (Fig. 6.5 and 6.6). Furthermore, 
there was no statistically significant correlation between vaccine dosage and time, 
and an increase in the magnitude of the anti-PVM IgG response. This suggested that 
the standard immunisation regime was unable to stimulate detectable anti-PVM IgG 
responses similar to those of positive control PVM-infected animals. To determine 
whether the IgG response increased further during an extended time course, the anti-
PVM IgG response was monitored over a 20 week period (Fig. 6.9). Again, these 
data indicated that the anti-PVM response did not reach the same magnitude as 
positive control PVM-infected animals (Fig 6.4). This suggested that the rAd PVM 
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constructs are less able to stimulate a detectable IgG response than a natural PVM 
infection.  
 
It was unknown whether these observations were as a result of the immunisation 
route used (the intranasal route), or due to the sensitivity of the ELISA assay. As 
such, the immune responses for rAd immunised animals via alternative routes such 
as the subcutaneous and intraperitoneal routes were investigated. The results 
demonstrated that immunisation was successful via these routes (Fig. 6.11B and 
12B), in that a response was detected against the rAd vector, but only a few animals 
made detectable anti-PVM responses (Fig. 6.11A and 6.12A). These data suggest 
that perhaps the systemic immunisation route was unable to stimulate a detectable 
anti-PVM response towards PVM antigen. Alternatively, the primary immune 
response directed towards PVM antigen expressed from rAd could have been an 
alternative isotype, IgA. However, no specific anti-PVM IgA responses were 
detected within BAL samples (Fig. 6.14) or serum (data not shown).  
 
The anti-PVM ELISA assay was thoroughly optimised. It was demonstrated to be 
specific for PVM serum, (App. C. Fig. C.4), and to be capable of detecting 
antibodies to PVM F and N proteins through the use of monoclonal antibodies (Fig. 
6.2). Thus, the PVM ELISA was demonstrated to be adequate for the studies 
described here and was deemed to be appropriately sensitive to detect PVM-specific 
IgG responses. A commercial anti-PVM ELISA is available from Charles River 
Laboratories (MA, USA). However, the PVM antigen used in this assay and the 
sensitivity of the assay when compared to the ELISA used in this study is unknown. 
If the anti-PVM ELISA used in this study does have a low threshold of sensitivity, it 
was not detected during optimisation, but may have decreased over time due to 
reagent degradation.  
 
The results described here are interesting as rAd PVM-immunised animals are 
protected from lethal PVM infection at the 10
7
 and 10
8
 p.f.u. doses in short and long 
term experiments. However, the magnitude and duration of the anti-PVM IgG 
response did not correlate with the protection data. The majority of animals did 
generate anti-Ad5 responses, suggesting that animals could be successfully 
immunised by all the routes investigated. However, few of these animals also 
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generated detectable anti-PVM responses, regardless of the rAd construct 
immunisation dose and route. As such, the humoral response is not the primary 
mediator of the protective effect.  
 
The lack of detectable anti-PVM IgG responses was unforeseen given that a response 
was detected for animals that had recovered from a mild PVM infection. However, 
this was achieved with a replication-competent virus. This increases the amount of 
antigen available for the immune response stimulation in contrast to the replication-
deficient Ad vectors which rely on high transgene expression levels to generate 
sufficient antigen for an immune response. In addition, PVM infection presents a 
greater array of PVM antigens and epitopes for the immune system to respond to in 
contrast to the rAd constructs which present only a few epitopes within a particular 
protein.  
 
The lack of correlation between antibody responses and protection suggested that the 
cellular response could be the primary mediator of this protective effect. To 
investigate this, ICS and ELISPOT assays were used to identify PVM-specific T-cell 
responses to both PVM protein (Figs. 6.15-19) and PVM N peptides (Figs. 6.20-21). 
The ICS assay successfully identified PVM-specific CD4
+
 splenocytes in cells from 
rAdN-immunised animals (Figs. 6.15 and 6.19). This indicated that rAdN antigen 
may have been able to stimulate the cellular response in immunised animals which 
could correlate with the protective effect previously observed with immunisation of 
the 10
7
 p.f.u. dose. 
 
To identify specific epitopes within the N protein to which the T-cell populations 
were directed, PVM N protein peptides were pooled into groups of eight and used to 
re-stimulated rAdN-immunised splenocytes and lung lymphocytes. Several peptide 
pools were identified to which rAdN-immunised animals possessed an apparent 
specific response (Table 6.1). These pools were able to re-stimulate both CD4
+ 
IFN+ 
and CD8
+ 
IFN+ splenocyte populations from rAdN-immunised animals in an ICS 
assay and additionally identified IFN+ secreting splenocytes and lung lymphocytes 
in an ELISPOT assay. Interestingly, four peptide pools were identified as able to re-
stimulate IFN+ secreting populations in both the ELISPOT and ICS assay which 
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were pools 9-16, 17-24, 33-40, and 57-64 (Table 6.1). Only pool 9-16 which 
corresponds to amino acids 41-90 was consistently identified across the different 
experimental assays for the two different lymphocyte populations. This suggests that 
this region of the N protein could contain an immunodominant epitope for the anti-
PVM cellular response. 
 
An unexpected finding with these data was that the CD4/CD8
+
 IFNγ+ populations 
were rare and much smaller in comparison to published data (Claassen et al., 2007, 
Claassen et al., 2005). A representative dot plot (Appendix C.6.), illustrated how rare 
this positive population was. A reason for the detection of such low CD4/CD8
+
 
IFNγ+ T-cell populations may have been the impairment of T-cells by the PVM virus 
used to stimulate the T-cells in vitro (Section 1.6.2.3). Although the virus was 
irradiated, the degree of inactivation was not assessed; therefore there remains the 
possibility that the virus was not completely inactivated, which may have led to the 
impairment of the T-cell population. Neither was this impairment rescued by the 
inclusion of the IL-2 cytokine in the medium, which has been previously 
demonstrated to aid the rescue of impaired T-cells (Chang & Braciale, 2002). An 
additional issue was that intracellular staining with an anti-IFNγ antibody requires 
the cells to be fully permeabilised to allow the antibody to enter the cell and bind to 
the specific cytokine. Incomplete permeabilisation may have led to sub-optimal 
staining and thus the apparent detection of low CD4/CD8
+
 IFNγ+ populations in 
response to PVM virus or PVM N peptide in vitro stimulation. In this study, 
complete permeabilisation of the cells suspension was not demonstrated and thus 
suboptimal staining from the anti-IFNγ antibody may have occurred. Furthermore, 
the antibodies used within the ICS experiment may not have been effective. 
Although these antibodies were used in the study described by Claassen et al, 
(Claassen et al., 2005), no positive controls were used in this study to evaluate their 
effectiveness and optimise the concentrations used. This may also have resulted in 
the detection of fewer CD4/CD8
+
 IFNγ+ populations in the experiments described in 
this chapter.  
 
Another issue with the results demonstrated here is that the positive and negative 
controls did not generate responses within expected ranges as previously published 
(Claassen et al., 2005, Kohlmann et al., 2009, Yu et al., 2008). For example, 
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CD4/CD8
+
 IFNγ+ T-cell populations were not strongly stimulated in response to 
PMA/Io treatment (data not shown), in addition, the responses generated from PBS 
treated animals restimulated with PVM in vitro were often greater than those 
observed from rAdN-immunised animals (Figs. 6.16-17). rAdN and rAdZ-
immunised animals also demonstrated strong CD4/CD8
+
 IFNγ+ responses to medium 
only controls (Figs. 6.20-21). These data cannot be explained wholly by 
contamination of these controls with a positive stimulant, such as observed in Fig. 
6.21A, and therefore, may represent a significant issue with the results from these 
assays. These results imply either that the responding CD4/CD8
+
 IFNγ+ population is 
so rare that any specific response could be masked by background or control 
responses in the assays illustrated in this chapter, or that due to the absence of assay 
repeats and replicates performed for the ICS assay, that the responses observed may 
not be a true representation of the CD4/CD8
+
 IFNγ+ T-cell populations stimulated 
upon rAd PVM construct immunisation of BALB/c mice.  
 
In conclusion, the data presented in this chapter suggests that a cellular response as 
opposed to a humoral response is a primary mediator of protection against PVM in 
rAdN-immunised animals. Although IFN was the only cytokine investigated in this 
study, its detection could indicate that a balanced T-cell response is being elicited 
towards PVM since this cytokine is characteristic of a Th1 CD4
+
 T-cell response. 
Therefore, the rAd PVM constructs provide a successful immunisation strategy to 
protect animals against pneumoviruses. 
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7.1 General discussion 
 
Since the 1960s, efforts to generate a successful vaccine against RSV have so far not 
yielded a clinically licensed candidate. In addition, vaccine efficacy has not been 
evaluated in an appropriate animal model. The studies presented in this thesis 
describe the development of ‘proof of principle’ vaccine candidates, to tackle 
pneumovirus infection. These have been generated using replication-deficient 
adenoviral vectors. The PVM infection model developed by Cook et al, was 
previously optimised to investigate the disease pathogenesis of PVM strain J3666 in 
the BALB/c mouse strain (Cook et al., 1998), and this model was used to allow the 
efficacy of recombinant adenoviral vaccines to be evaluated.  
 
The adenoviral vaccine candidates were developed using the AdEasy™ Adenoviral 
Vector System (He et al., 1998). Plasmids were engineered to express full length F, 
M, N and P genes from PVM, and the LacZ gene from E. coli. Sequence analysis 
confirmed that the constructs were correct (App. Fig. A. 1-4). Expression of PVM F 
mRNA/protein or PVM N protein was detected for these constructs and 
corresponded to previously published data (Barr et al., 1991, Chambers et al., 1992). 
The PVM M protein was localised in both the nucleus and the cytoplasm (Fig. 3.17), 
consistent with published literature for RSV M protein (Ghildyal et al., 2009). The M 
protein is usually located in the nucleus during early stages of infection, but when the 
switch to genome replication occurs, the protein localises to the cytoplasm; a 
function believed to be controlled by the M2 protein (Ghildyal et al., 2009, Li et al., 
2008). Expression of M protein in the absence of other PVM proteins, particularly 
M2, in rAdM-infected cells could explain why M localisation was detected in both 
the cytoplasm and nucleus of rAdM positive cells (Fig. 3.12). 
 
Interestingly, PVM P protein expression from either pShuttle_CMV_P and 
pAdEasy_P plasmids, or rAdP virus was not detectable (Fig. 3.21, 3.22). The 
constructs retained the full-length P gene sequence and the virus was able to replicate 
in complementing cell lines (Fig 3.20). However, the growth kinetics were impaired 
when compared to the other rAd viruses or wild-type Ad5. To address this, new 
pShuttle_CMV_P plasmids were generated using new primer pairs to account for 
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possible sequence alterations in the primer sequence. Expression of the P protein 
from both of these plasmids was undetectable. PVM P mRNA expressed from rAdP 
will be produced in the nucleus. This may have a role in the subsequent failure to 
express P protein. This is possible as the PVM P gene is usually expressed in the 
cytoplasm.  
 
rAd5 constructs have been generated using the AdEasy™ system for several RSV 
and non-RSV vaccine studies, and have been found to stimulate both humoral and 
cellular responses towards the transgene (Fu et al., 2009b, Guo et al., 2008, Jiang et 
al., 2008, Khanam et al., 2009, Kohlmann et al., 2009, Peng, 2008, Wu et al., 2007, 
Yu et al., 2008). In this study, rAdF, rAdM, rAdN constructs and a control construct 
rAdZ were used with the PVM infection model to determine vaccine efficacy in vivo. 
When delivered via the intranasal route, rAd PVM constructs were shown to protect 
several mouse strains with different MHC haplotypes against lethal PVM infection. 
This indicates that the immunity elicited by the vaccine constructs is likely to be 
protective in a mixed genetic population.  
 
In BALB/c mice, intranasal immunisation with rAd PVM constructs gave protection 
up to 20 weeks post immunisation with a 10
7
 p.f.u dose using the standard prime-
boost regime, and up to 6 six weeks post immunisation with a single 10
7
 p.f.u dose. 
Interestingly, while the rAd PVM constructs were able to elicit antigen-specific 
protection of mice at a 10
7
 p.f.u dose, all of the constructs, including rAdZ, 
demonstrated protection in mice against lethal PVM challenge when immunised with 
a 10
8
 p.f.u dose indicating an antigen non-specific effect. See et al have previously 
described such an effect, where a ∆E1/E3 replication-deficient empty Ad5 vector 
was used to immunise ferrets with a 10
9
 p.f.u dose, via the intranasal route (See et al., 
2008). The study indicated that ferrets immunised with the control construct 
demonstrated decreased SARS virus replication when compared to PBS-treated 
animals and they concluded that non-specific responses induced by the Ad5 vector 
interfered with SARS replication.  
 
There are several differences between the present study and the one conducted by 
See et al. Firstly, they employed different host/challenge virus systems. Secondly, 
mice are fully permissive to PVM infection, whereas ferrets are only semi-
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permissive to SARS. While ferrets exhibit signs similar to that observed in humans, 
(To et al., 2004), some studies have indicated that clinical signs are not always 
observed (Czub et al., 2005, Weingartl et al., 2004). This suggests that only a slight 
protective effect could be necessary in the ferret-SARS system to provide protection 
from virus replication.  
 
In the light of the non-specific protection against PVM seen here with high doses of 
rAd, the rAdZ construct was evaluated within the influenza A virus mouse model 
(Dimmock et al., 2008), to determine how broadly acting this non-specific protective 
effect was. C3H/He-mg mice have been shown to be fully susceptible to influenza 
infection and were immunised with the rAdZ at the 10
8
 p.f.u dose using the standard 
prime-boost regime, prior to challenge with a lethal dose of influenza A virus. The 
animals were not protected against the influenza challenge (Fig. 5.10), which 
suggested the protective effect may be linked to rAdZ stimulation of a particular 
immune response relevant to protection from PVM. 
 
Animals immunised with the 10
8
 p.f.u dose were still protected up to 11 weeks post 
prime dose after a prime-boost immunisation regime (Fig. 5.8), and up to 6 weeks 
with a single dose (Fig. 5.9). This could indicate that at the high dose the rAd vectors 
are able to persist for longer in the host. Previous studies investigating vector 
persistence indicated that Ad5 vectors do not persist longer than two weeks within 
the mouse model (Yang et al., 1995), and the length of time between immunisation 
and challenge in these experiments would suggest that innate immune responses are 
not mediating the anti-viral effects of rAdZ. One approach to investigate these 
theories would be to determine the longevity of the rAdZ and rAdGFP constructs in 
the mouse lung. Mice are usually non-permissive to Ad, but the virus can enter cells 
due to the expression of the mCAR receptor, the murine homologue of CAR, which 
allows transfection of a wide number of cell types including the brain, lungs, liver 
and kidneys (Bergelson et al., 1998, Kass-Eisler, 1994), however, the virus does not 
go through a full productive replication cycle due to problems with gene expression 
and regulation. As the brain is an immunoprivileged site, it implies that Ad5 may be 
capable of persistence in such sites, as has also been demonstrated for liver cells 
(Jager & Ehrhardt, 2009). This could allow continuous stimulation of the CD8
+
 T-
cell population by prolonged transgene expression (Finn et al., 2009), which could 
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elicit the protective effect observed at the high immunising dose. Although vector 
longevity and persistence were not measured in this study, this could be investigated 
using a β-galactosidase assay to measure LacZ expression in lung mucosa or the 
expression of Ad proteins through immunohistochemistry. Alternatively, transgene 
or Ad mRNA could be identified using in situ hybridisation. 
 
To determine whether the LacZ gene or the Ad5 vector was the source of the non-
specific protection produced by high rAd doses, alternative transgenes were 
investigated using a PVM challenge. rAdGFP and rAdEV both generated a similar 
effect when used to immunise mice at the high dose only (Fig. 5.11). This suggested 
that the Ad5 vector was the source of this protection through either an antibody- or 
cellular-based response. The level of neutralising antibody generated towards the 
Ad5 vector was unlikely to be the source of the protective effect, because the IgG 
titres elicited by 10
7 
or 10
8
 p.f.u prime-boost doses were similar (Fig 6.6B). In 
addition, similar anti-Ad IgG titres for rAdZ and rAd PVM constructs were seen with 
the short and long-term experiments (Figs. 6.5, 6.6A, 6.8). Thus, the neutralising 
antibody response is unlikely to cross-react with PVM antigen and mediate the 
protective effect. This suggests that a T-cell response may be the cause of the non-
specific protective effect observed.  
 
It is known that PVM and influenza virus require CD8
+
 and Th1 CD4
+ 
T-cell 
responses to mediate viral clearance (Claassen et al., 2005, Doherty, 2009). This 
suggests that the Ad5 vector is not stimulating a cytokine profile where the Th1 CD4
+
 
response or the CD8
+
 response could be biased, providing protection against 
influenza. Therefore, the apparent PVM specific protection by Ad5 could be 
mediated by two mechanisms; the first being cross-reactive T-cells and the second a 
bystander effect occurring during PVM infection. Cross-reactive T-cells have been 
observed during RSV infection between two different strains (Kulkarni, 1993) and 
during adenovirus infection (Hutnick, 2010). Thus, a rare population of Ad-PVM 
cross-reactive T-cells may have been stimulated upon high levels of rAd5 
immunisation. Alternatively, it has been shown that during viral infection large 
numbers of non-specific T-cells are actively recruited to sites of infection (Tough et 
al., 1996). This has been shown to be predominately the CD4
+
 memory population 
and this response is mediated by the induced cytokine profile (Bangs et al., 2009). 
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Thus, Ad5 could stimulate the recruitment of T-cells which would contribute to a 
strong induction of inflammation through cytokine release, generating an anti-viral 
state at the site of infection. In addition, Ad has been shown to induce Ad-specific T-
cells which are maintained in an effector state (Hutnick, 2010). If these cells were 
maintained in the lung mucosal tissue, they could enhance the development of a Th1-
biased CD4
+
 response and promote the more rapid recruitment of immune effector 
cells to the site of infection, perhaps stimulating a protective environment against 
PVM. A third possibility is that the protective effect from a high dose of rAdZ was 
mediated through a threshold effect. The anti-Ad response could have reached a 
threshold, where it was able to reduce PVM replication at the high 10
8
 p.f.u dose 
only. To address this, it would be of great interest to compare the titre of PVM in the 
mouse lung between the rAd PVM constructs and rAdZ construct immunised mice 
by plaque assay. If rAd PVM-immunised animals generated significantly lower PVM 
replication titres than rAdZ, it would suggest that the rAdZ construct generated a 
threshold of protective immunity, beyond which, innate responses were able to clear 
the infection.  
 
 
The rAdF, rAdM and rAdN constructs did not stimulate a robust anti-PVM IgG or 
IgA response and the levels of IgG achieved did not appear to correlate with 
protection against PVM (Fig. 6.3, 6.4). The immune response was also monitored 
during the long-term experiments, where it was demonstrated that the IgG response 
peaked at week 11 for rAdN-immunised animals and week 8 for rAdM-immunised 
animals. The antibody response then declined to undetectable levels. Anti-Ad5 IgG 
responses were more robust, and detectable for all of the constructs. This was in 
contrast to the published literature where immunisation with an rAd5 vaccine 
expressing full length RSV F protein, was able to induce robust antibody responses 
towards the F or the G protein transgene (Fu et al., 2009b, Kohlmann et al., 2009, 
Shao et al., 2009, Yu et al., 2008); however, both of these studies differed from this 
investigation. Firstly, UV inactivated RSV particles were used as the antigen source 
in the ELISA assay, whereas this study used a persistently infected cell line, as PVM 
could not be grown in sufficient bulk. Secondly, the time difference in the 
immunisation protocol used in the study by Kohlmann et al was 3 weeks instead of 
the 2 weeks used in this assay. The three week period could have allowed increased 
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time over which a robust response could be generated. However, the second sample 
time point used in the study by Kohlmann et al would correspond to the 6 weeks 
immunisation sample point during the long-term experiment described here which 
did not generate a robust response towards the transgene. The rAdF construct used in 
this study was not investigated during the long-term experiment, so the anti-PVM 
IgG titre at this point is unknown. The study by Shao et al also used a 2-week prime-
boost strategy, with sample collection on day-24 as opposed to day-28 used in this 
study. This suggests that the immunisation time course used in the experiments 
described in this thesis is unlikely to have a detrimental impact on the generation of 
antibody titres observed. The primary antibody response towards pneumoviruses is 
directed against the F and G proteins (Simoes, 1999). This is because as external 
proteins, they are more likely to be presented to the immune system in comparison to 
internal proteins, such as M and N. The absence of robust antibody titres directed 
against the M and N proteins is likely to reflect the level of the exposure of these 
proteins to the immune system rather than their immunogenicity. Interestingly, the 
longevity of the anti-RSV response was maintained at a higher level to the prime-
boost experiment in the Kohlmann et al study. All animals generated a detectable 
response at all of the time points examined, and IgG was detectable up to 35 weeks 
after immunisation. This pattern was not replicated in this investigation, as firstly, 
not all animals generated a detectable anti-PVM IgG response at the time points 
examined, and secondly, the response had decreased to undetectable levels by 20 
weeks. However, the titre of anti-PVM IgG response was, where detected, observed 
at a similar level to the prime-boost experiments.  
 
The immunity elicited by the rAd PVM constructs using different immunisation 
routes was also compared in this study. It was observed that the rAd PVM constructs 
were most immunogenic when delivered via the intranasal route. Subcutaneous and 
intraperitoneal immunisation only generated antibody titres when the higher 10
8
 p.f.u 
dose was used to immunise the animals. Neither did this response correlate with 
protection. This contrasts with other studies where immunisation of rAd constructs 
via routes other than intranasal were able to stimulate neutralising antibody responses 
(Kohlmann et al., 2009, Yu et al., 2008). However, it has been demonstrated that the 
intranasal immunisation route is superior at generating robust immune response 
towards the transgene in RSV virus systems (Kohlmann et al., 2009, Yu et al., 2008). 
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These findings confirm that the route of immunisation performed has a significant 
effect on the immune response induced and thus protection elicited against the 
pathogen.  
 
In this study, immunisation with a prime-boost strategy failed to elicit a detectable 
mucosal anti-PVM IgA response. This is in contrast to studies performed by Shao et 
al, and Yu et al, where rAd vaccines expressing full-length F protein or codon-
optimised G protein fragments were able to induce robust anti-RSV IgA titres against 
the transgene product. Again, a fundamental difference between these studies and the 
one described here is that the ELISA assay utilised purified RSV particles, as 
opposed to a persistently infected cell line, which may have increased the sensitivity 
of these assays. Thus, as described for the IgG response, the M and N proteins may 
not have been presented to the immune system in sufficient quantities in order to 
stimulate a robust, detectable response (Simoes, 1999). Alternatively, the lack of 
detectable PVM-specific IgA here may be due to problems with the BAL collection 
method. The BAL fluid was collected by one passage of PBS into the lung. Shao et 
al performed two washes and were able to detect PVM IgA in both BAL fluid and 
sera, whereas Yu et al, performed only one, similar to this study, and only 
immunised with a single 5x10
7
 p.f.u dose of the vaccine. For this study, the 
collection of BAL fluid was found to be difficult, thus one fluid passage was used 
which could have limited the recovery of IgA from the lung. In addition, due to time 
limitations, the sample size of the group was limited and neither was it possible to 
collect a positive control. Thus, the results from the IgA experiment may not 
represent the overall IgA response generated from rAd PVM construct immunisation.  
 
One avenue that requires further exploration is the comparison of sensitivity of the 
ELISA assay described in this study, with commercially available screening tests. 
This study demonstrated that a functional anti-PVM ELISA assay was developed 
using a persistently PVM infected cell line P2-2. The individual proteins were shown 
to be detectable within the ELISA system (Fig. 6.2), however a quantitative measure 
of assay sensitivity was not investigated. Serum from animals which had received a 
low, non-lethal dose of PVM was used to evaluate the sensitivity of the ELISA. The 
samples generated positive titres within the assay (Fig. 6.4), however this response 
would have been generated across multiple epitopes and antigens, as opposed to a 
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single PVM protein. Animals immunised with the rAd PVM constructs are therefore 
likely to have a lower overall antibody titre. This is because the immune system of 
these animals was exposed to only one antigen and the epitopes within the protein, as 
opposed to the wide range of epitopes and antigens from the whole PVM virus. 
Furthermore, the rAd constructs were unable to replicate within the host, thus epitope 
exposure to the immune system is limited by the degree of transgene expression from 
the construct. Therefore, although the anti-PVM ELISA is able to detect antibody 
titres, it may not be sensitive enough to detect low titres of antibody, which may be 
induced upon vaccine administration or low levels of antibody maintained over the 
long-term experiments. It may therefore be useful to compare the samples with a 
serological testing kit such as the ELISA assay provided by Charles River 
Laboratories (MA, USA). However, an alternative explanation is that the 
immunisation regimes used in this study do not induce systemic neutralising 
antibody responses and perhaps the immune response is primarily localised to the 
lung mucosa. This would suggest that serological analysis of the lung tissue or BAL 
fluid may provide greater insight of the serological response towards PVM antigen 
generated by the rAd PVM constructs. 
 
Immunisation with the rAd vector resulted in the generation of anti-Ad immunity 
which is consistent with several other studies using different virus systems (Shao et 
al., 2009, Yu et al., 2008). In these studies, anti-vector immunity did not appear to 
interfere with the establishment of transgene immunity, as 10
7
 p.f.u doses were 
associated with either protection or the establishment of anti-RSV IgG and IgA 
responses. The findings in this study support this concept as is was observed that 
anti-vector immunity also did not appear to interfere with the development of 
transgene immunity. This was observed upon immunisation with the rAdM construct, 
as an example. A single 10
7
 p.f.u dose was partially protective (Fig. 4.14) as a few 
fatalities were observed in this group. However, a prime-boost immunisation with the 
same dose was associated with full protection up to 18-weeks post boost, with no 
associated fatalities. Anti-Ad immunity was observed to increase over this time 
period (Fig. 6.8), as has been observed previously (Shao et al., 2009, Yu et al., 2008), 
but this did not interfere with protection from lethal PVM infection.  
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In the protection studies described in this study, the rAdN PVM construct appeared 
to be the most successful, in that protection against lethal PVM infection was always 
achieved using the 10
7
 p.f.u immunising dose. The rAdN candidate was therefore 
further investigated with regards to the cellular response elicited by this vaccine 
construct. 
 
BALB/c mice immunised with rAdN generated an IFNγ secreting CD8+ and CD4+ T-
cell populations in response to lung lymphocyte and splenocytes re-stimulation with 
PVM virus and PVM N peptide pools. In this study, it was observed that 
immunisation with a prime-boost strategy with 10
7
 p.f.u of the rAdN construct was 
able to induce large numbers of CD4
+
 cells to the lung and spleen. Re-stimulation of 
rAdN-immunised splenocytes led to the recruitment of CD4
+
 T-cells, which made up 
approximately 55% of the total number of cells analysed (Fig. 6.15). However, the 
total IFNγ-secreting T-cell population was only 0.15%. Similarly, 55% of lung 
lymphocytes analysed were CD4
+
, and only 0.15% of the total lymphocyte 
population secreted IFNγ (Fig. 6.17). This suggested that either the population of 
CD4
+
 T-cells stimulated were of the Th2
 
 
 
 type, which would not secrete IFNγ, or 
that the cells were active but not specific for PVM antigen, or lastly, that the PVM-
specific T-cells were inactivated. All of these possibilities could have contributed to 
the results obtained in this study.  
 
In the ICS experiments performed in this study using PVM virus to re-stimulate the 
T-cells, the frequency of IFNγ secreting T-cells was observed to be lower than 
previously published data (Kohlmann et al., 2009, Yu et al., 2008). Low frequencies 
of IFNγ secreting T-cells were also observed upon PVM peptide re-stimulation of T-
cells. This is in contrast to the observations of Claassen et al, where 10-20% of the 
CD8
+
 T-cells re-stimulated with PVM peptide from PVM-immunised mice were 
positive for IFNγ. This has also been observed with similar studies using RSV 
infected mice (Chang & Braciale, 2002, Gray et al., 2005). Furthermore, in humans a 
study suggested that 33% of CD8
+
 T-cells secreted IFNγ in RSV infected infants 
(Lukens et al., 2010). Interestingly, all of these studies commented that the frequency 
of IFNγ secreting T-cell populations was low, though they are still greater than the 
numbers observed in this study using PVM antigens for both CD8
+
 and CD4
+
 T-cell 
populations. These findings suggest that there is a difference between the results 
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observed with RSV and PVM virus systems and other viruses. As such, it appears 
that pneumovirus infection could lead to significant T-cell suppression. 
These data presented here indicate that the N protein of PVM is capable of inducing 
a cellular immune response in the BALB/c mouse model. In comparison to the 
cellular response observed for RSV, epitopes have been identified in the BALB/c 
mouse model include the dominant epitope M282-90 as well as epitopes within the N 
protein and the F, F85-93 (Bangham et al., 1986, Chang et al., 2001, Kulkarni et al., 
1995, Mok et al., 2008, Openshaw, 1990, Pemberton et al., 1987). Whereas for PVM, 
T-cell epitopes P261-269, M43-51 and F302-312 have been identified experimentally in 
mice, in addition to a theoretic epitope in the N protein (Claassen et al., 2005). For 
bRSV, the F, G and N proteins have been shown to induce a protective cellular 
responses in calves (Gaddum, 1996, Taylor et al., 1997). However, none of these 
studies attempts to identify the epitope to which the cellular response is directed 
against in the N protein. Thus, the identification of a potential PVM, and therefore 
possibly an RSV, T-cell stimulating region has been performed in this study and is 
likely to be N41-90.  
 
To compensate for possible T-cell inactivation, the cytokine IL-2 was added to the 
external medium in both the ELISPOT and ICS assays. IL-2 has previously been 
demonstrated to rescue inactivated T-cells (Chang & Braciale, 2002). However, IL-2 
addition did not significantly alter the total numbers of CD4
+ 
or CD8
+
 T-cells, or the 
number of IFNγ+ cells observed. Another possibility is that within the large 
population of CD8
+
/CD4
+
 T-cells detected within the ICS assay, a larger 
subpopulation could be Ad-antigen specific when compared to the PVM-specific 
population observed, suggesting that the immunogenic nature of Ad as a dominant 
effect over the immune response generated towards the N protein. One way to 
improve transgene immunogenicity would be to either use an Ad vector which 
expresses fewer Ad proteins as described in Section 1.3.4, or to codon-optimise the 
N gene, as previously described for the RSV G gene by Yu et al (Yu et al., 2008). As 
IFNγ is predominately a Th1 response cytokine, it is possible that the cellular 
response to PVM is Th2
 
biased. An avenue of interest not pursued in this study would 
be to investigate the cytokine profile induced upon rAdN-immunisation and whether 
this profile alters following PVM virus challenge. Cytokine release can be analysed 
using ELISA or ELISPOT assays. ELISPOT assays are inherently more sensitive as 
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they enable rare populations to be visualised by their ability to secrete IFNγ before 
the cytokine is diluted in the external medium. The rAdN construct used in this study 
was believed to stimulate a predominately Th1 response as Ads naturally stimulate a 
Th1 biased response which could also bias the response to the N protein to be of the 
Th1 type (Santra, 2005). The expression profiles of the Th2
 
response associated 
cytokines, such as IL-4, IL-5 and IL-13, could be measured by ELISPOT or ICS. If 
greater numbers of Th2
 
cytokine secreting T-cells were detected for animals 
immunised with rAdN than those which were IFNγ positive, it would suggest the 
response is Th2, as opposed to Th1 biased.  
 
Shao et al and Yu et al investigated the cytokine secretion levels following 
immunisation with rAd RSV vaccine candidates (Shao et al., 2009, Yu et al., 2008). 
The results suggested that the vaccine stimulated T-cell population secreted reduced 
levels of Th2
 
associated cytokines leading to reduced levels of eosinophils 
recruitment when compared to RSV infected animals. They therefore suggested that 
the immune response was Th1 biased. It is possible that a similar result would be 
obtained for the rAdN vaccine candidate used in this study.  
As described in Section 1.6.2.3, pneumovirus infection can lead to T-cell suppression 
through inactivation of PVM-specific T-cells. This could be investigated by 
determining the level of extracellular CD28 expression. A low level of expression on 
the PVM-specific T-cell population would indicate an inactive population which 
would therefore not contribute to protective immunity towards PVM. However, this 
is unlikely to have occurred as only one protein was used to immunise animals as 
opposed to whole PVM virus, 
 
A final possibility is that the method used to perform the IFNγ ELISPOT assay could 
result in variable numbers of IFNγ+ T-cell populations observed, A study comparing 
Mycobacterium tuberculosis IFNγ secreting T-cell populations compared four 
different ELISPOT methods across several sites (Smith et al., 2009). Significant 
variation was observed between sites and between the protocols investigated. The 
ELISPOT method described in this study was adapted from that described by 
Claassen et al (Claassen et al., 2005), suggesting that the lower frequency of PVM-
specific IFNγ+ T-cells detected could either be due to reagent and user variability or 
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the quality of the lymphocyte populations obtained. Thus, the ELISPOT method used 
may have contributed to the results presented in this study.  
Although no vaccine studies exist which utilise the N protein of a pneumovirus in an 
rAd vaccine construct, two studies have been described where a similar approach 
was used. One investigated bRSV N protein immunisation using plasmid DNA as the 
immunogen in a prime dose and purified N protein in a boost dose immunisation 
strategy (Carine et al., 2008). The results with this approach showed that IFNγ CD8+ 
T-cells were stimulated and proliferated in response to vaccination which was 
enhanced upon boosting. Immunisation provided a protective effect against bRSV 
challenge with calves exhibiting reduced viral titres and reduced levels of 
pathological lung lesions. Although this study utilised N protein in a DNA and 
protein delivery system, rather than the recombinant viral vector system used here, it 
evaluated protection of a vaccine against a pneumovirus in its natural host. This 
protective effect was associated with the cellular response rather than neutralising 
antibody (Carine et al., 2008). The other study investigated measles virus, another 
member of the paramyxoviridae (Fig. 1.2). The N protein of measles virus has been 
expressed in a replication-deficient Ad5 vector as a potential immunogen. 
Immunisation of BALB/c mice with a 10
7
 p.f.u dose with the rAd measles N 
construct via the intraperitoneal route resulted in the stimulation of N-specific 
antibody responses and a strong CD8
+
 T-cell response (Fooks et al., 1995). The 
vaccine construct was shown to be protective against measles challenge, resulting in 
a reduction in virus titre. These studies confirm the findings presented in this 
investigation that an internal protein can stimulate protective immune responses in a 
host.  
 
 
7.2 Future Experiments 
To continue the investigation into the immunogenicity of the rAd PVM constructs it 
would be useful to generate and evaluate in the protection model an additional 
construct expressing the M2 gene of PVM, as the RSV M2 protein is known to 
contain epitopes such as M282-90 that is recognised in BALB/c mice, correlating with 
a protective CD8
+
 T-cell response (Kulkarni et al., 1995, Mok et al., 2008, Openshaw, 
1990).  
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The immune response towards the rAd PVM constructs requires further study. 
Several questions remain about the mechanism of protective immunity and the 
duration of the response. The longevity experiments only continued up to 20 weeks 
post-immunisation due to time constraints. The next step would be to extend this 
study for up to 52 weeks, to determine the extent of the long-term protection elicited 
by the 10
7
 p.f.u. dose. It would also be prudent to incorporate a similar study using 
the 10
8
 p.f.u dose to determine how long lasting is the antigen non-specific protective 
effect observed at this high dose. As was demonstrated for the 20-week experiment, 
PVM rAd constructs did not generate IgG antibody responses in an ELISA assay at 
20 weeks, yet all animals were protected. Likewise, the anti-Ad IgG response was 
maintained at a high titre for the duration of the study. Thus, the immunological 
profile of protection could also be investigated further to determine if PVM-specific 
T-cells could be identified over a long-term experiment. If, for example, protection at 
the 10
7 
p.f.u dose wanes over the 52 week period, it would suggest that either PVM 
specific memory T-cells are not maintained in the long-term, or are naturally 
impaired due to pneumovirus infection.  
 
The mechanism of immunity could also be investigated by passive transfer of serum 
from rAd PVM and rAdZ-immunised mice, to non-immunised animals prior to PVM 
challenge. This would indicate whether a neutralising IgG or IgA response is 
required for the control of PVM infection. Such an experiment could also be 
performed using knockout mouse strains, such as the BALB/c nude mouse strain, 
which is T-cell deficient. Immunisation of this strain with the rAd PVM vaccines 
could determine whether protection is achieved through antibodies or innate immune 
responses. Innate responses could be investigated using SCID mice, as these animals 
are B and T-cell deficient, but have normal NK cell function. A SCID mouse strain is 
available which has defective NK cells, allowing the role of innate immunity in the 
development of protection against PVM to be investigated.  
 
Another interesting line of work would be to compare rAd immunisation via the oral 
route and intranasal routes. Although the subcutaneous and intraperitoneal routes 
were investigated for potential routes of eliciting protection towards PVM, (Figs. 
5.1-5.4); the subcutaneous route was not associated with protection at any dose 
investigated and the intraperitoneal route was associated with Ad vector-mediated 
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side effects. These routes primarily focus on systemic immunisation, which does not 
necessarily stimulate the mucosal response, reported to be important for protection 
against PVM (Kim et al., 2010). An investigation into the potential immunogenicity 
of the oral route for these vaccines would determine whether specific pulmonary 
localised mucosal responses are required for effective protection against PVM rather 
than a generalised mucosal response. Immunisation via this route was widely 
accepted for the oral polio vaccine (OPV) which was able to stimulate strong 
protective immunity towards poliovirus (Beale, 1991). However, oral immunisation 
has not yet been investigated for a respiratory pathogen.  
 
A further interesting avenue would be to determine whether rAd PVM immunisation 
could overcome maternal immunity. This could be achieved by immunising female 
mice before and during pregnancy with a non-lethal dose of PVM, generating strong 
neutralising antibody responses towards PVM as described in Fig. 6.2. Groups of the 
pups born to mothers immunised with PBS or rAd PVM constructs could then be 
challenged with a lethal PVM infection. An indication that the rAd PVM immunised 
animals were statistically more likely to survive, would indicate that the vaccine 
could overcome maternal immunity. Similarly, the possibility of pre-sensitising 
animals to PVM could be explored. This has been achieved for both PVM- and RSV-
infected mice using ovalbumin (Barends et al., 2004). This process stimulates a 
natural Th2 CD4
+ 
T-cell repsonse towards PVM and RSV. It would be appealing to 
sensitise animals towards PVM, immunise with the rAd PVM constructs and then 
monitor the resultant disease and cytokine profile by ELISA or ELISPOT assay for 
cytokines Il-4, IL-5 and IL-13 levels. This would indicate whether the vaccine 
construct could skew the immune response away from a non-protective Th2
 
 
 
 
response to a protective Th1 response. If this were the case, then it would have great 
implications for infant vaccination, as such a vaccine could be given around six 
months of age to reduce the severity of subsequent RSV infection. 
 
A final aspect worthy of further investigation is the effect of the pre-existing anti-Ad 
immunity on the establishment of transgene immune responses and thus protection. 
rAdEV or UV-inactivated wild-type virus could be used to pre-immunise animals 
before vaccination with the rAd PVM constructs to establish whether pre-existing 
immunity is detrimental to protection against PVM. Yu  et al demonstrated that a 10
7
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p.f.u dose does not have an effect on transgene immune responses, but higher doses 
may do (Yu et al., 2008). An alternative Ad serotype 19 ∆E1/E3 vaccine, rAd19-N, 
has been constructed which expresses the full-length N protein of PVM. This 
construct is also able to elicit protection in immunised mice in the PVM infection 
model (Mr S.N. Martin, personal communication). Constructs like rAd19-N could be 
used in conjunction with rAdN described in this study to determine the effect of a 
hetelogous prime-boost regime using alternative vaccine vectors. One study 
compared a prime-boost regime using different rAd vectors expressing the same 
genes of RSV (Hsu, 1994). This showed that different rAd immunisation serotype 
combinations exhibited different effects on the resulting immune responses generated. 
Therefore, the investigation of additional Ad serotype PVM constructs would be 
beneficial for further study.  
 
This thesis has presented the first proof of principle rAd5 vaccine strategy against 
pneumovirus using a natural pathogen in its natural host. rAd PVM constructs 
generated protective immunity against lethal PVM infection which was long-lasting 
in duration. This work identifies a new method which may be extended for the 
evaluation of vaccine candidates for RSV. Through evaluation of PVM vaccines,  
successful candidates can be developed for RSV for clinical trials. Ultimately, the 
work described here provides a positive scenario suggesting not only that the 
development of vaccines against RSV is possible, but that the PVM infection model 
can be used as a platform to evaluate potential vaccine candidates for pneumovirus 
infections.  
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Appendix A: Nucleotide sequences 
 
Figure A.1. Nucleotide sequence for analysis for pShuttle_CMV_M 
 
 
 
Figure A.1. Nucleotide sequence for analysis of pShuttle_CMV_M. 
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Figure A.2. Nucleotide sequence for analysis for pShuttle_CMV_F 
 
 
 
Figure A.2. Nucleotide sequence for analysis of pShuttle_CMV_F. 
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Figure A.3. Nucleotide sequence of pShuttle_CMV_N 
 
Figure A.3. Nucleotide sequence for analysis of pShuttle_CMV_N. 
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Figure A.3. Nucleotide sequence for analysis for pShuttle_CMV_P 
 
 
 
Figure A.4. Nucleotide sequence for analysis of pShuttle_CMV_P.  
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Appendix B: Plasmids and Virus stocks 
 
 
 
Figure B.1. pShuttle_CMV plasmid map.  
The pShuttle_CMV plasmid encodes three regions of homology with pAdEasy, the 
left and right arms of homology which encode regions of the Ad5 genome, and the 
pBR322 origin of replication (orange). The plasmid also encodes Kan
R
 (red), 
inverted terminal repeats (ITR), encapsidation sequence (ES), CMV promoter 
(purple), SV40 polyA sequence (royal blue), and MCS (light blue).  
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Table B.1 Virus stock titres for in vivo studies.  
The virus, stock number, adenoviral particle number, p.f.u./ml concentration, number 
of doses at 10
8
 p.f.u./50µl and total number of doses per viruses is indicated.  
  
Virus Stock 
Number 
Particle 
Number  
P.f.u./ml Particle/p.f.u. 
ratio 
Number of 
doses at 
10
8 
p.f.u./50µl 
Total 
number 
of doses 
rAdF 
 
 
1 
2 
3 
2.9x10
12
 
3.43x10
12
 
2.66x10
12
 
1x10
11
 
1x10
11 
7x10
10
 
29 
34 
38 
430 
500 
252 
 
 
1182 
rAdM 1 
2 
3 
4 
5 
6 
5.4x10
11
 
1.56x10
12
 
8.96x10
11 
3.8x10
12 
5.69x10
12 
4.3x10
12
 
1.15x10
10
 
1.5x10
10 
7.96x10
9
 
6.44x10
10
 
4.83x10
10
 
3.83x10
10
 
47 
104 
113 
59 
118 
112 
82 
75 
28 
289 
246 
145 
 
 
 
 
 
868 
rAdN 1 
2 
5 
6 
7 
8 
9 
10 
11 
12 
8.18x10
11
 
1.24x10
12
 
4.299x10
12
 
3.278x10
12
 
3.175x10
12
 
6.0x10
13
 
2.45x10
12
 
3.88x10
12
 
2.08x10
12
 
4.25x10
12
 
1.9x10
10
 
8.3x10
9
 
2.25x10
10
 
4.2x10
10
 
8x10
10
 
5.3x10
10
 
5.8x10
10
 
3x10
10
 
8.85x10
9
 
4.15x10
10
 
43 
149 
191 
78 
40 
1132 
42 
129 
235 
102 
57 
43 
100 
160 
304 
270 
240 
153 
41 
155 
 
 
 
 
 
 
 
 
 
1523 
rAdZ 1 
2 
5.75x10
12
 
1.25x10
12
 
6.33x10
10
 
1.17x10
10
 
91 
107 
822 
87 
 
909 
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Appendix C: Additional in vitro and in vivo 
experimental results 
 
 
 
 
 
Figure C.1. PVM P protein expression can be detected from plasmid 
pShuttle_CMV_Flag-P-intron.  
1x10
6
 HEK293 cells were mock-transfected or transfected with 2µg of 
pShuttle_CMV_Flag-P-intron. P2-2 cells, a positive control, were seeded at 
5x10
5
/well. Cells were lysed 72 hours later and lysates were separated by 10% SDS-
PAGE prior to Western blotting. The membrane was probed with mouse anti-FLAG 
M2 monoclonal antibody (Sigma) used 1:10,000, which recognises the FLAG 
epitope. PVM P protein (*) was detected in both the pShuttle_CMV_Flag-P-intron 
and P2-2 cells (lanes 1 and 3), proving that PVM P protein is expressed from the 
construct.  
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Figure. C.2. BALB/c mice immunised with a high dose of 10
8
 p.f.u. of either 
rAdN or rAdZ are protected against a super lethal PVM infection.  
BALB/c mice from one batch of animals were divided into groups of six, each with 
three male and three females per group. Animals were individually vaccinated with 
rAdN (group A) or rAdZ (group B) at10
8
 p.f.u. dose or PBS (group C) via the 
intranasal route using a prime boost immunisation regime as previously described in 
Fig. 4.2. Animals were immunised with the same dose of immunogen  on day 14, 
prior to inoculation with a super lethal dose of PVM strain J3666 of 500 p.f.u./50µl 
on day 28. Mean clinical score (A) and bodyweight loss (B) were monitored 
throughout the challenge period. Mean clinical score was calculated from the scores 
of each individual in an inoculation group. Bodyweight was calculated using the total 
weight per inoculated group, averaged per animal, with weight on day zero of PVM 
challenge, normalised to 100%. It should be noted that two animals were lost from 
group A prior to PVM challenge due to anaesthesia complications. 
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Figure. C.3. P2-2 cell lysate (PVM antigen) optimisation for PVM ELISA. 
P2-2 cell lysate was cultured in large roller bottles as detailed in Section 2.4.3 and 
the ELISA was performed as detailed in Section 2.9.1. P2-2 cell lysate was used at a 
concentration of either 5mg/ml or 1mg/ml and control BS-C-1 lysate at 5mg/ml 
concentration. Serum was collected from previously PVM infected but recovered 
animals and was analysed to determine whether an IgG response towards PVM could 
be detected using an anti-mouse IgG HRP conjugated secondary antibody (Section 2, 
Table 2.1.7). A PVM specific IgG response was detected from the positive serum 
sample. The response detected at 1mg/ml was sufficient therefore, this concentration 
was used throughout the ELISA analysis. The data are representative of two 
experimental repeats.  
 
 
 
 
Figure. C.4. The PVM ELISA is specific for PVM antigen.  
The PVM ELISA as performed as described in Section 2.9.1., using serum from 
either influenza infected but recovered animals (control serum, red) or PVM infected 
but recovered animals (PVM serum, green). Both serum samples were used from 
neat and only the PVM serum was able to generate a detectable anti-PVM IgG 
response within the ELISA, confirming that the ELISA was specific for PVM 
antigen.  
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Figure. C. 5. PVM specific IFNγ+ secreting splenocytes can be detected in the 
ELISPOT assay. 
BALB/c mice between 5 and 7 weeks of age were immunised intranasally. with 500 
p.f.u. non-pathogenic PVM strain 15 in a 50µl volume or with PBS (control). The 
animals were sacrificed at 21 days post immunisation and the spleens were collected 
from individual animals. Splenocytes were isolated for each individual animal and 
pooled for each immunisation group. The number of IFNγ+ cells in 5x105 splenocytes 
is illustrated in response to re-stimulation with either PVM J3666 at an M.O.I of 1 or 
the same volume of BS-C-1 control tissue culture fluid. 
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Figure. C. 6. Representative FACS fluorescent data profiles for CD4
+
 IFNγ+ and 
CD8
+
 IFNγ+ secreting splenocytes detected using the ICS assay. 
Splenocytes were isolated from individual animals and pooled according to 
immunisation group. The cells were stained for CD4
+
 and CD8
+
 expression on the 
cell surface, prior to fixing and intracellular staining for IFNγ, using antibodies as 
detailed in Table 2.1.7. The samples were analysed using a flow cytometer and 
lymphocyte populations were gated using CellQuest Pro software. Gated lymphocyte 
populations were analysed for CD4/CD8
+
 and IFNγ+ expression (A). Representative 
dot plots for PVM-immunised animals (B), rAdN-immunised animals (C), rAdZ-
immunised animals (D), and PBS treated animals (E) are shown.  
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Appendix D: Statistical analysis of antibody titres 
 
Antibody titres from rAd vaccine immunised animals were compared by the mann-
whitney U test, a non-parametric test using PRISM software. The resultant p values 
are represented in the tables below. 
 
rAdF 10
6
 day 
14 
10
6
 day 
28 
10
7
 day 
14 
10
7
 day 
28 
10
8
 day 14 10
8
 day 
28 
10
6
 day 
14 
xx 0.0002 0.0007 P<0.0001 P<0.0001 P<0.0001 
10
6
 day 
28 
0.0002 xx 0.0587 0.094 0.7925 0.1622 
10
7
 day 
14 
0.0007 0.0587 xx 0.0001 0.0479 0.0008 
10
7
 day 
28 
P<0.0001 0.094 0.0001 xx 0.0207 0.9301 
10
8
 day 
14 
P<0.0001 0.7925 0.0479 0.0207 xx 0.0581 
10
8
 day 
28 
P<0.0001 0.1622 0.0008 0.9301 0.0581 xx 
 
Table D.1. Statistical comparison of rAdF-immunised animals for the anti-Ad IgG 
response at the 10
6-8
 p.f.u. dose at the 24 and 28-day time points.  
 
 
rAdM 10
6
 day 
14 
10
6
 day 
28 
10
7
 day 
14 
10
7
 day 
28 
10
8
 day 14 10
8
 day 
28 
10
6
 day 
14 
xx 0.0042 0.837 P<0.0001 0.073 P<0.0001 
10
6
 day 
28 
0.0042 xx 0.0099 0.0172 0.3199 P<0.0001 
10
7
 day 
14 
0.837 0.0099 xx P<0.0001 0.1262 P<0.0001 
10
7
 day 
28 
P<0.0001 0.0172 P<0.0001 xx 0.0023 0.0003 
10
8
 day 
14 
0.073 0.3199 0.1262 0.0023 xx P<0.0001 
10
8
 day 
28 
P<0.0001 P<0.0001 P<0.0001 0.0003 P<0.0001 xx 
 
Table D.2. Statistical comparison of rAdM-immunised animals for the anti-Ad IgG 
response at the 10
6-8
 p.f.u. dose at the 24 and 28-day time points.  
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rAdN 10
6
 day 
14 
10
6
 day 
28 
10
7
 day 
14 
10
7
 day 
28 
10
8
 day 14 10
8
 day 
28 
10
6
 day 
14 
xx 0.1068 0.5465 P<0.0001 0.0002 0.0002 
10
6
 day 
28 
0.1068 xx 0.1511 0.0014 0.1951 0.0018 
10
7
 day 
14 
0.5465 0.1511 xx P<0.0001 0.0002 P<0.0001 
10
7
 day 
28 
P<0.0001 0.0014 P<0.0001 xx 0.0009 0.0797 
10
8
 day 
14 
0.0002 0.1951 0.0002 0.0009 xx 0.0005 
10
8
 day 
28 
0.0002 0.0018 P<0.0001 0.0797 0.0005 Xx 
 
Table D.3. Statistical comparison of rAdN-immunised animals for the anti-Ad IgG 
response at the 10
6-8
 p.f.u. dose at the 24 and 28-day time points.  
 
  
rAdZ 10
6
 day 
14 
10
6
 day 
28 
10
7
 day 
14 
10
7
 day 
28 
10
8
 day 14 10
8
 day 
28 
10
6
 day 
14 
xx 1 1 0.0856 0.1898 0.001 
10
6
 day 
28 
1 xx 1 0.0856 0.1898 0.001 
10
7
 day 
14 
1 1 xx 0.0856 0.1898 0.001 
10
7
 day 
28 
0.0856 0.0856 0.0856 xx 0.9083 0.0005 
10
8
 day 
14 
0.1898 0.1898 0.1898 0.9083 xx P<0.0001 
10
8
 day 
28 
0.001 0.001 0.001 0.0005 P<0.0001 xx 
 
Table D.4. Statistical comparison of rAdZ-immunised animals for the anti-Ad IgG 
response at the 10
6-8
 p.f.u. dose at the 24 and 28-day time points.  
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Appendix E: PVM N peptide sequences 
 
Table. E. PVM N peptide sequences 
 
Peptide 
number 
Peptide Sequence Corresponding amino 
acids in PVM N 
protein 
1 MSLDRLKLNDVSNKD 1-15 
2 LKLNDVSNKDSLLSN 6-20 
3 VSNKDSLLSNCKYSV 11-25 
4 SLLSNCKYSVTRSTG 16-30 
5 CKYSVTRSTGDVTSV 21-35 
6 TRSTGDVTSVSGHAM 26-40 
7 DVTSVSGHAMQKALA 31-45 
8 SGHAMQKALARTLGM 36-50 
9 QKALARTLGMFLLTA 41-55 
10 RTLGMFLLTA FNRCE 46-60 
11 FLLTA FNRCEEVAEI 51-65 
12 FNRCEEVAEIGLQYA 56-70 
13 EVAEIGLQYAMSLLG 61-75 
14 GLQYAMSLLGRDDSI 66-80 
15 MSLLGRDDSIKILRE 71-85 
16 RDDSIKILREAGYNV 76-90 
17 KILREAGYNVKCVDT 81-95 
18 AGYNVKCVDTQLKDF 86-100 
19 KCVDTQLKDFTIKLQ 91-105 
20 QLKDFTIKLQGKEYK 96-110 
21 TIKLQGKEYKIQVLD 101-115 
22 GKEYKIQVLDIVGID 106-120 
23 IQVLDIVGIDAANLA 111-125 
24 IVGIDAANLADLEIQ 116-130 
25 AANLADLEIQARGVV 121-135 
26 DLEIQARGVVAKELK 126-140 
27 ARGVVAKELKTGARL 131-145 
28 AKELKTGARLPDNQR 136-150 
29 TGARLPDNQRHDAPD 141-155 
30 PDNQRHDAPDCGVIV 146-160 
31 HDAPDCGVIVLCTAA 151-165 
32 CGVIVLCTAALVVSK 156-170 
33 LCTAALVVSKLAAGD 161-175 
34 LVVSKLAAGDRGGLD 166-180 
35 LAAGDRGGLDAVERR 171-185 
36 RGGLDAVERRALNVL 176-190 
37 AVERRALNVLKAEKA 181-195 
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38 ALNVLKAEKARYPNM 186-200 
39 KAEKARYPNMEVKQI 191-205 
40 RYPNMEVKQIAESFY 196-210 
41 EVKQIAESFYDLFER 201-215 
42 AESFYDLFERKPYYI 206-220 
43 DLFERKPYYIDVFIT 211-225 
44 KPYYIDVFITFGLAQ 216-230 
45 DVFITFGLAQSSVKG 221-235 
46 FGLAQSSVKGGSKVE 226-240 
47 SSVKGGSKVEGLFSG 231-245 
48 GSKVEGLFSGLFMNA 236-250 
49 GLFSGLFMNAYGAGQ 241-255 
50 LFMNAYGAGQVMLRW 246-260 
51 YGAGQVMLRWGLLAK 251-265 
52 VMLRWGLLAKSVKNI 256-270 
53 GLLAKSVKNIMLGHA 261-275 
54 VKNIMLGHASVQAE 266-280 
55 LGHASVQAEMEQVV 271-285 
56 VQAEMEQVVEVYEY 276-290 
57 EQVVEVYEYAQKQG 281-295 
58 VYEYAQKQGGEAGF 286-300 
59 QKQGGEAGFYHIRN 291-305 
60 EAGFYHIRNNPKAS 296-310 
61 HIRNNPKASLLSLT 301-315 
62 PKASLLSLTNCPNF 306-320 
63 LSLTNCPNFTSVVL 311-325 
64 CPNFTSVVLGNAAG 316-330 
65 SVVLGNAAGLGIIG 321-335 
66 NAAGLGIIGSYKGA 326-340 
67 GIIGSYKGAPRNRE 331-345 
68 YKGAPRNRELFDAA 336-350 
69 RNRELFDAAKDYAE 341-355 
70 FDAAKDYAERLKDN 346-360 
71 DYAERLKDNNVINY 351-365 
72 LKDNNVINYSALNL 356-370 
73 VINYSALNLTAEER 361-375 
74 ALNLTAEERELISQ 366-380 
75 AEERELISQQLNIV 371-385 
76 LISQQLNIVDDTPD 376-390 
77 QQLNIVDDTPDDDI 379-393 
 
